1560033|t|Hypertrophic chondrocytes undergo further differentiation in culture 
1560033|a|Conditions have been defined for promoting growth and differentiation of hypertrophic chondrocytes obtained in culture starting from chick embryo tibiae. Hypertrophic chondrocytes, grown in suspension culture as described (Castagnola P., G. Moro, F. Descalzi Cancedda, and R. Cancedda. 1986. J. Cell Biol. 102:2310-2317), when they reached the stage of single cells, were transferred to substrate-dependent culture conditions in the presence of ascorbic acid. Cells showed a change in morphology, became more elongated and flattened, expressed alkaline phosphatase, and eventually mineralized. Type II and X collagen synthesis was halted and replaced by type I collagen synthesis. In addition the cells started to produce and to secrete in large amount a protein with an apparent molecular mass of 82 KD in reducing conditions and 63 KD in unreducing conditions. This protein is soluble in acidic solutions, does not contain collagenous domains, and is glycosylated. The Ch21 protein, a marker of hypertrophic chondrocytes and bone cells, was synthesized throughout the culture. We have defined this additional differentiation stage as an osteoblast-like stage. Calcium deposition in the extracellular matrix occurred regardless of the addition of beta glycerophosphate to the culture medium. Comparable results were obtained both when the cells were plated at low density and when they were already at confluence and maintained in culture without passaging up to 50 d. When retinoic acid was added to the hypertrophic chondrocyte culture between day 1 and day 5 the maturation of the cells to the osteoblast-like stage was highly accelerated. The switch in the collagen secretion was already observed after 2 d and the production of the 63-kD protein after 3 d. Mineralization was observed after 15-20 d. 
1560033	0	12	Hypertrophic	Disease	MESH:D006984
1560033	202	207	chick	Species	9031
1560033	208	214	embryo	Species	6239
1560033	142	154	hypertrophic	Disease	MESH:D006984
1560033	1544	1557	retinoic acid	Chemical	MESH:D014212
1560033	1317	1338	beta glycerophosphate	Chemical	MESH:C031463
1560033	870	872	KD	Disease	MESH:C537014
1560033	223	248	Hypertrophic chondrocytes	Disease	MESH:D006984
1560033	1231	1238	Calcium	Chemical	MESH:D002118
1560033	514	527	ascorbic acid	Chemical	MESH:D001205
1560033	903	905	KD	Disease	MESH:C537014
1560033	1575	1587	hypertrophic	Disease	MESH:D006984
1560033	1066	1091	hypertrophic chondrocytes	Disease	MESH:D006984

1313813|t|Proteins are secreted by both constitutive and regulated secretory pathways in lactating mouse mammary epithelial cells 
1313813|a|Lactating mammary epithelial cells secrete high levels of caseins and other milk proteins. The extent to which protein secretion from these cells occurs in a regulated fashion was examined in experiments on secretory acini isolated from the mammary glands of lactating mice at 10 d postpartum. Protein synthesis and secretion were assayed by following the incorporation or release, respectively, of [35S]methionine-labeled TCA-precipitable protein. The isolated cells incorporated [35S]methionine into protein linearly for at least 5 h with no discernible lag period. In contrast, protein secretion was only detectable after a lag of approximately 1 h, consistent with exocytotic secretion of proteins immediately after passage through the secretory pathway and package into secretory vesicles. The extent of protein secretion was unaffected by the phorbol ester PMA, 8-bromo-cAMP, or 8- bromo-cGMP but was doubled by the Ca2+ ionophore ionomycin. In a pulse- label protocol in which proteins were prelabeled for 1 h before a chase period, constitutive secretion was unaffected by depletion of cytosolic Ca2+ but ionomycin was found to give a twofold stimulation of the secretion of presynthesized protein in a Ca(2+)-dependent manner. Ionomycin was still able to stimulate protein secretion after constitutive secretion had terminated. These results suggest that lactating mammary cells possess both a Ca(2+)-independent constitutive pathway and a Ca(2+)-activated regulatory pathway for protein secretion. The same proteins were secreted by both pathways. No ultrastructural evidence for apocrine secretion was seen in response to ionomycin and so it appears that regulated casein release involves exocytosis. Ionomycin was unlikely to be acting by disassembling the cortical actin network since cytochalasin D did not mimic its effects on secretion. The regulated pathway may be controlled by Ca2+ acting at a late step such as exocytotic membrane fusion. 
1313813	89	94	mouse	Species	10090
1313813	389	393	mice	Species	10090
1313813	1224	1228	Ca2+	Chemical	MESH:D002118
1313813	1042	1046	Ca2+	Chemical	MESH:D002118
1313813	1005	1018	8- bromo-cGMP	Chemical	MESH:C016276
1313813	519	534	[35S]methionine	Chemical	MESH:C013111
1313813	1356	1365	Ionomycin	Chemical	MESH:D015759
1313813	988	1000	8-bromo-cAMP	Chemical	MESH:D015124
1313813	969	986	phorbol ester PMA	Chemical	MESH:D010703
1313813	1832	1841	Ionomycin	Chemical	MESH:D015759
1313813	1331	1337	Ca(2+)	Chemical	MESH:D002118
1313813	601	616	[35S]methionine	Chemical	MESH:C013111
1313813	1753	1762	ionomycin	Chemical	MESH:D015759
1313813	1057	1066	ionomycin	Chemical	MESH:D015759
1313813	1233	1242	ionomycin	Chemical	MESH:D015759
1313813	543	546	TCA	Chemical	MESH:C000589078
1313813	1569	1575	Ca(2+)	Chemical	MESH:D002118
1313813	2016	2020	Ca2+	Chemical	MESH:D002118
1313813	1523	1529	Ca(2+)	Chemical	MESH:D002118

1560028|t|Transport of the lysosomal membrane glycoprotein lgp120 (lgp-A) to lysosomes does not require appearance on the plasma membrane 
1560028|a|We have used stably transfected CHO cell lines to characterize the pathway of intracellular transport of the lgp120 (lgp-A) to lysosomes. Using several surface labeling and internalization assays, our results suggest that lgp120 can reach its final destination with or without prior appearance on the plasma membrane. The extent to which lgp120 was transported via the cell surface was determined by two factors: expression level and the presence of a conserved glycine-tyrosine motif in the cytoplasmic tail. In cells expressing low levels of wild-type lgp120, the majority of newly synthesized molecules reached lysosomes without becoming accessible to antibody or biotinylation reagents added extracellularly at 4 degrees C. With increased expression levels, however, an increased fraction of transfected lgp120, as well as some endogenous lgp-B, appeared on the plasma membrane. The fraction of newly synthesized lgp120 reaching the cell surface was also increased by mutations affecting the cytoplasmic domain tyrosine or glycine residues. A substantial fraction of both mutants reached the surface even at low expression levels. However, only the lgp120G----A7 mutant was rapidly internalized and delivered from the plasma membrane to lysosomes. Taken together, our results show that the majority of newly synthesized wild-type lgp120 does not appear to pass through the cell surface en route to lysosomes. Instead, it is likely that lysosomal targeting involves a saturable intracellular sorting site whose affinity for lgp's is dependent on a glycine-tyrosine motif in the lgp120 cytoplasmic tail. 
1560028	57	62	lgp-A	Gene	100689406
1560028	245	250	lgp-A	Gene	100689406
1560028	971	976	lgp-B	Gene	100689316
1560028	160	174	CHO cell lines	Species	10029
1560028	590	606	glycine-tyrosine	Chemical	MESH:D005998
1560028	1143	1151	tyrosine	Chemical	
1560028	1155	1162	glycine	Chemical	MESH:D005998
1560028	1679	1695	glycine-tyrosine	Chemical	MESH:D005998

1373145|t|Regulation of fibronectin receptor distribution [published erratum appears in J Cell Biol 1992 Jul;118(2):491] 
1373145|a|To determine the role of each intracellular domain of the fibronectin receptor in receptor distribution, chimeric receptors were constructed containing the human interleukin-2 receptor (gp55 subunit) as the extracellular and transmembrane domains, in combination with either the alpha 5 or beta 1 intracellular domain of the fibronectin receptor as the cytoplasmic domain. These chimeric receptors were transiently expressed in normal fibroblasts, and their localization on the cell surface was determined by immunofluorescence using antibodies to the human interleukin-2 receptor. The alpha 5 chimera was expressed diffusely on the plasma membrane. The beta 1 chimera, however, colocalized with the endogenous fibronectin receptor at focal contacts of cells spread on fibronectin. On cells spread in the presence of serum, the beta 1 chimera colocalized both with the fibronectin receptor at sites of extracellular fibronectin fibrils and with the vitronectin receptor at focal contacts. The beta 1 intracellular domain alone, therefore, contains sufficient information to target the chimeric receptor to regions of the cell where ligand-occupied integrin receptors are concentrated. The finding that the beta 1 chimeric protein behaves like a ligand-occupied receptor, even though the beta 1 chimera cannot itself bind extracellular ligand, suggests an intracellular difference between occupied and unoccupied receptors, and predicts that the distribution of integrin receptors can be regulated by ligand occupancy. We tested this prediction by providing a soluble cell-binding fragment of fibronectin to cells spread on laminin. Under conditions preventing further ligand adsorption to the substrate, this treatment nevertheless resulted in the relocation of diffuse fibronectin receptors to focal contacts. Similarly, a redistribution of diffuse vitronectin receptors to focal contacts occurred on cells spread on laminin after the addition of the small soluble peptide GRGDS. We conclude that the propensity for receptor redistribution to focal contacts driven by the beta 1 cytoplasmic domain alone is suppressed in heterodimeric unoccupied fibronectin receptors, and that ligand occupancy can release this constraint. This redistribution of integrin receptors after the binding of a soluble substrate molecule may provide a direct means of assembling adhesion sites. 
1373145	14	25	fibronectin	Gene	2335
1373145	169	180	fibronectin	Gene	2335
1373145	297	301	gp55	Gene	27020
1373145	822	833	fibronectin	Gene	2335
1373145	880	891	fibronectin	Gene	2335
1373145	980	991	fibronectin	Gene	2335
1373145	1060	1071	vitronectin	Gene	7448
1373145	1703	1714	fibronectin	Gene	2335
1373145	1027	1038	fibronectin	Gene	2335
1373145	267	272	human	Species	9606
1373145	663	668	human	Species	9606
1373145	1961	1972	vitronectin	Gene	7448
1373145	2258	2269	fibronectin	Gene	2335
1373145	1881	1892	fibronectin	Gene	2335
1373145	436	447	fibronectin	Gene	2335

1560026|t|The 17-residue transmembrane domain of beta-galactoside alpha 2,6- sialyltransferase is sufficient for Golgi retention 
1560026|a|beta-Galactoside alpha 2,6-sialyltransferase (ST) is a type II integral membrane protein of the Golgi apparatus involved in the sialylation of N-linked glycans. A series of experiments has shown that the 17-residue transmembrane domain of ST is sufficient to confer localization to the Golgi apparatus when transferred to the corresponding region of a cell surface type II integral membrane protein. Lectin affinity chromatography of chimeric proteins bearing this 17-residue sequence suggests that these chimeric proteins are localized in the trans-Golgi cisternae and/or trans-Golgi network. Further experiments suggest that this 17-residue sequence functions as a retention signal for the Golgi apparatus. 
1560026	39	55	beta-galactoside	Chemical	MESH:C007816
1560026	103	118	Golgi retention	Disease	MESH:D016055
1560026	262	263	N	Chemical	MESH:D009584
1560026	119	135	beta-Galactoside	Chemical	MESH:C007816

1313814|t|Nerve growth factor nonresponsive pheochromocytoma cells: altered internalization results in signaling dysfunction 
1313814|a|Variant rat pheochromocytoma (PC12) cells which fail to respond to nerve growth factor (NGF) (PC12nnr5) (Green, S. H., R. E. Rydel, J. L. Connoly, and L. A. Greene. 1986. J. Cell Biol. 102:830-843) bind NGF at both high and low affinity sites. Although still undefined at the molecular level, these have been referred to as type I (high) and type II (low) receptors. They are apparently composed of two membrane-bound proteins, p75 and the protooncogene trk, both of which bind NGF, and apparently contribute singularly or in concert to the two observed affinities, and to the promotion of the NGF effects. In native PC12 cells, only the high affinity receptors are apparently capable of mediating internalization and degradation. PC12nnr5 cells also display type I binding, but the subsequent internalization is not the same fashion as in the parental cell line, nor is it subjected to lysosomal degradation. Rather it is initially sequestered during the first 15 min, and is eventually released intact into the medium. In contrast, EGF is bound, internalized, and degraded by PC12nnr5 cells, albeit less efficiently than in the parent cells. These observations argue that the defect(s) preventing the PC12nnr5 variants from responding to NGF prevents competent internalization, which in the case of NGF, may be required for the full expression of activity. The absence of trk, as one alteration in PC12nnr5 cells (Loeb, D. M., J. Maragos, D. Martin- Zanca, M. V. Chao, L. F. Parada, and L. A. Greene. 1991. Cell. 66:961- 966), is consistent with this conclusion. 
1313814	0	19	Nerve growth factor	Gene	310738
1313814	93	114	signaling dysfunction	Disease	MESH:C566796
1313814	34	50	pheochromocytoma	Disease	MESH:D010673
1313814	182	201	nerve growth factor	Gene	310738
1313814	203	206	NGF	Gene	310738
1313814	543	546	p75	Gene	24596
1313814	569	572	trk	Gene	59109
1313814	593	596	NGF	Gene	310738
1313814	709	712	NGF	Gene	310738
1313814	1355	1358	NGF	Gene	310738
1313814	1416	1419	NGF	Gene	310738
1313814	1489	1492	trk	Gene	59109
1313814	318	321	NGF	Gene	310738
1313814	123	126	rat	Species	10116
1313814	127	143	pheochromocytoma	Disease	MESH:D010673

1560035|t|Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the beta subunit of VLA 
1560035|a|Investigating the regulation of very late antigen (VLA)-mediated functions, we found that TS2/16, a mAb directed against the beta chain of the VLA group of integrins, can induce binding of resting peripheral blood lymphocytes, cloned T lymphocytes, and Epstein Barr virus- transformed B cells to extracellular matrix components, fibronectin, laminin, and collagen, but not to fibrinogen. The antibody stimulates VLA-4-, VLA-5-, and VLA-6-mediated binding. Furthermore, it induces VLA- 4-mediated binding to vascular cell adhesion molecule-1 expressed by rTNF-alpha-stimulated endothelial cells, but it does not stimulate homotypic aggregation of cells as described for a number of anti-VLA-4 alpha antibodies (Bednarczyk, J.L., and B. W. McIntyre. 1990. J. Immunol. 144: 777-784; Campanero, M. R., R. Pulido, M. A. Ursa, M. Rodriguez-Moya, M. O. de Landazuri, and F. Sanchez-Madrid. 1990. J. Cell Biol. 110:2157-2165). Therefore, the stimulating activity of this anti-beta 1 antibody clearly contrasts with that of the anti-VLA-4 alpha antibodies, which induce homotypic cell aggregation, but not binding of cells to extracellular matrix components or endothelial cells, indicating that TS2/16 may generate different signals. The observation that also F(ab')2 or Fab fragments of this anti-beta 1 antibody stimulate binding to extracellular matrix components and endothelial cells excludes the possibility that binding requires receptor crosslinking, or is Fc receptor mediated. Induction of this adhesion is cation and energy dependent and requires an intact cytoskeleton. Although changes in the conformation of VLA integrins induced by this antibody may regulate their functional activity, the dependence on metabolic energy indicates that intracellular processes may also play a role. 
1560035	547	552	VLA-5	Gene	3678
1560035	559	564	VLA-6	Gene	3655
1560035	634	667	vascular cell adhesion molecule-1	Gene	7412
1560035	681	691	rTNF-alpha	Gene	24835
1560035	1095	1101	beta 1	Gene	3779
1560035	1390	1393	Fab	Gene	2187
1560035	1417	1423	beta 1	Gene	3779
1560035	380	398	Epstein Barr virus	Species	10376

1373142|t|Distribution of the Na(+)-Ca2+ exchange protein in mammalian cardiac myocytes: an immunofluorescence and immunocolloidal gold-labeling study 
1373142|a|The present study reports on the location of the Na(+)-Ca2+ exchanger in cardiac sarcolemma with immunofluorescence and immunoelectron microscopy. Both polyclonal and monoclonal antibodies to the Na(+)-Ca2+ exchanger were used. The mAb was produced from a hybridoma cell line generated by the fusion of mouse myeloma NS-1 cells with spleen cells from a mouse repeatedly immunized with isolated reconstituted canine cardiac Na(+)-Ca2+ exchanger (Philipson, K. D. S. Longoni, and R. Ward. 1988. Biochim. Biophys. Acta. 945:298-306). The polyclonal antibody has been described previously and reacts with three proteins (70, 120, 160 kD) in cardiac sarcolemma associated with the Na(+)-Ca2+ exchanger (Nicoll, D. A., S. Longoni, and K. D. Philipson. 1990. Science (Wash. DC). 250:562-565). Both the monoclonal and the polyclonal antibodies appear to react with extracellular facing epitopes in the cardiac sarcolemma. Immunofluorescence studies showed labeling of the transverse tubular membrane and patchy labeling of the peripheral sarcolemma. The immunofluorescent labeling clearly delineates the highly interconnected T-tubular system of guinea pig myocytes. This localization of the exchanger to the sarcolemma, with an apparent high density in the transverse tubules, was also seen with immunoelectron microscopy. It is of great interest that the Na(+)-Ca2+ exchanger, as the main efflux route for Ca2+ in heart cells, would be abundantly located in sarcolemma closest to the release of Ca2+. 
1373142	51	60	mammalian	Species	9606
1373142	20	29	Na(+)-Ca2	Gene	342538
1373142	190	210	Na(+)-Ca2+ exchanger	Gene	6546
1373142	337	346	Na(+)-Ca2	Gene	342538
1373142	817	837	Na(+)-Ca2+ exchanger	Gene	6546
1373142	1490	1510	Na(+)-Ca2+ exchanger	Gene	6546
1373142	444	449	mouse	Species	10090
1373142	494	499	mouse	Species	10090
1373142	549	555	canine	Species	9615
1373142	1279	1289	guinea pig	Species	10141
1373142	564	573	Na(+)-Ca2	Gene	342538
1373142	778	796	cardiac sarcolemma	Disease	MESH:D006331
1373142	450	457	myeloma	Disease	MESH:D009101
1373142	1541	1545	Ca2+	Chemical	MESH:D002118
1373142	1630	1634	Ca2+	Chemical	MESH:D002118

1560029|t|Surface structure and properties of plant seed oil bodies 
1560029|a|Storage triacylglycerols (TAG) in plant seeds are present in small discrete intracellular organelles called oil bodies. An oil body has a matrix of TAG, which is surrounded by phospholipids (PL) and alkaline proteins, termed oleosins. Oil bodies isolated from mature maize (Zea mays) embryos maintained their discreteness, but coalesced after treatment with trypsin but not with phospholipase A2 or C. Phospholipase A2 or C exerted its activity on oil bodies only after the exposed portion of oleosins had been removed by trypsin. Attempts were made to reconstitute oil bodies from their constituents. TAG, either extracted from oil bodies or of a 1:2 molar mixture of triolein and trilinolein, in a dilute buffer were sonicated to produce droplets of sizes similar to those of oil bodies; these droplets were unstable and coalesced rapidly. Addition of oil body PL or dioleoyl phosphatidylcholine, with or without charged stearylamine/stearic acid, or oleosins, to the medium before sonication provided limited stabilization effects to the TAG droplets. High stability was achieved only when the TAG were sonicated with both oil body PL (or dioleoyl phosphatidylcholine) and oleosins of proportions similar to or higher than those in the native oil bodies. These stabilized droplets were similar to the isolated oil bodies in chemical properties, and can be considered as reconstituted oil bodies. Reconstituted oil bodies were also produced from TAG of a 1:2 molar mixture of triolein and trilinolein, dioleoyl phosphatidylcholine, and oleosins from rice (Oryza sativa), wheat (Triticum aestivum), rapeseed (Brassica napus), soybean (Glycine max), or jojoba (Simmondsia chinensis). It is concluded that both oleosins and PL are required to stabilize the oil bodies and that oleosins prevent oil bodies from coalescing by providing steric hindrance. A structural model of an oil body is presented. The current findings on seed oil bodies could be extended to the intracellular storage lipid particles present in diverse organisms. 
1560029	437	453	phospholipase A2	Gene	182374
1560029	460	476	Phospholipase A2	Gene	182374
1560029	325	330	maize	Species	4577
1560029	332	340	Zea mays	Species	4577
1560029	342	349	embryos	Species	6239
1560029	1610	1614	rice	Species	4530
1560029	1616	1628	Oryza sativa	Species	4530
1560029	1631	1636	wheat	Species	4565
1560029	1638	1655	Triticum aestivum	Species	4565
1560029	1668	1682	Brassica napus	Species	3708
1560029	1685	1692	soybean	Species	3847
1560029	1694	1705	Glycine max	Species	3847
1560029	660	663	TAG	Chemical	MESH:D014280
1560029	1536	1544	triolein	Chemical	MESH:D014304
1560029	1234	1242	oleosins	Chemical	MESH:C510904
1560029	1834	1842	oleosins	Chemical	MESH:C510904
1560029	551	559	oleosins	Chemical	MESH:C510904
1560029	283	291	oleosins	Chemical	MESH:C510904
1560029	1562	1590	dioleoyl phosphatidylcholine	Chemical	MESH:C017251
1560029	1200	1228	dioleoyl phosphatidylcholine	Chemical	MESH:C017251
1560029	1768	1776	oleosins	Chemical	MESH:C510904
1560029	66	82	triacylglycerols	Chemical	MESH:D014280
1560029	727	735	triolein	Chemical	MESH:D014304
1560029	84	87	TAG	Chemical	MESH:D014280
1560029	1011	1019	oleosins	Chemical	MESH:C510904
1560029	981	993	stearylamine	Chemical	MESH:C009317
1560029	1506	1509	TAG	Chemical	MESH:D014280
1560029	206	209	TAG	Chemical	MESH:D014280
1560029	1099	1102	TAG	Chemical	MESH:D014280
1560029	994	1006	stearic acid	Chemical	MESH:D013229
1560029	1155	1158	TAG	Chemical	MESH:D014280
1560029	927	955	dioleoyl phosphatidylcholine	Chemical	MESH:C017251
1560029	1596	1604	oleosins	Chemical	MESH:C510904
1560029	740	751	trilinolein	Chemical	MESH:C009564
1560029	1549	1560	trilinolein	Chemical	MESH:C009564

1374069|t|Regulation of the VLA integrin-ligand interactions through the beta 1 subunit 
1374069|a|Integrins from the very late activation antigen (VLA) subfamily are involved in cellular attachment to extracellular matrix (ECM) proteins and in intercellular adhesions. It is known that the interaction of integrin proteins with their ligands can be regulated during cellular activation. We have investigated the regulation of different VLA- mediated adhesive interactions through the common beta 1 chain. We have found that certain anti-beta 1 antibodies strongly enhance binding of myelomonocytic U-937 cells to fibronectin. This beta 1-mediated regulatory effect involved both VLA-4 and VLA-5 fibronectin receptors. Moreover, anti-beta 1 mAb also induced VLA-4-mediated binding to a recombinant soluble form of its endothelial cell ligand VCAM-1. Non- activated peripheral blood T lymphocytes, unable to mediate VLA-4 interactions with fibronectin or VCAM-1, acquired the ability to bind these ligands in the presence of anti-beta 1 mAb. The anti-beta 1- mediated changes in the affinities of beta 1 integrin for their ligands were comparable to those triggered by different lymphocyte activation agents such as anti-CD3 mAb or phorbol ester. Adhesion of melanoma cells to other ECM proteins such as laminin or collagen as well as that of alpha 2-transfected K-562 cells to collagen, was also strongly enhanced by anti-beta 1 mAb. These beta 1-mediated regulatory effects on different VLA-ligand interactions do not involve changes in cell surface membrane expression of different VLA heterodimers. The anti- beta 1-mediated functional effects required an active metabolism, cytoskeleton integrity and the existence of physiological levels of intracellular calcium as well as a functional Na+/H+ antiporter. Beta 1 antibodies not only increased cell attachment but also promoted spreading and cytoplasmic extension of endothelial cells on plates coated with either fibronectin, collagen, or laminin as well as induced the rapid appearance of microspikes in U-937 cells on fibronectin. Moreover, both beta 1 integrin and the cytoskeletal protein talin colocalized in the anti-beta 1 induced microspikes. These results emphasize the central role of the common beta 1 chain in regulating different adhesive functions mediated by VLA integrins as well as cellular morphology. 
1374069	63	69	beta 1	Gene	3779
1374069	517	523	beta 1	Gene	3779
1374069	593	604	fibronectin	Gene	2335
1374069	821	827	VCAM-1	Gene	7412
1374069	918	929	fibronectin	Gene	2335
1374069	933	939	VCAM-1	Gene	7412
1374069	1029	1035	beta 1	Gene	3779
1374069	1075	1090	beta 1 integrin	Gene	3688
1374069	1591	1597	beta 1	Gene	3779
1374069	1947	1958	fibronectin	Gene	2335
1374069	2054	2065	fibronectin	Gene	2335
1374069	2082	2097	beta 1 integrin	Gene	3688
1374069	2240	2246	beta 1	Gene	3779
1374069	2157	2163	beta 1	Gene	3779
1374069	1419	1425	beta 1	Gene	3779
1374069	1008	1014	beta 1	Gene	3779
1374069	611	617	beta 1	Gene	3779
1374069	1790	1796	Beta 1	Gene	3779
1374069	1401	1407	beta 1	Gene	3779
1374069	713	719	beta 1	Gene	3779
1374069	471	477	beta 1	Gene	3779
1374069	675	686	fibronectin	Gene	2335
1374069	2039	2044	U-937	CellLine	CVCL:0007
1374069	659	664	VLA-4	Chemical	MESH:D039041
1374069	1341	1346	K-562	CellLine	CVCL:0004
1374069	578	583	U-937	CellLine	CVCL:0007
1374069	1739	1746	calcium	Chemical	MESH:D002118
1374069	1237	1245	melanoma	Disease	MESH:D008545
1374069	1210	1223	phorbol ester	Chemical	MESH:D010703

1315314|t|Protein translocation across the ER requires a functional GTP binding site in the alpha subunit of the signal recognition particle receptor 
1315314|a|The signal recognition particle (SRP)-mediated translocation of proteins across the RER is a GTP dependent process. Analysis of the primary amino acid sequence of one protein subunit of SRP (SRP54), as well as the alpha subunit of the SRP receptor (SR alpha), has indicated that these proteins contain predicted GTP binding sites. Several point mutations confined to the GTP binding consensus elements of SR alpha were constructed by site specific mutagenesis to define a role for the GTP binding site in SR alpha during protein translocation. The SR alpha mutants were analyzed using an in vitro system wherein SR alpha- deficient microsomal membranes were repopulated with SR alpha by in vitro translation of wild-type or mutant mRNA transcripts. SRP receptors containing SR alpha point mutants were analyzed for their ability to function in protein translocation and to form guanylyl-5'- imidodiphosphate (Gpp[NH]p) stabilized complexes with the SRP. Mutations in SR alpha produced SRP receptors that were either impaired or inactive in protein translocation. These SRP receptors were likewise unable to form Gpp(NH)p stabilized complexes with the SRP. One SR alpha point mutant, Thr 588 to Asn 588, required 50- to 100-fold higher concentrations of GTP relative to the wild-type SR alpha to function in protein translocation. This mutant has provided information on the reaction step in protein translocation that involves the GTP binding site in the alpha subunit of the SRP receptor. 
1315314	331	336	SRP54	Gene	6729
1315314	389	397	SR alpha	Gene	4481
1315314	545	553	SR alpha	Gene	4481
1315314	645	653	SR alpha	Gene	4481
1315314	688	696	SR alpha	Gene	4481
1315314	752	760	SR alpha	Gene	4481
1315314	815	823	SR alpha	Gene	4481
1315314	914	922	SR alpha	Gene	4481
1315314	1089	1092	SRP	Gene	6729
1315314	1107	1115	SR alpha	Gene	4481
1315314	1125	1128	SRP	Gene	6729
1315314	1209	1212	SRP	Gene	6729
1315314	1423	1431	SR alpha	Gene	4481
1315314	1291	1294	SRP	Gene	6729
1315314	889	892	SRP	Gene	6729
1315314	326	329	SRP	Gene	6729
1315314	173	176	SRP	Gene	6729
1315314	1300	1308	SR alpha	Gene	4481
1315314	1616	1619	SRP	Gene	6729
1315314	375	378	SRP	Gene	6729
1315314	1256	1258	NH	Chemical	MESH:D000641
1315314	1018	1047	guanylyl-5'- imidodiphosphate	Chemical	MESH:D006165
1315314	1049	1057	Gpp[NH]p	Chemical	MESH:D006165
1315314	1323	1337	Thr 588 to Asn	ProteinMutation	p.T588N
1315314	1393	1396	GTP	Chemical	MESH:D006160

1572896|t|Transforming growth factor-beta stimulates collagen VII expression by cutaneous cells in vitro 
1572896|a|Collagen VII, the major component of cutaneous anchoring fibrils is expressed at a low level by normal human keratinocytes and fibroblasts in vitro. In cocultures of these two cell types, signals from fibroblasts enhance expression of collagen VII by keratinocytes and vice versa. In this study, the effects of a possible mediator of such a stimulation, transforming growth factor-beta (TGF-beta), were investigated. Its effect on the expression and deposition of the highly insoluble collagen VII was assessed in a semiquantitative manner by a newly developed enzyme-linked immunoassay which is based on immunoblotting. In keratinocyte monocultures, 0.5-20 ng/ml of TGF-beta 2 induced a dose-dependent stimulation of collagen VII expression as measured per microgram of DNA. The maximal enhancement was about sevenfold compared to controls. The effect of TGF-beta 2 was observed already after 12 h, with a steady increase at least up to 3 d. As previous studies have implicated, untreated cocultures of keratinocytes and fibroblasts exhibited a higher basic level of collagen VII expression, which could be further stimulated about twofold by TGF-beta 2. Fibroblasts alone synthesized very minor quantities of collagen VII and could be only weakly stimulated by TGF-beta 2. This growth factor seems a specific enhancer of collagen VII since the expression of laminin, collagen IV, as well as total protein was increased to a much lesser extent. Our data suggest that TGF-beta may be an important mediator of epithelial-mesenchymal interactions and may regulate the synthesis of the anchoring fibrils at the skin basement membrane zone. 
1572896	0	31	Transforming growth factor-beta	Gene	7040
1572896	449	480	transforming growth factor-beta	Gene	7040
1572896	482	490	TGF-beta	Gene	7040
1572896	762	772	TGF-beta 2	Gene	7042
1572896	951	961	TGF-beta 2	Gene	7042
1572896	1239	1249	TGF-beta 2	Gene	7042
1572896	1358	1368	TGF-beta 2	Gene	7042
1572896	1563	1571	TGF-beta	Gene	7040
1572896	198	203	human	Species	9606

1315318|t|Expression of beta-nerve growth factor and its receptor in rat seminiferous epithelium: specific function at the onset of meiosis 
1315318|a|beta-Nerve growth factor (NGF) is expressed in spermatogenic cells and has testosterone-downregulated low-affinity receptors on Sertoli cells suggesting a paracrine role in the regulation of spermatogenesis. An analysis of the stage-specific expression of NGF and its low affinity receptor during the cycle of the seminiferous epithelium in the rat revealed NGF mRNA and protein at all stages of the cycle. Tyrosine kinase receptor (trk) mRNA encoding an essential component of the high- affinity NGF receptor was also present at all stages. In contrast, expression of low affinity NGF receptor mRNA was only found in stages VIIcd and VIII of the cycle, the sites of onset of meiosis. The low- affinity NGF receptor protein was present in the plasma membrane of the apical Sertoli cell processes as well as in the basal plasma membrane of these cells at stages VIIcd to XI. NGF was shown to stimulate in vitro DNA synthesis of seminiferous tubule segments with preleptotene spermatocytes at the onset of meiosis while other segments remained nonresponsive. We conclude that NGF is a meiotic growth factor that acts through Sertoli cells. 
1315318	14	38	beta-nerve growth factor	Gene	310738
1315318	59	62	rat	Species	10116
1315318	122	129	meiosis	Disease	MESH:C536875
1315318	130	154	beta-Nerve growth factor	Gene	310738
1315318	156	159	NGF	Gene	310738
1315318	386	389	NGF	Gene	310738
1315318	488	491	NGF	Gene	310738
1315318	537	561	Tyrosine kinase receptor	Gene	59109
1315318	563	566	trk	Gene	59109
1315318	627	639	NGF receptor	Gene	24596
1315318	712	724	NGF receptor	Gene	24596
1315318	833	845	NGF receptor	Gene	24596
1315318	1004	1007	NGF	Gene	310738
1315318	1204	1207	NGF	Gene	310738
1315318	475	478	rat	Species	10116
1315318	205	217	testosterone	Chemical	MESH:D013739

1572893|t|Isolation of a Saccharomyces cerevisiae long chain fatty acyl:CoA synthetase gene (FAA1) and assessment of its role in protein N- myristoylation 
1572893|a|Regulation of myristoylCoA pools in Saccharomyces cerevisiae plays an important role in modulating the activity of myristoylCoA:protein N- myristoyltransferase (NMT), an essential enzyme with an ordered Bi Bi reaction that catalyzes the transfer of myristate from myristoylCoA to greater than or equal to 12 cellular proteins. At least two pathways are available for generating myristoylCoA: de novo synthesis by the multifunctional, multisubunit fatty acid synthetase complex (FAS) and activation of exogenous myristate by acylCoA synthetase. The FAA1 (fatty acid activation) gene has been isolated by genetic complementation of a faal mutant. This single copy gene, which maps to the right arm of chromosome XV, specifies a long chain acylCoA synthetase of 700 amino acids. Analyses of strains containing NMT1 and a faal null mutation indicated that FAA1 is not essential for vegetative growth when an active de novo pathway for fatty acid synthesis is present. The role of FAA1 in cellular lipid metabolism and protein N-myristoylation was therefore assessed in strains subjected to biochemical or genetic blockade of FAS. At 36 degrees C, FAA1 is required for the utilization of exogenous myristate by NMT and for the synthesis of several phospholipid species. This requirement is not apparent at 24 or 30 degrees C, suggesting that S. cerevisiae contains another acylCoA synthetase activity whose chain length and/or temperature optima may differ from Faalp. 
1572893	83	87	FAA1	Gene	854495
1572893	15	39	Saccharomyces cerevisiae	Species	4932
1572893	51	61	fatty acyl	Chemical	MESH:D000214
1572893	127	128	N	Chemical	MESH:D009584
1572893	693	697	FAA1	Gene	854495
1572893	952	956	NMT1	Gene	850892
1572893	997	1001	FAA1	Gene	854495
1572893	1121	1125	FAA1	Gene	854495
1572893	1288	1292	FAA1	Gene	854495
1572893	181	205	Saccharomyces cerevisiae	Species	4932
1572893	1482	1495	S. cerevisiae	Species	4932
1572893	1338	1347	myristate	Chemical	MESH:D009226
1572893	669	676	acylCoA	Chemical	MESH:D000214
1572893	159	171	myristoylCoA	Chemical	MESH:C040349
1572893	394	403	myristate	Chemical	MESH:D009226
1572893	260	272	myristoylCoA	Chemical	MESH:C040349
1572893	1513	1520	acylCoA	Chemical	MESH:D000214
1572893	592	602	fatty acid	Chemical	MESH:D005227
1572893	348	353	Bi Bi	Chemical	MESH:D001729
1572893	882	889	acylCoA	Chemical	MESH:D000214
1572893	1076	1086	fatty acid	Chemical	MESH:D005227
1572893	409	421	myristoylCoA	Chemical	MESH:C040349
1572893	656	665	myristate	Chemical	MESH:D009226
1572893	523	535	myristoylCoA	Chemical	MESH:C040349
1572893	699	709	fatty acid	Chemical	MESH:D005227

1572897|t|Domains of type X collagen: alteration of cartilage matrix by fibril association and proteoglycan accumulation 
1572897|a|During endochondral bone formation, hypertrophic cartilage is replaced by bone or by a marrow cavity. The matrix of hypertrophic cartilage contains at least one tissue-specific component, type X collagen. Structurally type X collagen contains both a collagenous domain and a COOH-terminal non-collagenous one. However, the function(s) of this molecule have remained largely speculative. To examine the behavior and functions of type X collagen within hypertrophic cartilage, we (Chen, Q., E. Gibney, J. M. Fitch, C. Linsenmayer, T. M. Schmid, and T. F. Linsenmayer. 1990. Proc. Natl. Acad. Sci. USA. 87:8046-8050) recently devised an in vitro system in which exogenous type X collagen rapidly (15 min to several hours) moves into non-hypertrophic cartilage. There the molecule becomes associated with preexisting cartilage collagen fibrils. In the present investigation, we find that the isolated collagenous domain of type X collagen is sufficient for its association with fibrils. Furthermore, when non-hypertrophic cartilage is incubated for a longer time (overnight) with "intact" type X collagen, the molecule is found both in the matrix and inside of the chondrocytes. The properties of the matrix of such type X collagen-infiltrated cartilage become altered. Such changes include: (a) antigenic masking of type X collagen by proteoglycans; (b) loss of the permissiveness for further infiltration by type X collagen; and (c) enhanced accumulation of proteoglycans. Some of these changes are dependent on the presence of the COOH-terminal non-collagenous domain of the molecule. In fact, the isolated collagenous domain of type X collagen appears to exert an opposite effect on proteoglycan accumulation, producing a net decrease in their accumulation, particularly of the light form(s) of proteoglycans. Certain of these matrix alterations are similar to ones that have been observed to occur in vivo. This suggests that within hypertrophic cartilage type X collagen has regulatory as well as structural functions, and that these functions are achieved specifically by its two different domains. 
1572897	1116	1138	hypertrophic cartilage	Disease	MESH:D002357
1572897	147	169	hypertrophic cartilage	Disease	MESH:D002357
1572897	1641	1645	COOH	Chemical	MESH:C102887
1572897	2045	2083	hypertrophic cartilage type X collagen	Disease	MESH:C535964
1572897	386	390	COOH	Chemical	MESH:C102887
1572897	227	249	hypertrophic cartilage	Disease	MESH:D002357
1572897	562	584	hypertrophic cartilage	Disease	MESH:D002357
1572897	845	867	hypertrophic cartilage	Disease	MESH:D002357

1533397|t|Suppression of kinesin expression in cultured hippocampal neurons using antisense oligonucleotides 
1533397|a|Kinesin, a microtubule-based force-generating molecule, is thought to translocate organelles along microtubules. To examine the function of kinesin in neurons, we sought to suppress kinesin heavy chain (KHC) expression in cultured hippocampal neurons using antisense oligonucleotides and study the phenotype of these KHC "null" cells. Two different antisense oligonucleotides complementary to the KHC sequence reduced the protein levels of the heavy chain by greater than 95% within 24 h after application and produced identical phenotypes. After inhibition of KHC expression for 24 or 48 h, neurons extended an array of neurites often with one neurite longer than the others; however, the length of all these neurites was significantly reduced. Inhibition of KHC expression also altered the distribution of GAP-43 and synapsin I, two proteins thought to be transported in association with membranous organelles. These proteins, which are normally localized at the tips of growing neurites, were confined to the cell body in antisense-treated cells. Treatment of the cells with the corresponding sense oligonucleotides affected neither the distribution of GAP-43 and synapsin I, nor the length of neurites. A full recovery of neurite length occurred after removal of the antisense oligonucleotides from the medium. These data indicate that KHC plays a role in the anterograde translocation of vesicles containing GAP-43 and synapsin I. A deficiency in vesicle delivery may also explain the inhibition of neurite outgrowth. Despite the inhibition of KHC and the failure of GAP- 43 and synapsin I to move out of the cell body, hippocampal neurons can extend processes and acquire as asymmetric morphology. 
1533397	281	300	kinesin heavy chain	Gene	3799
1533397	302	305	KHC	Gene	3799
1533397	416	419	KHC	Gene	3799
1533397	496	499	KHC	Gene	3799
1533397	660	663	KHC	Gene	3799
1533397	859	862	KHC	Gene	3799
1533397	907	913	GAP-43	Gene	2596
1533397	918	928	synapsin I	Gene	6853
1533397	1255	1261	GAP-43	Gene	2596
1533397	1266	1276	synapsin I	Gene	6853
1533397	1439	1442	KHC	Gene	3799
1533397	1512	1518	GAP-43	Gene	2596
1533397	1523	1533	synapsin I	Gene	6853
1533397	1648	1651	KHC	Gene	3799
1533397	1671	1678	GAP- 43	Gene	2596
1533397	1683	1693	synapsin I	Gene	6853

1315315|t|Misfolding and aggregation of newly synthesized proteins in the endoplasmic reticulum 
1315315|a|As a part of our studies on the folding of glycoproteins in the ER, we analyzed the fate of viral glycoproteins that have misfolded either spontaneously or through inhibition of N-linked glycosylation. Newly synthesized Semliki Forest virus spike glycoproteins E1 and p62 and influenza hemagglutinin were studied in infected and transfected tissue culture cells. Misfolded proteins aggregated in less than 1 min after release from polysomes and aberrant interchain disulfide bonds were formed immediately. When more than one protein was misfolded, mixed aggregates were generated. This indicated that the formation of complexes was nonspecific, random, and not restricted to products from single polysomes. The size of the aggregates varied from small oligomers to complexes of several million daltons. BiP was associated noncovalently with the aggregates and with some of the nonaggregated products. We conclude that aggregation reflects the poor solubility of incompletely folded polypeptide chains. 
1315315	889	892	BiP	Gene	3309
1315315	306	326	Semliki Forest virus	Species	11033
1315315	551	560	disulfide	Chemical	MESH:D004220
1315315	264	265	N	Chemical	MESH:D009584

1374068|t|Slow axonal transport mechanisms move neurofilaments relentlessly in mouse optic axons 
1374068|a|Pulse-labeling studies of slow axonal transport in many kinds of axons (spinal motor, sensory ganglion, oculomotor, hypoglossal, and olfactory) have led to the inference that axonal transport mechanisms move neurofilaments (NFs) unidirectionally as a single continuous kinetic population with a diversity of individual transport rates. One study in mouse optic axons (Nixon, R. A., and K. B. Logvinenko. 1986. J. Cell Biol. 102:647-659) has given rise to the different suggestion that a significant and distinct population of NFs may be entirely stationary within axons. In mouse optic axons, there are relatively few NFs and the NF proteins are more lightly labeled than other slowly transported slow component b (SCb) proteins (which, however, move faster than the NFs); thus, in mouse optic axons, the radiolabel of some of these faster-moving SCb proteins may confuse NF protein analyses that use one dimensional (1-D) SDS-PAGE, which separates proteins by size only. To test this possibility, we used a 2-mm "window" (at 3-5 mm from the posterior of the eye) to compare NF kinetics obtained by 1-D SDS-PAGE and by the higher resolution two- dimensional (2-D) isoelectric focusing/SDS-PAGE, which separates proteins both by their net charge and by their size. We found that 1-D SDS-PAGE is insufficient for definitive NF kinetics in the mouse optic system. By contrast, 2-D SDS-PAGE provides essentially pure NF kinetics, and these indicate that in the NF-poor mouse optic axons, most NFs advance as they do in other, NF-rich axons. In mice, greater than 97% of the radiolabeled NFs were distributed in a unimodal wave that moved at a continuum of rates, between 3.0 and 0.3 mm/d, and less than 0.1% of the NF population traveled at the very slowest rates of less than 0.005 mm/d. These results are inconsistent with the proposal (Nixon and Logvinenko, 1986) that 32% of the transported NFs remain within optic axons in an entirely stationary state. As has been found in other axons, the axonal transport system of mouse optic axons moves NFs and other cytoskeletal elements relentlessly from the cell body to the axon tip. 
1374068	69	74	mouse	Species	10090
1374068	436	441	mouse	Species	10090
1374068	661	666	mouse	Species	10090
1374068	869	874	mouse	Species	10090
1374068	1428	1433	mouse	Species	10090
1374068	1552	1557	mouse	Species	10090
1374068	1627	1631	mice	Species	10090
1374068	2106	2111	mouse	Species	10090
1374068	1272	1275	SDS	Chemical	MESH:C032259
1374068	1369	1372	SDS	Chemical	MESH:C032259
1374068	1190	1193	SDS	Chemical	MESH:C032259
1374068	1010	1013	SDS	Chemical	MESH:C032259
1374068	1461	1468	2-D SDS	Chemical	MESH:C032259

1374067|t|PKC epsilon-related kinase associates with and phosphorylates cytokeratin 8 and 18 
1374067|a|A 40-kD protein kinase C (PKC)epsilon related activity was found to associate with human epithelial specific cytokeratin (CK) polypeptides 8 and 18. The kinase activity coimmunoprecipitated with CK8 and 18 and phosphorylated immunoprecipitates of the CK. Immunoblot analysis of CK8/18 immunoprecipitates using an anti-PKC epsilon specific antibody showed that the 40-kD species, and not native PKC epsilon (90 kD) associated with the cytokeratins. Reconstitution experiments demonstrated that purified CK8 or CK18 associated with a 40-kD tryptic fragment of purified PKC epsilon, or with a similar species obtained from cells that express the fragment constitutively but do not express CK8/18. A peptide pseudosubstrate specific for PKC epsilon inhibited phosphorylation of CK8/18 in intact cells or in a kinase assay with CK8/18 immunoprecipitates. Tryptic peptide map analysis of the cytokeratins that were phosphorylated by purified rat brain PKC epsilon or as immunoprecipitates by the associated kinase showed similar phosphopeptides. Furthermore, PKC epsilon immunoreactive species and CK8/18 colocalized using immunofluorescent double staining. We propose that a kinase related to the catalytic fragment of PKC epsilon physically associates with and phosphorylates cytokeratins 8 and 18. 
1374067	62	75	cytokeratin 8	Gene	3856
1374067	0	11	PKC epsilon	Gene	5581
1374067	109	120	PKC)epsilon	Gene	5581
1374067	278	281	CK8	Gene	3856
1374067	361	364	CK8	Gene	3856
1374067	401	412	PKC epsilon	Gene	5581
1374067	477	488	PKC epsilon	Gene	5581
1374067	585	588	CK8	Gene	3856
1374067	592	596	CK18	Gene	3875
1374067	650	661	PKC epsilon	Gene	5581
1374067	769	772	CK8	Gene	3856
1374067	816	827	PKC epsilon	Gene	5581
1374067	857	863	CK8/18	Gene	3856;3875
1374067	906	909	CK8	Gene	3856
1374067	1136	1147	PKC epsilon	Gene	5581
1374067	1175	1178	CK8	Gene	3856
1374067	1297	1308	PKC epsilon	Gene	5581
1374067	166	171	human	Species	9606
1374067	1019	1022	rat	Species	10116
1374067	1023	1040	brain PKC epsilon	Disease	MESH:C566847

1374066|t|Balbiani ring hnRNP substructure visualized by selective staining and electron spectroscopic imaging 
1374066|a|The Balbiani Rings (BR) in the polytene chromosomes of Chironomus salivary glands are intense sites of transcription. The nascent RNPs fold during transcription into 40-50-nm granules, containing in the mature transcript approximately 37-kb RNA. Using a new nucleic acid specific stain, osmium ammine B on Lowicryl sections, in combination with electron energy filtered imaging of sections containing BR granules, we demonstrate a RNA-rich particulate substructure (10-nm particle diameter; 10-12 particles per BR granule). Elemental imaging supports that these particles are enriched in phosphorus. The possible relationship of these RNA-rich particles to ribonucleosomes is discussed, as well as models for their arrangement in the mature BR granules. 
1374066	14	19	hnRNP	Gene	9987
1374066	689	699	phosphorus	Chemical	MESH:D010758
1374066	388	403	osmium ammine B	Chemical	MESH:C058639

1315317|t|Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8 
1315317|a|In a previous study we observed that neutrophils respond with a rapid rise in [Ca2+]i during adherence to cytokine-activated endothelial cells (EC), caused by EC membrane-associated platelet-activating factor (PAF). In the present study, we investigated whether this form of PAF was important in neutrophil adherence and migration across monolayers of rIL-1 beta- or rTNF alpha-prestimulated EC. PAF receptor antagonists prevented neutrophil migration across cytokine-pretreated EC by approximately 60% (P less than 0.005) without interfering with the process of adherence. The antagonists WEB 2086 and L-652,731 had no effect on neutrophil migration across resting EC induced by formylmethionyl-leucyl-phenylalanine (FMLP). A murine anti-IL-8 antiserum was found to also partially inhibit the neutrophil transmigration across cytokine-activated EC. When the anti-IL-8 antiserum was used in combination with a PAF receptor antagonist, neutrophil migration across cytokine-pretreated monolayers of EC was completely prevented. During transmigration, LAM-1 and CD44 on the neutrophils were down-modulated; both WEB 2086 and anti-IL-8 antiserum partially prevented this down-modulation caused by cytokine- prestimulated EC. Our results indicate that human neutrophils are activated and guided by EC-associated PAF and EC-derived IL-8 during the in vitro diapedesis in between cytokine-stimulated EC. 
1315317	870	874	IL-8	Gene	3576
1315317	995	999	IL-8	Gene	3576
1315317	1180	1185	LAM-1	Gene	6402
1315317	1190	1194	CD44	Gene	960
1315317	1258	1262	IL-8	Gene	3576
1315317	1457	1461	IL-8	Gene	3576
1315317	406	409	PAF	Gene	9768
1315317	1438	1441	PAF	Gene	9768
1315317	341	344	PAF	Gene	9768
1315317	1378	1383	human	Species	9606
1315317	1041	1044	PAF	Gene	9768
1315317	527	530	PAF	Gene	9768
1315317	849	853	FMLP	Chemical	MESH:D009240
1315317	734	743	L-652,731	Chemical	MESH:C047504
1315317	210	214	Ca2+	Chemical	MESH:D002118
1315317	811	847	formylmethionyl-leucyl-phenylalanine	Chemical	MESH:D009240

1349305|t|Expression of unique sets of GPI-linked proteins by different primary neurons in vitro 
1349305|a|We have surveyed the proteins expressed at the surface of different primary neurons as a first step in elucidating how axons regulate their ensheathment by glial cells. We characterized the surface proteins of dorsal root ganglion neurons, superior cervical ganglion neurons, and cerebellar granule cells which are myelinated, ensheathed but unmyelinated, and unensheathed, respectively. We found that the most abundant proteins are common to all three types of neurons. Reproducible differences in the composition of the integral membrane proteins (enriched by partitioning into a Triton X-114 detergent phase) were detected. These differences were most striking when the expression of glycosylphosphatidyl-inositol (GPI)-anchored membrane proteins by these different neurons was compared. Variations in the relative abundance and degree of glycosylation of several well known GPI- anchored proteins, including Thy-1, F3/F11, and the 120-kD form of the neural cell adhesion molecule (N-CAM), and an abundant 60-kD GPI-linked protein were observed. In addition, we have identified several potentially novel GPI-anchored glycoproteins on each class of neurons. These include a protein that is present only on superior cervical ganglion neurons and is 90 kD; an abundant protein of 69 kD that is essentially restricted in its expression to dorsal root ganglion neurons; and proteins of 38 and 31 kD that are expressed only on granule cell neurons. Finally, the relative abundance of the three major isoforms of N-CAM was found to vary significantly between these different primary neurons. These results are the first demonstration that nerve fibers with diverse ensheathment fates differ significantly in the composition of their surface proteins and suggest an important role for GPI-anchored proteins in generating diversity of the neuronal cell surface. 
1349305	29	32	GPI	Chemical	MESH:D007294
1349305	999	1004	Thy-1	Gene	7070
1349305	1041	1070	neural cell adhesion molecule	Gene	4684
1349305	1072	1077	N-CAM	Gene	4684
1349305	1596	1601	N-CAM	Gene	4684
1349305	669	675	Triton	Chemical	MESH:D011092
1349305	774	803	glycosylphosphatidyl-inositol	Chemical	MESH:D007294
1349305	805	808	GPI	Chemical	MESH:D007294
1349305	1194	1197	GPI	Chemical	MESH:D007294
1349305	1867	1870	GPI	Chemical	MESH:D007294
1349305	965	968	GPI	Chemical	MESH:D007294
1349305	1102	1105	GPI	Chemical	MESH:D007294

1572894|t|Intermediates in the constitutive and regulated secretory pathways released in vitro from semi-intact cells 
1572894|a|Regulated secretory cells have two pathways that transport secreted proteins from the Golgi complex to the cell surface. To identify carrier vesicles involved in regulated and constitutive secretion, PC12 pheochromocytoma cells were labeled with [35S]sulfate to identify markers for the two secretory pathways, then mechanically permeabilized and incubated in vitro. Small constitutive secretory vesicles, containing mostly sulfated proteoglycans, accumulated during an in vitro incubation with ATP. In the presence of GTP gamma S, the constitutive vesicles became significantly more dense, suggesting that a coated intermediate was stabilized. Larger immature regulated secretory granules, enriched in sulfated secretogranin II, also escaped from the permeabilized cells in vitro. During granule maturation, their density increased and the amount of cofractionating proteoglycans diminished. The data suggest that sorting continues during secretory granule maturation. 
1572894	820	836	secretogranin II	Gene	24765
1572894	313	329	pheochromocytoma	Disease	MESH:D010673
1572894	354	366	[35S]sulfate	Chemical	MESH:C031512
1572894	627	638	GTP gamma S	Chemical	MESH:D016244
1572894	603	606	ATP	Chemical	MESH:D000255
1572894	308	312	PC12	CellLine	CVCL:0481

1572895|t|Opposite polarity of virus budding and of viral envelope glycoprotein distribution in epithelial cells derived from different tissues 
1572895|a|We compared the surface envelope glycoprotein distribution and the budding polarity of four RNA viruses in Fischer rat thyroid (FRT) cells and in CaCo-2 cells derived from a human colon carcinoma. Whereas both FRT and CaCo-2 cells sort similarly influenza hemagglutinin and vesicular stomatitis virus (VSV) G protein, respectively, to apical and basolateral membrane domains, they differ in their handling of two togaviruses, Sindbis and Semliki Forest virus (SFV). By conventional EM Sindbis virus and SFV were shown to bud apically in FRT cells and basolaterally in CaCo-2 cells. Consistent with this finding, the distribution of the p62/E2 envelope glycoprotein of SFV, assayed by immunoelectronmicroscopy and by domain-selective surface biotinylation was predominantly apical on FRT cells and basolateral on CaCo-2 cells. We conclude that a given virus and its envelope glycoprotein can be delivered to opposite membrane domains in epithelial cells derived from different tissues. The tissue specificity in the polarity of virus budding and viral envelope glycoprotein distribution indicate that the sorting machinery varies considerably between different epithelial cell types. 
1572895	21	26	virus	Species	12081
1572895	230	237	viruses	Species	10239
1572895	249	252	rat	Species	10116
1572895	308	313	human	Species	9606
1572895	572	592	Semliki Forest virus	Species	11033
1572895	594	597	SFV	Species	11033
1572895	619	632	Sindbis virus	Species	11034
1572895	637	640	SFV	Species	11033
1572895	802	805	SFV	Species	11033
1572895	985	990	virus	Species	12081
1572895	1161	1166	virus	Species	12081
1572895	946	952	CaCo-2	CellLine	CVCL:0025
1572895	408	434	vesicular stomatitis virus	Disease	MESH:D054243
1572895	352	358	CaCo-2	CellLine	CVCL:0025
1572895	280	286	CaCo-2	CellLine	CVCL:0025
1572895	436	439	VSV	Disease	MESH:D054243
1572895	314	329	colon carcinoma	Disease	MESH:D015179
1572895	702	708	CaCo-2	CellLine	CVCL:0025

1533398|t|The integrin alpha 6 beta 4 is a laminin receptor 
1533398|a|In this study, the putative laminin receptor function of the alpha 6 beta 4 integrin was assessed. For this purpose, we used a human cell line, referred to as clone A, that was derived from a highly invasive, colon adenocarcinoma. This cell line, which expresses the alpha 6 beta 4 integrin, adheres to the E8 and not to the P1 fragment of laminin. The adhesion of clone A cells to laminin is extremely rapid with half- maximal adhesion observed at 5 min after plating. Adhesion to laminin is blocked by GoH3, and alpha 6 specific antibody (60% inhibition), as well as by A9, a beta 4 specific antibody (30% inhibition). Most importantly, we demonstrate that alpha 6 beta 4 binds specifically to laminin-Sepharose columns in the presence of either Mg2+ or Mn2+ and it is eluted from these columns with EDTA but not with NaCl. The alpha 6 beta 4 integrin does not bind to collagen-Sepharose, but the alpha 2 beta 1 integrin does bind. Clone A cells do not express alpha 6 beta 1 as evidenced by the following observations: (a) no beta 1 integrin is detected in beta 1 immunoblots of GoH3 immunoprecipitates; and (b) no alpha 6 beta 1 integrin is seen in GoH3 immunoprecipitates of clone A extracts that had been immunodepleted of all beta 4 containing integrin using the A9 antibody. These data establish that laminin is a ligand for the alpha 6 beta 4 integrin and that this integrin can function as a laminin receptor independently of alpha 6 beta 1. 
1533398	1079	1094	beta 1 integrin	Gene	3688
1533398	177	182	human	Species	9606
1533398	1176	1191	beta 1 integrin	Gene	3688
1533398	957	972	beta 1 integrin	Gene	3688
1533398	259	279	colon adenocarcinoma	Disease	MESH:D015179
1533398	806	810	Mn2+	Chemical	MESH:D008345
1533398	798	802	Mg2+	Chemical	MESH:D008274
1533398	852	856	EDTA	Chemical	MESH:D004492
1533398	870	874	NaCl	Chemical	MESH:D012965

1315316|t|A multisubunit particle implicated in membrane fusion 
1315316|a|The N-ethylmaleimide sensitive fusion protein (NSF) is required for fusion of lipid bilayers at many locations within eukaryotic cells. Binding of NSF to Golgi membranes is known to require an integral membrane receptor and one or more members of a family of related soluble NSF attachment proteins (alpha-, beta-, and gamma-SNAPs). Here we demonstrate the direct interaction of NSF, SNAPs and an integral membrane component in a detergent solubilized system. We show that NSF only binds to SNAPs in the presence of the integral receptor, resulting in the formation of a multisubunit protein complex with a sedimentation coefficient of 20S. Particle assembly reveals striking differences between members of the SNAP protein family; gamma-SNAP associates with the complex via a binding site distinct from that used by alpha- and beta-SNAPs, which are themselves equivalent, alternative subunits of the particle. Once formed, the 20S particle is subsequently able to disassemble in a process coupled to the hydrolysis of ATP. We suggest how cycles of complex assembly and disassembly could help confer specificity to the generalized NSF-dependent fusion apparatus. 
1315316	58	99	N-ethylmaleimide sensitive fusion protein	Gene	4905
1315316	101	104	NSF	Gene	4905
1315316	201	204	NSF	Gene	4905
1315316	433	436	NSF	Gene	4905
1315316	527	530	NSF	Gene	4905
1315316	1185	1188	NSF	Gene	4905
1315316	329	352	NSF attachment proteins	Disease	MESH:D058495
1315316	1073	1076	ATP	Chemical	MESH:D000255

1533396|t|Structural and functional reconstitution of inner dynein arms in Chlamydomonas flagellar axonemes 
1533396|a|The inner row of dynein arms contains three dynein subforms. Each is distinct in composition and location in flagellar axonemes. To begin investigating the specificity of inner dynein arm assembly, we assessed the capability of isolated inner arm dynein subforms to rebind to their appropriate positions on axonemal doublet microtubules by recombining them with either mutant or extracted axonemes missing some or all dyneins. Densitometry of Coomassie blue-stained polyacrylamide gels revealed that for each inner dynein arm subform, binding to axonemes was saturable and stoichiometric. Using structural markers of position and polarity, electron microscopy confirmed that subforms bound to the correct inner arm position. Inner arms did not bind to outer arm or inappropriate inner arm positions despite the availability of sites. These and previous observations implicate specialized tubulin isoforms or nontubulin proteins in designation of specific inner dynein arm binding sites. Further, microtubule sliding velocities were restored to dynein-depleted axonemes upon rebinding of the missing inner arm subtypes as evaluated by an ATP-induced microtubule sliding disintegration assay. Therefore, not only were the inner arm dynein subforms able to identify and bind to the correct location on doublet microtubules but they bound in a functionally active conformation. 
1533396	65	78	Chlamydomonas	Species	3052
1533396	1235	1238	ATP	Chemical	MESH:D000255
1533396	564	578	polyacrylamide	Chemical	MESH:C040388
1533396	1158	1166	axonemes	Chemical	

1572892|t|A conserved phosphoprotein that specifically binds nuclear localization sequences is involved in nuclear import [published erratum appears in J Cell Biol 1992 Jul;118(1):215] 
1572892|a|We have purified proteins of 70 kD from Drosophila, HeLa cells, and Z. mays that specifically bind nuclear localization sequences (NLSs). These proteins are recognized by antibodies raised against a previously identified NLS-binding protein (NBP) from the yeast S. cerevisiae. All NBPs are associated with nuclei and also present in the cytosol. NBPs are phosphorylated and phosphatase treatment abolished NLS binding. The requirement for NBPs in nuclear protein uptake is demonstrated in semipermeabilized Drosophila melanogaster tissue culture cells. Proper import of a fluorescent protein containing the large T antigen NLS requires cytosol and ATP. In the absence of cytosol and/or ATP, NLS- containing proteins are bound to cytosolic structures and the nuclear envelope. Addition of cytosol and ATP results in movement of this bound intermediate into the nucleus. Anti-NBP antibodies specifically inhibited the binding part of this import reaction. These results indicate that a phosphoprotein common to several eukaryotes acts as a receptor that recognizes NLSs before their uptake into the nucleus. 
1572892	243	250	Z. mays	Species	4577
1572892	431	436	yeast	Species	4932
1572892	437	450	S. cerevisiae	Species	4932
1572892	682	705	Drosophila melanogaster	Species	7227
1572892	823	826	ATP	Chemical	MESH:D000255
1572892	1049	1052	NBP	Chemical	MESH:C540573
1572892	975	978	ATP	Chemical	MESH:D000255
1572892	215	225	Drosophila	Disease	
1572892	861	864	ATP	Chemical	MESH:D000255

1315319|t|H36-alpha 7 is a novel integrin alpha chain that is developmentally regulated during skeletal myogenesis [published erratum appears in J Cell Biol 1992 Jul;118(1):213] 
1315319|a|H36 is a 120,000-D membrane glycoprotein that is expressed during the differentiation of skeletal muscle. H36 cDNA clones were isolated from a lambda UniZapXR rat myotube cDNA library and sequenced. The deduced amino acid sequence demonstrates that H36 is a novel integrin alpha chain that shares extensive homology with other alpha integrins that includes: (a) the GFFKR sequence found in all alpha integrins; (b) a single membrane spanning region; (c) conservation of 18 of 22 cysteines; and (d) a protease cleavage site found in the non-I region integrin alpha chains. The cytoplasmic domain of H36 is unique and additional regions of nonhomology further indicate H36 is distinct from all other alpha chains. In keeping with current nomenclature we designate this alpha chain alpha 7. Northern blots demonstrate that expression of H36-alpha 7 mRNA is regulated both early in the development of the myogenic lineage and later, during terminal differentiation. Detection of H36-alpha 7 mRNA coincides with conversion of H36- myogenic precursor cells to H36+ cells. H36-alpha 7 mRNA is present in replicating myoblasts: expression increases upon terminal differentiation and is markedly reduced in developmentally defective myoblasts. In addition, H36-alpha 7 mRNA is not detected in C3H10T1/2 cells. It is in myotubes derived from myoblasts obtained by treatment of 10T1/2 cells with azacytidine or transfection with MRF4. Immunoblots and immunofluorescence demonstrate that the H36-alpha 7 chain is associated with integrin beta 1. Affinity chromatography demonstrates that H36-alpha 7 beta 1 selectively binds to laminin. The expression of H36-alpha 7 on secondary myoblasts during the development of the limb in vivo corresponds with the appearance of laminin in the limb, with the responsiveness of secondary myoblast proliferation to laminin, and with the onset of increased muscle mass, suggesting that H36-alpha 7 modulates this stage in limb development. We conclude that H36-alpha 7 is a novel alpha integrin laminin binding protein whose expression is developmentally regulated during skeletal myogenesis. 
1315319	0	11	H36-alpha 7	Gene	81008
1315319	1002	1013	H36-alpha 7	Gene	81008
1315319	1143	1154	H36-alpha 7	Gene	81008
1315319	1234	1245	H36-alpha 7	Gene	81008
1315319	1416	1427	H36-alpha 7	Gene	81008
1315319	1648	1659	H36-alpha 7	Gene	81008
1315319	1685	1700	integrin beta 1	Gene	24511
1315319	1811	1822	H36-alpha 7	Gene	81008
1315319	2078	2089	H36-alpha 7	Gene	81008
1315319	2149	2160	H36-alpha 7	Gene	81008
1315319	327	330	rat	Species	10116
1315319	1452	1461	C3H10T1/2	Species	10090
1315319	1744	1755	H36-alpha 7	Gene	81008
1315319	647	656	cysteines	Chemical	MESH:D003545
1315319	1553	1564	azacytidine	Chemical	MESH:D001374

1374413|t|The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide 
1374413|a|The selectins (lectin-EGF-complement binding-cell adhesion molecules [LEC-CAMs]) are a family of mammalian receptors implicated in the initial interactions between leukocytes and vascular endothelia, leading to lymphocyte homing, platelet binding, and neutrophil extravasation. The three known selectins, L-selectin (leukocyte adhesion molecule-1 [LECAM-1]), E-selectin (endothelial-leukocyte adhesion molecule-1 [ELAM-1]), and P-selectin (GMP-140) share structural features that include a calcium-dependent lectin domain. The sialyl Lewis(x) carbohydrate epitope has been reported as a ligand for both E- and P-selectins. Although L-selectin has been demonstrated to bind to carbohydrates, structural features of potential mammalian carbohydrate ligand(s) have not been well defined. Using an ELISA developed with a sialyl Lewis(x)-containing glycolipid and an E- selectin-IgG chimera, we have demonstrated the direct binding of the L- selectin-IgG chimera to sialyl Lewis(x). This recognition was calcium dependent, and could be blocked by Mel-14 antibody but not by other antibodies. Recognition was confirmed by the ability of cells expressing the native L-selectin to adhere to immobilized sialyl Lewis(x). These data suggest that the sialyl Lewis(x) oligosaccharide may form the basis of a recognition domain common to all three selectins. 
1374413	69	81	carbohydrate	Chemical	MESH:D002241
1374413	432	442	L-selectin	Gene	6402
1374413	444	473	leukocyte adhesion molecule-1	Gene	6402
1374413	475	482	LECAM-1	Gene	6402
1374413	486	496	E-selectin	Gene	6401
1374413	498	539	endothelial-leukocyte adhesion molecule-1	Gene	6401
1374413	541	547	ELAM-1	Gene	6401
1374413	555	565	P-selectin	Gene	6403
1374413	567	574	GMP-140	Gene	6403
1374413	759	769	L-selectin	Gene	6402
1374413	1061	1072	L- selectin	Gene	6402
1374413	1286	1296	L-selectin	Gene	6402
1374413	224	233	mammalian	Species	9606
1374413	851	860	mammalian	Species	9606
1374413	1126	1133	calcium	Chemical	MESH:D002118
1374413	861	873	carbohydrate	Chemical	MESH:D002241
1374413	803	816	carbohydrates	Chemical	MESH:D002241
1374413	617	624	calcium	Chemical	MESH:D002118
1374413	670	682	carbohydrate	Chemical	MESH:D002241

1577862|t|Neurolin, a cell surface glycoprotein on growing retinal axons in the goldfish visual system, is reexpressed during retinal axonal regeneration 
1577862|a|The mAb E 21 recognizes a cell surface glycoprotein selectively associated with fish retinal ganglion cell axons that are in a state of growth. All retinal axons and ganglion cells in goldfish embryos stained for E 21. In adult fish, however, E 21 immunoreactivity exhibited a patterned distribution in ganglion cells in the marginal growth zone of the continuously enlarging fish retina and the new axons emerging from these cells in the retina, optic nerve, and optic tract. The E 21 antigen was absent from older axons, except the terminal arbor layer in the tectum, the Stratum fibrosum et griseum superficiale where it was uniformly distributed. Upon optic nerve transection, the previously unlabeled axons reacquired E 21 positivity as they regenerated throughout their path to the tectum. Several months after ONS, however, E 21 staining disappeared from the regenerated axons over most of their lengths but reappeared as in normal fish in the terminal arbor layer. The immunoaffinity-purified E 21 antigen, called Neurolin, has an apparent molecular mass of 86 kD and contains the HNK1/L2 carbohydrate moiety, like several members of the class of cell adhesion molecules of the Ig superfamily. The NH2-terminal amino acid sequence has homologies to the cell adhesion molecule DM-Grasp recently described in the chicken. Thus, retinal ganglion cell axons express Neurolin during their development and are able to reexpress this candidate cell adhesion molecule during axonal regeneration, suggesting that Neurolin is functionally important for fish retinal axon growth. 
1577862	0	8	Neurolin	Gene	30194
1577862	70	78	goldfish	Species	7957
1577862	1166	1174	Neurolin	Gene	30194
1577862	1428	1436	DM-Grasp	Gene	396092
1577862	1514	1522	Neurolin	Gene	30194
1577862	1656	1664	Neurolin	Gene	30194
1577862	328	336	goldfish	Species	7957
1577862	337	344	embryos	Species	6239
1577862	1463	1470	chicken	Species	9031
1577862	1241	1253	carbohydrate	Chemical	MESH:D002241
1577862	1350	1353	NH2	Chemical	MESH:D000641

1577854|t|Transendothelial transport of serum albumin: a quantitative immunocytochemical study 
1577854|a|The steady-state distribution of endogenous albumin in mouse diaphragm was determined by quantitative postembedding protein A-gold immunocytochemistry using a specific anti-mouse albumin antibody. Labeling density was recorded over vascular lumen, endothelium, junctions, and subendothelial space. At equilibrium, the volume density of interstitial albumin was 18% of that in circulation. Despite this large difference in albumin concentration between capillary lumen and interstitium, plasmalemmal vesicles labeling was uniformly distributed across the endothelial profile. 68% of the junctions displayed labeling for albumin, which was however low and confined to the luminal and abluminal sides. The scarce labeling of the endothelial cell surface did not confirm the fiber matrix theory. The kinetics of albumin transcytosis was evaluated by injecting radioiodinated and DNP-tagged BSA. At 3, 10, 30, and 60 min, and 3, 5, and 24 h circulation time, blood radioactivity was measured and diaphragms were fixed and embedded. Anti-DNP antibodies were used to map the tracer in aforementioned compartments. A linear relationship between blood radioactivity and vascular labeling density was found, with a detection sensitivity approaching 1 gold particle per DNP-BSA molecule. Tracer presence over endothelial vesicles reached rapidly (10 min) a saturation value; initially localized near the luminal front, it evolved towards a uniform distribution across endothelium during the first hour. An hour was also needed to reach the saturation limit within the subendothelial space. Labeling of the junctions increased slowly, out of phase with the inferred transendothelial albumin fluxes. This suggests that they play little, if any, role in albumin transcytosis, which rather seems to proceed through the vesicular way. 
1577854	140	145	mouse	Species	10090
1577854	941	955	radioiodinated	Chemical	MESH:C418805

1577853|t|The efficient intracellular sequestration of the insulin-regulatable glucose transporter (GLUT-4) is conferred by the NH2 terminus 
1577853|a|GLUT-4 is the major facilitative glucose transporter isoform in tissues that exhibit insulin-stimulated glucose transport. Insulin regulates glucose transport by the rapid translocation of GLUT-4 from an intracellular compartment to the plasma membrane. A critical feature of this process is the efficient exclusion of GLUT-4 from the plasma membrane in the absence of insulin. To identify the amino acid domains of GLUT-4 which confer intracellular sequestration, we analyzed the subcellular distribution of chimeric glucose transporters comprised of GLUT-4 and a homologous isoform, GLUT-1, which is found predominantly at the cell surface. These chimeric transporters were transiently expressed in CHO cells using a double subgenomic recombinant Sindbis virus vector. We have found that wild-type GLUT-4 is targeted to an intracellular compartment in CHO cells which is morphologically similar to that observed in adipocytes and muscle cells. Sindbis virus-produced GLUT-1 was predominantly expressed at the cell surface. Substitution of the GLUT-4 amino-terminal region with that of GLUT-1 abolished the efficient intracellular sequestration of GLUT-4. Conversely, substitution of the NH2 terminus of GLUT-1 with that of GLUT-4 resulted in marked intracellular sequestration of GLUT-1. These data indicate that the NH2-terminus of GLUT-4 is both necessary and sufficient for intracellular sequestration. 
1577853	90	96	GLUT-4	Gene	6517
1577853	49	56	insulin	Gene	3630
1577853	118	121	NH2	Chemical	MESH:D000641
1577853	69	76	glucose	Chemical	MESH:D005947
1577853	131	137	GLUT-4	Gene	6517
1577853	320	326	GLUT-4	Gene	6517
1577853	450	456	GLUT-4	Gene	6517
1577853	500	507	insulin	Gene	3630
1577853	547	553	GLUT-4	Gene	6517
1577853	683	689	GLUT-4	Gene	6517
1577853	716	722	GLUT-1	Gene	6513
1577853	931	937	GLUT-4	Gene	6517
1577853	1100	1106	GLUT-1	Gene	6513
1577853	1176	1182	GLUT-4	Gene	6517
1577853	1218	1224	GLUT-1	Gene	6513
1577853	1280	1286	GLUT-4	Gene	6517
1577853	1336	1342	GLUT-1	Gene	6513
1577853	1356	1362	GLUT-4	Gene	6517
1577853	1413	1419	GLUT-1	Gene	6513
1577853	1466	1472	GLUT-4	Gene	6517
1577853	254	261	Insulin	Gene	3630
1577853	880	893	Sindbis virus	Species	11034
1577853	1077	1090	Sindbis virus	Species	11034
1577853	216	223	insulin	Gene	3630
1577853	164	171	glucose	Chemical	MESH:D005947
1577853	649	656	glucose	Chemical	MESH:D005947
1577853	1320	1323	NH2	Chemical	MESH:D000641
1577853	985	988	CHO	CellLine	CVCL:0213
1577853	272	279	glucose	Chemical	MESH:D005947
1577853	1183	1188	amino	Chemical	MESH:D000596
1577853	832	835	CHO	CellLine	CVCL:0213
1577853	1450	1453	NH2	Chemical	MESH:D000641
1577853	235	242	glucose	Chemical	MESH:D005947

1577855|t|Neutrophil migration across a cultured epithelial monolayer elicits a biphasic resistance response representing sequential effects on transcellular and paracellular pathways 
1577855|a|Migration of polymorphonuclear leukocytes across epithelia is a hallmark of many inflammatory disease states. Neutrophils traverse epithelia by migrating through the paracellular space and crossing intercellular tight junctions. We have previously shown (Nash, S., J. Stafford, and J.L. Madara. 1987. J. Clin. Invest. 80:1104-1113), that leukocyte migration across T84 monolayers, a model human intestinal epithelium, results in enhanced tight junction permeability--an effect quantitated by the use of a simple, standard electrical assay of transepithelial resistance. Here we show that detailed time course studies of the transmigration-elicited decline in resistance has two components, one of which is unrelated to junctional permeability. The initial decrease in resistance, maximal 5-13 min after initiation of transmigration, occurs despite inhibition of transmigration by an antibody to the common beta subunit of neutrophil beta 2 integrins, and is paralleled by an increase in transepithelial short-circuit current. Chloride ion substitution and inhibitor studies indicate that the early- phase resistance decline is not attributable to an increase in tight junction permeability but is due to decreased resistance across epithelial cells resulting from chloride secretion. Since T84 cells are accepted models for studies of the regulation of Cl- and water secretion, our results suggest that neutrophil transmigration across mucosal surfaces (for example, respiratory and intestinal tracts) may initially activate flushing of the surface by salt and water. Equally important, these studies, by providing a concrete example of sequential transcellular and paracellular effects on transepithelial resistance, highlight the fact that this widely used assay cannot simply be viewed as a direct functional probe of tight junction permeability. 
1577855	563	568	human	Species	9606
1577855	1438	1446	chloride	Chemical	MESH:D002712
1577855	1200	1208	Chloride	Chemical	MESH:D002712

1577852|t|Expression of individual forms of peptidylglycine alpha-amidating monooxygenase in AtT-20 cells: endoproteolytic processing and routing to secretory granules 
1577852|a|Peptidylglycine alpha-amidating monooxygenase (PAM: EC 1.14.17.3) is a bifunctional protein which catalyzes the COOH-terminal amidation of bioactive peptides; the NH2-terminal monooxygenase and mid-region lyase act in sequence to perform the peptide alpha-amidation reaction. Alternative splicing of the single PAM gene gives rise to mRNAs generating PAM proteins with and without a putative transmembrane domain, with and without a linker region between the two enzymes, and forms containing only the monooxygenase domain. The expression, endoproteolytic processing, storage, and secretion of this secretory granule-associated protein were examined after stable transfection of AtT-20 mouse pituitary cells with naturally occurring and truncated PAM proteins. The transfected proteins were examined using enzyme assays, subcellular fractionation, Western blotting, and immunocytochemistry. Western blots of crude membrane and soluble fractions of transfected cells demonstrated that all PAM proteins were endoproteolytically processed. When the linker region was present between the monooxygenase and lyase domains, monofunctional soluble enzymes were generated from bifunctional PAM proteins; without the linker region, bifunctional enzymes were generated. Soluble forms of PAM expressed in AtT-20 cells and soluble proteins generated through selective endoproteolysis of membrane-associated PAM were secreted in an active form into the medium; secretion of the transfected proteins and endogenous hormone were stimulated in parallel by secretagogues. PAM proteins were localized by immunocytochemistry in the perinuclear region near the Golgi apparatus and in secretory granules, with the greatest intensity of staining in the perinuclear region in cell lines expressing integral membrane forms of PAM. Monofunctional and bifunctional PAM proteins that were soluble or membrane-associated were all packaged into regulated secretory granules in AtT-20 cells. 
1577852	83	89	AtT-20	Species	10090
1577852	469	472	PAM	Gene	18484
1577852	905	908	PAM	Gene	18484
1577852	1146	1149	PAM	Gene	18484
1577852	1339	1342	PAM	Gene	18484
1577852	1434	1437	PAM	Gene	18484
1577852	1959	1962	PAM	Gene	18484
1577852	844	849	mouse	Species	10090
1577852	837	843	AtT-20	Species	10090
1577852	1451	1457	AtT-20	Species	10090
1577852	2105	2111	AtT-20	Species	10090
1577852	1996	1999	PAM	Gene	18484
1577852	1712	1715	PAM	Gene	18484
1577852	1552	1555	PAM	Gene	18484
1577852	509	512	PAM	Gene	18484
1577852	205	208	PAM	Gene	18484
1577852	270	274	COOH	Chemical	MESH:C102887
1577852	321	324	NH2	Chemical	MESH:D000641

1577861|t|Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons 
1577861|a|In mature neurons synaptic vesicles (SVs) undergo cycles of exo- endocytosis at synapses. It is currently unknown whether SV exocytosis and recycling occurs also in developing axons prior to synapse formation. To address this question, we have developed an immunocytochemical assay to reveal SV exo-endocytosis in hippocampal neurons developing in culture. In this assay antibodies directed against the lumenal domain of synaptotagmin I (Syt I), an intrinsic membrane protein of SVs, are used to reveal exposure of SV membranes at the cell surface. Addition of antibodies to the culture medium of living neurons for 1 hr at 37 degrees C resulted in their rapid and specific internalization by all neuronal processes and, particularly, by axons. Double immunofluorescence and electron microscopy immunocytochemistry indicated that the antibodies were retained within SVs in cell processes and underwent cycles of exo-endocytosis in parallel with SV membranes. In contrast, another endocytotic marker, wheat germ agglutinin, was rapidly cleared from the processes and transported to the cell body. Antibody-labeled SVs were still present in axons several days after antibody loading and became clustered at presynaptic sites in parallel with synaptogenesis. These results demonstrate that SVs undergo multiple cycles of exo-endocytosis in developing neuronal processes irrespective of the presence of synaptic contacts. 
1577861	1103	1108	wheat	Species	4565
1577861	225	238	SV exocytosis	Disease	

1577858|t|Transfection of nonmuscle beta- and gamma-actin genes into myoblasts elicits different feedback regulatory responses from endogenous actin genes 
1577858|a|We have examined the role of feedback-regulation in the expression of the nonmuscle actin genes. C2 mouse myoblasts were transfected with the human beta- and gamma-actin genes. In gamma-actin transfectants we found that the total actin mRNA and protein pools remained unchanged. Increasing levels of human gamma-actin expression resulted in a progressive down-regulation of mouse beta- and gamma-actin mRNAs. Transfection of the beta-actin gene resulted in an increase in the total actin mRNA and protein pools and induced an increase in the levels of mouse beta-actin mRNA. In contrast, transfection of a beta- actin gene carrying a single-point mutation (beta sm) produced a feedback-regulatory response similar to that of the gamma-actin gene. Expression of a beta-actin gene encoding an unstable actin protein had no impact on the endogenous mouse actin genes. This suggests that the nature of the encoded actin protein determines the feedback-regulatory response of the mouse genes. The role of the actin cytoskeleton in mediating this feedback-regulation was evaluated by disruption of the actin network with Cytochalasin D. We found that treatment with Cytochalasin D abolished the down-regulation of mouse gamma-actin in both the gamma- and beta sm-actin transfectants. In contrast, a similar level of increase was observed for the mouse beta-actin mRNA in both control and transfected cells. These experiments suggest that the down- regulation of mouse gamma-actin mRNA is dependent on the organization of the actin cytoskeleton. In addition, the mechanism responsible for the down-regulation of beta-actin may be distinct from that governing gamma-actin. We conclude that actin feedback-regulation provides a biochemical assay for differences between the two nonmuscle actin genes. 
1577858	36	47	gamma-actin	Gene	11465
1577858	293	314	beta- and gamma-actin	Gene	728378
1577858	451	462	gamma-actin	Gene	11465
1577858	525	546	beta- and gamma-actin	Gene	11461;11465
1577858	574	584	beta-actin	Gene	11461
1577858	703	713	beta-actin	Gene	11461
1577858	751	762	beta- actin	Gene	11461
1577858	874	885	gamma-actin	Gene	11465
1577858	908	918	beta-actin	Gene	11461
1577858	1359	1370	gamma-actin	Gene	11465
1577858	1491	1501	beta-actin	Gene	11461
1577858	1607	1618	gamma-actin	Gene	11465
1577858	1750	1760	beta-actin	Gene	11461
1577858	1797	1808	gamma-actin	Gene	11465
1577858	245	250	mouse	Species	10090
1577858	287	292	human	Species	9606
1577858	445	450	human	Species	9606
1577858	519	524	mouse	Species	10090
1577858	697	702	mouse	Species	10090
1577858	991	996	mouse	Species	10090
1577858	1120	1125	mouse	Species	10090
1577858	1353	1358	mouse	Species	10090
1577858	1485	1490	mouse	Species	10090
1577858	1601	1606	mouse	Species	10090
1577858	325	336	gamma-actin	Gene	11465

1349609|t|Expression of SV-40 T antigen in the small intestinal epithelium of transgenic mice results in proliferative changes in the crypt and reentry of villus-associated enterocytes into the cell cycle but has no apparent effect on cellular differentiation programs and does not cause neoplastic transformation 
1349609|a|The mouse intestinal epithelium represents a unique mammalian system for examining the relationship between cell division, commitment, and differentiation. Proliferation and differentiation are rapid, perpetual, and spatially well-organized processes that occur along the crypt-to-villus axis and involve clearly defined cell lineages derived from a common multipotent stem cell located near the base of each crypt. Nucleotides -1178 to +28 of the rat intestinal fatty acid binding protein gene were used to establish three pedigrees of transgenic mice that expressed SV-40 large T antigen (TAg) in epithelial cells situated in the uppermost portion of small intestinal crypts and in already committed, differentiating enterocytes as they exited these crypts and migrated up the villus. T antigen production was associated with increases in crypt cell proliferation but had no apparent effect on commitment to differentiate along enterocytic, enteroendocrine, or Paneth cell lineages. Single- and multilabel- immunocytochemical studies plus RNA blot hybridization analyses suggested that the differentiation programs of these lineages were similar in transgenic mice and their normal littermates. This included enterocytes which, based on the pattern of [3H]thymidine and 5-bromo-2'- deoxyuridine labeling and proliferating nuclear antigen expression, had reentered the cell cycle during their migration up the villus. The state of cellular differentiation and/or TAg production appeared to affect the nature of the cell cycle; analysis of the ratio of S-phase to M-phase cells (collected by metaphase arrest with vincristine) and of the intensities of labeling of nuclei by [3H]thymidine indicated that the duration of S phase was longer in differentiating, villus- associated enterocytes than in the less well-differentiated crypt epithelial cell population and that there may be a block at the G2/M boundary. Sustained increases in crypt and villus epithelial cell proliferation over a 9-mo period were not associated with the development of gut neoplasms--suggesting that tumorigenesis in the intestine may require that the initiated cell have many of the properties of the gut stem cell including functional anchorage. 
1349609	68	83	transgenic mice	Species	10090
1349609	278	303	neoplastic transformation	Disease	MESH:D002471
1349609	308	313	mouse	Species	10090
1349609	356	365	mammalian	Species	9606
1349609	752	755	rat	Species	10116
1349609	841	856	transgenic mice	Species	10090
1349609	1455	1470	transgenic mice	Species	10090
1349609	1488	1499	littermates	Species	10090
1349609	1918	1929	vincristine	Chemical	MESH:D014750
1349609	1576	1600	5-bromo-2'- deoxyuridine	Chemical	MESH:D001973
1349609	1979	1992	[3H]thymidine	Chemical	MESH:D013936
1349609	1558	1571	[3H]thymidine	Chemical	MESH:D013936

1577857|t|High level expression of transfected beta- and gamma-actin genes differentially impacts on myoblast cytoarchitecture 
1577857|a|The impact of the human beta- and gamma-actin genes on myoblast cytoarchitecture was examined by their stable transfection into mouse C2 myoblasts. Transfectant C2 clones expressing high levels of human beta-actin displayed increases in cell surface area. In contrast, C2 clones with high levels of human gamma-actin expression showed decreases in cell surface area. The changes in cell morphology were accompanied by changes in actin stress-fiber organization. The beta- actin transfectants displayed well-defined filamentous organization of actin; whereas the gamma-actin transfectants displayed a more diffuse organization of the actin cables. The role of the beta-actin protein in generating the enlarged cell phenotype was examined by transfecting a mutant form of the human beta-actin gene. Transfectant cells were shown to incorporate the aberrant actin protein into stress-fiber-like structures. High level expression of the mutant beta-actin produced decreases in cell surface area and disruption of the actin microfilament network similar to that seen with transfection of the gamma-actin gene. In contrast, transfection of another mutant form of the beta-actin gene which encodes an unstable protein had no impact on cell morphology or cytoarchitecture. These results strongly suggest that it is the nature of the encoded protein that determines the morphological response of the cell. We conclude that the relative gene expression of beta- and gamma-actin is of relevance to the control of myoblast cytoarchitecture. In particular, we conclude that the beta- and gamma-actin genes encode functionally distinct cytoarchitectural information. 
1577857	37	58	beta- and gamma-actin	Gene	728378
1577857	141	162	beta- and gamma-actin	Gene	728378
1577857	320	330	beta-actin	Gene	728378
1577857	780	790	beta-actin	Gene	728378
1577857	897	907	beta-actin	Gene	728378
1577857	1057	1067	beta-actin	Gene	728378
1577857	1278	1288	beta-actin	Gene	728378
1577857	1563	1584	beta- and gamma-actin	Gene	728378
1577857	1682	1703	beta- and gamma-actin	Gene	728378
1577857	135	140	human	Species	9606
1577857	245	250	mouse	Species	10090
1577857	314	319	human	Species	9606
1577857	416	421	human	Species	9606
1577857	891	896	human	Species	9606

1315783|t|Expression of a human hepatocyte growth factor/scatter factor cDNA in MDCK epithelial cells influences cell morphology, motility, and anchorage-independent growth 
1315783|a|The addition of exogenous hepatocyte growth factor (HGF)/scatter factor (SF) to MDCK epithelial cells results in fibroblastic morphology and cell motility. We generated HGF/SF producing MDCK cells by transfection with an expression plasmid containing human HGF/SF cDNA. Production of HGF/SF by these cells induced a change from an epithelial to a fibroblastic morphology and increased cell motility. In addition, the HGF/SF producing cells acquired efficient anchorage-independent growth in soft agar but did not form tumors in nude mice. The morphological change and the stimulation of the anchorage-independent growth were prevented by anti-HGF/SF antibody, suggesting that the factor is secreted and then exerts its effects through cell surface receptors. 
1315783	16	21	human	Species	9606
1315783	332	338	HGF/SF	Gene	15234
1315783	420	426	HGF/SF	Gene	15234
1315783	447	453	HGF/SF	Gene	15234
1315783	580	586	HGF/SF	Gene	15234
1315783	806	812	HGF/SF	Gene	15234
1315783	414	419	human	Species	9606
1315783	691	700	nude mice	Species	10090
1315783	681	687	tumors	Disease	MESH:D009369

1577860|t|BiP forms stable complexes with unassembled subunits of the acetylcholine receptor in transfected COS cells and in C2 muscle cells 
1577860|a|We have investigated the role of the immunoglobulin-binding protein (BiP) in the folding and assembly of subunits of the acetylcholine receptor (AChR) in COS cells and in C2 muscle cells. Immunoprecipitation in COS cells showed that alpha, beta, and delta subunits are associated with BiP. In the case of the alpha subunit, which first folds to acquire toxin-binding activity and is then assembled with the other subunits to form the AChR, BiP was associated only with a form that is unassembled and does not bind alpha- bungarotoxin. Similar results were found in C2 cells. Although the alpha and beta subunits of the AChR are minor membrane proteins in C2 cells, they were prominent among the proteins immunoprecipitated by antibodies to BiP, suggesting that BiP could play a role in their maturation or folding. In pulse-chase experiments in C2 cells, however, labeled alpha subunit formed a stable complex with BiP that was first detected after most of the alpha subunit had acquired toxin-binding activity and whose amount continued to increase for several hours. These kinetics are not compatible with a role for the BiP complex in the folding or assembly pathway of the AChR, and suggest that BiP is associated with a misfolded form of the subunit that is slowly degraded. 
1577860	0	3	BiP	Gene	3309
1577860	115	117	C2	CellLine	CVCL:0529
1577860	98	101	COS	CellLine	CVCL:0222
1577860	60	73	acetylcholine	Chemical	MESH:D000109
1577860	168	198	immunoglobulin-binding protein	Gene	3309
1577860	200	203	BiP	Gene	3309
1577860	416	419	BiP	Gene	3309
1577860	571	574	BiP	Gene	3309
1577860	871	874	BiP	Gene	3309
1577860	892	895	BiP	Gene	3309
1577860	1046	1049	BiP	Gene	3309
1577860	1254	1257	BiP	Gene	3309
1577860	1331	1334	BiP	Gene	3309
1577860	302	304	C2	CellLine	CVCL:0529
1577860	786	788	C2	CellLine	CVCL:0529
1577860	342	345	COS	CellLine	CVCL:0222
1577860	696	698	C2	CellLine	CVCL:0529
1577860	252	265	acetylcholine	Chemical	MESH:D000109
1577860	976	978	C2	CellLine	CVCL:0529
1577860	285	288	COS	CellLine	CVCL:0222

1577856|t|Relationship of F-actin distribution to development of polar shape in human polymorphonuclear neutrophils 
1577856|a|Polymerization of actin has been associated with development of polar shape in human neutrophils (PMN). To examine the relation of filamentous actin (F-actin) distribution to shape change in PMN, we developed a method using computerized video image analysis and fluorescence microscopy to quantify distribution of F-actin in single cells. PMN were labeled with fluorescent probe NBD-phallicidin to measure filamentous actin and Texas red to assess cell thickness. We show that Texas red fluorescence is a reasonable measure of cell thickness and that correction of the NBD-phallicidin image for cell thickness using the Texas red image permits assessment of focal F-actin content. Parameters were derived that quantify total F-actin content, movement of F-actin away from the center of the cell, asymmetry of F- actin distribution, and change from round to polar shape. The sequence of change in F-actin distribution and its relation to development of polar shape in PMN was determined using these parameters. After stimulation with chemotactic peptide at 25 degrees C, F-actin polymerized first at the rim of the PMN. This was followed by development of asymmetry of F-actin distribution and change to polar shape. The dominant pseudopod developed first in the region of lower F- actin concentration followed later by polymerization of actin in the end of the developed pseudopod. Asymmetric F-actin distribution was detected in round PMN before development of polar shape. Based upon these data, asymmetric distribution of F-actin is coincident with and probably precedes development of polar shape in PMN stimulated in suspension by chemotactic peptide. 
1577856	70	75	human	Species	9606
1577856	185	190	human	Species	9606
1577856	485	500	NBD-phallicidin	Chemical	MESH:C028877
1577856	1073	1076	PMN	Disease	

1577863|t|Involvement of the stress protein HSP47 in procollagen processing in the endoplasmic reticulum 
1577863|a|The 47,000-D collagen-binding glycoprotein, heat shock protein 47 (HSP47), is a stress-inducible protein localized in the ER of collagen- secreting cells. The location and collagen-binding activity of this protein led to speculation that HSP47 might participate in collagen processing. Chemical crosslinking studies were used to test this hypothesis both before and after the perturbation of procollagen processing. The association of procollagen with HSP47 was demonstrated using cleavable bifunctional crosslinking reagents. HSP47 and procollagen were shown to be coprecipitated by the treatment of intact cells with anti-HSP47 or with anticollagen antibodies. Furthermore, several proteins residing in the ER were noted to be crosslinked to and coprecipitated with HSP47, suggesting that these ER-resident proteins may form a large complex in the ER. When cells were heat shocked, or when stable triple-helix formation was inhibited by treatment with alpha,alpha'-dipyridyl, coprecipitation of procollagen with HSP47 was increased. This increase was due to the inhibition of procollagen secretion and to the accumulation of procollagen in the ER. Pulse label and chase experiments revealed that coprecipitated procollagen was detectable as long as procollagen was present in the endoplasmic reticulum of alpha,alpha'-dipyridyl-treated cells. Under normal growth conditions, coprecipitated procollagen was observed to decrease after a chase period of 10-15 min, whereas total procollagen decreased only after 20-25 min. In addition, the intracellular association between HSP47 and procollagen was shown to be disrupted by a change in physiological pH, suggesting that the dissociation of procollagen from HSP47 is pH dependent. These findings support a specific role for HSP47 in the intracellular processing of procollagen, and provide evidence of a new category of "molecular chaperones" in terms of its substrate specificity and the dissociation mechanism. 
1577863	34	39	HSP47	Gene	871
1577863	139	160	heat shock protein 47	Gene	871
1577863	162	167	HSP47	Gene	871
1577863	333	338	HSP47	Gene	871
1577863	547	552	HSP47	Gene	871
1577863	622	627	HSP47	Gene	871
1577863	719	724	HSP47	Gene	871
1577863	863	868	HSP47	Gene	871
1577863	1109	1114	HSP47	Gene	871
1577863	1668	1673	HSP47	Gene	871
1577863	1802	1807	HSP47	Gene	871
1577863	1868	1873	HSP47	Gene	871
1577863	1049	1071	alpha,alpha'-dipyridyl	Chemical	MESH:D015082
1577863	1402	1424	alpha,alpha'-dipyridyl	Chemical	MESH:D015082

1349608|t|Accumulation of a microtubule-binding protein, pp170, at desmosomal plaques 
1349608|a|The establishment of epithelial cell polarity correlates with the formation of specialized cell-cell junctions and striking changes in the organization of microtubules. A significant fraction of the microtubules in MDCK cells become stabilized, noncentrosomally organized, and arranged in longitudinal bundles in the apical-basal axis. This correlation suggests a functional link between cell-cell junction formation and control of microtubule organization. We have followed the distribution of pp170, a recently described microtubule- binding protein, during establishment of epithelial cell polarity. This protein shows the typical patchy distribution along microtubules in subconfluent fibroblasts and epithelial cells, often associated with the peripheral ends of a subpopulation of microtubules. In contrast to its localization in confluent fibroblasts (A72) and HeLa cells, however, pp170 accumulates in patches delineating the regions of cell- cell contacts in confluent polarizing epithelial cells (MDCK and Caco- 2). Double immunolocalization with antibodies specific for cell-cell junction proteins, confocal microscopy, and immunoelectron microscopy on polarized MDCK cells suggest that pp170 accumulates at desmosomal plaques. Furthermore, microtubules and desmosomes are found in close contact. Maintenance of the desmosomal association of pp170 is dependent on intact microtubules in 3-d-old, but not in 1-d-old MDCK cell cultures. This suggests a regulated interaction between microtubules and desmosomes and a role for pp170 in the control of changes in the properties of microtubules induced by epithelial cell- cell junction formation. 
1349608	935	938	A72	Species	9615
1349608	944	948	HeLa	CellLine	CVCL:0030

1577851|t|Retention of secretory proteins in an intermediate compartment and disappearance of the Golgi complex in an END4 mutant of Chinese hamster ovary cells 
1577851|a|Mutant V.24.1, a member of the End4 complementation group of temperature-sensitive CHO cells, is defective in secretion at the restrictive temperature (Wang, R.-H., P. A. Colbaugh, C.-Y. Kao, E. A. Rutledge, and R. K. Draper. 1990. J. Biol. Chem. 265:20179-20187; Presley, J. F., R. K. Draper, and D. T. Brown. 1991. J. Virol. 65:1332- 1339). We have further investigated the secretory lesion and report three main findings. First, the block in secretion is not due to aberrant folding or oligomerization of secretory proteins in the endoplasmic reticulum because the hemagglutinin of influenza virus folded and oligomerized at the same rate in mutant and parental cells at the restrictive temperature. Second, secretory proteins accumulated in a compartment intermediate between the ER and the Golgi. Several lines of evidence support this conclusion, the most direct being the colocalization by immunofluorescence microscopy of influenza virus hemagglutinin with a 58-kD protein that is known to reside in an intermediate compartment. Third, at the resolution of fluorescence microscopy, the Golgi complex in the mutant cells vanished at the restrictive temperature. 
1577851	123	138	Chinese hamster	Species	10029
1577851	234	237	CHO	CellLine	CVCL:0213

1577859|t|Meiosis, egg activation, and nuclear envelope breakdown are differentially reliant on Ca2+, whereas germinal vesicle breakdown is Ca2+ independent in the mouse oocyte 
1577859|a|During early development, intracellular Ca2+ mobilization is not only essential for fertilization, but has also been implicated during other meiotic and mitotic events, such as germinal vesicle breakdown (GVBD) and nuclear envelope breakdown (NEBD). In this study, the roles of intracellular and extracellular Ca2+ were examined during meiotic maturation and reinitiation at parthenogenetic activation and during first mitosis in a single species using the same methodologies. Cumulus- free metaphase II mouse oocytes immediately resumed anaphase upon the induction of a large, transient Ca2+ elevation. This resumption of meiosis and associated events, such as cortical granule discharge, were not sensitive to extracellular Ca2+ removal, but were blocked by intracellular Ca2+ chelators. In contrast, meiosis I was dependent on external Ca2+; in its absence, the formation and function of the first meiotic spindle was delayed, the first polar body did not form and an interphase-like state was induced. GVBD was not dependent on external Ca2+ and showed no associated Ca2+ changes. NEBD at first mitosis in fertilized eggs, on the other hand, was frequently, but not always associated with a brief Ca2+ transient and was dependent on Ca2+ mobilization. We conclude that GVBD is Ca2+ independent, but that the dependence of NEBD on Ca2+ suggests regulation by more than one pathway. As cells develop from Ca(2+)-independent germinal vesicle oocytes to internal Ca(2+)-dependent pronuclear eggs, internal Ca2+ pools increase by approximately fourfold. 
1577859	154	159	mouse	Species	10090
1577859	130	134	Ca2+	Chemical	MESH:D002118
1577859	86	90	Ca2+	Chemical	MESH:D002118
1577859	671	676	mouse	Species	10090
1577859	1404	1408	Ca2+	Chemical	MESH:D002118
1577859	941	945	Ca2+	Chemical	MESH:D002118
1577859	970	979	meiosis I	Disease	MESH:C536875
1577859	1574	1580	Ca(2+)	Chemical	MESH:D002118
1577859	1630	1636	Ca(2+)	Chemical	MESH:D002118
1577859	1501	1505	Ca2+	Chemical	MESH:D002118
1577859	755	759	Ca2+	Chemical	MESH:D002118
1577859	790	797	meiosis	Disease	MESH:C536875
1577859	1673	1677	Ca2+	Chemical	MESH:D002118
1577859	477	481	Ca2+	Chemical	MESH:D002118
1577859	893	897	Ca2+	Chemical	MESH:D002118
1577859	207	211	Ca2+	Chemical	MESH:D002118
1577859	1238	1242	Ca2+	Chemical	MESH:D002118
1577859	1448	1452	Ca2+	Chemical	MESH:D002118
1577859	1006	1010	Ca2+	Chemical	MESH:D002118
1577859	1208	1212	Ca2+	Chemical	MESH:D002118
1577859	1368	1372	Ca2+	Chemical	MESH:D002118

1315782|t|A soluble form of the F3 neuronal cell adhesion molecule promotes neurite outgrowth 
1315782|a|The F3 molecule is a member of the immunoglobulin superfamily anchored to membranes by a glycane-phosphatidylinositol, and is predominantly expressed on subsets of axons of the central and peripheral nervous system. In a previous paper (Gennarini, G., P. Durbec, A. Boned, G. Rougon, and C. Goridis. 1991. Neuron. 6:595-606), we have established that F3 fulfills the operational definition of a cell adhesion molecule and that it stimulates neurite outgrowth when presented to sensory neurons as a surface component of transfected CHO cells. In the present study the question as to whether soluble forms of F3 would be functionally active was addressed in vitro on cultures of mouse dorsal root ganglion neurons. We observed that preparations enriched in soluble F3 had no effect on neuron attachment but enhanced neurite initiation and neurite outgrowth in a dose-dependent manner. By contrast, soluble NCAM-120 does not have any measurable effect on these phenomena. Addition of anti-F3 monovalent antibodies reduced the number of process-bearing neurons and the neuritic output per neuron to control values. Addition of cerebrospinal fluid, a natural source of soluble F3, also stimulated neurite extension, and this effect was partially blocked by anti-F3 antibodies. Our results suggest that the soluble forms of adhesive proteins with neurite outgrowth-promoting properties could act at a distance from their site of release in a way reminiscent of growth and trophic factors. 
1315782	22	24	F3	Chemical	MESH:C056920
1315782	761	766	mouse	Species	10090
1315782	898	938	neurite initiation and neurite outgrowth	Disease	MESH:D058225
1315782	173	201	glycane-phosphatidylinositol	Chemical	MESH:D010716
1315782	615	618	CHO	CellLine	CVCL:0213

1374416|t|Regulation of alpha 2 beta 1-mediated fibroblast migration on type I collagen by shifts in the concentrations of extracellular Mg2+ and Ca2+ [published erratum appears in J Cell Biol 1992 Jul;118(1):219] 
1374416|a|Extracellular Ca2+ can reverse the Mg(2+)-dependent, alpha 2 beta 1- mediated adhesion of WI38 human fibroblasts to type I collagen substrates. Affinity chromatography data also demonstrate that Ca2+ can specifically elute the fibroblast alpha 2 beta 1 integrin bound to type I collagen-Sepharose in Mg2+. In modified Boyden chamber migration assays, Mg2+ alone supports the alpha 2 beta 1-mediated migration of fibroblasts on type I collagen substrates, while Ca2+ does not. However, a twofold enhancement in migration was observed when combinations of the two cations were used, with optimal migration observed when the Mg2+/Ca2+ ratio was higher than one. Inhibitory mAbs directed against various integrin subunits demonstrate that these observed cation effects appear to be mediated primarily by alpha 2 beta 1. These data, together with reports that under certain physiological conditions significant fluctuations in the concentrations of extracellular Ca2+ and Mg2+ can take place in vivo, suggest that the ratio between these two cations is involved in the up- and downregulation of integrin function, and thus, may influence cell migratory behavior. 
1374416	136	140	Ca2+	Chemical	MESH:D002118
1374416	127	131	Mg2+	Chemical	MESH:D008274
1374416	299	304	human	Species	9606
1374416	504	507	Mg2	Chemical	MESH:D008274
1374416	1171	1175	Mg2+	Chemical	MESH:D008274
1374416	826	830	Mg2+	Chemical	MESH:D008274
1374416	239	245	Mg(2+)	Chemical	MESH:D008274
1374416	831	835	Ca2+	Chemical	MESH:D002118
1374416	399	403	Ca2+	Chemical	MESH:D002118
1374416	555	559	Mg2+	Chemical	MESH:D008274
1374416	665	669	Ca2+	Chemical	MESH:D002118
1374416	218	222	Ca2+	Chemical	MESH:D002118
1374416	1162	1166	Ca2+	Chemical	MESH:D002118

1577867|t|Neurite outgrowth in peripherin-depleted PC12 cells 
1577867|a|Peripherin is the major neuronal intermediate filament (IF) protein in PC12 cells and both its synthesis and amount increase during nerve growth factor (NGF) promoted neuronal differentiation. To address the question of the biological function of peripherin in neurite initiation we have used an antisense oligonucleotide complementary to the 5' region of peripherin mRNA to specifically inhibit its transcription. The oligonucleotide blocks both the synthesis of peripherin and its increase in response to NGF. Peripherin was found to be a stable protein with a cellular half-life of approximately 7 d. 6 wk of incubation with the oligonucleotide decreases peripherin to 11% of the level in naive control cells and to 3% of that in NGF-treated control cells. Despite the depletion, NGF elicits apparently normal neurite outgrowth from the oligonucleotide-treated cells. As evaluated by EM, there are few IFs in these cells, either in the cell bodies or neurites. There is no compensatory increase in NF-M, NF-L, or vimentin levels as a result of the inhibition of peripherin synthesis. These findings suggest that peripherin is not required for neurite formation, but is necessary for the formation of a cellular IF network which could be involved in process stability. They also demonstrate the utility of antisense oligonucleotides for the study of proteins with long half- lives. 
1577867	21	31	peripherin	Gene	24688
1577867	41	45	PC12	CellLine	CVCL:0481
1577867	52	62	Peripherin	Gene	24688
1577867	184	203	nerve growth factor	Gene	310738
1577867	205	208	NGF	Gene	310738
1577867	299	309	peripherin	Gene	24688
1577867	408	418	peripherin	Gene	24688
1577867	516	526	peripherin	Gene	24688
1577867	559	562	NGF	Gene	310738
1577867	564	574	Peripherin	Gene	24688
1577867	785	788	NGF	Gene	310738
1577867	835	838	NGF	Gene	310738
1577867	1053	1057	NF-M	Gene	24588
1577867	1059	1063	NF-L	Gene	83613
1577867	1068	1076	vimentin	Gene	81818
1577867	1167	1177	peripherin	Gene	24688
1577867	710	720	peripherin	Gene	24688
1577867	1117	1127	peripherin	Gene	24688
1577867	123	127	PC12	CellLine	CVCL:0481

1577869|t|Laminin forms an independent network in basement membranes [published erratum appears in J Cell Biol 1992 Jun;118(2):493] 
1577869|a|Laminin self-assembles in vitro into a polymer by a reversible, entropy- driven and calcium-facilitated process dependent upon the participation of the short arm globular domains. We now find that this polymer is required for the structural integrity of the collagen-free basement membrane of cultured embryonal carcinoma cells (ECC) and for the supramolecular organization and anchorage of laminin in the collagen- rich basement membrane of the Engelbreth-Holm-Swarm tumor (EHS). First, low temperature and EDTA induced the dissolution of ECC basement membranes and released approximately 80% of total laminin from the EHS basement membrane. Second, laminin elastase fragments (E4 and E1') possessing the short arm globules of the B1, B2, and A chains selectively acted as competitive ligands that dissolved ECC basement membranes and displaced laminin from the EHS basement membrane into solution. The fraction of laminin released increased as a function of ligand concentration, approaching the level of the EDTA-reversible pool. The smaller (approximately 20%) residual pool of EHS laminin, in contrast, could only be effectively displaced by E1' and E4 if the collagenous network was first degraded with bacterial collagenase. The supramolecular architecture of freeze-etched and platinum/carbon replicated reconstituted laminin gel polymer, ECC, and collagenase- treated EHS basement membranes were compared and found to be similar, further supporting the biochemical data. We conclude that laminin forms a network independent of that of type IV collagen in basement membranes. Furthermore, in the EHS basement membrane four-fifths of laminin is anchored strictly through noncovalent bonds between laminin monomers while one-fifth is anchored through a combination of these bonds and laminin-collagen bridges. 
1577869	1331	1340	bacterial	Species	2
1577869	206	213	calcium	Chemical	MESH:D002118
1577869	662	665	ECC	CellLine	CVCL:M564
1577869	1416	1422	carbon	Chemical	MESH:D002244
1577869	1407	1415	platinum	Chemical	MESH:D010984
1577869	630	634	EDTA	Chemical	MESH:D004492
1577869	931	934	ECC	CellLine	CVCL:M564
1577869	1469	1472	ECC	CellLine	CVCL:M564
1577869	590	595	tumor	Disease	MESH:D009369
1577869	1133	1137	EDTA	Chemical	MESH:D004492
1577869	451	454	ECC	CellLine	CVCL:M564
1577869	424	443	embryonal carcinoma	Disease	MESH:D018236

1315784|t|Purification, characterization, and immunofluorescence localization of Saccharomyces cerevisiae capping protein 
1315784|a|Capping protein binds the barbed ends of actin filaments and nucleates actin filament assembly in vitro. We purified capping protein from Saccharomyces cervisiae. One of the two subunits is the product of the CAP2 gene, which we previously identified as the gene encoding the beta subunit of capping protein based on its sequence similarity to capping protein beta subunits in chicken and Dictyostelium (Amatruda, J. F., J. F. Cannon, K. Tatchell, C. Hug, and J. A. Cooper. 1990. Nature (Lond.) 344:352-354). Yeast capping protein has activity in critical concentration and low-shear viscometry assays consistent with barbed- end capping activity. Like chicken capping protein, yeast capping protein is inhibited by PIP2. By immunofluorescence microscopy yeast capping protein colocalizes with cortical actin spots at the site of bud emergence and at the tips of growing buds and shmoos. In contrast, capping protein does not colocalize with actin cables or with actin rings at the site of cytokinesis. 
1315784	71	95	Saccharomyces cerevisiae	Species	4932
1315784	321	325	CAP2	Gene	420847
1315784	828	832	PIP2	Gene	854545
1315784	250	263	Saccharomyces	Species	4932
1315784	489	496	chicken	Species	9031
1315784	621	626	Yeast	Species	4932
1315784	765	772	chicken	Species	9031
1315784	790	795	yeast	Species	4932
1315784	867	872	yeast	Species	4932

1533642|t|Requirement for p34cdc2 kinase is restricted to mitosis in the mammalian cdc2 mutant FT210 
1533642|a|The mouse FT210 cell line is a temperature-sensitive cdc2 mutant. FT210 cells are found to arrest specifically in G2 phase and unlike many alleles of cdc2 and cdc28 mutants of yeasts, loss of p34cdc2 at the nonpermissive temperature has no apparent effect on cell cycle progression through the G1 and S phases of the division cycle. FT210 cells and the parent wild-type FM3A cell line each possess at least three distinct histone H1 kinases. H1 kinase activities in chromatography fractions were identified using a synthetic peptide substrate containing the consensus phosphorylation site of histone H1 and the kinase subunit compositions were determined immunochemically with antisera prepared against the "PSTAIR" peptide, the COOH-terminus of mammalian p34cdc2 and the human cyclins A and B1. The results show that p34cdc2 forms two separate complexes with cyclin A and with cyclin B1, both of which exhibit thermal lability at the non-permissive temperature in vitro and in vivo. A third H1 kinase with stable activity at the nonpermissive temperature is comprised of cyclin A and a cdc2-like 34-kD subunit, which is immunoreactive with anti-"PSTAIR" antiserum but is not recognized with antiserum specific for the COOH- terminus of p34cdc2. The cyclin A-associated kinases are active during S and G2 phases and earlier in the division cycle than the p34cdc2- cyclin B1 kinase. We show that mouse cells possess at least two cdc2- related gene products which form cell cycle regulated histone H1 kinases and we propose that the murine homolog of yeast p34cdc/CDC28 is essential only during the G2-to-M transition in FT210 cells. 
1533642	16	23	p34cdc2	Gene	983
1533642	73	77	cdc2	Gene	983
1533642	63	72	mammalian	Species	9606
1533642	144	148	cdc2	Gene	12534
1533642	241	245	cdc2	Gene	12534
1533642	250	255	cdc28	Gene	852457
1533642	283	290	p34cdc2	Gene	983
1533642	847	854	p34cdc2	Gene	983
1533642	909	916	p34cdc2	Gene	983
1533642	951	959	cyclin A	Gene	890
1533642	969	978	cyclin B1	Gene	891
1533642	1163	1171	cyclin A	Gene	890
1533642	1328	1335	p34cdc2	Gene	983
1533642	1341	1349	cyclin A	Gene	890
1533642	1446	1453	p34cdc2	Gene	983
1533642	1519	1523	cdc2	Gene	12534
1533642	1653	1658	CDC28	Gene	852457
1533642	95	100	mouse	Species	10090
1533642	267	273	yeasts	Species	4932
1533642	837	846	mammalian	Species	9606
1533642	863	868	human	Species	9606
1533642	1486	1491	mouse	Species	10090
1533642	1622	1628	murine	Species	10090
1533642	1640	1645	yeast	Species	4932
1533642	461	465	FM3A	Species	10090
1533642	1455	1464	cyclin B1	Gene	891
1533642	1178	1182	cdc2	Gene	12534
1533642	1310	1314	COOH	Chemical	MESH:C102887
1533642	820	824	COOH	Chemical	MESH:C102887

1577865|t|Effects of profilin and profilactin on actin structure and function in living cells 
1577865|a|Previous studies have yielded conflicting results concerning the physiological role of profilin, a 12-15-kD actin- and phosphoinositide- binding protein, as a regulator of actin polymerization. We have addressed this question by directly microinjecting mammalian profilins, prepared either from an E. coli expression system or from bovine brain, into living normal rat kidney (NRK) cells. The microinjection causes a dose-dependent decrease in F-actin content, as indicated by staining with fluorescent phalloidin, and a dramatic reduction of actin and alpha-actinin along stress fibers. In addition, it has a strong inhibitory effect toward the extension of lamellipodia. However, the injection of profilin causes no detectable perturbation to the cell- substrate focal contact and no apparent depolymerization of filaments in either the nonlamellipodial circumferential band or the contractile ring of dividing cells. Furthermore, cytokinesis of injected cells occurs normally as in control cells. In contrast to pure profilin, high- affinity profilin-actin complexes from brain induce an increase in total cellular F-actin content and an enhanced ruffling activity, suggesting that the complex may dissociate readily in the cell and that there may be multiple states of profilin that differ in their ability to bind or release actin molecules. Our results indicate that profilin and profilactin can function as effective regulators for at least a subset of actin filaments in living cells. 
1577865	637	650	alpha-actinin	Gene	87
1577865	337	346	mammalian	Species	9606
1577865	382	389	E. coli	Species	562
1577865	416	422	bovine	Species	9913
1577865	449	452	rat	Species	10116
1577865	587	597	phalloidin	Chemical	MESH:D010590
1577865	461	464	NRK	CellLine	CVCL:3758

1315787|t|Local expression and exocytosis of viral glycoproteins in multinucleated muscle cells 
1315787|a|We have analyzed the distribution of enveloped viral infections in multinucleated L6 muscle cells. A temperature-sensitive vesicular stomatitis virus (mutant VSV ts045) was utilized at the nonpermissive temperature (39 degrees C). As expected, the glycoprotein (G protein) of this mutant was restricted to the ER when the multinucleated cells were maintained at 39 degrees C. We demonstrate that this G protein remained localized when the infection was performed at low dose. By 4 h after infection the G protein patches spanned an average of 220 microns. The localization was independent of nuclear positions, showing that the ER was a peripheric structure. Thus, the infection did not recognize nuclear domains characteristic of nuclearly encoded proteins. After release of the 39 degrees C block, transport through a perinuclear compartment into a restricted surface domain lying above the internal G protein patch occurred. Accordingly, the transport pathway was locally restricted. After a 16-h infection the G protein spanned 420 microns, while the matrix protein occupied 700-800 microns of the myotube length. Double infection of multinucleated L6 muscle cells with Semliki Forest virus and VSV at high multiplicities showed that the glycoprotein of each virus occupied intracellular domains which were devoid of the other respective glycoprotein. Taken together, these findings indicate that the viral glycoproteins did not range far from their site of synthesis within the ER or other intracellular membrane compartments in these large cells. This result also suggests that relocation of viral RNA synthesis occurred slowly. 
1315787	244	247	VSV	Species	11277
1315787	1260	1280	Semliki Forest virus	Species	11033
1315787	1285	1288	VSV	Species	11277
1315787	1349	1354	virus	Species	12081
1315787	755	764	infection	Disease	MESH:D007239
1315787	525	534	infection	Disease	MESH:D007239
1315787	133	149	viral infections	Disease	MESH:D014777
1315787	209	235	vesicular stomatitis virus	Disease	MESH:D054243

1315786|t|Localization of RAP1 and topoisomerase II in nuclei and meiotic chromosomes of yeast 
1315786|a|Topoisomerase II (topoII) and RAP1 (Repressor Activator Protein 1) are two abundant nuclear proteins with proposed structural roles in the higher-order organization of chromosomes. Both proteins co-fractionate as components of nuclear scaffolds from vegetatively growing yeast cells, and both proteins are present as components of pachytene chromosome, co-fractionating with an insoluble subfraction of meiotic nuclei. Immunolocalization using antibodies specific for topoII shows staining of an axial core of the yeast meiotic chromosome, extending the length of the synaptonemal complex. RAP1, on the other hand, is located at the ends of the paired bivalent chromosomes, consistent with its ability to bind telomeric sequences in vitro. In interphase nuclei, again in contrast to anti-topoII, anti-RAP1 gives a distinctly punctate staining that is located primarily at the nuclear periphery. Approximately 16 brightly staining foci can be identified in a diploid nucleus stained with anti-RAP1 antibodies, suggesting that telomeres are grouped together, perhaps through interaction with the nuclear envelope. 
1315786	16	20	RAP1	Chemical	MESH:C040523
1315786	356	361	yeast	Species	4932
1315786	599	604	yeast	Species	4932
1315786	675	679	RAP1	Chemical	MESH:C071212
1315786	115	119	RAP1	Chemical	MESH:C071212

1533643|t|In vitro microtubule-nucleating activity of spindle pole bodies in fission yeast Schizosaccharomyces pombe: cell cycle-dependent activation in xenopus cell-free extracts 
1533643|a|The spindle pole body (SPB) is the equivalent of the centrosome in fission yeast. In vivo it nucleates microtubules (MTs) during mitosis, but, unlike animal centrosomes, does not act as a microtubule organizing center (MTOC) during interphase. We have studied the MT- nucleating activity of SPBs in vitro and have found that SPBs in permeabilized cells retain in vivo characteristics. SPBs in cells permeabilized during mitosis can nucleate MTs, and are recognized by two antibodies: anti-gamma-tubulin and MPM-2 which recognizes phosphoepitopes. SPBs in cells permeabilized during interphase cannot nucleate MTs and are only recognized by anti-gamma-tubulin. Interphase SPBs which cannot nucleate can be converted to a nucleation competent state by incubation in cytostatic factor (CSF)-arrested Xenopus egg extracts. After incubation, they are recognized by MPM-2, and can nucleate MTs. The conversion does not occur in Xenopus interphase extract, but occurs in Xenopus interphase extract driven into mitosis by preincubation with exogenous cyclin B. The conversion is ATP dependent and inhibited by protein kinase inhibitors and alkaline phosphatase. Purified, active, cdc2 kinase/cyclin B complex in itself is not effective for activation of MT nucleation, although some interphase SPBs are now stained with MPM-2. These results suggest that the ability of SPBs in vitro to nucleate MTs after exposure to CSF- arrested extracts is activated through a downstream pathway which is regulated by cdc2 kinase. 
1533643	67	80	fission yeast	Species	4896
1533643	81	106	Schizosaccharomyces pombe	Species	4896
1533643	143	150	xenopus	Species	8355
1533643	237	250	fission yeast	Species	4896
1533643	967	974	Xenopus	Species	8355
1533643	1092	1099	Xenopus	Species	8355
1533643	1134	1141	Xenopus	Species	8355
1533643	1482	1487	MPM-2	Chemical	MESH:C476157
1533643	299	306	mitosis	Disease	OMIM:604588
1533643	1030	1035	MPM-2	Chemical	MESH:C476157
1533643	1241	1244	ATP	Chemical	MESH:D000255
1533643	677	682	MPM-2	Chemical	MESH:C476157

1374414|t|Specific association of the proto-oncogene product pp60c-src with an intracellular organelle, the PC12 synaptic vesicle 
1374414|a|The protein product of the proto-oncogene c-src is a membrane- associated tyrosine kinase of unknown function. Identification of pp60c- src target membranes may elucidate the function of the c-src protein. The available evidence indicates that pp60c-src associates with distinct membranes within single cell types and has different distributions in different cell types. Our experiments demonstrate targeting of pp60c-src to an isolatable and biochemically identified membrane fraction in the neuroendocrine cell line PC12. The c-src protein was found to be specifically associated with synaptic vesicles since: (a) the pp60c-src immunofluorescent pattern overlapped with a synaptic vesicle marker, synaptophysin; (b) a significant proportion (44%) of the pp60c-src from PC12 but not fibroblast postnuclear supernatants was recovered in a small vesicle fraction; (c) an anti- synaptophysin cytoplasmic domain antibody immunodepleted all of the pp60c-src vesicles in this fraction, and (d) pp60c-src copurified during a 100-fold purification of PC12 synaptic vesicles. These results suggest a role for the c-src protein in the regulation of synaptic vesicle function. 
1374414	98	102	PC12	CellLine	CVCL:0481
1374414	147	167	proto-oncogene c-src	Gene	6714
1374414	311	316	c-src	Gene	6714
1374414	648	653	c-src	Gene	6714
1374414	1225	1230	c-src	Gene	6714
1374414	996	1009	synaptophysin	Chemical	MESH:D016708
1374414	819	832	synaptophysin	Chemical	MESH:D016708
1374414	891	895	PC12	CellLine	CVCL:0481
1374414	638	642	PC12	CellLine	CVCL:0481
1374414	194	202	tyrosine	Chemical	
1374414	1164	1168	PC12	CellLine	CVCL:0481

1577868|t|Ganglioside modulation of neural cell adhesion molecule and N-cadherin- dependent neurite outgrowth 
1577868|a|We have used monolayers of control 3T3 cells and 3T3 cells expressing transfected human neural cell adhesion molecule (NCAM) or chick N- cadherin as a culture substrate for PC12 cells. NCAM and N-cadherin in the monolayer directly promote neurite outgrowth from PC12 cells via a G-protein-dependent activation of neuronal calcium channels. In the present study we show that ganglioside GM1 does not directly activate this pathway in PC12 cells. However, the presence of GM1 (12.5-100 micrograms/ml) in the co-culture was associated with a potentiation of NCAM and N-cadherin-dependent neurite outgrowth. Treatment of PC12 cells with GM1 (100 micrograms/ml) for 90 min led to trypsin-stable increases in both beta-cholera toxin binding to PC12 cells and an enhanced neurite outgrowth response to N-cadherin. The ganglioside response could be fully inhibited by treatment with pertussis toxin. These data are consistent with exogenous gangliosides enhancing neuritic growth by promoting cell adhesion molecule-induced calcium influx into neurons. 
1577868	60	70	N-cadherin	Gene	83501
1577868	26	55	neural cell adhesion molecule	Gene	24586
1577868	0	11	Ganglioside	Chemical	MESH:D005732
1577868	188	217	neural cell adhesion molecule	Gene	4684
1577868	234	245	N- cadherin	Gene	414745
1577868	285	289	NCAM	Gene	24586
1577868	294	304	N-cadherin	Gene	83501
1577868	655	659	NCAM	Gene	24586
1577868	664	674	N-cadherin	Gene	83501
1577868	895	905	N-cadherin	Gene	83501
1577868	219	223	NCAM	Gene	4684
1577868	182	187	human	Species	9606
1577868	228	233	chick	Species	9031
1577868	717	721	PC12	CellLine	CVCL:0481
1577868	533	537	PC12	CellLine	CVCL:0481
1577868	838	842	PC12	CellLine	CVCL:0481
1577868	149	152	3T3	CellLine	CVCL:0594
1577868	273	277	PC12	CellLine	CVCL:0481
1577868	1116	1123	calcium	Chemical	MESH:D002118
1577868	135	138	3T3	CellLine	CVCL:0594
1577868	362	366	PC12	CellLine	CVCL:0481
1577868	911	922	ganglioside	Chemical	MESH:D005732
1577868	422	429	calcium	Chemical	MESH:D002118
1577868	474	485	ganglioside	Chemical	MESH:D005732

1577866|t|Lattice defects in microtubules: protofilament numbers vary within individual microtubules 
1577866|a|We have used cryo-electron microscopy of vitrified specimens to study microtubules assembled both from three cycle purified tubulin (3x- tubulin) and in cell free extracts of Xenopus eggs. In vitro assembled 3x-tubulin samples have a majority of microtubules with 14 protofilaments whereas in cell extracts most microtubules have 13 protofilaments. Microtubule polymorphism was observed in both cases. The number of protofilaments can change abruptly along individual microtubules usually by single increments but double increments also occur. For 3x-tubulin, increasing the magnesium concentration decreases the proportion of 14 protofilament microtubules and decreases the average separation between transitions in these microtubules. Protofilament discontinuities may correspond to dislocation-like defects in the microtubule surface lattice. 
1577866	266	273	Xenopus	Species	8355
1577866	666	675	magnesium	Chemical	MESH:D008274

1577864|t|The vinculin/sarcomeric-alpha-actinin/alpha-actin nexus in cultured cardiac myocytes 
1577864|a|Experiments are described supporting the proposition that the assembly of stress fibers in non-muscle cells and the assembly of myofibrils in cardiac cells share conserved mechanisms. Double staining with a battery of labeled antibodies against membrane-associated proteins, myofibrillar proteins, and stress fiber proteins reveals the following: (a) dissociated, cultured cardiac myocytes reconstitute intercalated discs consisting of adherens junctions (AJs) and desmosomes at sites of cell-cell contact and sub-sarcolemmal adhesion plaques (SAPs) at sites of cell-substrate contact; (b) each AJ or SAP associates proximally with a striated myofibril, and conversely every striated myofibril is capped at either end by an AJ or a SAP; (C) the invariant association between a given myofibril and its SAP is especially prominent at the earliest stages of myofibrillogenesis; nascent myofibrils are capped by oppositely oriented SAPs; (d) the insertion of nascent myofibrils into AJs or into SAPs invariably involves vinculin, alpha-actin, and sarcomeric alpha-actinin (s-alpha-actinin); (e) AJs are positive for A- CAM but negative for talin and integrin; SAPs lack A-CAM but are positive for talin and integrin; (f) in cardiac cells all alpha-actinin- containing structures invariably are positive for the sarcomeric isoform, alpha-actin and related sarcomeric proteins; they lack non-s- alpha-actinin, gamma-actin, and caldesmon; (g) in fibroblasts all alpha- actinin-containing structures are positive for the non-sarcomeric isoform, gamma-actin, and related non-sarcomeric proteins, including caldesmon; and (h) myocytes differ from all other types of adherent cultured cells in that they do not assemble authentic stress fibers; instead they assemble stress fiber-like structures of linearly aligned I-Z-I-like complexes consisting exclusively of sarcomeric proteins. 
1577864	4	12	vinculin	Gene	7414
1577864	24	37	alpha-actinin	Gene	87
1577864	1101	1109	vinculin	Gene	7414
1577864	1139	1152	alpha-actinin	Gene	87
1577864	1474	1487	alpha-actinin	Gene	87
1577864	1323	1336	alpha-actinin	Gene	87
1577864	1156	1169	alpha-actinin	Gene	87

1315785|t|Sister chromatid separation in frog egg extracts requires DNA topoisomerase II activity during anaphase 
1315785|a|We have produced metaphase spindles and induced them to enter anaphase in vitro. Sperm nuclei were added to frog egg extracts, allowed to replicate their DNA, and driven into metaphase by the addition of cytoplasm containing active maturation promoting factor (MPF) and cytostatic factor (CSF), an activity that stabilizes MPF. Addition of calcium induces the inactivation of MPF, sister chromatid separation and anaphase chromosome movement. DNA topoisomerase II inhibitors prevent chromosome segregation at anaphase, demonstrating that the chromatids are catenated at metaphase and that decatenation occurs at the start of anaphase. Topoisomerase II activity towards exogenous substrates does not increase at the metaphase to anaphase transition, showing that chromosome separation at anaphase is not triggered by a bulk activation of topoisomerase II. 
1315785	374	391	cytostatic factor	Gene	1437
1315785	393	396	CSF	Gene	1437
1315785	444	451	calcium	Chemical	MESH:D002118

1374417|t|Immunological evidence for eight spans in the membrane domain of 3- hydroxy-3-methylglutaryl coenzyme A reductase: implications for enzyme degradation in the endoplasmic reticulum 
1374417|a|We have raised two monospecific antibodies against synthetic peptides derived from the membrane domain of the ER glycoprotein 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase, the rate limiting enzyme in the cholesterol biosynthetic pathway. This domain, which was proposed to span the ER membrane seven times (Liscum, L., J. Finer- Moore, R. M. Stroud, K. L. Luskey, M. S. Brown, and J. L. Goldstein. 1985. J. Biol. Chem. 260:522-538), plays a critical role in the regulated degradation of the enzyme in the ER in response to sterols. The antibodies stain the ER of cells and immunoprecipitate HMG-CoA reductase and HMGal, a chimeric protein composed of the membrane domain of the reductase fused to Escherichia coli beta-galactosidase, the degradation of which is also accelerated by sterols. We show that the sequence Arg224 through Leu242 of HMG-CoA reductase (peptide G) faces the cytoplasm both in cultured cells and in rat liver, whereas the sequence Thr284 through Glu302 (peptide H) faces the lumen of the ER. This indicates that a sequence between peptide G and peptide H spans the membrane of the ER. Moreover, by epitope tagging with peptide H, we show that the loop segment connecting membrane spans 3 and 4 is sequestered in the lumen of the ER. These results demonstrate that the membrane domain of HMG-CoA reductase spans the ER eight times and are inconsistent with the seven membrane spans topological model. The approximate boundaries of the proposed additional transmembrane segment are between Lys248 and Asp276. Replacement of this 7th span in HMGal with the first transmembrane helix of bacteriorhodopsin abolishes the sterol-enhanced degradation of the protein, indicating its role in the regulated turnover of HMG-CoA reductase within the endoplasmic reticulum. 
1374417	65	113	3- hydroxy-3-methylglutaryl coenzyme A reductase	Gene	25675
1374417	891	907	Escherichia coli	Species	562
1374417	1116	1119	rat	Species	10116
1374417	1504	1511	HMG-CoA	Chemical	MESH:C008047
1374417	1705	1708	Lys	Chemical	MESH:C026591
1374417	785	792	HMG-CoA	Chemical	MESH:C008047
1374417	976	983	sterols	Chemical	MESH:D013261
1374417	306	344	3-hydroxy-3- methylglutaryl coenzyme A	Chemical	MESH:C008047
1374417	1832	1838	sterol	Chemical	MESH:D013261
1374417	717	724	sterols	Chemical	MESH:D013261
1374417	1925	1932	HMG-CoA	Chemical	MESH:C008047
1374417	346	353	HMG-CoA	Chemical	MESH:C008047
1374417	1036	1043	HMG-CoA	Chemical	MESH:C008047
1374417	1716	1722	Asp276	Chemical	MESH:C505981
1374417	398	409	cholesterol	Chemical	MESH:D002784
1374417	1148	1151	Thr	Chemical	MESH:C055175

1577871|t|A single mRNA, transcribed from an alternative, erythroid-specific, promoter, codes for two non-myristylated forms of NADH-cytochrome b5 reductase 
1577871|a|Two forms of NADH-cytochrome b5 reductase are produced from one gene: a myristylated membrane-bound enzyme, expressed in all tissues, and a soluble, erythrocyte-specific, isoform. The two forms are identical in a large cytoplasmic domain (Mr approximately 30,000) and differ at the NH2-terminus, which, in the membrane form, is responsible for binding to the bilayer, and which contains the myristylation consensus sequence and an additional 14 uncharged amino acids. To investigate how the two differently targeted forms of the reductase are produced, we cloned a reductase transcript from reticulocytes, and studied its relationship to the previously cloned liver cDNA. The reticulocyte transcript differs from the liver transcript in the 5' non-coding portion and at the beginning of the coding portion, where the seven codons specifying the myristoylation consensus are replaced by a reticulocyte-specific sequence which codes for 13 non-charged amino acids. Analysis of genomic reductase clones indicated that the ubiquitous transcript is generated from an upstream "housekeeping" type promoter, while the reticulocyte transcript originates from a downstream, erythroid- specific, promoter. In vitro translation of the reticulocyte-specific mRNA generated two products: a minor one originating from the first AUG, and a major one starting from a downstream AUG, as indicated by mutational analysis. Both the AUGs used as initiation codons were in an unfavorable sequence context. The major, lower relative molecular mass product behaved as a soluble protein, while the NH2-terminally extended minor product interacted with microsomes in vitro. The generation of soluble reductase from a downstream AUG was confirmed in vivo, in Xenopus oocytes. Thus, differently localized products, with respect both to tissues and to subcellular compartments, are generated from the same gene by a combination of transcriptional and translational mechanisms. 
1577871	118	122	NADH	Chemical	MESH:D009243
1577871	1880	1887	Xenopus	Species	8355
1577871	1721	1724	NH2	Chemical	MESH:D000641
1577871	429	432	NH2	Chemical	MESH:D000641
1577871	160	164	NADH	Chemical	MESH:D009243

1577870|t|O-glycosylation of intact and truncated ribophorins in brefeldin A- treated cells: newly synthesized intact ribophorins are only transiently accessible to the relocated glycosyltransferases 
1577870|a|Ribophorins I and II are type I transmembrane glycoproteins of the ER that are segregated to the rough domains of this organelle. Both ribophorins appear to be part of the translocation apparatus for nascent polypeptides that is associated with membrane-bound ribosomes and participate in the formation of a proteinaceous network within the ER membrane that also includes other components of the translocation apparatus. The ribophorins are both highly stable proteins that lack O- linked sugars but each contains one high mannose N-linked oligosaccharide that remains endo H sensitive throughout their lifetimes. We have previously shown (Tsao, Y. S., N. E. Ivessa, M. Adesnik, D. D. Sabatini, and G. Kreibich. 1992. J. Cell Biol. 116:57- 67) that a COOH-terminally truncated variant of ribophorin I that contains only the first 332 amino acids of the luminal domain (RI332), when synthesized in permanent transformants of HeLa cells, undergoes a rapid degradation with biphasic kinetics in the ER itself and in a second, as yet unidentified nonlysosomal pre-Golgi compartment. We now show that in cells treated with brefeldin A (BFA) RI332 molecules undergo rapid O-glycosylation in a multistep process that involves the sequential addition of N-acetylgalactosamine, galactose, and terminal sialic acid residues. Addition of O-linked sugars affected all newly synthesized RI332 molecules and was completed soon after synthesis with a half time of about 10 min. In the same cells, intact ribophorins I and II also underwent O-linked glycosylation in the presence of BFA, but these molecules were modified only during a short time period immediately after their synthesis was completed, and the modification affected only a fraction of the newly synthesized polypeptides. More important, these molecules synthesized before the addition of BFA were not modified by O-glycosylation. The same is true for ribophorin I when overexpressed in HeLa cells although it is significantly less stable than the native polypeptide in control cells. We, therefore, conclude that soon after their synthesis, ribophorins lose their susceptibility to the relocated Golgi enzymes that effect the O-glycosylation, most likely as a consequence of a conformational change in the ribophorins that occurs during their maturation, although it cannot be excluded that rapid integration of these molecules into a supramolecular complex in the ER membrane leads to their inaccessibility to these enzymes. 
1577870	1436	1457	N-acetylgalactosamine	Chemical	MESH:D000116
1577870	2029	2032	BFA	Chemical	MESH:D020126
1577870	1308	1319	brefeldin A	Chemical	MESH:D020126
1577870	1526	1532	sugars	Chemical	MESH:D002241
1577870	941	945	COOH	Chemical	MESH:C102887
1577870	2127	2131	HeLa	CellLine	CVCL:0030
1577870	1757	1760	BFA	Chemical	MESH:D020126
1577870	679	685	sugars	Chemical	MESH:D002241
1577870	713	720	mannose	Chemical	MESH:D008358
1577870	1114	1118	HeLa	CellLine	CVCL:0030
1577870	1483	1494	sialic acid	Chemical	MESH:D012794
1577870	1321	1324	BFA	Chemical	MESH:D020126
1577870	1459	1468	galactose	Chemical	MESH:D005690

1374415|t|Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen 
1374415|a|FG human pancreatic carcinoma cells use integrin alpha v beta 5 as their primary vitronectin receptor since they fail to express integrin alpha v beta 3. These cells are unable to form focal contacts, spread, or migrate on vitronectin but readily do so on collagen in a beta 1 integrin-dependent manner. Transfection of FG cells with a cDNA encoding the integrin beta 3 subunit results in the surface expression of a functional integrin alpha v beta 3 heterodimer providing these cells with novel adhesive and biological properties. Specifically, FG cells expressing beta 3 acquire the capacity to attach and spread on vitronectin as well as fibrinogen with beta 3 localization to focal contacts. Moreover, these cells gain the capacity to migrate through a porous membrane in response to either vitronectin or fibrinogen. These results demonstrate that the beta 3 and beta 5 integrin subunits when associated with alpha v, promote distinct cellular responses to a vitronectin extracellular environment. 
1374415	88	99	vitronectin	Gene	7448
1374415	28	34	beta 3	Gene	1934
1374415	47	56	carcinoma	Disease	MESH:D002277
1374415	155	178	integrin alpha v beta 5	Gene	3693
1374415	244	267	integrin alpha v beta 3	Gene	3685;3690
1374415	338	349	vitronectin	Gene	7448
1374415	469	484	integrin beta 3	Gene	3690
1374415	543	566	integrin alpha v beta 3	Gene	3685;3690
1374415	734	745	vitronectin	Gene	7448
1374415	911	922	vitronectin	Gene	7448
1374415	926	936	fibrinogen	Gene	2244
1374415	973	990	beta 3 and beta 5	Gene	1934
1374415	1080	1091	vitronectin	Gene	7448
1374415	196	207	vitronectin	Gene	7448
1374415	757	767	fibrinogen	Gene	2244
1374415	118	123	human	Species	9606
1374415	773	779	beta 3	Gene	1934
1374415	682	688	beta 3	Gene	1934
1374415	124	144	pancreatic carcinoma	Disease	MESH:C562463

1577872|t|Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle 
1577872|a|Duchenne's muscular dystrophy (DMD) is caused by the absence or drastic decrease of the structural protein, dystrophin, and is characterized by sarcolemmal lesions in skeletal muscle due to the stress of contraction. Dystrophin has been localized to the sarcolemma, but its organization there is not known. We report immunofluorescence studies which show that dystrophin is concentrated, along with the major muscle isoform of beta-spectrin, in three distinct domains at the sarcolemma: in elements overlying both I bands and M lines, and in occasional strands running along the longitudinal axis of the myofiber. Vinculin, which has previously been found at the sarcolemma overlying the I bands and in longitudinal strands, was present in the same three structures as spectrin and dystrophin. Controls demonstrated that the labeling was intracellular. Comparison to labeling of the lipid bilayer and of the extracellular matrix showed that the labeling for spectrin and dystrophin is associated with the intact sarcolemma and is not a result of processing artifacts. Dystrophin is not required for this lattice- like organization, as similar domains containing spectrin but not dystrophin are present in muscle from the mdx mouse and from humans with Duchenne's muscular dystrophy. We discuss the possibility that dystrophin and spectrin, along with vinculin, may function to link the contractile apparatus to the sarcolemma of normal skeletal muscle. 
1577872	0	10	Dystrophin	Gene	1756
1577872	80	89	mammalian	Species	9606
1577872	214	224	dystrophin	Gene	1756
1577872	466	476	dystrophin	Gene	1756
1577872	720	728	Vinculin	Gene	7414
1577872	888	898	dystrophin	Gene	1756
1577872	1077	1087	dystrophin	Gene	1756
1577872	1174	1184	Dystrophin	Gene	13405
1577872	1421	1431	dystrophin	Gene	1756
1577872	1457	1465	vinculin	Gene	7414
1577872	323	333	Dystrophin	Gene	1756
1577872	1331	1336	mouse	Species	10090
1577872	1346	1352	humans	Species	9606
1577872	1285	1295	dystrophin	Gene	1756
1577872	1358	1387	Duchenne's muscular dystrophy	Disease	MESH:D020388
1577872	137	140	DMD	Disease	MESH:D020388
1577872	106	135	Duchenne's muscular dystrophy	Disease	MESH:D020388

1607384|t|Actin-facilitated assembly of smooth muscle myosin induces formation of actomyosin fibrils 
1607384|a|To identify regulatory mechanisms potentially involved in formation of actomyosin structures in smooth muscle cells, the influence of F-actin on smooth muscle myosin assembly was examined. In physiologically relevant buffers, AMPPNP binding to myosin caused transition to the soluble 10S myosin conformation due to trapping of nucleotide at the active sites. The resulting 10S myosin-AMPPNP complex was highly stable and thick filament assembly was suppressed. However, upon addition to F- actin, myosin readily assembled to form thick filaments. Furthermore, myosin assembly caused rearrangement of actin filament networks into actomyosin fibers composed of coaligned F-actin and myosin thick filaments. Severin-induced fragmentation of actin in actomyosin fibers resulted in immediate disassembly of myosin thick filaments, demonstrating that actin filaments were indispensable for mediating myosin assembly in the presence of AMPPNP. Actomyosin fibers also formed after addition of F-actin to nonphosphorylated 10S myosin monomers containing the products of ATP hydrolysis trapped at the active site. The resulting fibers were rapidly disassembled after addition of millimolar MgATP and consequent transition of myosin to the soluble 10S state. However, reassembly of myosin filaments in the presence of MgATP and F-actin could be induced by phosphorylation of myosin P-light chains, causing regeneration of actomyosin fiber bundles. The results indicate that actomyosin fibers can be spontaneously formed by F-actin-mediated assembly of smooth muscle myosin. Moreover, induction of actomyosin fibers by myosin light chain phosphorylation in the presence of actin filament networks provides a plausible hypothesis for contractile fiber assembly in situ. 
1607384	44	50	myosin	Gene	79784
1607384	335	341	myosin	Gene	79784
1607384	588	594	myosin	Gene	79784
1607384	651	657	myosin	Gene	79784
1607384	772	778	myosin	Gene	79784
1607384	985	991	myosin	Gene	79784
1607384	1306	1312	myosin	Gene	79784
1607384	1362	1368	myosin	Gene	79784
1607384	1698	1704	myosin	Gene	79784
1607384	1646	1652	myosin	Gene	79784
1607384	1109	1115	myosin	Gene	79784
1607384	468	474	myosin	Gene	79784
1607384	379	385	myosin	Gene	79784
1607384	250	256	myosin	Gene	79784
1607384	1455	1461	myosin	Gene	79784
1607384	796	803	Severin	Chemical	
1607384	1020	1026	AMPPNP	Chemical	MESH:D000266
1607384	893	915	myosin thick filaments	Disease	MESH:D009135
1607384	1271	1276	MgATP	Chemical	MESH:D000255
1607384	1398	1403	MgATP	Chemical	MESH:D000255
1607384	1152	1155	ATP	Chemical	MESH:D000255

1607382|t|Translocation of the glucose transporter (GLUT4) to the cell surface in permeabilized 3T3-L1 adipocytes: effects of ATP insulin, and GTP gamma S and localization of GLUT4 to clathrin lattices 
1607382|a|Insulin stimulates the movement of two glucose transporter isoforms (GLUT1 and GLUT4) to the plasma membrane (PM) in adipocytes. To study this process we have prepared highly purified PM fragments by gently sonicating 3T3-L1 adipocytes grown on glass coverslips. Using confocal laser immunofluorescence microscopy we observed increased PM labeling for GLUT1 (2.3-fold) and GLUT4 (eightfold) after insulin treatment in intact cells. EM immunolabeling of PM fragments indicated that in the nonstimulated state GLUT4 was mainly localized to flat clathrin lattices. Whereas GLUT4 labeling of clathrin lattices was only slightly increased after insulin treatment, labeling of uncoated PM regions was markedly increased with insulin. These data suggest that GLUT4 recycles from the cell surface both in the presence and absence of insulin. In streptolysin-O permeabilized adipocytes, insulin, and GTP gamma S increased PM levels of GLUT4 to a similar extent as observed with insulin in intact cells. In the absence of an exogenous ATP source the magnitude of these effects was considerably reduced. Removal of ATP per se caused a significant increase in cell surface levels of GLUT4 suggesting that ATP may be required for intracellular sequestration of these transporters. When insulin and GTP gamma S were added together, in the presence of ATP, PM GLUT4 levels were similar to levels observed when either insulin or GTP gamma S was added individually. Addition of GTP gamma S was able to overcome this ATP dependence of insulin- stimulated GLUT4 movement. GTP gamma S had no effect on constitutive secretion of adipsin in permeabilized cells. In addition, there was no effect of insulin or GTP gamma S on GLUT4 movement to the PM in noninsulin sensitive streptolysin-O-permeabilized 3T3-L1 fibroblasts overexpressing GLUT4. We conclude that the insulin-stimulated movement of GLUT4 to the cell surface in adipocytes may require ATP early in the insulin signaling pathway and a GTP-binding protein(s) at a later step(s). We propose that the association of GLUT4 with clathrin lattices may be important in maintaining the exclusive intracellular location of this transporter in the absence of insulin. 
1607382	42	47	GLUT4	Gene	6517
1607382	165	170	GLUT4	Gene	6517
1607382	120	127	insulin	Gene	3630
1607382	21	28	glucose	Chemical	MESH:D005947
1607382	116	119	ATP	Chemical	MESH:D000255
1607382	261	266	GLUT1	Gene	6513
1607382	271	276	GLUT4	Gene	6517
1607382	544	549	GLUT1	Gene	6513
1607382	565	570	GLUT4	Gene	6517
1607382	700	705	GLUT4	Gene	6517
1607382	762	767	GLUT4	Gene	6517
1607382	944	949	GLUT4	Gene	6517
1607382	1017	1024	insulin	Gene	3630
1607382	1070	1077	insulin	Gene	3630
1607382	1118	1123	GLUT4	Gene	6517
1607382	1363	1368	GLUT4	Gene	6517
1607382	1537	1542	GLUT4	Gene	6517
1607382	1709	1716	insulin	Gene	3630
1607382	1729	1734	GLUT4	Gene	6517
1607382	1800	1807	adipsin	Gene	1675
1607382	1868	1890	insulin or GTP gamma S	Gene	3630
1607382	1894	1899	GLUT4	Gene	6517
1607382	2006	2011	GLUT4	Gene	6517
1607382	2065	2070	GLUT4	Gene	6517
1607382	2244	2249	GLUT4	Gene	6517
1607382	2380	2387	insulin	Gene	3630
1607382	911	918	insulin	Gene	3630
1607382	832	839	insulin	Gene	3630
1607382	589	596	insulin	Gene	3630
1607382	192	199	Insulin	Gene	3630
1607382	2134	2141	insulin	Gene	3630
1607382	2034	2041	insulin	Gene	3630
1607382	1594	1616	insulin or GTP gamma S	Gene	3630
1607382	1465	1472	insulin	Gene	3630
1607382	1161	1168	insulin	Gene	3630
1607382	1745	1756	GTP gamma S	Chemical	MESH:D016244
1607382	1217	1220	ATP	Chemical	MESH:D000255
1607382	2117	2120	ATP	Chemical	MESH:D000255
1607382	1653	1664	GTP gamma S	Chemical	MESH:D016244
1607382	1529	1532	ATP	Chemical	MESH:D000255
1607382	1083	1094	GTP gamma S	Chemical	MESH:D016244
1607382	231	238	glucose	Chemical	MESH:D005947
1607382	1296	1299	ATP	Chemical	MESH:D000255
1607382	1691	1694	ATP	Chemical	MESH:D000255
1607382	1385	1388	ATP	Chemical	MESH:D000255

1607387|t|Gas2, a growth arrest-specific protein, is a component of the microfilament network system 
1607387|a|In this report we analyze the protein product of a growth arrest- specific gene, gas2, by means of an affinity-purified antibody raised against the protein produced in bacteria. The regulation of Gas2 biosynthesis reflects the pattern of mRNA expression (Schneider, C., R. King, and L. Philipson. 1988. Cell. 54:787-793): its relative level is tightly associated with growth arrest. Gas2 seems to be regulated also at the posttranslational level via a phosphorylation mechanism. Gas2 is well conserved during the evolution with the same apparent molecular mass (36 kD) between mouse and human. We also demonstrate that Gas2 is a component of the microfilament system. It colocalizes with actin fiber, at the cell border and also along the stress fiber, in growth- arrested NIH 3T3 cells. The pattern of distribution, detected in arrested cells, can also be observed in growing cells when they are microinjected with the purified GST-Gas2 protein. In none of the analyzed oncogene-transformed NIH 3T3 cell lines was Gas2 expression induced under serum starvation. 
1607387	0	4	Gas2	Gene	14453
1607387	172	176	gas2	Gene	14453
1607387	287	291	Gas2	Gene	14453
1607387	474	478	Gas2	Gene	14453
1607387	570	574	Gas2	Gene	14453
1607387	710	714	Gas2	Gene	14453
1607387	1024	1028	Gas2	Gene	14453
1607387	1106	1110	Gas2	Gene	14453
1607387	259	267	bacteria	Species	562
1607387	668	673	mouse	Species	10090
1607387	678	683	human	Species	9606
1607387	1083	1090	NIH 3T3	CellLine	CVCL:0594
1607387	864	871	NIH 3T3	CellLine	CVCL:0594
1607387	459	472	growth arrest	Disease	MESH:D006323

1318883|t|Mechanism of cholera toxin action on a polarized human intestinal epithelial cell line: role of vesicular traffic 
1318883|a|The massive secretion of salt and water in cholera-induced diarrhea involves binding of cholera toxin (CT) to ganglioside GM1 in the apical membrane of intestinal epithelial cells, translocation of the enzymatically active A1-peptide across the membrane, and subsequent activation of adenylate cyclase located on the cytoplasmic surface of the basolateral membrane. Studies on nonpolarized cells show that CT is internalized by receptor-mediated endocytosis, and that the A1-subunit may remain membrane associated. To test the hypothesis that toxin action in polarized cells may involve intracellular movement of toxin- containing membranes, monolayers of the polarized intestinal epithelial cell line T84 were mounted in modified Ussing chambers and the response to CT was examined. Apical CT at 37 degrees C elicited a short circuit current (Isc: 48 +/- 2.1 microA/cm2; half-maximal effective dose, ED50 integral of 0.5 nM) after a lag of 33 +/- 2 min which bidirectional 22Na+ and 36Cl- flux studies showed to be due to electrogenic Cl- secretion. The time course of the CT-induced Isc response paralleled the time course of cAMP generation. The dose response to basolateral toxin at 37 degrees C was identical to that of apical CT but lag times (24 +/- 2 min) and initial rates were significantly less. At 20 degrees C, the Isc response to apical CT was more strongly inhibited (30-50%) than the response to basolateral CT, even though translocation occurred in both cases as evidenced by the formation of A1-peptide. A functional rhodamine-labeled CT-analogue applied apically or basolaterally at 20 degrees C was visualized only within endocytic vesicles close to apical or basolateral membranes, whereas movement into deeper apical structures was detected at 37 degrees C. At 15 degrees C, in contrast, reduction to the A1-peptide was completely inhibited and both apical and basolateral CT failed to stimulate Isc although Isc responses to 1 nM vasoactive intestinal peptide, 10 microM forskolin, and 3 mM 8Br- cAMP were intact. Re-warming above 32 degrees C restored CT-induced Isc. Preincubating monolayers for 30 min at 37 degrees C before cooling to 15 degrees C overcame the temperature block of basolateral CT but the response to apical toxin remained completely inhibited. These results identify a temperature-sensitive step essential to apical toxin action on polarized epithelial cells. We suggest that this event involves vesicular transport of toxin-containing membranes beyond the apical endosomal compartment. 
1318883	49	54	human	Species	9606
1318883	2133	2137	cAMP	Chemical	MESH:D000242
1318883	2108	2117	forskolin	Chemical	MESH:D005576
1318883	1649	1658	rhodamine	Chemical	MESH:C027024
1318883	224	235	ganglioside	Chemical	MESH:D005732
1318883	173	181	diarrhea	Disease	MESH:D003967
1318883	2151	2153	Re	Chemical	MESH:D012211
1318883	1242	1246	cAMP	Chemical	MESH:D000242
1318883	2128	2131	8Br	Chemical	MESH:C068746

1607378|t|Examining the function and regulation of hsp 70 in cells subjected to metabolic stress 
1607378|a|Members of the heat-shock protein (hsp) 70 family, distributed within various cellular compartments, have been implicated in facilitating protein maturation events. In particular, related hsp 70 family members appear to bind nascent polypeptides which are in the course of synthesis and/or translocation into organelles. We previously reported that in normal, unstressed cells, cytosolic hsp 70 (hsp 72/73) interacted transiently with nascent polypeptides. We suspect that such interactions function to prevent or slow down the folding of the nascent polypeptide chain. Once synthesis is complete, and now with all of the information for folding present, the newly synthesized protein appears to commence along its folding pathway, accompanied by the ATP- dependent release of hsp 72/73. Herein, we examined how these events occur in cells subjected to different types of metabolic stress. In cells exposed to either an amino acid analog or sodium arsenite, two potent inducers of the stress response, newly synthesized proteins bind to but are not released from hsp 70. Under these conditions of metabolic stress, we suspect that the newly synthesized proteins are unable to commence proper folding and consequently remain bound to their hsp 70 chaperone. In cells subjected to heat shock, a large number of both newly synthesized as well as mature proteins are rendered insoluble. Within this insoluble material are appreciable amounts of hsp 72/73. Finally, we show that in cells depleted of ATP, the release of hsp 70 from maturing proteins is inhibited. Thus, in cells experiencing metabolic stress, newly synthesized proteins unable to properly fold, as will as mature proteins which begin to unfold become stably bound to hsp 72/73. As a consequence and over time, the free or available levels of pre-existing hsp 72/73 are reduced. We propose that this reduction in the available levels of hsp 72/73 is the trigger by which the stress response is initiated. 
1607378	41	47	hsp 70	Gene	3308
1607378	70	86	metabolic stress	Disease	MESH:D008659
1607378	102	129	heat-shock protein (hsp) 70	Gene	3308
1607378	275	281	hsp 70	Gene	3308
1607378	475	481	hsp 70	Gene	3308
1607378	864	870	hsp 72	Gene	3303
1607378	1150	1156	hsp 70	Gene	3308
1607378	1528	1534	hsp 72	Gene	3303
1607378	1602	1608	hsp 70	Gene	3308
1607378	1816	1822	hsp 72	Gene	3303
1607378	1904	1910	hsp 72	Gene	3303
1607378	1985	1991	hsp 72	Gene	3303
1607378	1326	1332	hsp 70	Gene	3308
1607378	483	489	hsp 72	Gene	3303
1607378	1582	1585	ATP	Chemical	MESH:D000255
1607378	1028	1043	sodium arsenite	Chemical	MESH:C017947
1607378	838	841	ATP	Chemical	MESH:D000255
1607378	1371	1376	shock	Disease	MESH:D012769

1376731|t|Identification of amino acid sequences in the integrin beta 1 cytoplasmic domain implicated in cytoskeletal association 
1376731|a|Wild-type and mutant chicken integrin beta 1 subunit (beta 1c) cDNAs were expressed in NIH 3T3 cells and assayed for localization in focal adhesions of cells plated on fibronectin substrates. Focal adhesion localization in stable transfected cells was assayed by indirect immunofluorescent staining with chicken-specific anti-beta 1c antibodies. Mutant beta 1c integrins containing internal deletions of 13 amino acids adjacent to the membrane, delta 759-771, and 20 centrally located amino acids, delta 771-790, localized in focal adhesions demonstrating that sequences required for direction to focal adhesion structures were not limited to one region of the cytoplasmic domain. Point mutations revealed three clusters of amino acids which contribute to localization in focal adhesions. These three clusters or signals are: cyto-1 (764-774), cyto-2 (785-788), and cyto-3 (797-800). The 11-residue cyto-1 signal is only found on integrin beta subunit sequences, except beta 4. Four residues within this region, D764, F768, F771, and E774, could not be altered without reducing focal adhesion staining intensities, and likely form a signal that occupies one side of an alpha helix. Mutations involving two cyto-1 residues, K770 and F771, also appeared to affect heterodimer affinity and specificity. Cyto-2 (785-788,), NPIY, is an NPXY signal that forms a tight turn motif. Cyto-2 provides a structural conformation, which when perturbed by proline removal or addition, inhibits integrin localization in focal adhesions. Cyto-3 (797-800), NPKY, resembles cyto-2, however, the nonconserved proline residue can be replaced without alteration of the localization phenotype. Cyto-3, therefore, constitutes a unique integrin signal, NXXY. Both serine and tyrosine residues at positions 790 and 788, respectively, which have been implicated in integrin phosphorylation/regulation, were conservatively replaced without detectable effect on focal adhesion localization. However, acidic replacements for these amino acids reduced focal adhesion staining intensities, suggesting that phosphorylation at these sites may negatively regulate integrin function. 
1376731	46	61	integrin beta 1	Gene	16412
1376731	288	299	fibronectin	Gene	14268
1376731	141	148	chicken	Species	9031
1376731	149	164	integrin beta 1	Gene	16412
1376731	1144	1148	F771	Chemical	MESH:C021597
1376731	1859	1865	serine	Chemical	MESH:C047902
1376731	565	578	delta 759-771	Chemical	MESH:C021597
1376731	207	214	NIH 3T3	CellLine	CVCL:0594
1376731	1561	1568	proline	Chemical	MESH:C489032
1376731	1138	1142	F768	Chemical	MESH:C055434
1376731	1870	1878	tyrosine	Chemical	
1376731	1709	1716	proline	Chemical	MESH:C489032

1607389|t|Separate domains of KAR1 mediate distinct functions in mitosis and nuclear fusion 
1607389|a|The yeast KAR1 gene is essential for mitotic growth and important for nuclear fusion. Mutations in KAR1 prevent duplication of the spindle pole body (SPB), and affect functions associated with both the nuclear and cytoplasmic microtubules. The localization of hybrid Kar1-lacZ proteins, described elsewhere (Vallen, E. A., T. Y. Scherson, T. Roberts, K. van Zee, and M. D. Rose. 1992. Cell. In press), suggest that the protein is associated with the SPB. In this paper, we report a deletion analysis demonstrating that the mitotic and karyogamy functions of KAR1 are separate and independent, residing in discrete functional domains. One region, here shown to be essential for mitosis, coincided with a part of the protein that is both necessary and sufficient to target Karl-lacZ hybrid proteins to the SPB (Vallen, E. A., T. Y. Scherson, T. Roberts, K. van Zee, and M. D. Rose. 1992. Cell. In press). Complementation testing demonstrated that deletions in this interval did not affect nuclear fusion. A second region, required only for karyogamy, was necessary for the localization of a Kar3-lacZ hybrid protein to the SPB. These data suggest a model for the roles of Kar1p and Kar3p, a kinesin-like protein, in nuclear fusion. Finally, a third region of KAR1 was found to be important for both mitosis and karyogamy. This domain included the hydrophobic carboxy terminus and is sufficient to target a lacZ-Kar1 hybrid protein to the nuclear envelope (Vallen E. A., T. Y. Scherson, T. Roberts, K. van Zee, and M. D. Rose. 1992. Cell. In press). Altogether, the essential mitotic regions of KAR1 comprised 20% of the coding sequence. We propose a model for Kar1p in which the protein is composed of several protein-binding domains tethered to the nuclear envelope via its hydrophobic tail. 
1607389	20	24	KAR1	Gene	855533
1607389	55	62	mitosis	Disease	OMIM:604588
1607389	92	96	KAR1	Gene	855533
1607389	181	185	KAR1	Gene	855533
1607389	349	353	Kar1	Gene	855533
1607389	640	644	KAR1	Gene	855533
1607389	1252	1257	Kar1p	Gene	855533
1607389	1262	1267	Kar3p	Gene	856263
1607389	1339	1343	KAR1	Gene	855533
1607389	1491	1495	Kar1	Gene	855533
1607389	1674	1678	KAR1	Gene	855533
1607389	1740	1745	Kar1p	Gene	855533
1607389	86	91	yeast	Species	4932
1607389	1171	1175	Kar3	Gene	856263
1607389	1379	1386	mitosis	Disease	OMIM:604588
1607389	759	766	mitosis	Disease	OMIM:604588
1607389	1439	1446	carboxy	Chemical	MESH:C015732

1607380|t|Biosynthesis of lipoprotein: location of nascent apoAI and apoB in the rough endoplasmic reticulum of chicken hepatocytes 
1607380|a|Our previous studies showed that in hepatic RER of young chickens, nascent apoAI is not associated with lipoprotein particles and only becomes part of these lipoprotein structures in the Golgi. In this study, we have used three different methodologies to determine the locations of apoAI and apoB in the RER and compared them to that of albumin. Immunoelectron microscopic examination of the RER cell fractions showed that both apoAI and apoB were associated only with the RER membrane whereas albumin was located both within the lumen and on the limiting membrane of the vesicles. To examine the possibility of membrane integration of nascent apoAI and apoB in the RER, we administered L-[3H]leucine to young chickens for 10 min, isolated RER, treated this cell fraction with buffers of varying pH, and measured the release of radioactive albumin, apoAI, and apoB. The majority of nascent apoAI (64%), nascent apoB (100%), and nascent albumin (97%) was released from RER vesicles at pH 11.2, suggesting that, like albumin, apolipoproteins are not integrated within the membrane. To determine if nascent apoproteins are exposed to the cytoplasmic surface, we administered L-[3H]leucine to young chickens and at various times isolated RER and Golgi cell fractions. Radioactive RER and Golgi cell fractions were treated with exogenous protease and the percent of nascent apoAI and apoB accessible to proteolysis was determined and compared to that of albumin. At 5, 10, and 20 min of labeling, 35-56% of nascent apoAI and 60-75% of apoB in RER were degraded, while albumin was refractive to this treatment. At all times both apolipoproteins and albumin present in Golgi cell fractions were protected from proteolysis. These biochemical and morphological findings indicate that apoAI and apoB are associated with the rough microsomal membrane and are partially exposed to the cytoplasmic surface at early stages of secretion. They may later enter the luminal side of the ER and, on entering the Golgi, form lipoprotein particles. 
1607380	59	63	apoB	Gene	396535
1607380	49	54	apoAI	Gene	396536
1607380	102	109	chicken	Species	9031
1607380	414	418	apoB	Gene	396535
1607380	776	780	apoB	Gene	396535
1607380	982	986	apoB	Gene	396535
1607380	1501	1505	apoB	Gene	396535
1607380	1897	1902	apoAI	Gene	396536
1607380	1632	1637	apoAI	Gene	396536
1607380	1491	1496	apoAI	Gene	396536
1607380	1012	1017	apoAI	Gene	396536
1607380	971	976	apoAI	Gene	396536
1607380	766	771	apoAI	Gene	396536
1607380	550	555	apoAI	Gene	396536
1607380	404	409	apoAI	Gene	396536
1607380	197	202	apoAI	Gene	396536
1607380	1907	1911	apoB	Gene	396535
1607380	1652	1656	apoB	Gene	396535
1607380	1033	1037	apoB	Gene	396535
1607380	560	564	apoB	Gene	396535
1607380	179	187	chickens	Species	9031
1607380	832	840	chickens	Species	9031
1607380	1317	1325	chickens	Species	9031
1607380	809	822	L-[3H]leucine	Chemical	MESH:C027819
1607380	1294	1307	L-[3H]leucine	Chemical	MESH:C027819

1607385|t|Release of myosin II from the membrane-cytoskeleton of Dictyostelium discoideum mediated by heavy-chain phosphorylation at the foci within the cortical actin network 
1607385|a|Membrane-cytoskeletons were prepared from Dictyostelium amebas, and networks of actin and myosin II filaments were visualized on the exposed cytoplasmic surfaces of the cell membranes by fluorescence staining (Yumura, S., and T. Kitanishi-Yumura. 1990. Cell Struct. Funct. 15:355-364). Addition of ATP caused contraction of the cytoskeleton with aggregation of part of actin into several foci within the network, but most of myosin II was released via the foci. However, in the presence of 10 mM MgCl2, which stabilized myosin II filaments, myosin II remained at the foci. Ultrastructural examination revealed that, after contraction, only traces of monomeric myosin II remained at the foci. By contrast, myosin II filaments remained in the foci in the presence of 10 mM MgCl2. These observations suggest that myosin II was released not in a filamentous form but in a monomeric form. Using [gamma 32P]ATP, we found that the heavy chains of myosin II released from membrane-cytoskeletons were phosphorylated, and this phosphorylation resulted in disassembly of myosin filaments. Using ITP (a substrate for myosin II ATPase) and/or ATP gamma S (a substrate for myosin II heavy-chain kinase [MHCK]), we demonstrated that phosphorylation of myosin heavy chains occurred at the foci within the actin network, a result that suggests that MHCK was localized at the foci. These results together indicate that, during contraction, the heavy chains of myosin II that have moved toward the foci within the actin network are phosphorylated by a specific MHCK, with the resultant disassembly of filaments which are finally released from membrane- cytoskeletons. This series of reactions could represent the mechanism for the relocation of myosin II from the cortical region to the endoplasm. 
1607385	55	79	Dictyostelium discoideum	Species	44689
1607385	937	942	MgCl2	Chemical	MESH:D015636
1607385	1306	1307	S	Chemical	MESH:D013455
1607385	256	275	myosin II filaments	Disease	MESH:C579880
1607385	662	667	MgCl2	Chemical	MESH:D015636
1607385	1056	1070	[gamma 32P]ATP	Chemical	MESH:C022571
1607385	1250	1253	ITP	Chemical	MESH:C024164
1607385	1296	1299	ATP	Chemical	MESH:D000255
1607385	464	467	ATP	Chemical	MESH:D000255

1607383|t|Proteolysis of the major yolk glycoproteins is regulated by acidification of the yolk platelets in sea urchin embryos 
1607383|a|The precise function of the yolk platelets of sea urchin embryos during early development is unknown. We have shown previously that the chemical composition of the yolk platelets remains unchanged in terms of phospholipid, triglyceride, hexose, sialic acid, RNA, and total protein content after fertilization and early development. However, the platelet is not entirely static because the major 160-kD yolk glycoprotein YP-160 undergoes limited, step-wise proteolytic cleavage during early development. Based on previous studies by us and others, it has been postulated that yolk platelets become acidified during development, leading to the activation of a cathepsin B-like yolk proteinase that is believed to be responsible for the degradation of the major yolk glycoprotein. To investigate this possibility, we studied the effect of addition of chloroquine, which prevents acidification of lysosomes. Consistent with the postulated requirement for acidification, it was found that chloroquine blocked YP-160 breakdown but had no effect on embryonic development. To directly test the possibility that acidification of the yolk platelets over the course of development temporally correlated with YP-160 proteolysis, we added 3-(2,4-dinitroanilo)-3-amino-N-methyldipropylamine (DAMP) to eggs or embryos. This compound localizes to acidic organelles and can be detected in these organelles by EM. The results of these studies revealed that yolk platelets did, in fact, become transiently acidified during development. This acidification occurred at the same time as yolk protein proteolysis, i.e., at 6 h after fertilization (64-cell stage) in Strongylocentrotus purpuratus and at 48 h after fertilization (late gastrula) in L. pictus. Furthermore, the pH value at the point of maximal acidification of the yolk platelets in vivo was equal to the pH optimum of the enzyme measured in vitro, indicating that this acidification is sufficient to activate the enzyme. For both S. purpuratus and Lytechinus pictus, the observed decrease in the pH was approximately 0.8 U, from 7.0 to 6.2. The trypsin inhibitor benzamidine was found to inhibit the yolk proteinase in vivo. By virtue of the fact that this inhibitor was reversible we established that the activity of the yolk proteinase is developmentally regulated even though the enzyme is present throughout the course of development. These findings indicate that acidification of yolk platelets is a developmentally regulated process that is a prerequisite to initiation of the catabolism of the major yolk glycoprotein. 
1607383	175	182	embryos	Species	6239
1607383	1413	1420	embryos	Species	6239
1607383	1761	1790	Strongylocentrotus purpuratus	Species	7668
1607383	1842	1851	L. pictus	Species	9622
1607383	2090	2103	S. purpuratus	Species	311201
1607383	363	374	sialic acid	Chemical	MESH:D012794
1607383	1344	1394	3-(2,4-dinitroanilo)-3-amino-N-methyldipropylamine	Chemical	MESH:C033506
1607383	341	353	triglyceride	Chemical	MESH:D014280
1607383	966	977	chloroquine	Chemical	MESH:D002738
1607383	1396	1400	DAMP	Chemical	MESH:C033506
1607383	2223	2234	benzamidine	Chemical	MESH:C032157
1607383	355	361	hexose	Chemical	MESH:D006601
1607383	1102	1113	chloroquine	Chemical	MESH:D002738

1607393|t|Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates 
1607393|a|Circumsporozoite (CS) proteins, which densely coat malaria (Plasmodia) sporozoites, contain an amino acid sequence that is homologous to segments in other proteins which bind specifically to sulfated glycoconjugates. The presence of this homology suggests that sporozoites and CS proteins may also bind sulfated glycoconjugates. To test this hypothesis, recombinant P. yoelii CS protein was examined for binding to sulfated glycoconjugate-Sepharoses. CS protein bound avidly to heparin-, fucoidan-, and dextran sulfate-Sepharose, but bound comparatively poorly to chondroitin sulfate A- or C-Sepharose. CS protein also bound with significantly lower affinity to a heparan sulfate biosynthesis-deficient mutant cell line compared with the wild- type line, consistent with the possibility that the protein also binds to sulfated glycoconjugates on the surfaces of cells. This possibility is consistent with the observation that CS protein binding to hepatocytes, cells invaded by sporozoites during the primary stage of malaria infection, was inhibited by fucoidan, pentosan polysulfate, and heparin. The effects of sulfated glycoconjugates on sporozoite infectivity were also determined. P. berghei sporozoites bound specifically to sulfatide (galactosyl[3-sulfate]beta 1-1ceramide), but not to comparable levels of cholesterol-3-sulfate, or several examples of neutral glycosphingolipids, gangliosides, or phospholipids. Sporozoite invasion into hepatocytes was inhibited by fucoidan, heparin, and dextran sulfate, paralleling the observed binding of CS protein to the corresponding Sepharose derivatives. These sulfated glycoconjugates blocked invasion by inhibiting an event occurring within 3 h of combining sporozoites and hepatocytes. Sporozoite infectivity in mice was significantly inhibited by dextran sulfate 500,000 and fucoidan. Taken together, these data indicate that CS proteins bind selectively to certain sulfated glycoconjugates, that sporozoite infectivity can be inhibited by such compounds, and that invasion of host hepatocytes by sporozoites may involve interactions with these types of compounds. 
1607393	24	40	circumsporozoite	Chemical	
1607393	0	19	Malaria sporozoites	Disease	MESH:D008288
1607393	462	471	P. yoelii	Species	5861
1607393	1283	1293	P. berghei	Species	5821
1607393	1862	1866	mice	Species	10090
1607393	1647	1649	CS	Chemical	
1607393	1602	1609	sulfate	Chemical	MESH:D013431
1607393	96	112	Circumsporozoite	Chemical	
1607393	1465	1483	glycosphingolipids	Chemical	MESH:D006028
1607393	1517	1527	Sporozoite	Chemical	MESH:C061194
1607393	768	775	sulfate	Chemical	MESH:D013431
1607393	574	581	heparin	Chemical	MESH:D006493
1607393	699	701	CS	Chemical	
1607393	142	154	coat malaria	Disease	MESH:D058456
1607393	2048	2058	sporozoite	Chemical	MESH:C061194
1607393	1411	1432	cholesterol-3-sulfate	Chemical	MESH:C007045
1607393	1022	1024	CS	Chemical	
1607393	472	474	CS	Chemical	
1607393	1114	1131	malaria infection	Disease	MESH:D008288
1607393	1186	1193	heparin	Chemical	MESH:D006493
1607393	547	549	CS	Chemical	
1607393	1339	1376	galactosyl[3-sulfate]beta 1-1ceramide	Chemical	MESH:C511581
1607393	1906	1913	sulfate	Chemical	MESH:D013431
1607393	599	614	dextran sulfate	Chemical	MESH:D016264
1607393	114	116	CS	Chemical	
1607393	1238	1248	sporozoite	Chemical	MESH:C061194
1607393	1485	1497	gangliosides	Chemical	MESH:D005732
1607393	1581	1588	heparin	Chemical	MESH:D006493
1607393	373	375	CS	Chemical	
1607393	1160	1180	pentosan polysulfate	Chemical	MESH:D010426
1607393	1571	1579	fucoidan	Chemical	MESH:C007789
1607393	1150	1158	fucoidan	Chemical	MESH:C007789
1607393	1977	1979	CS	Chemical	
1607393	660	681	chondroitin sulfate A	Chemical	MESH:D002809
1607393	1836	1858	Sporozoite infectivity	Disease	MESH:D007239
1607393	1328	1337	sulfatide	Chemical	MESH:D013433

1607379|t|Heat shock gene regulation by nascent polypeptides and denatured proteins: hsp70 as a potential autoregulatory factor 
1607379|a|Heat shock genes encode proteins (hsp's) that play important structural roles under normal circumstances and are essential to the cells' ability to survive environmental insults. Evidence is presented herein that transcriptional regulation of hsp gene expression is linked with the regulation of overall protein synthesis as well as with the accumulation of proteins denatured by stressful events. The factor that connects the three processes appears to be one of the hsp's, presumably a member(s) of the hsp70 family. Biochemical experiments demonstrate that complexes containing hsp70 and heat shock transcription factor, the specific regulator of hsp gene activity, are formed in the cells. 
1607379	75	80	hsp70	Gene	3308
1607379	361	364	hsp	Gene	7190
1607379	623	628	hsp70	Gene	3308
1607379	699	704	hsp70	Gene	3308
1607379	768	771	hsp	Gene	7190
1607379	586	589	hsp	Gene	7190
1607379	152	155	hsp	Gene	7190

1607392|t|Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived, heparin-binding synthetic peptide 
1607392|a|Cell surface heparan sulfate proteoglycan (HSPG) from metastatic mouse melanoma cells initiates cell adhesion to the synthetic peptide FN-C/H II, a heparin-binding peptide from the 33-kD A chain-derived fragment of fibronectin. Mouse melanoma cell adhesion to FN-C/H II was sensitive to soluble heparin and pretreatment of mouse melanoma cells with heparitinase. In contrast, cell adhesion to the fibronectin synthetic peptide CS1 is mediated through an alpha 4 beta 1 integrin and was resistant to heparin or heparitinase treatment. Mouse melanoma cell HSPG was metabolically labeled with [35S]sulfate and extracted with detergent. After HPLC-DEAE purification, 35S-HSPG eluted from a dissociative CL-4B column with a Kav approximately 0.45, while 35S- heparan sulfate (HS) chains eluted with a Kav approximately 0.62. The HSPG contained a major 63-kD core protein after heparitinase digestion. Polyclonal antibodies generated against HSPG purified from mouse melanoma cells grown in vivo also identified a 63-kD core protein. This HSPG is an integral plasma membrane component by virtue of its binding to Octyl Sepharose affinity columns and that anti-HSPG antibody staining exhibited a cell surface localization. The HSPG is anchored to the cell surface through phosphatidylinositol (PI) linkages, as evidenced in part by the ability of PI-specific phospholipase C to eliminate binding of the detergent-extracted HSPG to Octyl Sepharose. Furthermore, the mouse melanoma HSPG core protein could be metabolically labeled with 3H-ethanolamine. The involvement of mouse melanoma cell surface HSPG in cell adhesion to fibronectin was also demonstrated by the ability of anti-HSPG antibodies and anti-HSPG IgG Fab monomers to inhibit mouse melanoma cell adhesion to FN-C/H II. 35S- HSPG and 35S-HS bind to FN-C/H II affinity columns and require 0.25 M NaCl for elution. However, heparitinase-treated 125I-labeled HSPG failed to bind FN-C/H II, suggesting that HS, and not HSPG core protein, binds FN-C/H II. These data support the hypothesis that a phosphatidylinositol-anchored HSPG on mouse melanoma cells (MPIHP-63) initiates recognition to FN-C/H II, and implicate PI-associated signal transduction pathways in mediating melanoma cell adhesion to this defined ligand. 
1607392	43	71	heparan sulfate proteoglycan	Gene	15529
1607392	82	87	mouse	Species	10090
1607392	116	127	fibronectin	Gene	14268
1607392	88	96	melanoma	Disease	MESH:D008545
1607392	137	144	heparin	Chemical	MESH:D006493
1607392	13	33	phosphatidylinositol	Chemical	MESH:D010716
1607392	214	218	HSPG	Gene	15529
1607392	386	397	fibronectin	Gene	14268
1607392	568	579	fibronectin	Gene	14268
1607392	598	601	CS1	Gene	70599
1607392	725	729	HSPG	Gene	15529
1607392	838	842	HSPG	Gene	15529
1607392	995	999	HSPG	Gene	15529
1607392	1107	1111	HSPG	Gene	15529
1607392	1204	1208	HSPG	Gene	15529
1607392	1391	1395	HSPG	Gene	15529
1607392	1587	1591	HSPG	Gene	15529
1607392	1762	1766	HSPG	Gene	15529
1607392	1787	1798	fibronectin	Gene	14268
1607392	1869	1873	HSPG	Gene	15529
1607392	2140	2144	HSPG	Gene	15529
1607392	2247	2251	HSPG	Gene	15529
1607392	2081	2085	HSPG	Gene	15529
1607392	1950	1954	HSPG	Gene	15529
1607392	1844	1848	HSPG	Gene	15529
1607392	1325	1329	HSPG	Gene	15529
1607392	184	212	heparan sulfate proteoglycan	Gene	15529
1607392	236	241	mouse	Species	10090
1607392	399	404	Mouse	Species	10090
1607392	494	499	mouse	Species	10090
1607392	705	710	Mouse	Species	10090
1607392	1126	1131	mouse	Species	10090
1607392	1629	1634	mouse	Species	10090
1607392	1734	1739	mouse	Species	10090
1607392	1902	1907	mouse	Species	10090
1607392	2255	2260	mouse	Species	10090
1607392	1908	1916	melanoma	Disease	MESH:D008545
1607392	1132	1140	melanoma	Disease	MESH:D008545
1607392	500	508	melanoma	Disease	MESH:D008545
1607392	311	315	H II	Chemical	MESH:D006859
1607392	1698	1713	3H-ethanolamine	Chemical	MESH:D004983
1607392	2261	2269	melanoma	Disease	MESH:D008545
1607392	933	940	sulfate	Chemical	MESH:D013431
1607392	2020	2024	NaCl	Chemical	MESH:D012965
1607392	2217	2237	phosphatidylinositol	Chemical	MESH:D010716
1607392	319	326	heparin	Chemical	MESH:D006493
1607392	2170	2174	H II	Chemical	MESH:D006859
1607392	2106	2110	H II	Chemical	MESH:D006859
1607392	242	250	melanoma	Disease	MESH:D008545
1607392	436	440	H II	Chemical	MESH:D006859
1607392	761	773	[35S]sulfate	Chemical	MESH:C031512
1607392	466	473	heparin	Chemical	MESH:D006493
1607392	1635	1653	melanoma HSPG core	Disease	MESH:D009084
1607392	1740	1748	melanoma	Disease	MESH:D008545
1607392	2317	2321	H II	Chemical	MESH:D006859
1607392	1436	1456	phosphatidylinositol	Chemical	MESH:D010716
1607392	2393	2401	melanoma	Disease	MESH:D008545
1607392	405	413	melanoma	Disease	MESH:D008545
1607392	1595	1600	Octyl	Chemical	MESH:C059676
1607392	2277	2285	MPIHP-63	Chemical	MESH:C495909
1607392	711	719	melanoma	Disease	MESH:D008545
1607392	670	677	heparin	Chemical	MESH:D006493
1607392	2068	2072	125I	Chemical	MESH:C492712

1607381|t|100-kD proteins of Golgi- and trans-Golgi network-associated coated vesicles have related but distinct membrane binding properties 
1607381|a|The 100-110-kD proteins (alpha-, beta-, beta'-, and gamma-adaptins) of clathrin-coated vesicles and the 110-kD protein (beta-COP) of the nonclathrin-coated vesicles that mediate constitutive transport through the Golgi have homologous protein sequences. To determine whether homologous processes are involved in assembly of the two types of coated vesicles, the membrane binding properties of their coat proteins were compared. After treatment of MDBK cells with the fungal metabolite Brefeldin A (BFA), beta-COP was redistributed to the cytoplasm within 15 s, gamma-adaptin and clathrin in the trans-Golgi network (TGN) dispersed within 30 s, but the alpha-adaptin and clathrin present on coated pits and vesicles derived from the plasma membrane remained membrane associated even after a 15-min exposure to BFA. In PtK1 cells and MDCK cells, BFA did not affect beta-COP binding or Golgi morphology but still induced redistribution of gamma-adaptin and clathrin from TGN membranes to the cytoplasm. Thus BFA affects the binding of coat proteins to membranes in the Golgi region (Golgi apparatus and TGN) but not plasma membranes. However, the Golgi binding interactions of beta- COP and gamma-adaptin are distinct and differentially sensitive to BFA. BFA treatment did not release gamma-adaptin or clathrin from purified clathrin-coated vesicles, suggesting that their distribution to the cytoplasm after BFA treatment of cells was due to interference with their rebinding to TGN membranes after a normal cycle of disassembly. This was confirmed using an in vitro assay in which gamma-adaptin binding to TGN membranes was blocked by BFA and enhanced by GTP gamma S, similar to the binding of beta-COP to Golgi membranes. These results suggest the involvement of GTP-dependent proteins in the association of the 100-kD coat proteins with membranes in the Golgi region of the cell. 
1607381	251	259	beta-COP	Gene	281706
1607381	635	643	beta-COP	Gene	281706
1607381	994	1002	beta-COP	Gene	281706
1607381	1305	1314	beta- COP	Gene	281706
1607381	1824	1832	beta-COP	Gene	281706
1607381	598	604	fungal	Species	4751
1607381	948	952	PtK1	Species	9310
1607381	1383	1386	BFA	Chemical	MESH:D020126
1607381	1765	1768	BFA	Chemical	MESH:D020126
1607381	629	632	BFA	Chemical	MESH:D020126
1607381	821	832	coated pits	Disease	MESH:D058456
1607381	940	943	BFA	Chemical	MESH:D020126
1607381	1136	1139	BFA	Chemical	MESH:D020126
1607381	1537	1540	BFA	Chemical	MESH:D020126
1607381	616	627	Brefeldin A	Chemical	MESH:D020126
1607381	1785	1796	GTP gamma S	Chemical	MESH:D016244
1607381	183	197	gamma-adaptins	Chemical	MESH:C020361
1607381	1319	1332	gamma-adaptin	Chemical	MESH:C020361
1607381	975	978	BFA	Chemical	MESH:D020126
1607381	1067	1080	gamma-adaptin	Chemical	MESH:C020361
1607381	1378	1381	BFA	Chemical	MESH:D020126

1607391|t|Evidence for heterophilic adhesion of embryonic retinal cells and neuroblastoma cells to substratum-adsorbed NCAM 
1607391|a|The adhesion of embryonic chicken retinal cells and mouse N2A neuroblastoma cells to purified embryonic chicken retinal NCAM adsorbed on a solid substratum was examined using a quantitative centrifugal adhesion assay. Both cell types adhered to NCAM and the adhesion was specifically inhibited by monovalent anti-NCAM antibody fragments. N2A cell adhesion depended on the amount of NCAM applied to the substratum, was cation independent, and was insensitive to treatment with the cytoskeletal perturbing drugs colchicine and cytochalasin D. These results indicated that the tubulin and actin cytoskeletons were not critically required for adhesion to NCAM and make it unlikely that the cell surface ligand for NCAM is an integrin. Adhesion was however temperature dependent, strengthening greatly after a brief incubation at 37 degrees C. CHO cells transfected with NCAM cDNAs did not adhere specifically to substratum-bound NCAM and pretreatment of N2A cells and retinal cells with anti-NCAM antibodies did not inhibit adhesion to substratum-bound NCAM. These results suggest that a heterophilic interaction between substratum-adsorbed NCAM and a non-NCAM ligand on the surface of the probe cells affects adhesion in this system and support the possibility that heterophilic adhesion may be a function of NCAM in vivo. 
1607391	66	79	neuroblastoma	Disease	MESH:D009447
1607391	38	55	embryonic retinal	Disease	MESH:D012173
1607391	234	238	NCAM	Gene	428253
1607391	359	363	NCAM	Gene	428253
1607391	427	431	NCAM	Gene	428253
1607391	496	500	NCAM	Gene	428253
1607391	765	769	NCAM	Gene	428253
1607391	824	828	NCAM	Gene	428253
1607391	980	984	NCAM	Gene	428253
1607391	1039	1043	NCAM	Gene	428253
1607391	1102	1106	NCAM	Gene	428253
1607391	1163	1167	NCAM	Gene	428253
1607391	1251	1255	NCAM	Gene	428253
1607391	1266	1270	NCAM	Gene	428253
1607391	1420	1424	NCAM	Gene	428253
1607391	140	147	chicken	Species	9031
1607391	166	171	mouse	Species	10090
1607391	218	225	chicken	Species	9031
1607391	176	189	neuroblastoma	Disease	MESH:D009447
1607391	1064	1067	N2A	CellLine	CVCL:G626
1607391	953	956	CHO	CellLine	CVCL:0213
1607391	172	175	N2A	CellLine	CVCL:G626
1607391	624	634	colchicine	Chemical	MESH:D003078
1607391	452	455	N2A	CellLine	CVCL:G626

1318884|t|Molecular cloning and functional expression of mouse connexin40, a second gap junction gene preferentially expressed in lung 
1318884|a|From a mouse genomic library, a clone has been isolated that codes for a connexin-homologous sequence of 358 amino acids. Because of its theoretical molecular mass of 40.418 kD it is named connexin40 (Cx40). Based on both protein and nucleotide sequence, mouse Cx40 is more closely related to mouse Cx43 (alpha subgroup of connexins) than to mouse Cx32 (beta subgroup). The highest overall homology detected, however, was to chick Cx42 (67% amino acid and 86% nucleotide identity), raising the possibility that Cx40 may be the mouse analogue. The coding region of Cx40 is uninterrupted by introns and is detected as a single copy gene in the mouse genome. High stringency hybridization of Northern blots with the coding sequence of Cx40 identified a single transcript of 3.5 kb that is at least 16-fold more abundant in lung-similar to mouse Cx37-than in other adult tissues (kidney, heart, and skin). In embryonic kidney, skin, and liver the level of the Cx40 transcript is two- to fourfold higher than in the corresponding adult tissues. Microinjection of Cx40 cRNA into Xenopus oocytes induced functional cell-to-cell channels between pairs. These channels show a symmetrical and markedly cooperative closure in response to transjunctional voltage (Boltzmann parameters of Vo = +/- 35 mV; A = 0.32) which is also fast relative to other connexin channels recorded similarly (tau = 580 ms at Vj of +/- 50 mV). Although Cx40- expressing oocytes did not couple efficiently with oocytes expressing endogenous connexins, they did couple well to Cx37-expressing oocytes. The heterotypic channels which formed had voltage-gating properties modified from those of the original homotypic forms. Transfection of mouse Cx40 DNA, under control of the SV-40 early promoter, into coupling-deficient human HeLa or SK-Hep-1 cells resulted in expression of the expected transcript and restoration of fluorescent dye transfer in transfected clones. 
1318884	53	63	connexin40	Gene	14613
1318884	47	52	mouse	Species	10090
1318884	120	124	lung	Disease	MESH:D008171
1318884	314	324	connexin40	Gene	14613
1318884	326	330	Cx40	Gene	14613
1318884	386	390	Cx40	Gene	14613
1318884	424	428	Cx43	Gene	14611
1318884	473	477	Cx32	Gene	14618
1318884	556	560	Cx42	Gene	396502
1318884	636	640	Cx40	Gene	14613
1318884	689	693	Cx40	Gene	14613
1318884	857	861	Cx40	Gene	14613
1318884	967	971	Cx37	Gene	14612
1318884	1081	1085	Cx40	Gene	14613
1318884	1183	1187	Cx40	Gene	108707841
1318884	1545	1549	Cx40	Gene	14613
1318884	1667	1671	Cx37	Gene	14612
1318884	1835	1839	Cx40	Gene	14613
1318884	132	137	mouse	Species	10090
1318884	380	385	mouse	Species	10090
1318884	418	423	mouse	Species	10090
1318884	467	472	mouse	Species	10090
1318884	550	555	chick	Species	9031
1318884	652	657	mouse	Species	10090
1318884	767	772	mouse	Species	10090
1318884	961	966	mouse	Species	10090
1318884	1198	1205	Xenopus	Species	8355
1318884	1829	1834	mouse	Species	10090
1318884	1030	1046	embryonic kidney	Disease	MESH:D007674
1318884	1893	1922	coupling-deficient human HeLa	Disease	MESH:D015658
1318884	1926	1934	SK-Hep-1	CellLine	CVCL:0525

1607388|t|Cloning and expression of a human kinesin heavy chain gene: interaction of the COOH-terminal domain with cytoplasmic microtubules in transfected CV-1 cells 
1607388|a|To understand the interactions between the microtubule-based motor protein kinesin and intracellular components, we have expressed the kinesin heavy chain and its different domains in CV-1 monkey kidney epithelial cells and examined their distributions by immunofluorescence microscopy. For this study, we cloned and sequenced cDNAs encoding a kinesin heavy chain from a human placental library. The human kinesin heavy chain exhibits a high level of sequence identity to the previously cloned invertebrate kinesin heavy chains; homologies between the COOH-terminal domain of human and invertebrate kinesins and the nonmotor domain of the Aspergillus kinesin-like protein bimC were also found. The gene encoding the human kinesin heavy chain also contains a small upstream open reading frame in a G-C rich 5' untranslated region, features that are associated with translational regulation in certain mRNAs. After transient expression in CV-1 cells, the kinesin heavy chain showed both a diffuse distribution and a filamentous staining pattern that coaligned with microtubules but not vimentin intermediate filaments. Altering the number and distribution of microtubules with taxol or nocodazole produced corresponding changes in the localization of the expressed kinesin heavy chain. The expressed NH2-terminal motor and the COOH-terminal tail domains, but not the alpha-helical coiled coil rod domain, also colocalized with microtubules. The finding that both the kinesin motor and tail domains can interact with cytoplasmic microtubules raises the possibility that kinesin could crossbridge and induce sliding between microtubules under certain circumstances. 
1607388	34	53	kinesin heavy chain	Gene	3799
1607388	28	33	human	Species	9606
1607388	145	149	CV-1	CellLine	CVCL:0229
1607388	79	83	COOH	Chemical	MESH:C102887
1607388	500	519	kinesin heavy chain	Gene	3799
1607388	562	581	kinesin heavy chain	Gene	3799
1607388	878	897	kinesin heavy chain	Gene	3799
1607388	527	532	human	Species	9606
1607388	556	561	human	Species	9606
1607388	732	737	human	Species	9606
1607388	872	877	human	Species	9606
1607388	1419	1438	kinesin heavy chain	Gene	3799
1607388	1109	1128	kinesin heavy chain	Gene	3799
1607388	291	310	kinesin heavy chain	Gene	3799
1607388	340	344	CV-1	CellLine	CVCL:0229
1607388	1340	1350	nocodazole	Chemical	MESH:D015739
1607388	1093	1097	CV-1	CellLine	CVCL:0229
1607388	1481	1485	COOH	Chemical	MESH:C102887
1607388	1331	1336	taxol	Chemical	MESH:D017239
1607388	708	712	COOH	Chemical	MESH:C102887
1607388	1454	1457	NH2	Chemical	MESH:D000641

1376732|t|Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility [published erratum appears in J Cell Biol 1992 Aug;118(3):753] 
1376732|a|A cDNA encoding a unique hyaluronan receptor has been molecularly cloned from a lambda GT11 3T3 cDNA expression library. Immunoblot analyses of cell lysates, using antibodies to peptides encoded in the cDNA, specifically react with a 58-kD protein. This protein is regulated by the mutant H-ras gene in cells containing a metallothionein promoter H-ras hybrid gene. Further, antibodies to peptide sequences encoded in the cDNA block the increase in locomotion resulting from induction of the mutant H-ras gene in this cell line. In a transblot assay, the bacterially expressed protein binds to biotinylated hyaluronan. Antibodies to peptides encoded in the cDNA react in immunoblot assays with the 58- and 52-kD proteins of a novel hyaluronan receptor complex previously implicated in cell locomotion. Furthermore, antibodies specific to the 58- and 52-kD proteins, which block ras-induced locomotion, also cross-react with the expressed, encoded protein. The gene product described here appears to be a new type of hyaluronan receptor that is involved in cell locomotion. It is named RHAMM, an acronym for receptor for hyaluronan-mediated motility. 
1376732	63	68	tumor	Disease	MESH:D009369
1376732	435	440	H-ras	Gene	3265
1376732	645	650	H-ras	Gene	3265
1376732	1231	1236	RHAMM	Gene	3161
1376732	1253	1294	receptor for hyaluronan-mediated motility	Gene	3161
1376732	493	498	H-ras	Gene	3265

1607386|t|Localization and specificity of the phospholipid and actin binding sites on the tail of Acanthamoeba myosin IC 
1607386|a|We used bacterially expressed beta-galactosidase fusion proteins to localize the phospholipid binding domain of Acanthamoeba myosin IC to the region between amino acids 701 and 888 in the NH2-terminal half of the tail. Using a novel immobilized ligand lipid binding assay, we determined that myosin I can bind to several different acidic phospholipids, and that binding requires a minimum of 5 mol% acidic phospholipid in a neutral lipid background. The presence of di- and triglycerides and sterols in the lipid bilayer do not contribute to the affinity of myosin I for membranes. We confirm that the ATP-insensitive actin binding site is contained in the COOH-terminal 30 kD of the tail as previously shown for Acanthamoeba myosin IA. We conclude that the association of the myosin IC tail with acidic phospholipid head groups supplies much of the energy for binding myosin I to biological membranes, but probably not specificity for targeting myosin I isoforms to different cellular locations. 
1607386	88	110	Acanthamoeba myosin IC	Disease	MESH:D015823
1607386	141	159	beta-galactosidase	Gene	2720
1607386	236	245	myosin IC	Gene	4641
1607386	888	897	myosin IC	Gene	4641
1607386	585	598	triglycerides	Chemical	MESH:D014280
1607386	768	772	COOH	Chemical	MESH:C102887
1607386	713	716	ATP	Chemical	MESH:D000255
1607386	603	610	sterols	Chemical	MESH:D013261
1607386	824	846	Acanthamoeba myosin IA	Disease	MESH:D015823
1607386	299	302	NH2	Chemical	MESH:D000641

1607390|t|Flagellar microtubule dynamics in Chlamydomonas: cytochalasin D induces periods of microtubule shortening and elongation; and colchicine induces disassembly of the distal, but not proximal, half of the flagellum 
1607390|a|To study the mechanisms responsible for the regulation of flagellar length, we examined the effects of colchicine and Cytochalasin D (CD) on the growth and maintenance of Chlamydomonas flagella on motile wild type cells as well as on pf 18 cells, whose flagella lack the central microtubules and are immobile. CD had no effect on the regeneration of flagella after deflagellation but it induced fully assembled flagella to shorten at an average rate of 0.03 microns-min. Cells remained fully motile in CD and even stubby flagella continued to move, indicating that flagellar shortening did not selectively disrupt machinery necessary for motility. To observe the effects of the drug on individual cells, pf 18 cells were treated with CD and flagella on cells were monitored by direct observation over a 5-hour period. Flagella on control pf 18 cells maintained their initial lengths throughout the experiment but flagella on CD-treated cells exhibited periods of elongation, shortening, and regrowth suggestive of the dynamic behavior of cytoplasmic microtubules observed in vitro and in vitro. Cells behaved individually, with no two cells exhibiting the same flagellar behavior at any given time although both flagella on any single cell behaved identically. The rate of drug-induced flagellar shortening and elongation in pf 18 cells varied from 0.08 to 0.17 microns-min-1, with each event occurring over 10-60-min periods. Addition of colchicine to wild type and pf 18 cells induced flagella to shorten at an average rate of 0.06 microns-min-1 until the flagella reached an average of 73% of their initial length, after which they exhibited no further shortening or elongation. Cells treated with colchicine and CD exhibited nearly complete flagellar resorption, with little variation in flagellar length among cells. The effects of these drugs were reversible and flagella grew to normal stable lengths after drug removal. Taken together, these results show that the distal half to one-third of the Chlamydomonas flagellum is relatively unstable in the presence of colchicine but that the proximal half to two-thirds of the flagellum is stable to this drug. In contrast to colchicine, CD can induce nearly complete flagellar microtubule disassembly as well as flagellar assembly. Flagellar microtubules must, therefore, be inherently unstable, and flagellar length is stabilized by factors that are sensitive, either directly or indirectly, to the effects of CD. 
1607390	34	47	Chlamydomonas	Species	3052
1607390	126	136	colchicine	Chemical	MESH:D003078
1607390	383	396	Chlamydomonas	Species	3052
1607390	2216	2229	Chlamydomonas	Species	3052
1607390	1913	1923	colchicine	Chemical	MESH:D003078
1607390	1651	1661	colchicine	Chemical	MESH:D003078
1607390	2282	2292	colchicine	Chemical	MESH:D003078
1607390	465	478	flagella lack	Disease	MESH:D001259
1607390	2390	2400	colchicine	Chemical	MESH:D003078
1607390	315	325	colchicine	Chemical	MESH:D003078

1352300|t|Selective inhibition of protein targeting to the apical domain of MDCK cells by brefeldin A 
1352300|a|Dipeptidyl peptidase IV (DPPIV) is mainly vectorially targeted to the apical surface in MDCK cells. BFA was found to abolish the apical targeting of DPPIV. This BFA effect could be achieved under conditions where the ER to Golgi transport and the total surface expression of DPPIV were essentially unaffected. BFA executed its effect during the transport from the trans-Golgi network (TGN) to the surface. The inhibition of apical targeting resulted in enhanced mis-targeting to the basolateral surface. The mistargeted DPPIV was transcytosed back to the apical domain only after BFA withdrawal. In contrast, the basolateral targeting of uvomorulin was unaffected by BFA. These results established that the apical targeting of DPPIV was selectively abolished by BFA. 
1352300	80	91	brefeldin A	Chemical	MESH:D020126
1352300	730	740	uvomorulin	Gene	442858
1352300	253	256	BFA	Chemical	MESH:C524118
1352300	672	675	BFA	Chemical	MESH:C524118
1352300	192	195	BFA	Chemical	MESH:C524118
1352300	819	824	DPPIV	Chemical	MESH:D018819
1352300	759	762	BFA	Chemical	MESH:C524118
1352300	854	857	BFA	Chemical	MESH:C524118

1320035|t|Immunocytochemical analysis of the transfer of vesicular stomatitis virus G glycoprotein from the intermediate compartment to the Golgi complex 
1320035|a|We performed an immunocytochemical analysis to study the transfer of a marker protein (G glycoprotein coded by vesicular stomatitis virus ts 045 strain) from the intermediate compartment to the Golgi stacks in infected Vero cells. The intermediate compartment seemed to consist of about 30-40 separate units of clustered small vesicles and short tubules. The units contained Rab2 protein and were spread throughout the cytoplasm, with a ratio of about 6:4 in the peripheral versus perinuclear site. Time-course experiments revealed a progressive transfer of G glycoprotein from the intermediate compartment to the Golgi stacks, while the tubulo-vesicular units did not appear to change their intracellular distribution. Moreover, the labeling density of peripheral and perinuclear units decreased in parallel during the transfer. These results support the notion that the intermediate compartment is a station in the secretory pathway, and that a vesicular transport connects this station to the Golgi complex. 
1320035	68	73	virus	Species	12081
1320035	47	67	vesicular stomatitis	Disease	MESH:D054243
1320035	276	281	virus	Species	12081
1320035	255	275	vesicular stomatitis	Disease	MESH:D054243

1618904|t|Chondrodysplasia in transgenic mice harboring a 15-amino acid deletion in the triple helical domain of pro alpha 1(II) collagen chain 
1618904|a|We have generated transgenic mice by microinjection of a 39-kb mouse pro alpha 1(II) collagen gene construct containing a deletion of exon 7 and intron 7. This mutation was expected to disturb the assembly and processing of the homotrimeric type II collagen molecule in cartilage. Expression of transgene mRNA at levels equivalent or higher than the endogenous mRNA in the offspring of two founder animals resulted in a severe chondrodysplastic phenotype with short limbs, hypoplastic thorax, abnormal craniofacial development, and other skeletal deformities. The affected pups died at birth due to respiratory distress. Light microscopy of epiphyseal growth plates of transgenic pups demonstrated a marked reduction in cartilaginous extracellular matrix and disruption of the normal organization of the growth plate. The zone of proliferating chondrocytes was greatly reduced whereas the zone of hypertrophic chondrocytes was markedly increased extending deep into the diaphysis suggestive of a defect in endochondral ossification. Electron microscopic examination revealed chondrocytes with extended RER, a very severe reduction in the amount of cartilage collagen fibrils, and abnormalities in their structure. We postulate that the deletion in the alpha 1(II) collagen acts as a dominant negative mutation disrupting the assembly and secretion of type II collagen molecules. The consequences of the mutation include interference with normal endochondral ossification. These mice constitute a valuable model to study the mechanisms underlying human chondrodysplasias and normal bone formation. 
1618904	20	35	transgenic mice	Species	10090
1618904	0	16	Chondrodysplasia	Disease	MESH:D010009
1618904	48	61	15-amino acid	Chemical	MESH:D000596
1618904	152	167	transgenic mice	Species	10090
1618904	197	202	mouse	Species	10090
1618904	707	711	pups	Species	10090
1618904	814	818	pups	Species	10090
1618904	1612	1616	mice	Species	10090
1618904	1680	1685	human	Species	9606
1618904	672	692	skeletal deformities	Disease	MESH:D009139
1618904	733	753	respiratory distress	Disease	MESH:D012128
1618904	561	578	chondrodysplastic	Disease	
1618904	1686	1703	chondrodysplasias	Disease	MESH:D010009
1618904	1031	1043	hypertrophic	Disease	MESH:D006984

1618896|t|Export of mRNA from microinjected nuclei of Xenopus laevis oocytes 
1618896|a|Export of mRNA from the nucleus to the cytoplasm was studied in mature Xenopus laevis oocytes. In vitro transcribed, capped 32P-labeled mRNA was microinjected into nuclei, and its appearance in the cytoplasm measured by counting radioactivity or by RNA extraction and gel electrophoresis. Both for a 5.0-kb transferrin receptor mRNA and a 2.0- kb 4F2 antigen heavy chain mRNA we found saturable transport with an apparent Km of 3.6 x 10(8) molecules per oocyte nucleus. Under non- saturating conditions the half-time for mRNA export from the nucleus was approximately 2 min at 20 degrees C. At higher concentrations of injected mRNA this half-time was prolonged, and the maximal transport rate was reached at approximately 1.6 x 10(8) molecules/min. mRNA transport showed properties of an energy-dependent mechanism, since it was inhibited at 4 degrees C or by ATP depletion. Co-injection of the cap dinucleotide m7GpppG blocked the export effectively, suggesting a role for the cap in this process. The export was also inhibited by the pre-injection of wheat germ agglutinin. The effect of the lectin was specific and abolished by co-injection of N-acetylglucosamine. Finally, we found significant competitive inhibition in mRNA export by the presence of tRNA. Our results suggest that mRNA transport is a facilitated process which may share common steps with tRNA transport. Preliminary gel retardation experiments show that injected mRNA associates with endogenous nuclear proteins and suggest an exchange of some of the bound components during the transport to the cytoplasm. 
1618896	44	58	Xenopus laevis	Species	8355
1618896	374	385	transferrin	Gene	379502
1618896	414	417	4F2	Gene	379133
1618896	138	152	Xenopus laevis	Species	8355
1618896	1121	1126	wheat	Species	4565
1618896	1460	1471	retardation	Disease	MESH:D008607
1618896	928	931	ATP	Chemical	MESH:D000255
1618896	1215	1234	N-acetylglucosamine	Chemical	MESH:C014088

1618903|t|Different extracellular domains of the neural cell adhesion molecule (N- CAM) are involved in different functions 
1618903|a|The neural cell adhesion molecule (N-CAM) engages in diverse functional roles in neural cell interactions. Its extracellular part consists of five Ig-like domains and two fibronectin type III homologous (type III) repeats. To investigate the functional properties of the different structural domains of the molecule in cell interactions and signal transduction to the cell interior, we have synthesized, in a bacterial expression system, the individual domains and tandem sets of individual domains as protein fragments. These protein fragments were tested for their capacity to influence adhesion and spreading of neuronal cell bodies, promote neurite outgrowth, and influence cellular migration patterns from cerebellar microexplants in vitro. Ig-like domains I and II and the combined type III repeats I-II were most efficient for adhesion of neuronal cell bodies, when coated as substrates. Neurite outgrowth was best on the substrate-coated combined type III repeats I- II, followed by the combined Ig-like domains I-V and Ig-like domain I. Spreading of neuronal cell bodies was best on substrate-coated combined type III repeats I-II, followed by Ig-like domain I and the combined Ig- like domains I-V. The cellular migration pattern from cerebellar microexplant cultures plated on a mixture of laminin and poly-L-lysine was modified by Ig-like domains I, III, and IV, while Ig-like domains II and V and the combined type III repeats I-II did not show significant modifications, when added as soluble fragments. Outgrowth of astrocytic processes from the explant core was influenced only by Ig- like domain I. Metabolism of inositol phosphates was strongly increased by Ig-like domain I and less by the Ig-like domains II, III, IV, and V, and not influenced by the combined type III repeats I-II. Intracellular concentrations of Ca2+ and pH values were increased only by the Ig-like domains I and II. Intracellular levels of cAMP and GMP were not influenced by any protein fragment. These experiments indicate that different domains of N-CAM subserve different functional roles in cell recognition and signal transduction, and are functionally competent without nervous system-derived carbohydrate structures. 
1618903	70	71	N	Chemical	MESH:D009584
1618903	523	532	bacterial	Species	2
1618903	149	150	N	Chemical	MESH:D009584
1618903	2045	2049	cAMP	Chemical	MESH:D000242
1618903	1744	1763	inositol phosphates	Chemical	MESH:D007295
1618903	1949	1953	Ca2+	Chemical	MESH:D002118
1618903	1427	1440	poly-L-lysine	Chemical	MESH:D011107
1618903	2305	2317	carbohydrate	Chemical	MESH:D002241
1618903	2156	2157	N	Chemical	MESH:D009584
1618903	2054	2057	GMP	Chemical	MESH:C068152

1618905|t|Kinetochores and chromatin diminution in early embryos of Parascaris univalens 
1618905|a|In Parascaris the mitotic chromosomes of gonial germline cells are holocentric and possess a continuous kinetochore along their entire length. By contrast, in meiotic cells, the centromeric activity is restricted to the heterochromatic tips where direct insertion of spindle microtubules into chromatin without any kinetochore plate is seen. In the presomatic cells of early embryos, which undergo heterochromatin elimination, only euchromatin shows kinetic activity. After developing a technique to separate the very resistant egg shell from the embryos, we studied the cell divisions during early embryogenesis by immunochemical and EM approaches. The results reported here show that in presomatic cells microtubules bind only the euchromatin where a continuous kinetochore plate is present. We also report observations suggesting that the binding of the long kinetochores to the mitotic spindle initiates to a limited number of sites and extends along the entire length, during chromosome condensation. The existence of different centromere stages in different cell types, rends Parascaris chromosomes a very good model to study centromere organization. 
1618905	47	54	embryos	Species	6239
1618905	58	78	Parascaris univalens	Disease	
1618905	454	461	embryos	Species	6239
1618905	626	633	embryos	Species	6239

1618902|t|A multifunctional cell surface developmental stage-specific antigen in the cockroach embryo: involvement in pathfinding by CNS pioneer axons 
1618902|a|mAb DSS-8 binds to a 164-kD developmental stage-specific cell surface antigen in the nervous system of the cockroach, Periplaneta americana. The antigen is localized to different subsets of cells at various stages of development. The spatial and temporal distributions of DSS-8 binding were determined and are consistent with this antigen playing multiple roles in the development of the nervous system. Direct identification of some of these functions was made by perturbation experiments in which pioneer axon growth occurs in embryos that are cultured in vitro in the presence of mAb DSS-8 or its Fab fragment. Under these conditions the pioneer axons of the median fiber tract grow but follow altered pathways. In a smaller percentage of the ganglia, the immunoreagents additionally produce defasciculation of a subset of DSS-8 labeled axons. Therefore, direct roles for the DSS-8 antigen in both the guidance of pioneer axons and selective fasciculation have been demonstrated. 
1618902	85	91	embryo	Species	6239
1618902	670	677	embryos	Species	6239
1618902	1086	1099	fasciculation	Disease	MESH:D005207
1618902	936	951	defasciculation	Disease	

1618910|t|Kinesin-related proteins required for assembly of the mitotic spindle 
1618910|a|We identified two new Saccharomyces cerevisiae kinesin-related genes, KIP1 and KIP2, using polymerase chain reaction primers corresponding to highly conserved regions of the kinesin motor domain. Both KIP proteins are expressed in vivo, but deletion mutations conferred no phenotype. Moreover, kip1 kip2 double mutants and a triple mutant with kinesin- related kar3 had no synthetic phenotype. Using a genetic screen for mutations that make KIP1 essential, we identified another gene, KSL2, which proved to be another kinesin-related gene, CIN8. KIP1 and CIN8 are functionally redundant: double mutants arrested in mitosis whereas the single mutants did not. The microtubule organizing centers of arrested cells were duplicated but unseparated, indicating that KIP1 or CIN8 is required for mitotic spindle assembly. Consistent with this role, KIP1 protein was found to colocalize with the mitotic spindle. 
1618910	140	144	KIP1	Gene	852216
1618910	149	153	KIP2	Gene	855948
1618910	364	373	kip1 kip2	Gene	852216;855948
1618910	511	515	KIP1	Gene	852216
1618910	555	559	KSL2	Gene	856648
1618910	610	614	CIN8	Gene	856648
1618910	616	620	KIP1	Gene	852216
1618910	625	629	CIN8	Gene	856648
1618910	831	835	KIP1	Gene	852216
1618910	839	843	CIN8	Gene	856648
1618910	913	917	KIP1	Gene	852216
1618910	92	116	Saccharomyces cerevisiae	Species	4932

1618898|t|Intracellular distribution of the U1A protein depends on active transport and nuclear binding to U1 snRNA 
1618898|a|Nuclear transport of the U1 snRNP-specific protein U1A has been examined. U1A moves to the nucleus by an active process which is independent of interaction with U1 snRNA. Nuclear localization requires an unusually large sequence element situated between amino acids 94 and 204 of the protein. U1A transport is not unidirectional. The protein shuttles between nucleus and cytoplasm. At equilibrium, the concentration of the protein in the nucleus and cytoplasm is not, however, determined solely by transport rates, but can be perturbed by introducing RNA sequences that can specifically bind U1A in either the nuclear or cytoplasmic compartment. Thus, U1A represents a novel class of protein which shuttles between cytoplasm and nucleus and whose intracellular distribution can be altered by the number of free binding sites for the protein present in the cytoplasm or the nucleus. 
1618898	34	37	U1A	Gene	6626
1618898	180	183	U1A	Gene	6626
1618898	267	275	U1 snRNA	Gene	26871
1618898	399	402	U1A	Gene	6626
1618898	758	761	U1A	Gene	6626
1618898	698	701	U1A	Gene	6626
1618898	157	160	U1A	Gene	6626

1618906|t|Correct folding of alpha-lytic protease is required for its extracellular secretion from Escherichia coli 
1618906|a|alpha-Lytic protease is a bacterial serine protease of the trypsin family that is synthesized as a 39-kD preproenzyme (Silen, J. L., C. N. McGrath, K. R. Smith, and D. A. Agard. 1988. Gene (Amst.). 69: 237- 244). The 198-amino acid mature protease is secreted into the culture medium by the native host, Lysobacter enzymogenes (Whitaker, D. R. 1970. Methods Enzymol. 19:599-613). Expression experiments in Escherichia coli revealed that the 166-amino acid pro region is transiently required either in cis (Silen, J. L., D. Frank, A. Fujishige, R. Bone, and D. A. Agard. 1989. J. Bacteriol. 171:1320-1325) or in trans (Silen, J. L., and D. A. Agard. 1989. Nature (Lond.). 341:462-464) for the proper folding and extracellular accumulation of the enzyme. The maturation process is temperature sensitive in E. coli; unprocessed precursor accumulates in the cells at temperatures above 30 degrees C (Silen, J. L., D. Frank, A. Fujishige, R. Bone, and D. A. Agard. 1989. J. Bacteriol. 171:1320-1325). Here we show that full- length precursor produced at nonpermissive temperatures is tightly associated with the E. coli outer membrane. The active site mutant Ser 195----Ala (SA195), which is incapable of self-processing, also accumulates as a precursor in the outer membrane, even when expressed at permissive temperatures. When the protease domain is expressed in the absence of the pro region, the misfolded, inactive protease also cofractionates with the outer membrane. However, when the folding requirement for either wild-type or mutant protease domains is provided by expressing the pro region in trans, both are efficiently secreted into the extracellular medium. Attempts to separate folding and secretion functions by extensive deletion mutagenesis within the pro region were unsuccessful. Taken together, these results suggest that only properly folded and processed forms of alpha-lytic protease are efficiently transported to the medium. 
1618906	132	141	bacterial	Species	2
1618906	512	528	Escherichia coli	Species	562
1618906	910	917	E. coli	Species	562
1618906	1213	1220	E. coli	Species	562
1618906	547	561	166-amino acid	Chemical	MESH:C478787
1618906	142	148	serine	Chemical	MESH:C047902
1618906	1260	1274	Ser 195----Ala	ProteinMutation	p.S195A

1618900|t|Nerve growth factor transcriptional control of c-fos promoter transfected in cultured spinal sensory neurons 
1618900|a|High efficiency gene transfer (greater than 90%) in chicken dorsal root ganglion neurons has been obtained by DNA calcium phosphate co- precipitation, hence providing an important tool to study control of gene expression in primary neurons. Transfection with c-fos promoter sequences linked to the chloramphenicol acetyltransferase reporter gene showed that the serum responsive element functions as a strong transcriptional enhancer. Transcription from this element is developmentally regulated, and mediates the genetic response to nerve growth factor (NGF) in developing avian sensory neurons. Furthermore, NGF exerts a negative effect on transcription from the cyclic AMP responsive element, thereby supporting the involvement of tyrosine kinase activation by NGF in primary sensory neurons. 
1618900	161	168	chicken	Species	9031
1618900	843	851	tyrosine	Chemical	
1618900	774	784	cyclic AMP	Chemical	MESH:D000242
1618900	223	240	calcium phosphate	Chemical	MESH:C020243
1618900	407	422	chloramphenicol	Chemical	MESH:D002701

1618908|t|How Listeria exploits host cell actin to form its own cytoskeleton. I. Formation of a tail and how that tail might be involved in movement 
1618908|a|After Listeria is phagocytosed by a macrophage, it dissolves the phagosomal membrane and enters the cytoplasm. The Listeria then nucleates actin filaments from its surface. These actin filaments rearrange to form a tail with which the Listeria moves to the macrophage surface as a prelude to spreading. Since individual actin filaments appear to remain in their same positions in the tail in vitro after extraction with detergent, the component filaments must be cross- bridged together. From careful examination of the distribution of actin filaments attached to the surface of Listeria and in the tail, and the fact that during and immediately after division filaments are not nucleated from the new wall formed during septation, we show how a cloud of actin filaments becomes rearranged into a tail simply by the mechanics of growth. From lineage studies we can relate the length of the tail to the age of the surface of Listeria and make predictions as to the ratio of Listeria with varying tail lengths at a particular time after the initial infection. Since we know that division occurs about every 50 min, after 4 h we would predict that if we started with one Listeria in a macrophage, 16 bacteria would be found, two with long tails, two with medium tails, four with tiny tails, and eight with no tails or a ratio of 1:1:2:4. We measured the lengths of the tails on Listeria 4 h after infection in serial sections and confirmed this prediction. By decorating the actin filaments that make up the tail of Listeria with subfragment 1 of myosin we find (a) that the filaments are indeed short (maximally 0.3 microns in length); (b) that the filament length is approximately the same at the tip and the base of the tail; and (c) that the polarity of these filaments is inappropriate for myosin to be responsible or to facilitate movement through the cytoplasm, but the polarity insures that the bacterium will be located at the tip of a pseudopod, a location that is essential for spreading to an adjacent cell. Putting all this information together we can begin to unravel the problem of how the Listeria forms the cytoskeleton and what is the biological purpose of this tail. Two functions are apparent: movement and pseudopod formation. 
1618908	4	12	Listeria	Species	1637
1618908	130	138	movement	Disease	MESH:D020820
1618908	145	153	Listeria	Species	1637
1618908	254	262	Listeria	Species	1637
1618908	374	382	Listeria	Species	1637
1618908	718	726	Listeria	Species	1637
1618908	1063	1071	Listeria	Species	1637
1618908	1112	1120	Listeria	Species	1637
1618908	1307	1315	Listeria	Species	1637
1618908	1336	1344	bacteria	Species	562
1618908	1514	1522	Listeria	Species	1637
1618908	1652	1660	Listeria	Species	1637
1618908	2241	2249	Listeria	Species	1637
1618908	1533	1542	infection	Disease	MESH:D007239

25497491|t|Models of alpha-synuclein aggregation in Parkinson's disease 
25497491|a|Parkinson's disease (PD) is not only characterized by motor disturbances but also, by cognitive, sensory, psychiatric and autonomic dysfunction. It has been proposed that some of these symptoms might be related to the widespread pathology of alpha-synuclein (alpha-syn) aggregation in different nuclei of the central and peripheral nervous system. However, the pathogenic formation of alpha-syn aggregates in different brain areas of PD patients is poorly understood. Most experimental models of PD are valuable to assess specific aspects of its pathogenesis, such as toxin-induced dopaminergic neurodegeneration. However, new models are required that reflect the widespread and progressive formation of alpha-syn aggregates in different brain areas. Such alpha-syn aggregation is induced in only a few animal models, for example perikaryon inclusions are found in rats administered rotenone, aggregates with a neuritic morphology develop in mice overexpressing either mutated or wild-type alpha-syn, and in Smad3 deficient mice, aggregates form extensively in the perikaryon and neurites of specific brain nuclei. In this review we focus on alpha-syn aggregation in the human disorder, its genetics and the availability of experimental models. Indeed, evidences show that dopamine (DA) metabolism may be related to alpha-syn and its conformational plasticity, suggesting an interesting link between the two pathological hallmarks of PD: dopaminergic neurodegeneration and Lewy body (LB) formation. 
25497491	10	25	alpha-synuclein	Gene	20617
25497491	41	60	Parkinson's disease	Disease	MESH:D010300
25497491	303	318	alpha-synuclein	Gene	20617
25497491	320	329	alpha-syn	Gene	20617
25497491	446	455	alpha-syn	Gene	6622
25497491	765	774	alpha-syn	Gene	20617
25497491	817	826	alpha-syn	Gene	29219
25497491	1051	1060	alpha-syn	Gene	20617
25497491	1069	1074	Smad3	Gene	17127
25497491	1203	1212	alpha-syn	Gene	6622
25497491	1377	1386	alpha-syn	Gene	20617
25497491	498	506	patients	Species	9606
25497491	926	930	rats	Species	10116
25497491	1003	1007	mice	Species	10090
25497491	1085	1089	mice	Species	10090
25497491	1232	1237	human	Species	9606
25497491	167	178	psychiatric	Disease	MESH:D001523
25497491	557	559	PD	Disease	MESH:D010300
25497491	495	497	PD	Disease	MESH:D010300
25497491	1344	1346	DA	Chemical	MESH:D004298
25497491	61	80	Parkinson's disease	Disease	MESH:D010300
25497491	1495	1497	PD	Disease	MESH:D010300
25497491	1534	1538	Lewy	Chemical	
25497491	1334	1342	dopamine	Chemical	MESH:D004298
25497491	944	952	rotenone	Chemical	MESH:D012402
25497491	1512	1529	neurodegeneration	Disease	MESH:D019636
25497491	643	673	dopaminergic neurodegeneration	Disease	MESH:D019636
25497491	82	84	PD	Disease	MESH:D010300
25497491	183	204	autonomic dysfunction	Disease	MESH:D012735
25497491	2206	2214	patients	Species	9606
25497491	2544	2546	PD	Disease	MESH:D010300
25497491	2203	2205	PD	Disease	MESH:D010300
25497491	1769	1778	Parkinson	Disease	MESH:D010302
25497491	2071	2073	PD	Disease	MESH:D010300
25497491	1625	1627	PD	Disease	MESH:D010300
25497491	1871	1880	sclerosis	Disease	MESH:D012598
25497491	1854	1856	PD	Disease	MESH:D010300
25497491	1604	1623	Parkinson's disease	Disease	MESH:D010300
25497491	1932	1938	tremor	Disease	MESH:D014202
25497491	2774	2779	human	Species	9606
25497491	2850	2858	rigidity	Disease	MESH:D009127
25497491	2840	2848	akinesia	Disease	MESH:D004409
25497491	2730	2756	neurodegenerative disorder	Disease	MESH:D019636
25497491	2701	2703	PD	Disease	MESH:D010300
25497491	2961	2997	degeneration of dopaminergic neurons	Disease	MESH:D009410
25497491	2868	2874	tremor	Disease	MESH:D014202
25497491	3939	3949	hypocretin	Gene	15171
25497491	3504	3512	patients	Species	9606
25497491	3963	3975	hypothalamus	Disease	MESH:D007029
25497491	4155	4167	hypothalamus	Disease	MESH:D007029
25497491	3663	3676	neuronal loss	Disease	MESH:D009410
25497491	4466	4500	psychiatric and autonomic disorder	Disease	MESH:D001523
25497491	4517	4519	PD	Disease	MESH:D010300
25497491	5148	5174	Hallervorden-Spatz disease	Disease	MESH:D006211
25497491	5116	5126	brain iron	Chemical	MESH:D007501
25497491	5011	5019	dementia	Disease	MESH:D003704
25497491	5214	5241	eye movement sleep disorder	Disease	MESH:D015835
25497491	5055	5074	Alzheimer's disease	Disease	MESH:D000544
25497491	5243	5264	parkinsonism-dementia	Disease	MESH:C537240
25497491	5093	5110	neurodegeneration	Disease	MESH:D019636
25497491	4959	4961	PD	Disease	MESH:D010300
25497491	4563	4589	neurodegenerative diseases	Disease	MESH:D019636
25497491	5282	5299	Gaucher's disease	Disease	MESH:D005776
25497491	5030	5053	multiple system atrophy	Disease	MESH:D019578
25497491	5303	5317	Pick's disease	Disease	MESH:D020774
25497491	5177	5206	progressive autonomic failure	Disease	MESH:D012791
25497491	5542	5554	haematoxylin	Chemical	MESH:C018328
25497491	6054	6068	dystrophic LNs	Disease	MESH:D058225
25497491	5978	5983	eosin	Chemical	MESH:D004801
25497491	5555	5560	eosin	Chemical	MESH:D004801
25497491	6330	6339	alpha-syn	Gene	20617
25497491	6174	6184	LB disease	Disease	MESH:D020961
25497491	6160	6168	dementia	Disease	MESH:D003704
25497491	6881	6890	alpha-syn	Gene	20617
25497491	7163	7172	alpha-syn	Gene	20617
25497491	7263	7272	alpha-syn	Gene	20617
25497491	7320	7329	alpha-syn	Gene	20617
25497491	7519	7547	Leucine-rich repeat kinase 2	Gene	66725
25497491	7549	7554	LRRK2	Gene	66725
25497491	7562	7583	histone deacetylase 6	Gene	15185
25497491	7585	7590	HDAC6	Gene	15185
25497491	7601	7639	charged multivesicular body protein 2B	Gene	68942
25497491	7641	7647	CHMP2B	Gene	68942
25497491	7699	7704	LRRK2	Gene	66725
25497491	7775	7780	HDAC6	Gene	15185
25497491	7874	7880	CHMP2B	Gene	68942
25497491	8812	8817	HSC71	Gene	3312
25497491	8741	8749	patients	Species	9606
25497491	8485	8504	Alzheimer's disease	Disease	MESH:D000544
25497491	8122	8131	molecular	Disease	MESH:D030342
25497491	8730	8740	LB disease	Disease	MESH:D020961
25497491	8716	8724	dementia	Disease	MESH:D003704
25497491	9564	9567	CA2	Gene	12349
25497491	9885	9888	CA1	Gene	12346
25497491	9890	9893	CA3	Gene	12350
25497491	10304	10323	parkinsonian brains	Disease	MESH:D010300
25497491	10114	10116	PD	Disease	MESH:D010300
25497491	10645	10654	alpha-syn	Gene	20617
25497491	10483	10489	rodent	Species	10116
25497491	10531	10533	DA	Chemical	MESH:D004298
25497491	10703	10706	PrP	Gene	19122
25497491	10712	10721	alpha-syn	Gene	20617
25497491	10748	10753	Smad3	Gene	25631
25497491	10722	10726	mice	Species	10090
25497491	10741	10745	rats	Species	10116
25497491	10759	10763	mice	Species	10090
25497491	10867	10869	LN	Chemical	MESH:C045084
25497491	10807	10809	OB	Disease	MESH:D009765
25497491	11101	11105	Th 4	Chemical	MESH:D013910
25497491	10766	10768	DA	Chemical	MESH:D004298
25497491	11269	11271	LN	Chemical	MESH:C045084
25497491	11057	11064	LN ++++	Chemical	MESH:C045084
25497491	11025	11027	LN	Chemical	MESH:C045084
25497491	10875	10883	Sc 2 +++	Chemical	MESH:D012538
25497491	11170	11172	LN	Chemical	MESH:C045084
25497491	11198	11205	LN   Pn	Chemical	MESH:C045084
25497491	11017	11023	LN +++	Chemical	MESH:C045084
25497491	10983	10985	LN	Chemical	MESH:C045084
25497491	11066	11068	LN	Chemical	MESH:C045084
25497491	11246	11248	LN	Chemical	MESH:C045084
25497491	10729	10737	Rotenone	Chemical	MESH:D012402
25497491	10839	10841	LN	Chemical	MESH:C045084
25497491	11004	11011	LN ++++	Chemical	MESH:C045084
25497491	10928	10930	LN	Chemical	MESH:C045084
25497491	10847	10849	LN	Chemical	MESH:C045084
25497491	11235	11240	LB-LN	Chemical	MESH:C045084
25497491	11044	11051	LN ++++	Chemical	MESH:C045084
25497491	10707	10711	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	11639	11648	alpha-syn	Gene	6622
25497491	11378	11386	patients	Species	9606
25497491	11584	11592	patients	Species	9606
25497491	11807	11809	PD	Disease	MESH:D010300
25497491	11614	11616	PD	Disease	MESH:D010300
25497491	11388	11396	Braak PD	Disease	MESH:D010300
25497491	11699	11701	PD	Disease	MESH:D010300
25497491	11768	11772	iLBD	Disease	MESH:D020961
25497491	11756	11766	LB disease	Disease	MESH:D020961
25497491	11375	11377	PD	Disease	MESH:D010300
25497491	11835	11844	alpha-syn	Gene	20617
25497491	12273	12282	alpha-syn	Gene	20617
25497491	11934	11940	silver	Chemical	MESH:D012834
25497491	12668	12676	patients	Species	9606
25497491	12682	12684	PD	Disease	MESH:D010300
25497491	12733	12741	patients	Species	9606
25497491	12867	12875	patients	Species	9606
25497491	13146	13148	PD	Disease	MESH:D010300
25497491	13437	13448	familial PD	Disease	MESH:D010300
25497491	13345	13347	PD	Disease	MESH:D010300
25497491	13182	13213	multifactorial complex disorder	Disease	MESH:C537708
25497491	12864	12866	PD	Disease	MESH:D010300
25497491	12747	12749	PD	Disease	MESH:D010300
25497491	13583	13602	protein aggregation	Disease	MESH:D058495
25497491	13753	13762	alpha-syn	Gene	20617
25497491	13781	13786	LRRK2	Gene	66725
25497491	13937	13941	SNCA	Gene	20617
25497491	13764	13768	SNCA	Gene	20617
25497491	14076	14085	alpha-syn	Gene	20617
25497491	14087	14091	SNCA	Gene	20617
25497491	14277	14281	SNCA	Gene	20617
25497491	14439	14443	SNCA	Gene	20617
25497491	14670	14674	SNCA	Gene	6622
25497491	14975	14979	Rep1	Gene	104354
25497491	14738	14746	patients	Species	9606
25497491	14771	14779	patients	Species	9606
25497491	15073	15077	SNCA	Gene	20617
25497491	15265	15267	PD	Disease	MESH:D010300
25497491	14515	14517	PD	Disease	MESH:D010300
25497491	14326	14328	PD	Disease	MESH:D010300
25497491	14131	14135	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	14735	14737	PD	Disease	MESH:D010300
25497491	14209	14220	familial PD	Disease	MESH:D010300
25497491	15155	15157	PD	Disease	MESH:D010300
25497491	15286	15290	SNCA	Gene	20617
25497491	15363	15372	alpha-syn	Gene	20617
25497491	15687	15691	SNCA	Gene	6622
25497491	15753	15762	alpha-syn	Gene	6622
25497491	15874	15878	SNCA	Gene	20617
25497491	15770	15775	human	Species	9606
25497491	15799	15804	mouse	Species	10090
25497491	16312	16316	SNCA	Gene	20617
25497491	16412	16414	PD	Disease	MESH:D010300
25497491	15670	15674	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	16006	16008	PD	Disease	MESH:D010300
25497491	15846	15857	impairments	Disease	MESH:D008569
25497491	16036	16053	neurodegeneration	Disease	MESH:D019636
25497491	15729	15749	neuritic aggregation	Disease	MESH:D058225
25497491	16420	16428	dementia	Disease	MESH:D003704
25497491	16442	16446	SNCA	Gene	20617
25497491	16474	16508	microtubule-associated protein tau	Gene	17762
25497491	16510	16514	MAPT	Gene	17762
25497491	16787	16789	PD	Disease	MESH:D010300
25497491	16587	16589	PD	Disease	MESH:D010300
25497491	16791	16819	Leucine-rich repeat kinase 2	Gene	66725
25497491	16821	16826	LRRK2	Gene	66725
25497491	16851	16856	LRRK2	Gene	66725
25497491	16959	16964	LRRK2	Gene	120892
25497491	17014	17022	patients	Species	9606
25497491	17808	17816	patients	Species	9606
25497491	17986	17992	person	Species	9606
25497491	17567	17573	G2385R	ProteinMutation	p.G2385R;RS#:34778348
25497491	18090	18096	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	17134	17136	PD	Disease	MESH:D010300
25497491	16891	16893	PD	Disease	MESH:D010300
25497491	16955	16957	PD	Disease	MESH:D010300
25497491	17578	17584	R1628P	ProteinMutation	p.R1628P;RS#:33949390
25497491	17432	17438	Y1699C	ProteinMutation	p.Y1699C;RS#:35801418
25497491	17451	17457	I2020T	ProteinMutation	p.I2020T;RS#:35870237
25497491	16933	16941	familial	Disease	MESH:C562840
25497491	17420	17430	R1441G/C/H	ProteinMutation	p.R1441G,C,H;RS#:33939927|33939927|34995376
25497491	17082	17112	autosomal dominant familial PD	Disease	MESH:D010300
25497491	17412	17418	N1437H	ProteinMutation	p.N1437H;RS#:74163686
25497491	17602	17608	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	17011	17013	PD	Disease	MESH:D010300
25497491	17440	17446	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	18231	18236	LRRK2	Gene	66725
25497491	18385	18390	LRRK2	Gene	66725
25497491	18688	18693	LRRK2	Gene	66725
25497491	18808	18813	LRRK2	Gene	66725
25497491	18938	18943	LRRK2	Gene	120892
25497491	19084	19089	LRRK2	Gene	120892
25497491	19187	19192	LRRK2	Gene	66725
25497491	19350	19359	alpha-syn	Gene	20617
25497491	18929	18937	patients	Species	9606
25497491	19070	19078	patients	Species	9606
25497491	18926	18928	PD	Disease	MESH:D010300
25497491	18520	18526	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	18722	18728	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	19067	19069	PD	Disease	MESH:D010300
25497491	18793	18801	toxicity	Disease	MESH:D064420
25497491	19253	19276	dysfunctional autophagy	Disease	MESH:C564093
25497491	19472	19476	DJ-1	Gene	57320
25497491	20671	20686	alpha-synuclein	Gene	20617
25497491	19704	19712	patients	Species	9606
25497491	20210	20218	patients	Species	9606
25497491	19684	19686	PD	Disease	MESH:D010300
25497491	19592	19605	neuronal loss	Disease	MESH:D009410
25497491	19520	19531	familial PD	Disease	MESH:D010300
25497491	20046	20059	neuronal loss	Disease	MESH:D009410
25497491	19565	19567	PD	Disease	MESH:D010300
25497491	20857	20863	PINK-1	Gene	68943
25497491	20873	20877	DJ-1	Gene	57320
25497491	20981	20984	GBA	Gene	14466
25497491	20995	21013	Glucocerebrosidase	Gene	2629
25497491	21015	21018	GBA	Gene	2629
25497491	21199	21202	GBA	Gene	2629
25497491	21239	21242	GBA	Gene	14466
25497491	21459	21462	GBA	Gene	2629
25497491	21155	21163	patients	Species	9606
25497491	21479	21487	patients	Species	9606
25497491	21476	21478	PD	Disease	MESH:D010300
25497491	21392	21400	dementia	Disease	MESH:D003704
25497491	21134	21146	parkinsonism	Disease	MESH:D010302
25497491	21323	21325	PD	Disease	MESH:D010300
25497491	21371	21388	cognitive decline	Disease	MESH:D003072
25497491	21303	21311	levodopa	Chemical	MESH:D007980
25497491	21075	21111	recessive lysosomal storage disorder	Disease	MESH:D016464
25497491	21152	21154	PD	Disease	MESH:D010300
25497491	21054	21071	Gaucher's disease	Disease	MESH:D005776
25497491	21340	21354	hallucinations	Disease	MESH:D006212
25497491	21649	21658	alpha-syn	Gene	20617
25497491	21659	21670	aggregation	Disease	MESH:D001791
25497491	21741	21746	human	Species	9606
25497491	21956	21961	human	Species	9606
25497491	21962	21969	patient	Species	9606
25497491	22158	22164	humans	Species	9606
25497491	22250	22256	humans	Species	9606
25497491	22425	22430	human	Species	9606
25497491	22521	22525	mice	Species	10090
25497491	22530	22536	humans	Species	9606
25497491	22650	22668	cognitive deficits	Disease	MESH:D003072
25497491	22386	22403	neurodegeneration	Disease	MESH:D019636
25497491	22408	22417	correlate	Chemical	
25497491	23547	23556	alpha-syn	Gene	20617
25497491	23352	23357	human	Species	9606
25497491	22902	22904	PD	Disease	MESH:D010300
25497491	23019	23027	dopamine	Chemical	MESH:D004298
25497491	23474	23476	PD	Disease	MESH:D010300
25497491	23258	23260	PD	Disease	MESH:D010300
25497491	23621	23627	rodent	Species	10116
25497491	24100	24106	rodent	Species	10116
25497491	24328	24334	humans	Species	9606
25497491	24216	24220	MPTP	Chemical	MESH:D015632
25497491	23738	23742	MPTP	Chemical	MESH:D015632
25497491	23744	23752	rotenone	Chemical	MESH:D012402
25497491	24179	24191	parkinsonian	Disease	MESH:D010300
25497491	23812	23822	epoxomicin	Chemical	MESH:C078846
25497491	24723	24729	6-OHDA	Chemical	MESH:D016627
25497491	24730	24740	neurotoxic	Disease	MESH:D020258
25497491	23700	23717	6-hydroxydopamine	Chemical	MESH:D016627
25497491	24011	24013	PD	Disease	MESH:D010300
25497491	24714	24718	MPTP	Chemical	MESH:D015632
25497491	23638	23640	PD	Disease	MESH:D010300
25497491	23757	23765	paraquat	Chemical	MESH:D010269
25497491	25381	25385	SNCA	Gene	20617
25497491	25389	25394	LRRK2	Gene	66725
25497491	25536	25542	PINK-1	Gene	68943
25497491	25554	25558	DJ-1	Gene	57320
25497491	25654	25657	GBA	Gene	14466
25497491	25818	25823	Smad3	Gene	17127
25497491	25863	25872	alpha-syn	Gene	20617
25497491	26145	26154	alpha-syn	Gene	20617
25497491	26214	26219	Smad3	Gene	17127
25497491	25040	25048	patients	Species	9606
25497491	25251	25255	mice	Species	10090
25497491	25285	25307	Caenorhabditis elegans	Species	6239
25497491	25528	25532	mice	Species	10090
25497491	26230	26234	mice	Species	10090
25497491	25792	25804	neurotrophic	Disease	MESH:D009133
25497491	26193	26197	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	25947	25949	PD	Disease	MESH:D010300
25497491	25705	25707	PD	Disease	MESH:D010300
25497491	25161	25163	PD	Disease	MESH:D010300
25497491	25477	25494	neurodegeneration	Disease	MESH:D019636
25497491	26125	26133	rotenone	Chemical	MESH:D012402
25497491	26457	26462	human	Species	9606
25497491	27082	27091	alpha-syn	Gene	20617
25497491	26552	26557	human	Species	9606
25497491	26663	26669	humans	Species	9606
25497491	26604	26606	PD	Disease	MESH:D010300
25497491	27153	27157	MPTP	Chemical	MESH:D015632
25497491	26910	26928	cognitive deficits	Disease	MESH:D003072
25497491	27040	27061	neurological symptoms	Disease	MESH:D009422
25497491	27018	27035	neurodegeneration	Disease	MESH:D019636
25497491	26785	26787	PD	Disease	MESH:D010300
25497491	26939	26943	MPTP	Chemical	MESH:D015632
25497491	26472	26476	MPTP	Chemical	MESH:D015632
25497491	26478	26522	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	MESH:D015632
25497491	26888	26905	sleep disturbance	Disease	MESH:D012893
25497491	26862	26874	constipation	Disease	MESH:D003248
25497491	26979	26987	toxicity	Disease	MESH:D064420
25497491	26647	26659	parkinsonism	Disease	MESH:D010302
25497491	27228	27232	MPTP	Chemical	MESH:D015632
25497491	27591	27600	alpha-syn	Gene	20617
25497491	27714	27723	alpha-syn	Gene	20617
25497491	27958	27967	alpha-syn	Gene	20617
25497491	28314	28323	alpha-syn	Gene	20617
25497491	28511	28520	alpha-syn	Gene	20617
25497491	27244	27248	mice	Species	10090
25497491	27350	27363	Swiss Webster	Species	10090
25497491	27364	27368	mice	Species	10090
25497491	28130	28135	human	Species	9606
25497491	28163	28174	lipofuscins	Chemical	MESH:D008062
25497491	27777	27781	MPTP	Chemical	MESH:D015632
25497491	28670	28674	MPTP	Chemical	MESH:D015632
25497491	27867	27871	MPTP	Chemical	MESH:D015632
25497491	28235	28239	MPTP	Chemical	MESH:D015632
25497491	27254	27258	MPTP	Chemical	MESH:D015632
25497491	28830	28838	Rotenone	Chemical	MESH:D012402
25497491	29402	29411	alpha-syn	Gene	20617
25497491	29534	29543	alpha-syn	Gene	20617
25497491	29792	29801	alpha-syn	Gene	20617
25497491	29899	29908	alpha-syn	Gene	6622
25497491	30190	30199	alpha-syn	Gene	29219
25497491	29320	29324	rats	Species	10116
25497491	29883	29888	human	Species	9606
25497491	30047	30051	rats	Species	10116
25497491	29592	29595	LPS	Disease	
25497491	29277	29294	neurodegeneration	Disease	MESH:D019636
25497491	30000	30008	toxicity	Disease	MESH:D064420
25497491	29098	29100	PD	Disease	MESH:D010300
25497491	29368	29376	rotenone	Chemical	MESH:D012402
25497491	29991	29999	rotenone	Chemical	MESH:D012402
25497491	28847	28855	Rotenone	Chemical	MESH:D012402
25497491	29501	29503	PD	Disease	MESH:D010300
25497491	30403	30405	PD	Disease	MESH:D010300
25497491	29141	29149	rotenone	Chemical	MESH:D012402
25497491	29748	29756	rotenone	Chemical	MESH:D012402
25497491	30592	30594	LB	Chemical	MESH:D007657
25497491	30566	30583	neurodegeneration	Disease	MESH:D019636
25497491	30485	30493	paraquat	Chemical	MESH:D010269
25497491	30675	30713	ubiquitin carboxy terminal hydrolase-1	Gene	22223
25497491	30715	30721	UCH-L1	Gene	22223
25497491	30824	30833	alpha-syn	Gene	20617
25497491	31750	31759	alpha-syn	Gene	20617
25497491	32219	32228	alpha-syn	Gene	20617
25497491	31338	31342	mice	Species	10090
25497491	31344	31348	rats	Species	10116
25497491	31577	31581	mice	Species	10090
25497491	31796	31807	aggregation	Disease	MESH:D001791
25497491	30812	30820	toxicity	Disease	MESH:D064420
25497491	31492	31494	PD	Disease	MESH:D010300
25497491	31017	31027	epoxomicin	Chemical	MESH:C078846
25497491	30735	30737	PD	Disease	MESH:D010300
25497491	32236	32261	Mitochondrial dysfunction	Disease	MESH:D028361
25497491	32654	32663	alpha-syn	Gene	20617
25497491	32798	32807	alpha-syn	Gene	6622
25497491	32906	32915	alpha-syn	Gene	6622
25497491	33065	33069	TFAM	Gene	21780
25497491	33252	33261	alpha-syn	Gene	20617
25497491	33364	33373	alpha-syn	Gene	20617
25497491	32448	32456	patients	Species	9606
25497491	32469	32475	humans	Species	9606
25497491	32613	32628	Transgenic mice	Species	10090
25497491	32756	32771	transgenic mice	Species	10090
25497491	32787	32792	human	Species	9606
25497491	32988	32992	mice	Species	10090
25497491	33164	33168	mice	Species	10090
25497491	32320	32322	PD	Disease	MESH:D010300
25497491	33233	33250	neurodegeneration	Disease	MESH:D019636
25497491	32725	32744	neural degeneration	Disease	MESH:D009410
25497491	32363	32380	neurodegeneration	Disease	MESH:D019636
25497491	32445	32447	PD	Disease	MESH:D010300
25497491	32562	32570	rotenone	Chemical	MESH:D012402
25497491	32830	32857	mitochondrial abnormalities	Disease	MESH:D028361
25497491	32793	32797	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	32553	32557	MPTP	Chemical	MESH:D015632
25497491	32916	32924	toxicity	Disease	MESH:D064420
25497491	33426	33435	alpha-syn	Gene	20617
25497491	33550	33559	alpha-syn	Gene	20617
25497491	33607	33616	alpha-syn	Gene	20617
25497491	33751	33760	alpha-syn	Gene	20617
25497491	34076	34096	tyrosine hydroxylase	Gene	7054
25497491	34262	34271	alpha-syn	Gene	20617
25497491	34466	34475	alpha-syn	Gene	20617
25497491	34591	34600	alpha-syn	Gene	20617
25497491	35025	35034	alpha-syn	Gene	6622
25497491	34212	34218	humans	Species	9606
25497491	34626	34631	mouse	Species	10090
25497491	34705	34709	mice	Species	10090
25497491	35146	35151	human	Species	9606
25497491	33531	33535	A30P	ProteinMutation	p.A30P;RS#:104893878
25497491	35244	35261	neurodegeneration	Disease	MESH:D019636
25497491	35349	35351	PD	Disease	MESH:D010300
25497491	33970	33987	neurodegeneration	Disease	MESH:D019636
25497491	35306	35323	neurodegeneration	Disease	MESH:D019636
25497491	34730	34743	motor failure	Disease	MESH:D017093
25497491	34774	34783	paralysis	Disease	MESH:D010243
25497491	35011	35014	SDS	Chemical	MESH:C032259
25497491	35119	35130	filamentous	Disease	MESH:C579880
25497491	33525	33529	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	34339	34341	PD	Disease	MESH:D010300
25497491	33799	33825	pathological abnormalities	Disease	MESH:D013568
25497491	34586	34590	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	33701	33703	PD	Disease	MESH:D010300
25497491	35396	35401	LRRK2	Gene	66725
25497491	35415	35420	LRRK2	Gene	66725
25497491	35591	35600	alpha-syn	Gene	20617
25497491	35671	35676	LRRK2	Gene	66725
25497491	35802	35813	D2 receptor	Gene	13489
25497491	35863	35872	alpha-syn	Gene	20617
25497491	35935	35940	LRRK2	Gene	66725
25497491	36012	36021	alpha-syn	Gene	20617
25497491	36058	36063	LRRK2	Gene	66725
25497491	36121	36130	alpha-syn	Gene	20617
25497491	35426	35430	mice	Species	10090
25497491	35713	35717	mice	Species	10090
25497491	35892	35896	Mice	Species	10090
25497491	36131	36135	mice	Species	10090
25497491	36116	36120	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	35916	35922	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	35747	35764	neurodegeneration	Disease	MESH:D019636
25497491	35652	35658	R1441C	ProteinMutation	p.R1441C;RS#:33939927
25497491	35777	35779	DA	Chemical	MESH:D004298
25497491	35522	35535	renal atrophy	Disease	MESH:D007674
25497491	36871	36880	alpha-syn	Gene	20617
25497491	36911	36920	alpha-syn	Gene	20617
25497491	37089	37098	alpha-syn	Gene	20617
25497491	36228	36230	PD	Disease	MESH:D010300
25497491	36673	36684	LB diseases	Disease	MESH:D020961
25497491	36658	36660	PD	Disease	MESH:D010300
25497491	37277	37281	Atg7	Gene	74244
25497491	37548	37554	SQSTM1	Gene	18412
25497491	37621	37630	alpha-syn	Gene	20617
25497491	37693	37697	TFEB	Gene	7942
25497491	37817	37826	alpha-syn	Gene	6622
25497491	37881	37890	alpha-syn	Gene	29219
25497491	37938	37948	synapsin-1	Gene	24949
25497491	37996	38000	TFEB	Gene	316214
25497491	38083	38092	alpha-syn	Gene	29219
25497491	38177	38186	alpha-syn	Gene	20617
25497491	37220	37224	mice	Species	10090
25497491	37524	37528	mice	Species	10090
25497491	37643	37651	patients	Species	9606
25497491	37907	37911	rats	Species	10116
25497491	38093	38101	toxicity	Disease	MESH:D064420
25497491	37377	37379	DA	Chemical	MESH:D004298
25497491	38067	38069	DA	Chemical	MESH:D004298
25497491	37640	37642	PD	Disease	MESH:D010300
25497491	38288	38293	Smad3	Gene	17127
25497491	38294	38304	deficiency	Disease	
25497491	38305	38309	GDNF	Gene	14573
25497491	38560	38564	GDNF	Gene	2668
25497491	38709	38713	GDNF	Gene	14573
25497491	38739	38748	alpha-syn	Gene	20617
25497491	38799	38803	GDNF	Gene	14573
25497491	38817	38826	alpha-syn	Gene	20617
25497491	38858	38867	alpha-syn	Gene	20617
25497491	38979	38988	alpha-syn	Gene	20617
25497491	39055	39059	GDNF	Gene	14573
25497491	38512	38520	patients	Species	9606
25497491	38526	38528	PD	Disease	MESH:D010300
25497491	38931	38941	dystrophic	Disease	MESH:D020388
25497491	38414	38420	6-OHDA	Chemical	MESH:D016627
25497491	38757	38765	toxicity	Disease	MESH:D064420
25497491	38424	38428	MPTP	Chemical	MESH:D015632
25497491	39095	39104	TGF-beta1	Gene	21803
25497491	39240	39249	TGF-beta1	Gene	7040
25497491	39373	39382	TGF-beta1	Gene	21803
25497491	39606	39615	TGF-beta1	Gene	21803
25497491	39724	39729	Smad3	Gene	17127
25497491	39783	39792	TGF-beta1	Gene	21803
25497491	40122	40127	Smad3	Gene	17127
25497491	40164	40173	alpha-syn	Gene	20617
25497491	40293	40302	alpha-syn	Gene	20617
25497491	40487	40496	alpha-syn	Gene	6622
25497491	40665	40674	alpha-syn	Gene	20617
25497491	40740	40749	alpha-syn	Gene	20617
25497491	40898	40907	alpha-syn	Gene	20617
25497491	41082	41091	alpha-syn	Gene	20617
25497491	39187	39192	mouse	Species	10090
25497491	39232	39238	humans	Species	9606
25497491	39328	39336	patients	Species	9606
25497491	39443	39447	mice	Species	10090
25497491	39454	39464	adenoviral	Species	10535
25497491	40633	40638	human	Species	9606
25497491	39293	39318	ventricular cerebrospinal	Disease	MESH:D014693
25497491	39552	39554	DA	Chemical	MESH:D004298
25497491	39899	39916	neurodegeneration	Disease	MESH:D019636
25497491	39342	39344	PD	Disease	MESH:D010300
25497491	40528	40531	Ser	Chemical	MESH:C530429
25497491	39179	39181	PD	Disease	MESH:D010300
25497491	39985	39987	DA	Chemical	MESH:D004298
25497491	39430	39434	MPTP	Chemical	MESH:D015632
25497491	40845	40864	diencephalic nuclei	Disease	MESH:D007027
25497491	39860	39862	PD	Disease	MESH:D010300
25497491	41588	41597	alpha-syn	Gene	20617
25497491	41697	41706	alpha-syn	Gene	20617
25497491	41833	41837	SNCA	Gene	6622
25497491	42006	42015	alpha-syn	Gene	6622
25497491	42100	42105	Smad3	Gene	17127
25497491	42126	42135	alpha-syn	Gene	20617
25497491	42190	42195	Smad3	Gene	17127
25497491	42245	42250	Smad3	Gene	17127
25497491	42440	42445	Smad3	Gene	17127
25497491	42524	42527	CA1	Gene	12346
25497491	42786	42791	Smad3	Gene	17127
25497491	42951	42960	alpha-syn	Gene	20617
25497491	41416	41424	patients	Species	9606
25497491	41513	41521	patients	Species	9606
25497491	41574	41579	mouse	Species	10090
25497491	41909	41917	patients	Species	9606
25497491	42079	42087	patients	Species	9606
25497491	42116	42120	mice	Species	10090
25497491	41510	41512	PD	Disease	MESH:D010300
25497491	41233	41235	PD	Disease	MESH:D010300
25497491	41954	41962	dementia	Disease	MESH:D003704
25497491	41946	41948	PD	Disease	MESH:D010300
25497491	42976	42996	cognitive impairment	Disease	MESH:D003072
25497491	42887	42889	PD	Disease	MESH:D010300
25497491	41245	41265	cognitive impairment	Disease	MESH:D003072
25497491	41270	41290	behavioral disorders	Disease	MESH:D002653
25497491	41413	41415	PD	Disease	MESH:D010300
25497491	42076	42078	PD	Disease	MESH:D010300
25497491	42756	42778	neurological disorders	Disease	MESH:D009422
25497491	42034	42054	cognitive impairment	Disease	MESH:D003072
25497491	41378	41399	cognitive dysfunction	Disease	MESH:D003072
25497491	43592	43601	alpha-syn	Gene	6622
25497491	43848	43853	LRRK2	Gene	66725
25497491	43109	43114	human	Species	9606
25497491	43388	43396	nematode	Species	6239
25497491	43403	43425	Caenorhabditis elegans	Species	6239
25497491	43566	43571	human	Species	9606
25497491	43605	43615	C. elegans	Species	6239
25497491	43785	43795	C. elegans	Species	6239
25497491	43896	43899	syn	Gene	16473
25497491	43817	43820	syn	Gene	16473
25497491	43682	43685	syn	Gene	16473
25497491	43245	43248	syn	Gene	16473
25497491	43146	43149	syn	Gene	16473
25497491	43509	43527	parkinsonian toxic	Disease	MESH:D010300
25497491	43200	43221	locomotor dysfunction	Disease	MESH:D009069
25497491	43637	43654	neurodegeneration	Disease	MESH:D019636
25497491	43119	43129	Drosophila	Disease	
25497491	43115	43117	PD	Disease	MESH:D010300
25497491	43770	43780	Drosophila	Disease	
25497491	44016	44018	PD	Disease	MESH:D010300
25497491	44105	44113	Dopamine	Chemical	MESH:D004298
25497491	44165	44174	alpha-syn	Gene	20617
25497491	44245	44254	alpha-syn	Gene	20617
25497491	44264	44284	tyrosine hydroxylase	Gene	21823
25497491	44505	44514	alpha-syn	Gene	20617
25497491	44314	44316	DA	Chemical	MESH:D004298
25497491	44493	44501	toxicity	Disease	MESH:D064420
25497491	44405	44411	L-Dopa	Chemical	MESH:D007980
25497491	44345	44364	aromatic amino acid	Chemical	MESH:D065105
25497491	44449	44451	DA	Chemical	MESH:D004298
25497491	44415	44417	DA	Chemical	MESH:D004298
25497491	44184	44186	DA	Chemical	MESH:D004298
25497491	44526	44531	Smad3	Gene	17127
25497491	44588	44597	alpha-syn	Gene	20617
25497491	44625	44630	Smad3	Gene	17127
25497491	44649	44658	alpha-syn	Gene	20617
25497491	44851	44860	alpha-syn	Gene	20617
25497491	44870	44874	DJ-1	Gene	57320
25497491	44878	44883	PINK1	Gene	68943
25497491	45049	45052	DAT	Gene	13162
25497491	45473	45482	alpha-syn	Gene	20617
25497491	45821	45830	alpha-syn	Gene	20617
25497491	45883	45888	Smad3	Gene	17127
25497491	46023	46038	alpha-synuclein	Gene	20617
25497491	46088	46097	alpha-syn	Gene	20617
25497491	44542	44547	mouse	Species	10090
25497491	44829	44834	mouse	Species	10090
25497491	44889	44893	mice	Species	10090
25497491	45159	45163	mice	Species	10090
25497491	45305	45309	mice	Species	10090
25497491	45357	45361	mice	Species	10090
25497491	45493	45497	mice	Species	10090
25497491	45697	45701	mice	Species	10090
25497491	45899	45903	mice	Species	10090
25497491	45282	45286	DJ-1	Gene	57320
25497491	45792	45794	PD	Disease	MESH:D010300
25497491	45849	45862	neuronal loss	Disease	MESH:D009410
25497491	45336	45338	DA	Chemical	MESH:D004298
25497491	46146	46166	SN neurodegeneration	Disease	MESH:D019636
25497491	45987	45989	DA	Chemical	MESH:D004298
25497491	44760	44762	DA	Chemical	MESH:D004298
25497491	46170	46172	PD	Disease	MESH:D010300
25497491	44996	45009	neuronal loss	Disease	MESH:D009410
25497491	45549	45551	DA	Chemical	MESH:D004298
25497491	45064	45067	GSH	Chemical	MESH:D005978
25497491	44602	44604	DA	Chemical	MESH:D004298
25497491	45390	45392	DA	Chemical	MESH:D004298
25497491	45445	45447	DA	Chemical	MESH:D004298
25497491	45946	45951	DOPAL	Chemical	MESH:C007430
25497491	45846	45848	DA	Chemical	MESH:D004298
25497491	45652	45654	DA	Chemical	MESH:D004298
25497491	45913	45944	3,4-dihydroxyphenylacetaldehyde	Chemical	MESH:C007430
25497491	45112	45114	DA	Chemical	MESH:D004298
25497491	45517	45519	DA	Chemical	MESH:D004298
25497491	45035	45037	DA	Chemical	MESH:D004298
25497491	45244	45246	DA	Chemical	MESH:D004298
25497491	45142	45158	Parkin deficient	Disease	
25497491	45739	45741	DA	Chemical	MESH:D004298
25497491	44722	44724	DA	Chemical	MESH:D004298
25497491	46070	46072	DA	Chemical	MESH:D004298
25497491	44929	44931	DA	Chemical	MESH:D004298
25497491	46418	46427	alpha-syn	Gene	20617
25497491	46498	46507	alpha-syn	Gene	20617
25497491	46602	46611	alpha-syn	Gene	20617
25497491	46743	46752	alpha-syn	Gene	20617
25497491	46806	46815	alpha-syn	Gene	20617
25497491	46863	46872	alpha-syn	Gene	20617
25497491	47095	47104	alpha-syn	Gene	20617
25497491	47150	47159	alpha-syn	Gene	20617
25497491	47253	47262	alpha-syn	Gene	20617
25497491	47346	47355	alpha-syn	Gene	20617
25497491	47427	47436	alpha-syn	Gene	20617
25497491	47469	47478	alpha-syn	Gene	20617
25497491	46775	46790	transgenic mice	Species	10090
25497491	46925	46929	mice	Species	10090
25497491	46942	46957	transgenic mice	Species	10090
25497491	47062	47066	mice	Species	10090
25497491	47367	47369	DA	Chemical	MESH:D004298
25497491	47441	47443	DA	Chemical	MESH:D004298
25497491	46900	46904	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	46913	46917	E46K	ProteinMutation	p.E46K;RS#:104893875
25497491	47050	47054	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	46254	46256	PD	Disease	MESH:D010300
25497491	47593	47602	alpha-syn	Chemical	MESH:C002934
25497491	47690	47699	alpha-syn	Gene	20617
25497491	47735	47744	alpha-syn	Gene	20617
25497491	47961	47970	alpha-syn	Gene	20617
25497491	48261	48270	alpha-syn	Gene	20617
25497491	48584	48593	alpha-syn	Gene	20617
25497491	48022	48025	IDP	Gene	15926
25497491	48425	48455	reduced aggregation tendencies	Disease	MESH:C536965
25497491	47852	47854	DA	Chemical	MESH:D004298
25497491	48927	48936	alpha-syn	Gene	20617
25497491	48985	48994	alpha-syn	Gene	20617
25497491	49098	49107	alpha-syn	Gene	20617
25497491	49348	49351	NAC	Gene	195046
25497491	49247	49250	NAC	Gene	195046
25497491	49164	49165	N	Chemical	MESH:D009584
25497491	49422	49429	proline	Chemical	MESH:C489032
25497491	49519	49528	alpha-syn	Gene	20617
25497491	49568	49571	Syn	Gene	16473
25497491	49672	49675	Syn	Gene	16473
25497491	50005	50014	alpha-syn	Gene	29219
25497491	50040	50045	Smad3	Gene	17127
25497491	50118	50127	alpha-syn	Gene	20617
25497491	50145	50150	Smad3	Gene	17127
25497491	50203	50208	Smad3	Gene	17127
25497491	50365	50374	alpha-syn	Gene	20617
25497491	50376	50381	LRRK2	Gene	66725
25497491	50450	50459	alpha-syn	Gene	20617
25497491	49560	49567	A alpha	Gene	14960
25497491	49994	49998	rats	Species	10116
25497491	50031	50035	mice	Species	10090
25497491	50056	50060	mice	Species	10090
25497491	50175	50177	DA	Chemical	MESH:D004298
25497491	49965	49975	B Rotenone	Chemical	MESH:D012402
25497491	50113	50117	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	50190	50198	rotenone	Chemical	MESH:D012402
25497491	50000	50004	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	50524	50533	alpha-syn	Gene	20617
25497491	50862	50871	alpha-syn	Gene	20617
25497491	51110	51113	NAC	Gene	195046
25497491	51876	51885	alpha-syn	Gene	20617
25497491	51991	51995	SNCA	Gene	20617
25497491	52090	52099	alpha-syn	Gene	20617
25497491	52258	52267	alpha-syn	Gene	20617
25497491	52464	52473	alpha-syn	Gene	20617
25497491	52542	52551	alpha-syn	Gene	20617
25497491	52751	52760	alpha-syn	Gene	20617
25497491	52821	52830	alpha-syn	Gene	20617
25497491	52281	52282	C	Chemical	MESH:D002244
25497491	53209	53213	SNCA	Gene	6622
25497491	53284	53293	alpha-syn	Gene	6622
25497491	53225	53233	patients	Species	9606
25497491	53370	53374	A30P	ProteinMutation	p.A30P;RS#:104893878
25497491	53321	53325	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	53222	53224	PD	Disease	MESH:D010300
25497491	53330	53334	G46L	ProteinMutation	p.G46L
25497491	53451	53460	alpha-syn	Chemical	MESH:C002934
25497491	53505	53514	alpha-syn	Gene	20617
25497491	53880	53889	alpha-syn	Gene	20617
25497491	53978	53987	alpha-syn	Gene	20617
25497491	54055	54064	alpha-syn	Gene	20617
25497491	54492	54501	alpha-syn	Gene	20617
25497491	54566	54575	alpha-syn	Gene	20617
25497491	54767	54776	alpha-syn	Gene	20617
25497491	54960	54969	alpha-syn	Gene	20617
25497491	53681	53690	alpha-syn	Gene	20617
25497491	54260	54265	human	Species	9606
25497491	54654	54673	protein aggregation	Disease	MESH:D058495
25497491	53844	53852	toxicity	Disease	MESH:D064420
25497491	54737	54738	C	Chemical	MESH:D002244
25497491	54590	54601	PD deposits	Disease	MESH:D010300
25497491	53791	53797	serine	Chemical	MESH:C047902
25497491	53935	53939	poly	Chemical	MESH:C017937
25497491	53658	53664	serine	Chemical	MESH:C047902
25497491	55178	55187	alpha-syn	Gene	20617
25497491	55312	55321	alpha-syn	Gene	20617
25497491	55454	55463	alpha-syn	Gene	20617
25497491	55481	55486	Smad3	Gene	17127
25497491	55497	55501	mice	Species	10090
25497491	55345	55347	PD	Disease	MESH:D010300
25497491	55444	55452	rotenone	Chemical	MESH:D012402
25497491	55395	55412	neurodegeneration	Disease	MESH:D019636
25497491	55417	55419	DA	Chemical	MESH:D004298
25497491	55650	55652	DA	Chemical	MESH:D004298
25497491	55653	55661	Dopamine	Chemical	MESH:D004298
25497491	55680	55698	disordered protein	Disease	MESH:D058495
25497491	55728	55730	PD	Disease	MESH:D010300
25497491	55731	55750	Parkinson's disease	Disease	MESH:D010300
25497491	55756	55772	Substantia nigra	Disease	
25497491	55773	55782	alpha-syn	Chemical	MESH:C002934
25497491	55904	55923	Parkinson's disease	Disease	MESH:D010300
25497491	55982	55999	Paralysis agitans	Disease	MESH:D010300
25497491	56021	56040	Parkinson's disease	Disease	MESH:D010300
25497491	56116	56131	alpha-synuclein	Gene	20617
25497491	56165	56184	Parkinson's disease	Disease	MESH:D010300
25497491	56231	56235	loss	Chemical	MESH:D019440
25497491	56215	56223	dopamine	Chemical	MESH:D004298
25497491	56239	56258	Parkinson's disease	Disease	MESH:D010300
25497491	56283	56302	Parkinson's disease	Disease	MESH:D010300
25497491	56370	56400	idiopathic Parkinson's disease	Disease	MESH:D010300
25497491	56403	56416	Neuronal loss	Disease	MESH:D009410
25497491	56510	56528	Parkinson diseases	Disease	MESH:D010300
25497491	56496	56505	Alzheimer	Disease	MESH:D000544
25497491	56541	56558	Parkinson disease	Disease	MESH:D010300
25497491	56529	56537	Dementia	Disease	MESH:D003704
25497491	56683	56702	Parkinson's disease	Disease	MESH:D010300
25497491	56746	56756	Hypocretin	Gene	15171
25497491	56779	56798	Parkinson's disease	Disease	MESH:D010300
25497491	56831	56850	Parkinson's disease	Disease	MESH:D010300
25497491	56853	56868	alpha-Synuclein	Gene	20617
25497491	56889	56897	dementia	Disease	MESH:D003704
25497491	56983	57030	Neuropathological spectrum of synucleinopathies	Disease	MESH:D002659
25497491	57128	57143	alpha-synuclein	Gene	20617
25497491	57160	57167	thiazin	Chemical	MESH:C419142
25497491	57197	57212	alpha-synuclein	Gene	20617
25497491	57369	57378	disorders	Disease	MESH:D009358
25497491	57301	57320	protein aggregation	Disease	MESH:D058495
25497491	57337	57356	Parkinson's disease	Disease	MESH:D010300
25497491	57464	57468	NACP	Gene	20617
25497491	57469	57484	alpha-synuclein	Gene	20617
25497491	57568	57576	dementia	Disease	MESH:D003704
25497491	57541	57560	Parkinson's disease	Disease	MESH:D010300
25497491	57790	57805	Alpha-synuclein	Gene	20617
25497491	57821	57836	alpha-Synuclein	Gene	20617
25497491	57910	57927	neurodegeneration	Disease	MESH:D019636
25497491	57928	57956	Leucine-rich repeat kinase 2	Gene	66725
25497491	58072	58089	Parkinson disease	Disease	MESH:D010300
25497491	58106	58127	histone deacetylase 6	Gene	15185
25497491	58253	58259	CHMP2B	Gene	68942
25497491	58324	58345	alpha-synucleinopathy	Disease	MESH:D005935
25497491	58544	58571	neurodegenerative disorders	Disease	MESH:D019636
25497491	58585	58600	alpha-synuclein	Gene	20617
25497491	58656	58675	Parkinson's disease	Disease	MESH:D010300
25497491	58701	58730	argyrophilic glial inclusions	Disease	MESH:D004194
25497491	58734	58753	Parkinson's disease	Disease	MESH:D010300
25497491	58771	58786	alpha-synuclein	Gene	20617
25497491	58886	58905	Parkinson's disease	Disease	MESH:D010300
25497491	58952	58971	Parkinson's disease	Disease	MESH:D010300
25497491	59028	59047	Parkinson's disease	Disease	MESH:D010300
25497491	59106	59114	patients	Species	9606
25497491	59120	59139	Parkinson's disease	Disease	MESH:D010300
25497491	59142	59185	Familial aggregation of Parkinson's disease	Disease	MESH:D010300
25497491	59218	59261	Familial aggregation of Parkinson's disease	Disease	MESH:D010300
25497491	59287	59304	Parkinson disease	Disease	MESH:D010300
25497491	59360	59379	Parkinson's disease	Disease	MESH:D010300
25497491	59545	59564	Parkinson's disease	Disease	MESH:D010300
25497491	59567	59582	alpha-Synuclein	Gene	20617
25497491	59609	59628	Parkinson's disease	Disease	MESH:D010300
25497491	59696	59715	Parkinson's disease	Disease	MESH:D010300
25497491	59731	59736	LRRK2	Gene	66725
25497491	59743	59774	autosomal-dominant parkinsonism	Disease	MESH:D010300
25497491	59841	59856	alpha-synuclein	Gene	20617
25497491	59860	59879	Parkinson's disease	Disease	MESH:D010300
25497491	59909	59924	alpha-synuclein	Gene	20617
25497491	59900	59904	E46K	ProteinMutation	p.E46K;RS#:104893875
25497491	59932	59964	Parkinson and Lewy body dementia	Disease	MESH:D010300
25497491	60041	60056	alpha-synuclein	Gene	20617
25497491	59965	59984	Parkinson's disease	Disease	MESH:D010300
25497491	60090	60105	alpha-synuclein	Gene	20617
25497491	60125	60137	parkinsonism	Disease	MESH:D010302
25497491	60138	60153	Alpha-Synuclein	Gene	20617
25497491	60194	60211	Parkinson disease	Disease	MESH:D010300
25497491	60288	60292	A30P	ProteinMutation	p.A30P;RS#:104893878
25497491	60212	60233	Familial parkinsonism	Disease	MESH:D010302
25497491	60368	60372	SNCA	Gene	20617
25497491	60423	60451	familial Parkinson's disease	Disease	MESH:D010300
25497491	60373	60377	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	60387	60406	Parkinson's disease	Disease	MESH:D010300
25497491	60482	60497	alpha-synuclein	Gene	20617
25497491	60528	60545	Parkinson disease	Disease	MESH:D010300
25497491	60597	60612	alpha-synuclein	Gene	20617
25497491	60619	60623	Rep1	Gene	104354
25497491	60614	60618	NACP	Gene	20617
25497491	60646	60665	Parkinson's disease	Disease	MESH:D010300
25497491	60668	60683	alpha-Synuclein	Gene	20617
25497491	60720	60739	Parkinson's disease	Disease	MESH:D010300
25497491	60742	60757	Alpha-synuclein	Gene	20617
25497491	60791	60810	Parkinson's disease	Disease	MESH:D010300
25497491	60885	60900	alpha-synuclein	Gene	20617
25497491	61008	61027	Parkinson's disease	Disease	MESH:D010300
25497491	61090	61105	alpha-synuclein	Gene	20617
25497491	61043	61069	Familial Parkinson disease	Disease	MESH:D010300
25497491	61206	61221	alpha-synuclein	Gene	20617
25497491	61155	61176	Parkinsonian syndrome	Disease	MESH:D010300
25497491	61355	61370	alpha-synuclein	Gene	20617
25497491	61334	61338	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	61231	61259	Abundant neuritic inclusions	Disease	MESH:D058225
25497491	61307	61324	Lewy body disease	Disease	MESH:D020961
25497491	61440	61444	mice	Species	10090
25497491	61461	61466	human	Species	9606
25497491	61456	61460	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	61376	61406	Neuronal alpha-synucleinopathy	Disease	MESH:D009410
25497491	61419	61436	movement disorder	Disease	MESH:D009069
25497491	61514	61529	alpha-synuclein	Gene	20617
25497491	61581	61589	dopamine	Chemical	MESH:D004298
25497491	61680	61695	alpha-synuclein	Gene	20617
25497491	61738	61746	dementia	Disease	MESH:D003704
25497491	61710	61733	hereditary parkinsonism	Disease	MESH:D009386
25497491	61831	61835	MAPT	Gene	17762
25497491	61818	61822	SNCA	Gene	20617
25497491	61870	61887	Parkinson disease	Disease	MESH:D010300
25497491	61950	61969	Parkinson's disease	Disease	MESH:D010300
25497491	62070	62089	Parkinson's disease	Disease	MESH:D010300
25497491	62118	62123	LRRK2	Gene	66725
25497491	62146	62165	Parkinson's disease	Disease	MESH:D010300
25497491	62253	62259	tremor	Disease	MESH:D014202
25497491	62221	62238	Parkinson disease	Disease	MESH:D010300
25497491	62260	62265	LRRK2	Gene	66725
25497491	62305	62322	Parkinson disease	Disease	MESH:D010300
25497491	62380	62385	LRRK2	Gene	66725
25497491	62397	62416	Parkinson's disease	Disease	MESH:D010300
25497491	62469	62474	LRRK2	Gene	66725
25497491	62493	62501	toxicity	Disease	MESH:D064420
25497491	62502	62507	Lrrk2	Gene	66725
25497491	62512	62529	Lewy body disease	Disease	MESH:D020961
25497491	62644	62659	alpha-synuclein	Gene	20617
25497491	62664	62669	LRRK2	Gene	66725
25497491	62581	62602	dendrite degeneration	Disease	MESH:D007635
25497491	62693	62708	alpha-synuclein	Gene	20617
25497491	62757	62782	LRRK2 Parkinson's disease	Disease	MESH:D058495
25497491	62750	62756	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	62856	62875	Parkinson's disease	Disease	MESH:D010300
25497491	62983	63016	parkin-linked Parkinson's disease	Disease	MESH:D010300
25497491	63082	63097	alpha-synuclein	Gene	20617
25497491	63108	63123	alpha-Synuclein	Gene	20617
25497491	63214	63231	Parkinson disease	Disease	MESH:D010300
25497491	63248	63253	PINK1	Gene	68943
25497491	63291	63308	Parkinson disease	Disease	MESH:D010300
25497491	63309	63313	DJ-1	Gene	57320
25497491	63328	63387	parkinsonism-dementia-amyotrophic lateral sclerosis complex	Disease	OMIM:105500
25497491	63415	63433	glucocerebrosidase	Gene	14466
25497491	63448	63460	parkinsonism	Disease	MESH:D010302
25497491	63461	63479	Glucocerebrosidase	Gene	14466
25497491	63528	63547	Parkinson's disease	Disease	MESH:D010300
25497491	63574	63592	glucocerebrosidase	Gene	14466
25497491	63606	63625	Parkinson's disease	Disease	MESH:D010300
25497491	63645	63650	mouse	Species	10090
25497491	63709	63714	mouse	Species	10090
25497491	63725	63751	neurodegenerative diseases	Disease	MESH:D019636
25497491	63807	63832	neurobehavioral disorders	Disease	MESH:D019954
25497491	63884	63894	depression	Disease	MESH:D003866
25497491	63912	63931	Parkinson's disease	Disease	MESH:D010300
25497491	64019	64038	Parkinson's disease	Disease	MESH:D010300
25497491	64058	64068	dyskinesia	Disease	MESH:D004409
25497491	64043	64049	L-dopa	Chemical	MESH:D007980
25497491	64141	64160	Parkinson's disease	Disease	MESH:D010300
25497491	64216	64221	mouse	Species	10090
25497491	64206	64215	Parkinson	Disease	MESH:D010302
25497491	64280	64295	alpha-synuclein	Gene	20617
25497491	64324	64353	glucocerebrosidase deficiency	Disease	MESH:D005776
25497491	64394	64400	LIMP-2	Gene	12492
25497491	64428	64451	beta-glucocerebrosidase	Gene	14466
25497491	64465	64480	alpha-synuclein	Gene	20617
25497491	64593	64612	Parkinson's disease	Disease	MESH:D010300
25497491	64515	64519	MPTP	Chemical	MESH:D015632
25497491	64636	64655	Parkinson's disease	Disease	MESH:D010300
25497491	64766	64778	parkinsonism	Disease	MESH:D010302
25497491	64713	64757	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	MESH:D015632
25497491	64845	64864	Parkinson's disease	Disease	MESH:D010300
25497491	64930	64942	Parkinsonism	Disease	MESH:D010302
25497491	64925	64929	MPTP	Chemical	MESH:D015632
25497491	64943	64953	Neurotoxic	Disease	MESH:D020258
25497491	65021	65036	methamphetamine	Chemical	MESH:D008694
25497491	64965	65009	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	MESH:D015632
25497491	65011	65015	MPTP	Chemical	MESH:D015632
25497491	65098	65113	alpha-synuclein	Gene	20617
25497491	65143	65148	mouse	Species	10090
25497491	65158	65177	Parkinson's disease	Disease	MESH:D010300
25497491	65208	65212	mice	Species	10090
25497491	65189	65191	PD	Disease	MESH:D010300
25497491	65238	65242	MPTP	Chemical	MESH:D015632
25497491	65298	65302	MPTP	Chemical	MESH:D015632
25497491	65252	65275	Parkinson-like syndrome	Disease	MESH:D020734
25497491	65461	65465	MPTP	Chemical	MESH:D015632
25497491	65385	65427	Modelling Parkinson-like neurodegeneration	Disease	MESH:D020721
25497491	65432	65439	osmotic	Chemical	MESH:D004234
25497491	65596	65611	alpha-synuclein	Gene	20617
25497491	65527	65531	mice	Species	10090
25497491	65570	65591	neuronal degeneration	Disease	MESH:D009410
25497491	65522	65526	MPTP	Chemical	MESH:D015632
25497491	65671	65676	mouse	Species	10090
25497491	65686	65705	Parkinson's disease	Disease	MESH:D010300
25497491	65666	65670	MPTP	Chemical	MESH:D015632
25497491	65733	65741	rotenone	Chemical	MESH:D012402
25497491	65752	65771	Parkinson's disease	Disease	MESH:D010300
25497491	65721	65729	toxicity	Disease	MESH:D064420
25497491	65846	65865	Parkinson's disease	Disease	MESH:D010300
25497491	65927	65946	Parkinson's disease	Disease	MESH:D010300
25497491	66034	66049	alpha-synuclein	Gene	20617
25497491	65962	65970	rotenone	Chemical	MESH:D012402
25497491	66050	66061	aggregation	Disease	MESH:D001791
25497491	66017	66029	degeneration	Disease	MESH:D009410
25497491	66127	66142	alpha-synuclein	Gene	20617
25497491	66159	66167	dopamine	Chemical	MESH:D004298
25497491	66239	66247	rotenone	Chemical	MESH:D012402
25497491	66304	66319	alpha-Synuclein	Gene	20617
25497491	66324	66332	Rotenone	Chemical	MESH:D012402
25497491	66388	66403	alpha-synuclein	Gene	20617
25497491	66443	66462	Parkinson's disease	Disease	MESH:D010300
25497491	66473	66481	rotenone	Chemical	MESH:D012402
25497491	66502	66553	Parkinson's disease gastrointestinal neuropathology	Disease	MESH:D010300
25497491	66593	66612	Parkinson's disease	Disease	MESH:D010300
25497491	66657	66665	rotenone	Chemical	MESH:D012402
25497491	66693	66712	Parkinson's disease	Disease	MESH:D010300
25497491	66841	66849	toxicity	Disease	MESH:D064420
25497491	66775	66783	Rotenone	Chemical	MESH:D012402
25497491	66982	67001	Parkinson's disease	Disease	MESH:D010300
25497491	67036	67041	mouse	Species	10090
25497491	67117	67122	human	Species	9606
25497491	67063	67080	neurodegeneration	Disease	MESH:D019636
25497491	67085	67089	Lewy	Chemical	
25497491	67234	67239	mouse	Species	10090
25497491	67174	67191	neurodegeneration	Disease	MESH:D019636
25497491	67336	67355	Parkinson's disease	Disease	MESH:D010300
25497491	67290	67315	Mitochondrial dysfunction	Disease	MESH:D028361
25497491	67455	67472	Parkinson disease	Disease	MESH:D010300
25497491	67502	67521	Parkinson's disease	Disease	MESH:D010300
25497491	67473	67483	Neurotoxic	Disease	MESH:D020258
25497491	67529	67537	advances	Disease	MESH:D020178
25497491	67604	67613	Parkinson	Disease	MESH:D010302
25497491	67682	67701	Parkinson's disease	Disease	MESH:D010300
25497491	67732	67736	mice	Species	10090
25497491	67704	67728	Progressive parkinsonism	Disease	MESH:D010302
25497491	67770	67778	dopamine	Chemical	MESH:D004298
25497491	67795	67810	alpha-synuclein	Gene	20617
25497491	67856	67875	Parkinson's disease	Disease	MESH:D010300
25497491	67940	67955	alpha-synuclein	Gene	20617
25497491	67905	67924	Parkinson's disease	Disease	MESH:D010300
25497491	68012	68029	neurodegeneration	Disease	MESH:D019636
25497491	68112	68131	Parkinson's disease	Disease	MESH:D010300
25497491	68167	68182	alpha-synuclein	Gene	20617
25497491	68201	68216	transgenic mice	Species	10090
25497491	68235	68252	neurodegeneration	Disease	MESH:D019636
25497491	68196	68200	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	68328	68343	alpha-synuclein	Gene	6622
25497491	68322	68327	human	Species	9606
25497491	68344	68348	A30P	ProteinMutation	p.A30P;RS#:104893878
25497491	68275	68282	gliosis	Disease	MESH:D005911
25497491	68253	68270	Motor dysfunction	Disease	MESH:D004194
25497491	68385	68400	alpha-synuclein	Gene	20617
25497491	68401	68416	transgenic mice	Species	10090
25497491	68470	68475	death	Disease	MESH:D003643
25497491	68365	68384	Parkinson's disease	Disease	MESH:D010300
25497491	68425	68460	neuronal mitochondrial degeneration	Disease	MESH:D009410
25497491	68517	68522	LRRK2	Gene	66725
25497491	68533	68537	mice	Species	10090
25497491	68541	68545	MPTP	Chemical	MESH:D015632
25497491	68547	68591	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	MESH:D015632
25497491	68497	68513	hypersensitivity	Disease	MESH:D004342
25497491	68601	68629	leucine-rich repeat kinase 2	Gene	66725
25497491	68697	68712	alpha-synuclein	Gene	20617
25497491	68771	68776	LRRK2	Gene	66725
25497491	68752	68758	R1441C	ProteinMutation	p.R1441C;RS#:33939927
25497491	68829	68834	LRRK2	Gene	66725
25497491	68905	68910	mouse	Species	10090
25497491	68860	68870	exacerbate	Chemical	
25497491	68917	68945	Leucine-rich repeat kinase 2	Gene	66725
25497491	69001	69020	Parkinson's-disease	Disease	MESH:D010300
25497491	69141	69156	transgenic mice	Species	10090
25497491	69113	69137	autophagic abnormalities	Disease	MESH:C536522
25497491	69082	69108	reduced neurite complexity	Disease	MESH:D058225
25497491	69067	69080	neuronal loss	Disease	MESH:D009410
25497491	69168	69174	G2019S	ProteinMutation	p.G2019S;RS#:34637584
25497491	69334	69349	alpha-synuclein	Gene	20617
25497491	69297	69316	Parkinson's disease	Disease	MESH:D010300
25497491	69397	69416	Parkinson's disease	Disease	MESH:D010300
25497491	69450	69465	alpha-synuclein	Gene	20617
25497491	69631	69635	TFEB	Gene	21425
25497491	69694	69709	alpha-synuclein	Gene	20617
25497491	69672	69680	dopamine	Chemical	MESH:D004298
25497491	69710	69718	toxicity	Disease	MESH:D064420
25497491	69719	69734	alpha-Synuclein	Gene	20617
25497491	69762	69767	Nurr1	Gene	18227
25497491	69777	69781	GDNF	Gene	14573
25497491	69802	69810	dopamine	Chemical	MESH:D004298
25497491	69819	69823	GDNF	Gene	25453
25497491	69864	69879	alpha-synuclein	Gene	29219
25497491	69860	69863	rat	Species	10116
25497491	69889	69908	Parkinson's disease	Disease	MESH:D010300
25497491	69941	69945	GDNF	Gene	25453
25497491	69911	69921	Lentiviral	Species	11646
25497491	69994	69997	rat	Species	10116
25497491	70007	70026	Parkinson's disease	Disease	MESH:D010300
25497491	69963	69980	neurodegeneration	Disease	MESH:D019636
25497491	70029	70062	Transforming growth factor-beta-1	Gene	21803
25497491	70141	70160	Parkinson's disease	Disease	MESH:D010300
25497491	70106	70137	ventricular cerebrospinal fluid	Disease	MESH:D065634
25497491	70163	70173	TGF beta 1	Gene	21803
25497491	70178	70188	TGF beta 2	Gene	21808
25497491	70243	70274	ventricular cerebrospinal fluid	Disease	MESH:D065634
25497491	70220	70239	Parkinson's disease	Disease	MESH:D010300
25497491	70277	70310	Transforming growth factor beta 1	Gene	21803
25497491	70392	70396	MPTP	Chemical	MESH:D015632
25497491	70441	70451	TGF beta 1	Gene	21803
25497491	70402	70412	Adenovirus	Species	10535
25497491	70546	70556	TGF-beta 1	Gene	21803
25497491	70583	70598	alpha-synuclein	Gene	20617
25497491	70614	70619	Smad3	Gene	17127
25497491	70570	70578	Dopamine	Chemical	MESH:D004298
25497491	70721	70740	Parkinson's disease	Disease	MESH:D010300
25497491	70751	70766	alpha-synuclein	Gene	20617
25497491	70848	70863	alpha-synuclein	Gene	20617
25497491	70924	70928	NMDA	Chemical	
25497491	70949	70954	Smad3	Gene	17127
25497491	71068	71078	Drosophila	Disease	
25497491	71088	71107	Parkinson's disease	Disease	MESH:D010300
25497491	71110	71125	alpha-Synuclein	Gene	20617
25497491	71137	71147	Drosophila	Disease	
25497491	71162	71181	Parkinson's Disease	Disease	MESH:D010300
25497491	71194	71211	Synucleinopathies	Disease	
25497491	71240	71255	alpha-synuclein	Gene	20617
25497491	71263	71271	dopamine	Chemical	MESH:D004298
25497491	71214	71232	Familial Parkinson	Disease	MESH:D010302
25497491	71305	71327	Caenorhabditis elegans	Disease	
25497491	71377	71399	Caenorhabditis elegans	Species	6239
25497491	71415	71420	human	Species	9606
25497491	71341	71354	neuronal loss	Disease	MESH:D009410
25497491	71486	71501	alpha-synuclein	Gene	20617
25497491	71437	71447	C. elegans	Species	6239
25497491	71545	71560	alpha-synuclein	Gene	20617
25497491	71586	71606	tyrosine hydroxylase	Gene	21823
25497491	71619	71623	MN9D	CellLine	CVCL:U508
25497491	71630	71645	Alpha-synuclein	Gene	20617
25497491	71691	71711	tyrosine hydroxylase	Gene	21823
25497491	71750	71765	Alpha-synuclein	Gene	20617
25497491	71901	71916	alpha-synuclein	Gene	20617
25497491	71853	71861	dopamine	Chemical	MESH:D004298
25497491	71952	71956	mice	Species	10090
25497491	72071	72079	dopamine	Chemical	MESH:D004298
25497491	72128	72132	mice	Species	10090
25497491	72159	72171	parkinsonism	Disease	MESH:D010302
25497491	72263	72282	Parkinsonism-linked	Disease	MESH:C564486
25497491	72172	72223	Nigrostriatal dopaminergic deficits and hypokinesia	Disease	MESH:D018476
25497491	72362	72367	PINK1	Gene	68943
25497491	72302	72310	dopamine	Chemical	MESH:D004298
25497491	72396	72411	alpha-synuclein	Gene	20617
25497491	72383	72387	Mice	Species	10090
25497491	72461	72469	dopamine	Chemical	MESH:D004298
25497491	72589	72593	mice	Species	10090
25497491	72664	72679	alpha-synuclein	Gene	20617
25497491	72694	72703	monoamine	Chemical	MESH:D015306
25497491	72683	72688	DOPAL	Chemical	MESH:C007430
25497491	72726	72734	dopamine	Chemical	MESH:D004298
25497491	72786	72801	alpha-synuclein	Gene	20617
25497491	72773	72780	calcium	Chemical	MESH:D002118
25497491	72763	72771	dopamine	Chemical	MESH:D004298
25497491	73024	73043	Parkinson's disease	Disease	MESH:D010300
25497491	73059	73074	alpha-synuclein	Gene	20617
25497491	73098	73130	Parkinson-like neurodegeneration	Disease	MESH:D010300
25497491	73134	73147	nontransgenic	Chemical	
25497491	73163	73178	alpha-synuclein	Gene	20617
25497491	73257	73262	death	Disease	MESH:D003643
25497491	73290	73305	alpha-synuclein	Gene	20617
25497491	73318	73333	alpha-synuclein	Gene	20617
25497491	73411	73426	alpha-synuclein	Gene	20617
25497491	73508	73523	alpha-synuclein	Gene	20617
25497491	73554	73572	Lewy body diseases	Disease	MESH:D020961
25497491	73585	73600	alpha-Synuclein	Gene	20617
25497491	73632	73638	Cav2.2	Gene	12287
25497491	73657	73665	Dopamine	Chemical	MESH:D004298
25497491	73706	73721	alpha-synuclein	Gene	20617
25497491	73798	73813	alpha-synuclein	Gene	20617
25497491	73834	73849	alpha-Synuclein	Gene	20617
25497491	73917	73928	aggregation	Disease	MESH:D001791
25497491	73939	73954	alpha-synuclein	Gene	20617
25497491	74034	74049	alpha-synuclein	Gene	20617
25497491	74013	74032	Parkinson's disease	Disease	MESH:D010300
25497491	74072	74087	alpha-synuclein	Gene	20617
25497491	74166	74185	Parkinson's disease	Disease	MESH:D010300
25497491	74270	74285	alpha-synuclein	Gene	20617
25497491	74318	74337	Parkinson's disease	Disease	MESH:D010300
25497491	74414	74429	alpha-synuclein	Gene	20617
25497491	74531	74546	alpha-synuclein	Gene	20617
25497491	74682	74697	alpha-synuclein	Gene	20617
25497491	74751	74766	alpha-Synuclein	Gene	20617
25497491	74823	74838	alpha-synuclein	Gene	20617
25497491	74891	74906	alpha-synuclein	Gene	20617
25497491	74990	75001	endocytosis	Disease	
25497491	75031	75046	alpha-synuclein	Gene	20617
25497491	75073	75088	alpha-synuclein	Gene	20617
25497491	75064	75072	dopamine	Chemical	MESH:D004298
25497491	75096	75104	Dopamine	Chemical	MESH:D004298
25497491	75109	75115	L-dopa	Chemical	MESH:D007980
25497491	75179	75198	Alzheimer's disease	Disease	MESH:D000544
25497491	75163	75174	Parkinson's	Disease	MESH:D010300
25497491	75226	75241	alpha-synuclein	Gene	20617
25497491	75443	75448	human	Species	9606
25497491	75375	75379	A53T	DNAMutation	c.53A>T;RS#:104893877
25497491	75366	75370	A30P	ProteinMutation	p.A30P;RS#:104893878
25497491	75427	75439	fibrillation	Disease	MESH:D014693
25497491	75321	75349	familial Parkinson's disease	Disease	MESH:D010300
25497491	75530	75545	alpha-synuclein	Gene	29219
25497491	75565	75568	rat	Species	10116
25497491	75578	75597	Parkinson's disease	Disease	MESH:D010300
25497491	75646	75661	alpha-synuclein	Gene	6622
25497491	75640	75645	human	Species	9606
25497491	75696	75699	rat	Species	10116
25497491	75629	75632	Ser	Chemical	MESH:C530429
25497491	75709	75726	Parkinson disease	Disease	MESH:D010300
25497491	75673	75690	neurodegeneration	Disease	MESH:D019636
25497491	75853	75872	Parkinson's disease	Disease	MESH:D010300
25497491	75811	75819	toxicity	Disease	MESH:D064420
25497491	75930	75945	alpha-Synuclein	Gene	20617
25497491	76155	76160	yeast	Species	4932
25497491	76120	76121	N	Chemical	MESH:D009584
25497491	76211	76226	alpha-synuclein	Gene	20617

25491129|t|The perceived effects of faculty presence vs. absence on small-group learning and group dynamics: a quasi-experimental study 
25491129|a|Background Medical education increasingly relies on small-group learning. Small group learning provides more active learning, better retention, higher satisfaction, and facilitates development of problem-solving and team-working abilities. However, less is known about student experience and preference for different small groups teaching models. We evaluated group educational dynamics and group learning process in medical school clerkship small group case-based settings, with a faculty member present versus absent. Methods Students completed surveys after cases when the faculty was present ("in") or absent ("out") for the bulk of the discussion. 228 paired surveys (114 pairs) were available for paired analysis, assessing group dynamics, group learning process, student preference, and participation through self-report and self-rating of group behaviors tied to learning and discussion quality. Results Ratings of group dynamics and group learning process were significantly higher with the faculty absent vs. present (p range <0.001 to 0.015). Students also reported higher levels of participation when the faculty member was absent (p = 0.03). Students were more likely to express a preference for having the faculty member present after "in" case vs. "out" case discussions. (p < 0.001). There was no difference in reported success of the case discussion after "in" vs. "out" cases (p = 0.67). Conclusions Student groups without faculty present reported better group dynamics, group learning processes, and participation with faculty absent. Students reported that they feel somewhat dependent on faculty, especially when the faculty is present, though there was no significant difference in students reporting that they obtained the most they could from the discussion of the case after both "in" and "out" cases. 
25491129	7789	7793	male	Species	9606
25491129	7856	7868	participants	Species	9606
25491129	8618	8625	patient	Species	9606
25491129	9178	9185	patient	Species	9606
25491129	8710	8718	diabetes	Disease	MESH:D003920
25491129	8676	8688	hypertension	Disease	MESH:D006973
25491129	12755	12762	patient	Species	9606
25491129	13421	13433	participants	Species	9606
25491129	18901	18913	psychosocial	Disease	MESH:C535569
25491129	22517	22525	diabetes	Disease	MESH:D003920
25491129	25549	25558	Wilkinson	Disease	MESH:D012872

25530808|t|The role of the Cronobacter sakazakii ProP C-terminal coiled coil domain in osmotolerance 
25530808|a|Background We investigate the role of the C-terminal coiled coil of the secondary proline porter ProP in contributing to Cronobacter sakazakii osmotolerance. Findings The extended C-terminal domain of ProP1 (encoded by ESA_02131) was spliced onto the truncated C-terminal end of ProP2 (encoded by ESA_01706); creating a chimeric protein (ProPc) which exhibits increased osmotolerance relative to the wild type. Conclusions It appears that the C-terminal coiled coil domain tunes ProP at low osmolality, whereas ProP transporters lacking the coiled coil domain are more active at a higher osmolality range. 
25530808	16	37	Cronobacter sakazakii	Species	28141
25530808	43	44	C	Chemical	MESH:D002244
25530808	211	232	Cronobacter sakazakii	Species	28141
25530808	132	133	C	Chemical	MESH:D002244
25530808	172	179	proline	Chemical	MESH:C489032
25530808	351	352	C	Chemical	MESH:D002244
25530808	270	271	C	Chemical	MESH:D002244
25530808	533	534	C	Chemical	MESH:D002244
25530808	745	766	Cronobacter sakazakii	Species	28141
25530808	822	828	infant	Species	9606
25530808	1248	1264	Escherichia coli	Species	562
25530808	1300	1309	bacterial	Species	2
25530808	1542	1549	E. coli	Species	562
25530808	1750	1762	C. sakazakii	Species	28141
25530808	1849	1856	E. coli	Species	562
25530808	2021	2028	E. coli	Species	562
25530808	2199	2211	C. sakazakii	Species	28141
25530808	2242	2254	C. sakazakii	Species	28141
25530808	2147	2148	C	Chemical	MESH:D002244
25530808	1456	1463	proline	Chemical	MESH:C489032
25530808	2056	2064	carboxyl	Chemical	MESH:C041069
25530808	1643	1650	carboxy	Chemical	MESH:C015732
25530808	1468	1475	glycine	Chemical	MESH:D005998
25530808	2341	2348	E. coli	Species	562
25530808	3128	3140	C. sakazakii	Species	28141
25530808	2556	2564	carboxyl	Chemical	MESH:C041069
25530808	3169	3170	C	Chemical	MESH:D002244
25530808	2878	2879	C	Chemical	MESH:D002244
25530808	2642	2643	C	Chemical	MESH:D002244
25530808	2986	2998	amino acid C	Chemical	MESH:D000596
25530808	3412	3419	E. coli	Species	562
25530808	3633	3645	C. sakazakii	Species	28141
25530808	3582	3583	C	Chemical	MESH:D002244
25530808	3482	3490	carboxyl	Chemical	MESH:C041069
25530808	3802	3803	C	Chemical	MESH:D002244
25530808	3390	3398	carboxyl	Chemical	MESH:C041069
25530808	3722	3723	C	Chemical	MESH:D002244
25530808	3871	3880	Bacterial	Species	2
25530808	3912	3921	Bacterial	Species	2
25530808	4420	4441	Cronobacter sakazakii	Species	28141
25530808	4451	4469	C.sakazakii strain	Species	28141
25530808	4553	4569	Escherichia coli	Species	562
25530808	4325	4326	C	Chemical	MESH:D002244
25530808	4693	4731	MC4100Delta(putPA)101Delta(proP)2Delta	Disease	MESH:C538052
25530808	4744	4749	MKH13	Chemical	MESH:C093183
25530808	5050	5059	Bacterial	Species	2
25530808	5253	5260	02131 F	Chemical	MESH:C094836
25530808	5606	5625	Chimeric-02131CTE F	Chemical	MESH:C016800
25530808	5921	5940	C. sakazakii strain	Species	28141
25530808	7654	7661	E. coli	Species	562
25530808	6463	6470	leucine	Chemical	MESH:C038361
25530808	6757	6758	C	Chemical	MESH:D002244
25530808	6471	6481	isoleucine	Chemical	MESH:C043801
25530808	7494	7502	01706CTE	Chemical	MESH:C016800
25530808	6482	6491	threonine	Chemical	MESH:C061951
25530808	7077	7112	Chimeric-01706-F Chimeric-02131tail	Chemical	MESH:D000922
25530808	7720	7727	E. coli	Species	562
25530808	8460	8467	E. coli	Species	562
25530808	8241	8245	NaCl	Chemical	MESH:D012965
25530808	7960	7970	isoleucine	Chemical	MESH:C043801
25530808	7978	7984	valine	Chemical	MESH:C521924
25530808	7929	7936	glucose	Chemical	MESH:D005947
25530808	7944	7952	arginine	Chemical	MESH:D001127
25530808	8557	8569	C. sakazakii	Species	28141
25530808	8570	8574	ProP	Chemical	MESH:C075239
25530808	8750	8757	E. coli	Species	562
25530808	8854	8866	C. sakazakii	Species	28141
25530808	8954	8961	E. coli	Species	562
25530808	9226	9238	C. sakazakii	Species	28141
25530808	9395	9402	carboxy	Chemical	MESH:C015732
25530808	9139	9146	carboxy	Chemical	MESH:C015732
25530808	10019	10026	E. coli	Species	562
25530808	10095	10102	carboxy	Chemical	MESH:C015732
25530808	9705	9712	carboxy	Chemical	MESH:C015732
25530808	10158	10165	E. coli	Species	562
25530808	10258	10265	E. coli	Species	562
25530808	10427	10434	E. coli	Species	562
25530808	10715	10719	NaCl	Chemical	MESH:D012965
25530808	10670	10677	proline	Chemical	MESH:C489032
25530808	10877	10884	E. coli	Species	562
25530808	11092	11096	NaCl	Chemical	MESH:D012965
25530808	10968	10972	NaCl	Chemical	MESH:D012965
25530808	11057	11064	proline	Chemical	MESH:C489032
25530808	11127	11134	E. coli	Species	562
25530808	11326	11333	E. coli	Species	562
25530808	11436	11440	NaCl	Chemical	MESH:D012965
25530808	11298	11302	NaCl	Chemical	MESH:D012965
25530808	11515	11522	E. coli	Species	562
25530808	11941	11948	E. coli	Species	562
25530808	12037	12044	E. coli	Species	562
25530808	12252	12259	E. coli	Species	562
25530808	11978	11982	NaCl	Chemical	MESH:D012965
25530808	11463	11467	NaCl	Chemical	MESH:D012965
25530808	11821	11825	NaCl	Chemical	MESH:D012965
25530808	12969	12976	E. coli	Species	562
25530808	13075	13082	E. coli	Species	562
25530808	13305	13312	E. coli	Species	562
25530808	13746	13753	E. coli	Species	562
25530808	13886	13898	C. sakazakii	Species	28141
25530808	13665	13669	NaCl	Chemical	MESH:D012965
25530808	13904	13905	C	Chemical	MESH:D002244
25530808	13254	13258	NaCl	Chemical	MESH:D012965
25530808	13144	13148	NaCl	Chemical	MESH:D012965
25530808	13493	13497	NaCl	Chemical	MESH:D012965
25530808	14013	14025	C. sakazakii	Species	28141
25530808	14118	14124	infant	Species	9606
25530808	14209	14216	infants	Species	9606
25530808	14231	14243	C. sakazakii	Species	28141
25530808	14349	14362	hydrocephalus	Disease	MESH:D006849
25530808	14330	14345	brain abscesses	Disease	MESH:D001922
25530808	14307	14328	neurological symptoms	Disease	MESH:D009422
25530808	14537	14557	hyper-osmotic stress	Disease	MESH:D054549
25530808	14622	14629	E. coli	Species	562
25530808	15252	15264	C. sakazakii	Species	28141
25530808	15429	15441	C. sakazakii	Species	28141
25530808	15160	15161	C	Chemical	MESH:D002244
25530808	15293	15294	C	Chemical	MESH:D002244
25530808	15485	15497	C. sakazakii	Species	28141
25530808	15827	15834	E. coli	Species	562
25530808	16207	16214	E. coli	Species	562
25530808	16421	16425	NaCl	Chemical	MESH:D012965
25530808	15913	15920	proline	Chemical	MESH:C489032
25530808	15759	15760	C	Chemical	MESH:D002244
25530808	16345	16349	NaCl	Chemical	MESH:D012965
25530808	16613	16639	Corynebacterium glutamicum	Species	1718
25530808	16651	16668	Bacillus subtilis	Species	1423
25530808	16911	16918	E. coli	Species	562
25530808	17104	17111	E. coli	Species	562
25530808	17116	17141	Agrobacterium tumefaciens	Species	358
25530808	17289	17302	C. glutamicum	Species	1718
25530808	17474	17481	E. coli	Species	562
25530808	18029	18036	E. coli	Species	562
25530808	18223	18235	C. sakazakii	Species	28141
25530808	18470	18482	C. sakazakii	Species	28141
25530808	17344	17345	C	Chemical	MESH:D002244
25530808	16549	16550	C	Chemical	MESH:D002244
25530808	18128	18132	NaCl	Chemical	MESH:D012965
25530808	18336	18337	C	Chemical	MESH:D002244
25530808	16890	16891	C	Chemical	MESH:D002244
25530808	18684	18706	hyperosmotic challenge	Disease	
25530808	18964	18971	E. coli	Species	562
25530808	19085	19092	E. coli	Species	562
25530808	19044	19048	NaCl	Chemical	MESH:D012965
25530808	19549	19551	AL	Disease	MESH:D009101
25530808	19491	19493	AF	Disease	MESH:D001281
25530808	19438	19440	AF	Disease	MESH:D001281
25530808	19835	19857	Listeria monocytogenes	Species	1639
25530808	19910	19916	murine	Species	10090
25530808	19867	19874	proline	Chemical	MESH:C489032
25530808	19917	19926	infection	Disease	MESH:D007239
25530808	19927	19936	Bacterial	Species	2
25530808	19978	19987	bacterial	Species	2
25530808	20037	20053	escherichia coli	Species	562
25530808	20151	20155	ProP	Chemical	MESH:C075239
25530808	20122	20129	proline	Chemical	MESH:C489032
25530808	20172	20180	carboxyl	Chemical	MESH:C041069
25530808	20306	20327	Cronobacter sakazakii	Species	28141
25530808	20421	20437	Escherichia coli	Species	562
25530808	20441	20450	carnitine	Chemical	MESH:D002331
25530808	20587	20608	Cronobacter sakazakii	Species	28141
25530808	20792	20799	glycine	Chemical	MESH:D005998
25530808	20904	20926	Listeria monocytogenes	Species	1639
25530808	21073	21078	human	Species	9606
25530808	21120	21142	Enterobacter sakazakii	Species	28141
25530808	21198	21203	human	Species	9606
25530808	21302	21324	Enterobacter sakazakii	Species	28141
25530808	21445	21461	Escherichia coli	Species	562

25530820|t|Nucleosome positioning is unaltered at MLH1 splice site mutations in cells derived from Lynch syndrome patients 
25530820|a|Background Splicing is more efficient when coupled with transcription and it has been proposed that nucleosomes enriched in exons are important for splice site recognition. Lynch syndrome is a familial cancer syndrome that can be caused by the autosomal dominant inheritance of splice site mutations in the MutL homolog 1 (MLH1) gene. To better understand the role of nucleosomes in splicing, we used MLH1 splice site mutations in Lynch syndrome cases as a model to investigate if abnormal splicing was associated with altered nucleosome positioning at exon-intron boundaries. Findings Nucleosome Occupancy and Methylome sequencing (NOMe-seq) was used to determine the allele-specific positioning of nucleosomes around heterozygous splice site mutations in lymphoblastoid cells lines (LCLs) derived from six Lynch syndrome patients. These mutations were previously shown to cause exon skipping in five of the six patients. Allele-specific high-resolution nucleosome mapping across exons and exon-intron boundaries revealed high levels of nucleosomes across all regions examined. Alleles containing donor or acceptor splice site mutations showed no consistent alteration in nucleosome positioning or occupancy. Conclusion Nucleosomes were enriched at MLH1 exons in LCLs derived from Lynch syndrome patients, and in this model system the positioning of nucleosomes was unaltered at exon-intron boundaries containing splice site mutations. Thus, these splice site mutations alone do not significantly change the local organisation of nucleosomes. 
25530820	39	43	MLH1	Gene	17350
25530820	88	102	Lynch syndrome	Disease	MESH:D003123
25530820	419	433	MutL homolog 1	Gene	4292
25530820	435	439	MLH1	Gene	4292
25530820	513	517	MLH1	Gene	4292
25530820	543	557	Lynch syndrome	Disease	MESH:D003123
25530820	285	299	Lynch syndrome	Disease	MESH:D003123
25530820	305	329	familial cancer syndrome	Disease	MESH:D009386
25530820	935	943	patients	Species	9606
25530820	1025	1033	patients	Species	9606
25530820	1210	1215	donor	Species	9606
25530820	920	934	Lynch syndrome	Disease	MESH:D003123
25530820	1362	1366	MLH1	Gene	4292
25530820	1409	1417	patients	Species	9606
25530820	1394	1408	Lynch syndrome	Disease	MESH:D003123
25530820	1781	1786	donor	Species	9606
25530820	2877	2882	human	Species	9606
25530820	3008	3009	C	Chemical	MESH:D002244
25530820	3615	3619	MLH1	Gene	4292
25530820	3624	3628	MSH2	Gene	4436
25530820	3657	3661	MLH1	Gene	4292
25530820	3813	3821	patients	Species	9606
25530820	3798	3812	Lynch syndrome	Disease	MESH:D003123
25530820	3308	3322	Lynch syndrome	Disease	MESH:D003123
25530820	3687	3701	Lynch syndrome	Disease	MESH:D003123
25530820	3414	3425	endometrial	Disease	MESH:D016889
25530820	3402	3412	colorectal	Disease	MESH:D015179
25530820	3329	3372	autosomal dominant familial cancer syndrome	Disease	MESH:D009386
25530820	3436	3443	cancers	Disease	MESH:D009369
25530820	4010	4014	MLH1	Gene	4292
25530820	4060	4064	MLH1	Gene	4292
25530820	4111	4125	Lynch syndrome	Disease	MESH:D003123
25530820	4331	4336	Donor	Species	9606
25530820	4631	4636	Donor	Species	9606
25530820	4865	4870	Donor	Species	9606
25530820	5096	5111	r.[1559_1667del	DNAMutation	r.[1559_1667del
25530820	4909	4921	r.791_884del	DNAMutation	r.791_884del
25530820	4374	4386	r.546_588del	DNAMutation	r.546_588del
25530820	4540	4552	r.589_592del	DNAMutation	r.589_592del
25530820	5113	5126	1559_1731del]	ProteinMutation	c.1559_1731del]
25530820	4782	4794	r.791_884del	DNAMutation	r.791_884del
25530820	5326	5330	MLH1	Gene	4292
25530820	5488	5523	Gastrointestinal Hereditary Tumours	Disease	MESH:D005770
25530820	5558	5569	InSiGHT VIC	Chemical	MESH:D005765
25530820	5621	5628	patient	Species	9606
25530820	5845	5853	patients	Species	9606
25530820	6034	6041	patient	Species	9606
25530820	5914	5927	c.1559-2A > T	DNAMutation	c.1559-2A>T;RS#:267607836
25530820	5855	5869	c.588 + 1G > T	DNAMutation	c.588+1G>T;RS#:267607772
25530820	5799	5802	CO2	Chemical	MESH:D002245
25530820	5885	5897	c.791-1G > C	DNAMutation	c.791-1G>C;RS#:267607795
25530820	6051	6065	c.790 + 1G > T	DNAMutation	c.790+1G>T;RS#:267607789
25530820	5899	5909	c.884G > A	DNAMutation	c.884G>A;RS#:63750144
25530820	5965	5982	Colorectal Cancer	Disease	MESH:D015179
25530820	5871	5883	c.589-2A > G	DNAMutation	c.589-2A>G;RS#:267607767
25530820	6152	6156	NOMe	Chemical	
25530820	6162	6166	NOMe	Chemical	
25530820	7114	7119	HSPA5	Gene	3309
25530820	6262	6263	C	Chemical	MESH:D002244
25530820	6969	6976	1559-2A	Chemical	MESH:C090124
25530820	6698	6701	C F	Chemical	MESH:C504520
25530820	6511	6541	CACAAAATCTAAAAAATTACATACACCTAA	Chemical	
25530820	7392	7395	GpC	Gene	2995
25530820	8191	8194	GpC	Gene	2995
25530820	8273	8276	GpC	Gene	2995
25530820	7820	7827	patient	Species	9606
25530820	7590	7593	SDS	Chemical	MESH:C032259
25530820	7575	7579	NaCl	Chemical	MESH:D012965
25530820	7857	7866	bisulfite	Chemical	MESH:C042345
25530820	7690	7699	bisulfite	Chemical	MESH:C042345
25530820	7441	7461	S-adenosylmethionine	Chemical	MESH:D012436
25530820	7556	7559	HCl	Chemical	MESH:C014843
25530820	7664	7671	ethanol	Chemical	MESH:D000431
25530820	7604	7608	EDTA	Chemical	MESH:D004492
25530820	7634	7651	phenol chloroform	Chemical	MESH:D002725
25530820	8699	8703	MLH1	Gene	4292
25530820	8722	8726	MLH1	Gene	4292
25530820	9273	9276	GpC	Gene	2995
25530820	9494	9497	GpC	Gene	2995
25530820	9560	9563	GpC	Gene	2995
25530820	9616	9619	GpC	Gene	2995
25530820	8840	8848	patients	Species	9606
25530820	8880	8884	NOMe	Chemical	
25530820	9846	9851	HSPA5	Gene	3309
25530820	9946	9951	HSPA5	Gene	3309
25530820	10107	10112	HSPA5	Gene	3309
25530820	10189	10193	MLH1	Gene	4292
25530820	10228	10231	GpC	Gene	2995
25530820	10368	10371	GpC	Gene	2995
25530820	10434	10437	GpC	Gene	2995
25530820	10490	10493	GpC	Gene	2995
25530820	10619	10622	GpC	Gene	2995
25530820	10733	10737	MLH1	Gene	4292
25530820	11099	11102	GpC	Gene	2995
25530820	11187	11192	HSPA5	Gene	3309
25530820	11385	11388	GpC	Gene	2995
25530820	10783	10791	patients	Species	9606
25530820	10858	10863	donor	Species	9606
25530820	10768	10782	Lynch syndrome	Disease	MESH:D003123
25530820	11879	11884	donor	Species	9606
25530820	12781	12785	CTCF	Gene	10664
25530820	13015	13020	HSPA5	Gene	3309
25530820	13235	13238	GpC	Gene	2995
25530820	13263	13267	MLH1	Gene	4292
25530820	13574	13578	MLH1	Gene	4292
25530820	13727	13731	MLH1	Gene	4292
25530820	13513	13518	human	Species	9606
25530820	13407	13412	HSPA5	Gene	3309
25530820	13658	13662	NOMe	Chemical	
25530820	13770	13774	MLH1	Gene	4292
25530820	14167	14171	MLH1	Gene	4292
25530820	14114	14121	Delta10	DNAMutation	c.del10
25530820	15132	15137	donor	Species	9606
25530820	14529	14533	NOMe	Chemical	
25530820	15568	15573	donor	Species	9606
25530820	15753	15758	donor	Species	9606
25530820	15931	15936	donor	Species	9606
25530820	16048	16053	donor	Species	9606
25530820	16300	16305	donor	Species	9606
25530820	15601	15610	Bisulfite	Chemical	MESH:C042345
25530820	16152	16167	c.588 + 1 G > T	DNAMutation	c.588+1G>T;RS#:267607772
25530820	17043	17047	MLH1	Gene	4292
25530820	16808	16814	humans	Species	9606
25530820	16822	16844	Caenorhabditis elegans	Species	6239
25530820	16855	16878	Drosophila melanogaster	Species	7227
25530820	17164	17168	MLH1	Gene	4292
25530820	17225	17231	IKBKAP	Gene	8518
25530820	17632	17635	PPT	Gene	5536
25530820	18218	18222	MLH1	Gene	4292
25530820	17935	17940	donor	Species	9606
25530820	17609	17623	polypyrimidine	Chemical	
25530820	18752	18756	MLH1	Gene	4292
25530820	18851	18855	MLH1	Gene	4292
25530820	18947	18955	patients	Species	9606
25530820	18932	18946	Lynch syndrome	Disease	MESH:D003123
25530820	19171	19174	LBH	Gene	81606
25530820	19069	19072	LBH	Gene	81606
25530820	19577	19586	mammalian	Species	9606
25530820	19830	19833	CTD	Gene	1283
25530820	19966	19985	Extracolonic cancer	Disease	MESH:D009369
25530820	19989	20030	hereditary nonpolyposis colorectal cancer	Disease	MESH:D003123
25530820	20057	20088	non-polyposis colorectal cancer	Disease	MESH:D015179
25530820	20415	20427	Colon Cancer	Disease	MESH:D015179
25530820	20374	20379	tumor	Disease	MESH:D009369
25530820	20457	20474	Colorectal Cancer	Disease	MESH:D015179
25530820	20558	20564	tumour	Disease	MESH:D009369
25530820	20746	20752	cancer	Disease	MESH:D009369
25530820	20830	20839	bisulfite	Chemical	MESH:C042345
25530820	20851	20856	H2A.Z	Gene	3015
25530820	21231	21237	cancer	Disease	MESH:D009369
25530820	21404	21409	human	Species	9606
25530820	21504	21514	Spurdle AB	Disease	MESH:D049290
25530820	21689	21697	androgen	Chemical	MESH:D000728
25530820	21745	21760	prostate cancer	Disease	MESH:D011471
25530820	21767	21776	Bisulfite	Chemical	MESH:C042345

25481785|t|Targeted mutagenesis of aryl hydrocarbon receptor 2a and 2b genes in Atlantic killifish (Fundulus heteroclitus) 
25481785|a|Understanding molecular mechanisms of toxicity is facilitated by experimental manipulations, such as disruption of function by gene targeting, that are especially challenging in non-standard model species with limited genomic resources. While loss-of-function approaches have included gene knock-down using morpholino-modified oligonucleotides and random mutagenesis using mutagens or retroviruses, more recent approaches include targeted mutagenesis using zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technology. These latter methods provide more accessible opportunities to explore gene function in non-traditional model species. To facilitate evaluations of toxic mechanisms for important categories of aryl hydrocarbon pollutants, whose actions are known to be receptor mediated, we used ZFN and CRISPR-Cas9 approaches to generate aryl hydrocarbon receptor 2a (AHR2a) and AHR2b gene mutations in Atlantic killifish (Fundulus heteroclitus) embryos. This killifish is a particularly valuble non-traditional model for this study, with multiple paralogs of AHR whose functions are not well characterized. In addition, some populations of this species have evolved resistance to toxicants such as halogenated aromatic hydrocarbons. AHR-null killifish will be valuable for characterizing the role of the individual AHR paralogs in evolved resistance, as well as in normal development. We first used five-finger ZFNs targeting exons 1 and 3 of AHR2a. Subsequently, CRISPR-Cas9 guide RNAs were designed to target regions in exon 2 and 3 of AHR2a and AHR2b. We successfully induced frameshift mutations in AHR2a exon 3 with ZFN and CRISPR-Cas9 guide RNAs, with mutation frequencies of 10% and 16%, respectively. In AHR2b, mutations were induced using CRISPR-Cas9 guide RNAs targeting sites in both exon 2 (17%) and exon 3 (63%). We screened AHR2b exon 2 CRISPR-Cas9-injected embryos for off-target effects in AHR paralogs. No mutations were observed in closely related AHR genes (AHR1a, AHR1b, AHR2a, AHRR) in the CRISPR-Cas9-injected embryos. Overall, our results demonstrate that targeted genome-editing methods are efficient in inducing mutations at specific loci in embryos of a non-traditional model species, without detectable off-target effects in paralogous genes. 
25481785	69	87	Atlantic killifish	Species	8078
25481785	89	110	Fundulus heteroclitus	Species	8078
25481785	24	40	aryl hydrocarbon	Chemical	MESH:D006838
25481785	497	509	retroviruses	Species	31931
25481785	1127	1145	Atlantic killifish	Species	8078
25481785	1147	1168	Fundulus heteroclitus	Species	8078
25481785	1170	1177	embryos	Species	6239
25481785	1184	1193	killifish	Species	8078
25481785	1467	1476	killifish	Species	8078
25481785	2097	2104	embryos	Species	6239
25481785	2257	2264	embryos	Species	6239
25481785	2392	2399	embryos	Species	6239
25481785	1062	1078	aryl hydrocarbon	Chemical	MESH:D006838
25481785	933	949	aryl hydrocarbon	Chemical	MESH:D006838
25481785	150	158	toxicity	Disease	MESH:D064420
25481785	1423	1456	halogenated aromatic hydrocarbons	Chemical	MESH:D006846
25481785	3894	3898	AHR2	Gene	30517
25481785	2515	2533	Atlantic killifish	Species	8078
25481785	2535	2556	Fundulus heteroclitus	Species	8078
25481785	2962	2971	killifish	Species	8078
25481785	3081	3090	killifish	Species	8078
25481785	3721	3730	Killifish	Species	8078
25481785	2791	2797	oxygen	Chemical	MESH:D010100
25481785	3978	3982	PAHs	Chemical	MESH:D011084
25481785	3566	3582	aryl hydrocarbon	Chemical	MESH:D006838
25481785	3369	3394	polychlorinated biphenyls	Chemical	MESH:D011078
25481785	3327	3360	halogenated aromatic hydrocarbons	Chemical	MESH:D006846
25481785	3664	3668	PCBs	Chemical	MESH:D011078
25481785	3658	3662	PAHs	Chemical	MESH:D011084
25481785	3674	3678	TCDD	Chemical	MESH:D013749
25481785	3316	3320	PAHs	Chemical	MESH:D011084
25481785	3396	3400	PCBs	Chemical	MESH:D011078
25481785	3244	3260	aryl hydrocarbon	Chemical	MESH:D006838
25481785	3711	3719	toxicity	Disease	MESH:D064420
25481785	3293	3314	aromatic hydrocarbons	Chemical	MESH:D006841
25481785	3440	3444	TCDD	Chemical	MESH:D013749
25481785	3403	3438	2,3,7,8-tetrachlorodibenzo-p-dioxin	Chemical	MESH:D013749
25481785	3466	3472	dioxin	Chemical	MESH:D004147
25481785	3987	3991	PCBs	Chemical	MESH:D011078
25481785	4416	4433	cytochrome P4501A	Gene	105930482
25481785	4435	4440	CYP1A	Gene	105930482
25481785	4127	4136	killifish	Species	8078
25481785	4350	4359	killifish	Species	8078
25481785	4514	4523	killifish	Species	8078
25481785	4445	4467	developmental toxicity	Disease	MESH:D064420
25481785	4385	4401	aryl hydrocarbon	Chemical	MESH:D006838
25481785	6027	6040	rainbow trout	Species	8022
25481785	6042	6048	medaka	Species	8090
25481785	6062	6076	yellow catfish	Species	1234273
25481785	6233	6242	killifish	Species	8078
25481785	6281	6290	mammalian	Species	9606
25481785	6395	6404	killifish	Species	8078
25481785	6467	6474	embryos	Species	6239
25481785	6050	6057	tilapia	Disease	
25481785	6643	6652	Killifish	Species	8078
25481785	6679	6683	male	Species	9606
25481785	6695	6713	Atlantic killifish	Species	8078
25481785	6893	6902	killifish	Species	8078
25481785	7751	7756	males	Species	9606
25481785	8014	8019	males	Species	9606
25481785	8074	8081	embryos	Species	6239
25481785	8150	8157	embryos	Species	6239
25481785	7441	7449	Tricaine	Chemical	MESH:C003636
25481785	7472	7490	sodium bicarbonate	Chemical	MESH:D017693
25481785	7581	7584	IVF	Disease	MESH:C566179
25481785	8698	8707	killifish	Species	8078
25481785	8708	8715	embryos	Species	6239
25481785	9852	9859	poly(A)	Chemical	MESH:C017937
25481785	10092	10101	killifish	Species	8078
25481785	10102	10109	embryos	Species	6239
25481785	10240	10247	embryos	Species	6239
25481785	10432	10438	embryo	Species	6239
25481785	10909	10918	killifish	Species	8078
25481785	10919	10925	embryo	Species	6239
25481785	11337	11343	embryo	Species	6239
25481785	11471	11478	embryos	Species	6239
25481785	11540	11547	embryos	Species	6239
25481785	11079	11094	aluminosilicate	Chemical	MESH:C049037
25481785	10866	10878	borosilicate	Chemical	MESH:C415406
25481785	10697	10712	Aluminosilicate	Chemical	MESH:C049037
25481785	11941	11948	embryos	Species	6239
25481785	12097	12104	embryos	Species	6239
25481785	12118	12125	Embryos	Species	6239
25481785	12281	12295	polyacrylamide	Chemical	MESH:C040388
25481785	12535	12539	NaCl	Chemical	MESH:D012965
25481785	12515	12519	Tris	Chemical	MESH:C053576
25481785	12178	12198	beta-mercaptoethanol	Chemical	MESH:D008623
25481785	12555	12560	Tween	Chemical	MESH:D011136
25481785	13353	13360	Embryos	Species	6239
25481785	13372	13379	embryos	Species	6239
25481785	14031	14047	ethidium bromide	Chemical	MESH:D004996
25481785	15008	15017	killifish	Species	8078
25481785	15018	15025	embryos	Species	6239
25481785	15065	15071	embryo	Species	6239
25481785	15211	15218	embryos	Species	6239
25481785	15347	15354	embryos	Species	6239
25481785	15387	15394	Embryos	Species	6239
25481785	15723	15732	killifish	Species	8078
25481785	15785	15792	embryos	Species	6239
25481785	15988	15995	embryos	Species	6239
25481785	16117	16124	embryos	Species	6239
25481785	16128	16135	embryos	Species	6239
25481785	16334	16340	embryo	Species	6239
25481785	16706	16713	embryos	Species	6239
25481785	17026	17033	embryos	Species	6239
25481785	17188	17195	embryos	Species	6239
25481785	17209	17216	embryos	Species	6239
25481785	17226	17233	embryos	Species	6239
25481785	17402	17409	embryos	Species	6239
25481785	17799	17806	embryos	Species	6239
25481785	17926	17933	embryos	Species	6239
25481785	17947	17954	embryos	Species	6239
25481785	17964	17971	embryos	Species	6239
25481785	18418	18425	embryos	Species	6239
25481785	18462	18469	embryos	Species	6239
25481785	19440	19446	embryo	Species	6239
25481785	19803	19810	embryos	Species	6239
25481785	19111	19112	N	Chemical	MESH:D009584
25481785	21193	21202	killifish	Species	8078
25481785	21203	21210	embryos	Species	6239
25481785	21218	21225	embryos	Species	6239
25481785	21337	21346	killifish	Species	8078
25481785	21597	21606	killifish	Species	8078
25481785	21617	21626	killifish	Species	8078
25481785	22574	22581	embryos	Species	6239
25481785	22827	22836	zebrafish	Species	7955
25481785	22837	22844	embryos	Species	6239
25481785	23151	23160	zebrafish	Species	7955
25481785	23211	23220	killifish	Species	8078
25481785	23370	23377	embryos	Species	6239
25481785	23393	23402	Zebrafish	Species	7955
25481785	23403	23410	embryos	Species	6239
25481785	23458	23467	killifish	Species	8078
25481785	22879	22895	aryl hydrocarbon	Chemical	MESH:D006838
25481785	24043	24050	embryos	Species	6239
25481785	24145	24152	embryos	Species	6239
25481785	25091	25103	cytotoxicity	Disease	MESH:D064420
25481785	26168	26175	embryos	Species	6239
25481785	26287	26293	embryo	Species	6239
25481785	26509	26518	killifish	Species	8078
25481785	26519	26526	embryos	Species	6239
25481785	26544	26553	zebrafish	Species	7955
25481785	26554	26561	embryos	Species	6239
25481785	26634	26643	killifish	Species	8078
25481785	26644	26651	embryos	Species	6239
25481785	26694	26703	zebrafish	Species	7955
25481785	26742	26748	embryo	Species	6239
25481785	26774	26780	embryo	Species	6239
25481785	26805	26811	medaka	Species	8090
25481785	26864	26870	embryo	Species	6239
25481785	26912	26918	embryo	Species	6239
25481785	26991	26997	embryo	Species	6239
25481785	27010	27019	killifish	Species	8078
25481785	27209	27218	killifish	Species	8078
25481785	27353	27362	killifish	Species	8078
25481785	26781	26789	toxicity	Disease	MESH:D064420
25481785	26466	26474	toxicity	Disease	MESH:D064420
25481785	26199	26221	developmental toxicity	Disease	MESH:D064420
25481785	27324	27332	toxicity	Disease	MESH:D064420
25481785	26998	27006	toxicity	Disease	MESH:D064420
25481785	26871	26879	toxicity	Disease	MESH:D064420
25481785	27996	28005	Killifish	Species	8078
25481785	28406	28420	yellow catfish	Species	1234273
25481785	28422	28435	rainbow trout	Species	8022
25481785	28440	28455	Atlantic salmon	Species	8030
25481785	27725	27729	PCBs	Chemical	MESH:D011078
25481785	27734	27738	PAHs	Chemical	MESH:D011084
25481785	27577	27581	PAHs	Chemical	MESH:D011084
25481785	27568	27572	PCBs	Chemical	MESH:D011078
25481785	29387	29394	embryos	Species	6239
25481785	29970	29988	Atlantic killifish	Species	8078
25481785	30060	30069	Killifish	Species	8078
25481785	30561	30568	embryos	Species	6239
25481785	31275	31293	Atlantic killifish	Species	8078
25481785	31384	31391	embryos	Species	6239
25481785	31431	31438	embryos	Species	6239
25481785	31539	31548	killifish	Species	8078
25481785	32488	32504	aryl hydrocarbon	Chemical	MESH:D006838
25481785	32777	32783	medaka	Species	8090
25481785	32846	32852	medaka	Species	8090
25481785	32954	32975	Fundulus heteroclitus	Disease	
25481785	33011	33024	Aedes aegypti	Species	7159
25481785	33287	33305	Atlantic killifish	Species	8078
25481785	33307	33328	Fundulus heteroclitus	Species	8078
25481785	33560	33570	Drosophila	Disease	
25481785	33637	33655	Xenopus tropicalis	Species	8364
25481785	33656	33663	embryos	Species	6239
25481785	33910	33933	Heteropneustes fossilis	Species	93621
25481785	33856	33865	vasotocin	Chemical	MESH:D014668
25481785	33870	33877	steroid	Chemical	MESH:D013256
25481785	33964	33968	AHR2	Gene	105937229
25481785	34051	34069	Atlantic killifish	Species	8078
25481785	34071	34092	Fundulus heteroclitus	Species	8078
25481785	34040	34047	PCB-126	Chemical	MESH:C023035
25481785	34003	34035	polycyclic aromatic hydrocarbons	Chemical	MESH:D011084
25481785	34147	34161	yellow catfish	Species	1234273
25481785	34163	34186	Pelteobagrus fulvidraco	Species	1234273
25481785	34129	34138	myostatin	Chemical	MESH:D055435
25481785	34265	34274	zebrafish	Species	7955
25481785	34336	34351	Atlantic Salmon	Species	8030
25481785	34353	34364	Salmo salar	Species	8030
25481785	34465	34470	CYP1A	Gene	105930482
25481785	34485	34506	Fundulus heteroclitus	Species	8078
25481785	34518	34524	larvae	Species	6239
25481785	34688	34695	axolotl	Species	8296
25481785	34843	34846	SDS	Chemical	MESH:C032259
25481785	35243	35249	dioxin	Chemical	MESH:D004147
25481785	35340	35344	AHR1	Gene	172788
25481785	35349	35353	AHR2	Gene	30517
25481785	35321	35327	dioxin	Chemical	MESH:D004147
25481785	35303	35319	aryl hydrocarbon	Chemical	MESH:D006838
25481785	35584	35591	embryos	Species	6239
25481785	35633	35642	zebrafish	Species	7955
25481785	35696	35703	embryos	Species	6239
25481785	35784	35793	zebrafish	Species	7955
25481785	35848	35852	AHR2	Gene	30517
25481785	35970	35980	zebra fish	Species	7955
25481785	35934	35955	morphological defects	Disease	MESH:D065308
25481785	36027	36062	2,3,7,8-tetrachlorodibenzo-p-dioxin	Chemical	MESH:D013749
25481785	35992	36023	3,3',4,4',5-pentachlorobiphenyl	Chemical	MESH:C023035
25481785	36162	36166	AHR1	Gene	105937232
25481785	36171	36175	AHR2	Gene	105937229
25481785	36192	36213	Fundulus heteroclitus	Species	8078
25481785	36134	36150	aryl hydrocarbon	Chemical	MESH:D006838
25481785	36365	36383	Ciona intestinalis	Species	7719
25481785	36660	36667	Xenopus	Species	8355
25481785	36668	36675	embryos	Species	6239
25481785	36742	36748	TALENs	Chemical	MESH:C013094
25481785	36880	36888	estrogen	Chemical	MESH:D004967
25481785	37054	37075	Fundulus heteroclitus	Species	8078
25481785	37229	37247	Xenopus tropicalis	Species	8364
25481785	37325	37334	nematodes	Species	6239
25481785	37449	37457	silkworm	Species	7091
25481785	37536	37557	Fundulus heteroclitus	Species	8078
25481785	37770	37779	zebrafish	Species	7955
25481785	37869	37890	Fundulus heteroclitus	Species	8078
25481785	38001	38018	monarch butterfly	Species	13037
25481785	38066	38071	CYP1A	Gene	105930482
25481785	38047	38064	Cytochrome P4501A	Gene	105930482
25481785	38076	38085	killifish	Species	8078
25481785	38087	38108	Fundulus heteroclitus	Species	8078
25481785	38255	38276	Fundulus heteroclitus	Species	8078
25481785	38351	38372	Fundulus heteroclitus	Species	8078
25481785	38374	38392	Atlantic Killifish	Species	8078
25481785	38397	38422	Polychlorinated Biphenyls	Chemical	MESH:D011078
25481785	38424	38428	PCBs	Chemical	MESH:D011078
25481785	38451	38469	Xenopus tropicalis	Species	8364
25481785	38701	38705	SGK1	Gene	105930542
25481785	38670	38691	Fundulus heteroclitus	Species	8078
25481785	38769	38775	embryo	Species	6239
25481785	38847	38856	Mammalian	Species	9606
25481785	38955	38960	human	Species	9606
25481785	39015	39019	AHR1	Gene	246224
25481785	39021	39025	AHR2	Gene	30517
25481785	39031	39036	ARNT2	Gene	64277
25481785	39103	39124	Fundulus heteroclitus	Disease	
25481785	39040	39046	dioxin	Chemical	MESH:D004147
25481785	39198	39220	developmental toxicity	Disease	MESH:D064420
25481785	39162	39197	2,3,7,8-tetrachlorodibenzo-p-dioxin	Chemical	MESH:D013749
25481785	39125	39141	Aryl hydrocarbon	Chemical	MESH:D006838
25481785	39299	39308	mammalian	Species	9606
25481785	39434	39452	Atlantic killifish	Species	8078
25481785	39454	39475	Fundulus heteroclitus	Species	8078
25481785	39379	39395	aryl hydrocarbon	Chemical	MESH:D006838
25481785	40107	40118	Bombyx mori	Species	7091
25481785	40468	40476	silkworm	Species	7091
25481785	40528	40534	medaka	Species	8090
25481785	40736	40758	Tetraodon nigroviridis	Disease	
25481785	40826	40835	killifish	Species	8078
25481785	40947	40956	killifish	Species	8078
25481785	40958	40979	Fundulus heteroclitus	Species	8078
25481785	41195	41208	rainbow trout	Species	8022
25481785	41210	41229	Oncorhynchus mykiss	Species	8022
25481785	41323	41341	Ciona intestinalis	Species	7719
25481785	41435	41453	Xenopus tropicalis	Species	8364
25481785	41573	41579	medaka	Species	8090
25481785	42275	42284	killifish	Species	8078
25481785	42321	42330	killifish	Species	8078
25481785	42331	42338	embryos	Species	6239
25481785	42375	42382	embryos	Species	6239
25481785	42730	42737	embryos	Species	6239
25481785	42831	42838	embryos	Species	6239
25481785	42473	42476	SDS	Chemical	MESH:C032259
25481785	42531	42536	COS-7	CellLine	CVCL:0224
25481785	43340	43349	killifish	Species	8078
25481785	43501	43508	embryos	Species	6239
25481785	43616	43623	embryos	Species	6239
25481785	44006	44015	killifish	Species	8078
25481785	44168	44175	embryos	Species	6239
25481785	44287	44294	embryos	Species	6239
25481785	44791	44798	embryos	Species	6239
25481785	44906	44913	embryos	Species	6239
25481785	45774	45781	embryos	Species	6239
25481785	45880	45887	embryos	Species	6239
25481785	45954	45961	embryos	Species	6239
25481785	46291	46295	AHR2	Gene	30517

25495467|t|A modified evidence-based practice- knowledge, attitudes, behaviour and decisions/outcomes questionnaire is valid across multiple professions involved in pain management 
25495467|a|Background A validated and reliable instrument was developed to knowledge, attitudes and behaviours with respect to evidence-based practice (EBB-KABQ) in medical trainees but requires further adaptation and validation to be applied across different health professionals. Methods A modified 33-item evidence-based practice scale (EBP-KABQ) was developed to evaluate EBP perceptions and behaviors in clinicians. An international sample of 673 clinicians interested in treatment of pain (mean age = 45 years, 48% occupational therapists/physical therapists, 25% had more than 5 years of clinical training) completed an online English version of the questionnaire and demographics. Scaling properties (internal consistency, floor/ceiling effects) and construct validity (association with EBP activities, comparator constructs) were examined. A confirmatory factor analysis was used to assess the 4-domain structure EBP knowledge, attitudes, behavior, outcomes/decisions). Results The EBP-KABQ scale demonstrated high internal consistency (Cronbach's alpha = 0.85), no evident floor/ceiling effects, and support for a priori construct validation hypotheses. A 4-factor structure provided the best fit statistics (CFI =0.89, TLI =0.86, and RMSEA = 0.06). Conclusions The EBP-KABQ scale demonstrates promising psychometric properties in this sample. Areas for improvement are described. Electronic supplementary material The online version of this article (doi:10.1186/s12909-014-0263-4) contains supplementary material, which is available to authorized users. 
25495467	154	158	pain	Disease	MESH:D010146
25495467	311	319	EBB-KABQ	Chemical	
25495467	499	507	EBP-KABQ	Gene	10682
25495467	535	538	EBP	Gene	10682
25495467	954	957	EBP	Gene	10682
25495467	1081	1084	EBP	Gene	10682
25495467	649	653	pain	Disease	MESH:D010146
25495467	1156	1164	EBP-KABQ	Gene	10682
25495467	1451	1459	EBP-KABQ	Gene	10682
25495467	1776	1779	EBP	Gene	10682
25495467	1920	1923	EBP	Gene	10682
25495467	2074	2077	EBP	Gene	10682
25495467	2164	2167	EBP	Gene	10682
25495467	2455	2458	EBP	Gene	10682
25495467	1846	1854	patients	Species	9606
25495467	1981	1988	patient	Species	9606
25495467	2521	2524	EBP	Gene	10682
25495467	2554	2557	EBP	Gene	10682
25495467	2616	2619	EBP	Gene	10682
25495467	2648	2651	EBP	Gene	10682
25495467	2672	2675	EBP	Gene	10682
25495467	2695	2698	EBP	Gene	10682
25495467	2750	2753	EBP	Gene	10682
25495467	2806	2809	EBP	Gene	10682
25495467	3041	3044	EBP	Gene	10682
25495467	3078	3081	EBP	Gene	10682
25495467	3110	3113	EBP	Gene	10682
25495467	3324	3327	EBP	Gene	10682
25495467	3391	3394	EBP	Gene	10682
25495467	3635	3638	EBP	Gene	10682
25495467	3732	3735	EBP	Gene	10682
25495467	3156	3164	openness	Disease	MESH:D005597
25495467	3840	3843	EBP	Gene	10682
25495467	4330	4333	EBP	Gene	10682
25495467	4656	4659	EBP	Gene	10682
25495467	4830	4838	EBP-KABQ	Gene	10682
25495467	4786	4789	JMD	Disease	
25495467	5346	5349	EBP	Gene	10682
25495467	5098	5106	EBP-KABQ	Gene	10682
25495467	5519	5522	EBP	Gene	10682
25495467	5793	5796	EBP	Gene	10682
25495467	5830	5833	EBP	Gene	10682
25495467	5957	5960	EBP	Gene	10682
25495467	6021	6024	EBP	Gene	10682
25495467	6172	6179	patient	Species	9606
25495467	6253	6261	EBP-KABQ	Gene	10682
25495467	5469	5477	EBP-KABQ	Gene	10682
25495467	6402	6414	participants	Species	9606
25495467	7128	7136	EBP-KABQ	Gene	10682
25495467	7166	7170	pain	Disease	MESH:D010146
25495467	6498	6502	pain	Disease	MESH:D010146
25495467	6469	6473	pain	Disease	MESH:D010146
25495467	7700	7703	EBP	Gene	10682
25495467	8007	8015	EBP-KABQ	Gene	10682
25495467	8826	8829	EBP	Gene	10682
25495467	8964	8967	EBP	Gene	10682
25495467	9204	9207	EBP	Gene	10682
25495467	9504	9507	EBP	Gene	10682
25495467	9322	9330	EBP-KABQ	Gene	10682
25495467	8900	8908	EBP-KABQ	Gene	10682
25495467	8388	8396	EBP-KABQ	Gene	10682
25495467	9644	9663	Structural validity	Disease	MESH:D020914
25495467	9811	9814	EBP	Gene	10682
25495467	9694	9697	CFA	Species	31658
25495467	10794	10797	CFA	Species	31658
25495467	10920	10923	CFA	Species	31658
25495467	10996	11004	EBP-KABQ	Gene	10682
25495467	10980	10992	participants	Species	9606
25495467	11034	11035	N	Chemical	MESH:D009584
25495467	11266	11273	Diploma	Disease	
25495467	11840	11852	participants	Species	9606
25495467	12108	12120	participants	Species	9606
25495467	11736	11744	EBP-KABQ	Gene	10682
25495467	12273	12281	EBP-KABQ	Gene	10682
25495467	12842	12850	EBP-KABQ	Gene	10682
25495467	13722	13725	EBP	Gene	10682
25495467	13829	13832	EBP	Gene	10682
25495467	13943	13946	EBP	Gene	10682
25495467	14138	14141	EBP	Gene	10682
25495467	14176	14179	EBP	Gene	10682
25495467	14216	14219	EBP	Gene	10682
25495467	14098	14101	EBP	Gene	10682
25495467	14058	14061	EBP	Gene	10682
25495467	14021	14024	EBP	Gene	10682
25495467	13981	13984	EBP	Gene	10682
25495467	13903	13906	EBP	Gene	10682
25495467	13866	13869	EBP	Gene	10682
25495467	13787	13790	EBP	Gene	10682
25495467	13667	13670	EBP	Gene	10682
25495467	13630	13633	EBP	Gene	10682
25495467	13567	13570	EBP	Gene	10682
25495467	13502	13505	EBP	Gene	10682
25495467	13462	13465	EBP	Gene	10682
25495467	13425	13428	EBP	Gene	10682
25495467	13385	13388	EBP	Gene	10682
25495467	13321	13324	EBP	Gene	10682
25495467	13264	13267	EBP	Gene	10682
25495467	13225	13228	EBP	Gene	10682
25495467	13186	13189	EBP	Gene	10682
25495467	13147	13150	EBP	Gene	10682
25495467	13083	13086	EBP	Gene	10682
25495467	14542	14550	EBP-KABQ	Gene	10682
25495467	14497	14505	EBP-KABQ	Gene	10682
25495467	15101	15104	EBP	Gene	10682
25495467	15624	15627	EBP	Gene	10682
25495467	15722	15725	EBP	Gene	10682
25495467	15035	15038	EBP	Gene	10682
25495467	16336	16343	diploma	Disease	
25495467	16645	16652	patient	Species	9606
25495467	16875	16883	EBP-KABQ	Gene	10682
25495467	17038	17045	diploma	Disease	
25495467	18377	18385	beta = 2	Gene	10242
25495467	18493	18496	EBP	Gene	10682
25495467	18544	18547	EBP	Gene	10682
25495467	18446	18454	beta = 4	Gene	10381
25495467	18318	18326	beta = 4	Gene	10381
25495467	18711	18730	Structural validity	Disease	MESH:D020914
25495467	18855	18863	ellipses	Species	301928
25495467	19149	19157	ellipses	Species	301928
25495467	18781	18789	EBP-KABQ	Gene	10682
25495467	20545	20548	EBP	Gene	10682
25495467	20660	20663	EBP	Gene	10682
25495467	20806	20809	EBP	Gene	10682
25495467	21686	21689	EBP	Gene	10682
25495467	21867	21870	EBP	Gene	10682
25495467	22071	22074	EBP	Gene	10682
25495467	21520	21528	EBP-KABQ	Gene	10682
25495467	20720	20728	EBP-KABQ	Gene	10682
25495467	22304	22307	EBP	Gene	10682
25495467	22227	22235	EBP-KABQ	Gene	10682
25495467	22832	22835	EBP	Gene	10682
25495467	22958	22961	EBP	Gene	10682
25495467	24054	24057	EBP	Gene	10682
25495467	24252	24255	EBP	Gene	10682
25495467	24148	24151	CFA	Species	31658
25495467	24386	24389	EBP	Gene	10682
25495467	25018	25021	EBP	Gene	10682
25495467	25096	25099	EBP	Gene	10682
25495467	25692	25695	EBP	Gene	10682
25495467	25883	25886	EBP	Gene	10682
25495467	26159	26162	EBP	Gene	10682
25495467	26258	26261	EBP	Gene	10682
25495467	26461	26464	EBP	Gene	10682
25495467	25697	25703	People	Species	9606
25495467	26595	26598	EBP	Gene	10682
25495467	27290	27293	EBP	Gene	10682
25495467	27664	27667	EBP	Gene	10682
25495467	28332	28335	EBP	Gene	10682
25495467	28464	28467	EBP	Gene	10682
25495467	28581	28584	EBP	Gene	10682
25495467	27711	27723	participants	Species	9606
25495467	28349	28356	patient	Species	9606
25495467	28481	28488	patient	Species	9606
25495467	28501	28508	patient	Species	9606
25495467	29159	29166	patient	Species	9606
25495467	29267	29275	EBP-KABQ	Gene	10682
25495467	29099	29103	pain	Disease	MESH:D010146
25495467	29135	29139	pain	Disease	MESH:D010146
25495467	29507	29510	EBP	Gene	10682
25495467	29460	29468	EBP-KABQ	Gene	10682
25495467	29435	29439	pain	Disease	MESH:D010146
25495467	29764	29767	TLI	Disease	MESH:C536923
25495467	30278	30285	patient	Species	9606
25495467	30656	30661	EBPAS	Chemical	MESH:C568745
25495467	30853	30857	pain	Disease	MESH:D010146
25495467	32213	32220	patient	Species	9606
25495467	32466	32480	ISRCTN46272378	Chemical	
25495467	33330	33338	patients	Species	9606

24548058|t|Degradation of Benzodiazepines after 120 Days of EMS Deployment 
24548058|a|Introduction EMS treatment of status epilepticus improves outcomes, but the benzodiazepine best suited for EMS use is unclear, given potential high environmental temperature exposures. Objective To describe the degradation of diazepam, lorazepam, and midazolam as a function of temperature exposure and time over 120 days of storage on active EMS units. Methods Study boxes containing vials of diazepam, lorazepam, and midazolam were distributed to 4 active EMS units in each of 2 EMS systems in the southwestern United States during May-August 2011. The boxes logged temperature every minute and were stored in EMS units per local agency policy. Two vials of each drug were removed from each box at 30-day intervals and underwent high-performance liquid chromatography to determine drug concentration. Concentration was analyzed as mean (and 95%CI) percent of initial labeled concentration as a function of time and mean kinetic temperature (MKT). Results 192 samples were collected (2 samples of each drug from each of 4 units per city at 4 time-points). After 120 days, the mean relative concentration (95%CI) of diazepam was 97.0% (95.7-98.2%) and of midazolam was 99.0% (97.7-100.2%). Lorazepam experienced modest degradation by 60 days (95.6% [91.6-99.5%]) and substantial degradation at 90 days (90.3% [85.2-95.4%]) and 120 days (86.5% [80.7-92.3%]). Mean MKT was 31.6 C (95%CI 27.1-36.1). Increasing MKT was associated with greater degradation of lorazepam, but not midazolam or diazepam. Conclusions Midazolam and diazepam experienced minimal degradation throughout 120 days of EMS deployment in high-heat environments. Lorazepam experienced significant degradation over 120 days and appeared especially sensitive to higher MKT exposure. 
24548058	15	30	Benzodiazepines	Chemical	MESH:D001569
24548058	94	112	status epilepticus	Disease	MESH:D013226
24548058	140	154	benzodiazepine	Chemical	MESH:D001569
24548058	315	324	midazolam	Chemical	MESH:D008874
24548058	290	298	diazepam	Chemical	MESH:D003975
24548058	300	309	lorazepam	Chemical	MESH:D008140
24548058	458	466	diazepam	Chemical	MESH:D003975
24548058	468	477	lorazepam	Chemical	MESH:D008140
24548058	483	492	midazolam	Chemical	MESH:D008874
24548058	1182	1190	diazepam	Chemical	MESH:D003975
24548058	1553	1561	diazepam	Chemical	MESH:D003975
24548058	1540	1549	midazolam	Chemical	MESH:D008874
24548058	1521	1530	lorazepam	Chemical	MESH:D008140
24548058	1256	1265	Lorazepam	Chemical	MESH:D008140
24548058	1221	1230	midazolam	Chemical	MESH:D008874
24548058	1706	1715	Lorazepam	Chemical	MESH:D008140
24548058	1600	1608	diazepam	Chemical	MESH:D003975
24548058	1586	1595	Midazolam	Chemical	MESH:D008874
24548058	2369	2378	lorazepam	Chemical	MESH:D008140
24548058	1883	1901	status epilepticus	Disease	MESH:D013226
24548058	2313	2327	benzodiazepine	Chemical	MESH:D001569
24548058	2356	2364	Diazepam	Chemical	MESH:D003975
24548058	1997	2012	benzodiazepines	Chemical	MESH:D001569
24548058	2014	2023	midazolam	Chemical	MESH:D008874
24548058	2428	2437	midazolam	Chemical	MESH:D008874
24548058	2063	2070	seizure	Disease	MESH:D012640
24548058	1907	1922	benzodiazepines	Chemical	MESH:D001569
24548058	2630	2638	diazepam	Chemical	MESH:D003975
24548058	2655	2664	midazolam	Chemical	MESH:D008874
24548058	2640	2649	lorazepam	Chemical	MESH:D008140
24548058	3058	3067	lorazepam	Chemical	MESH:D008140
24548058	3396	3411	benzodiazepines	Chemical	MESH:D001569
24548058	3332	3340	diazepam	Chemical	MESH:D003975
24548058	3487	3496	midazolam	Chemical	MESH:D008874
24548058	3472	3481	lorazepam	Chemical	MESH:D008140
24548058	3462	3470	diazepam	Chemical	MESH:D003975
24548058	4064	4078	benzodiazepine	Chemical	MESH:D001569
24548058	5413	5427	benzodiazepine	Chemical	MESH:D001569
24548058	5932	5940	diazepam	Chemical	MESH:D003975
24548058	5919	5928	midazolam	Chemical	MESH:D008874
24548058	5897	5906	lorazepam	Chemical	MESH:D008140
24548058	6585	6594	midazolam	Chemical	MESH:D008874
24548058	6415	6423	Diazepam	Chemical	MESH:D003975
24548058	6815	6824	lorazepam	Chemical	MESH:D008140
24548058	6620	6629	Lorazepam	Chemical	MESH:D008140
24548058	6546	6554	diazepam	Chemical	MESH:D003975
24548058	6380	6395	benzodiazepines	Chemical	MESH:D001569
24548058	6428	6437	midazolam	Chemical	MESH:D008874
24548058	6245	6259	Benzodiazepine	Chemical	MESH:D001569
24548058	7512	7520	diazepam	Chemical	MESH:D003975
24548058	6917	6925	diazepam	Chemical	MESH:D003975
24548058	7499	7508	midazolam	Chemical	MESH:D008874
24548058	7539	7548	Lorazepam	Chemical	MESH:D008140
24548058	7051	7060	lorazepam	Chemical	MESH:D008140
24548058	7087	7096	lorazepam	Chemical	MESH:D008140
24548058	6903	6912	Midazolam	Chemical	MESH:D008874
24548058	7830	7838	diazepam	Chemical	MESH:D003975
24548058	7816	7825	midazolam	Chemical	MESH:D008874
24548058	7932	7941	Lorazepam	Chemical	MESH:D008140
24548058	8204	8213	midazolam	Chemical	MESH:D008874
24548058	8629	8637	diazepam	Chemical	MESH:D003975
24548058	8726	8735	midazolam	Chemical	MESH:D008874
24548058	8767	8776	lorazepam	Chemical	MESH:D008140
24548058	8190	8199	lorazepam	Chemical	MESH:D008140
24548058	8349	8358	midazolam	Chemical	MESH:D008874
24548058	8396	8405	lorazepam	Chemical	MESH:D008140
24548058	8655	8669	benzodiazepine	Chemical	MESH:D001569
24548058	9139	9148	Lorazepam	Chemical	MESH:D008140
24548058	9072	9080	diazepam	Chemical	MESH:D003975
24548058	8894	8903	lorazepam	Chemical	MESH:D008140
24548058	9015	9023	diazepam	Chemical	MESH:D003975
24548058	8881	8889	diazepam	Chemical	MESH:D003975
24548058	10068	10077	lorazepam	Chemical	MESH:D008140
24548058	9510	9519	lorazepam	Chemical	MESH:D008140
24548058	10351	10360	lorazepam	Chemical	MESH:D008140
24548058	11152	11161	lorazepam	Chemical	MESH:D008140
24548058	11241	11250	midazolam	Chemical	MESH:D008874
24548058	10942	10951	lorazepam	Chemical	MESH:D008140
24548058	11254	11262	diazepam	Chemical	MESH:D003975
24548058	10966	10975	lorazepam	Chemical	MESH:D008140
24548058	11470	11479	midazolam	Chemical	MESH:D008874
24548058	11484	11493	lorazepam	Chemical	MESH:D008140
24548058	12317	12332	benzodiazepines	Chemical	MESH:D001569
24548058	12292	12301	lorazepam	Chemical	MESH:D008140
24548058	12623	12632	lorazepam	Chemical	MESH:D008140
24548058	12490	12499	Midazolam	Chemical	MESH:D008874
24548058	12504	12512	diazepam	Chemical	MESH:D003975
24548058	13644	13647	BSN	Chemical	MESH:C480682
24548058	13602	13605	MPH	Chemical	MESH:C041626
24548058	13789	13792	MPA	Chemical	MESH:C051945
24548058	13937	13940	PhD	Chemical	MESH:C411141
24548058	13882	13885	PhD	Chemical	MESH:C411141
24548058	13863	13866	PhD	Chemical	MESH:C411141
24548058	14040	14043	PhD	Chemical	MESH:C411141
24548058	14002	14005	PhD	Chemical	MESH:C411141
24548058	14019	14022	PhD	Chemical	MESH:C411141
24548058	14368	14371	MPH	Chemical	MESH:C041626
24548058	14476	14479	PhD	Chemical	MESH:C411141
24548058	14168	14170	MS	Disease	MESH:D009103
24548058	14216	14219	MPH	Chemical	MESH:C041626
24548058	14507	14518	Detroit EMS	Disease	MESH:D004630
24548058	14425	14431	O'Neil	Chemical	MESH:D008455
24548058	14920	14933	Laura Heitsch	CellLine	
24548058	14643	14646	BSN	Chemical	MESH:C480682
24548058	14718	14721	MPA	Chemical	MESH:C051945
24548058	15546	15549	PhD	Chemical	MESH:C411141
24548058	15688	15708	MD Participating EMS	Disease	MESH:D009436
24548058	15332	15335	MAS	Disease	MESH:D005359
24548058	15750	15762	EMS Division	Disease	MESH:D004630
24548058	15384	15387	BSN	Chemical	MESH:C480682
24548058	15961	15989	Laura LaChance EMS Directors	Disease	MESH:D004630
24548058	15946	15949	BSN	Chemical	MESH:C480682
24548058	16028	16036	Didonato	Chemical	
24548058	16527	16530	EMS	Disease	MESH:D004630
24548058	16443	16445	Sr	Chemical	MESH:D013324
24548058	16469	16472	MPH	Chemical	MESH:C041626
24548058	16962	16965	BSN	Chemical	MESH:C480682
24548058	17323	17330	Redwood	Species	28980
24548058	17119	17121	MS	Disease	MESH:D009103
24548058	17239	17259	MD Participating EMS	Disease	MESH:D009436
24548058	17556	17563	CEP EMS	Chemical	MESH:D003281
24548058	18211	18214	BSN	Chemical	MESH:C480682
24548058	18335	18338	EMS	Disease	MESH:D004630
24548058	18451	18459	Joseph T	Disease	MESH:D017827
24548058	18703	18706	MBA	Chemical	MESH:C111608
24548058	18677	18680	MFA	Chemical	MESH:C032354
24548058	19163	19166	BSN	Chemical	MESH:C480682
24548058	19783	19788	Lions	Species	9689
24548058	19675	19695	MD Participating EMS	Disease	MESH:D009436
24548058	19915	19918	MPH	Chemical	MESH:C041626
24548058	19940	19943	MPH	Chemical	MESH:C041626
24548058	20231	20234	PhD	Chemical	MESH:C411141
24548058	20382	20385	PhD	Chemical	MESH:C411141
24548058	20896	20900	Lion	Species	9689
24548058	20901	20904	EMS	Disease	MESH:D004630
24548058	21099	21103	Rice	Species	4530
24548058	21364	21367	EMS	Disease	MESH:D004630
24548058	21250	21270	MD Participating EMS	Disease	MESH:D009436
24548058	21216	21232	Robert Rosenthal	Chemical	MESH:C015161
24548058	21465	21483	status epilepticus	Disease	MESH:D013226
24548058	21406	21414	diazepam	Chemical	MESH:D003975
24548058	21395	21404	lorazepam	Chemical	MESH:D008140
24548058	21542	21560	status epilepticus	Disease	MESH:D013226
24548058	21631	21639	children	Species	9606
24548058	21609	21627	status epilepticus	Disease	MESH:D013226
24548058	21579	21587	diazepam	Chemical	MESH:D003975
24548058	21562	21571	Midazolam	Chemical	MESH:D008874
24548058	21891	21906	tranexamic acid	Chemical	MESH:D014148
24548058	22161	22169	diazepam	Chemical	MESH:D003975
24548058	22174	22183	lorazepam	Chemical	MESH:D008140
24548058	22247	22256	lorazepam	Chemical	MESH:D008140
24548058	22233	22242	midazolam	Chemical	MESH:D008874
24548058	22397	22412	benzodiazepines	Chemical	MESH:D001569
24548058	22534	22543	lorazepam	Chemical	MESH:D008140
24548058	22837	22852	benzodiazepines	Chemical	MESH:D001569

25530839|t|The miR-206/133b cluster is dispensable for development, survival and regeneration of skeletal muscle 
25530839|a|Background Three different gene clusters code for the muscle-specific miRNAs miR-206, miR-1 and miR-133a/b. The two miR-1/133a clusters generate identical mature miR-1 and miR-133a miRNAs in heart and skeletal muscle, while the cognate miR-206/133b cluster is exclusively expressed in skeletal muscle. Since sequences of the miRNAs miR-133a and miR-133b are almost identical, it seems likely that they share potential targets. Similarly, miR-1 and miR-206 are structurally related and contain identical seed sequences important for miRNA-target recognition. In the past, different functions of these miRNAs were suggested for development, function and regeneration of skeletal muscle using different in vivo and in vitro models; however, mutants lacking the complete miR-206/133b cluster, which generates a single pri-miRNA constituting a functional unit, have not been analyzed. Methods We generated miR-206/133b knock-out mice and analyzed these mice morphologically; at the transcriptome and proteome level to elucidate the contribution of this miRNA cluster for skeletal muscle development, differentiation, regeneration in vivo; and by systematic analysis. In addition, we studied the consequences of a genetic loss of miR-206/133b for expression of Pax7 and satellite cell differentiation in vitro. Results Deletion of the miR-206/133b cluster did not reveal any obvious essential function of the miRNA-cluster for development and differentiation of skeletal muscle. Careful examination of skeletal muscles of miR-206/133b mutants revealed no structural alterations or molecular changes at the transcriptome and proteome level. In contrast to previous studies, deletion of the miR-206/133b cluster did not impair regeneration of skeletal muscle in mdx mice. Likewise, differentiation of miR-206/133b deficient satellite cells in vitro was unaffected and no change in Pax7 protein concentration was apparent. Conclusions We conclude that the miR-206/133b cluster is dispensable for development, function and regeneration of skeletal muscle, probably due to overlapping functions of the related miR-1/133a clusters, which are strongly expressed in skeletal muscle. We reason that the miR-206/133b cluster alone is not an essential regulator of skeletal muscle regeneration, although more subtle functions might exist that are not apparent under laboratory conditions. 
25530839	4	11	miR-206	Gene	387202
25530839	179	186	miR-206	Gene	387202
25530839	188	193	miR-1	Gene	260145
25530839	218	223	miR-1	Gene	260145
25530839	264	269	miR-1	Gene	260145
25530839	338	345	miR-206	Gene	387202
25530839	447	455	miR-133b	Gene	723817
25530839	540	545	miR-1	Gene	260145
25530839	550	557	miR-206	Gene	387202
25530839	869	876	miR-206	Gene	387202
25530839	434	437	miR	Gene	735281
25530839	274	277	miR	Gene	735281
25530839	198	201	miR	Gene	735281
25530839	1003	1010	miR-206	Gene	387202
25530839	1326	1333	miR-206	Gene	387202
25530839	1357	1361	Pax7	Gene	18509
25530839	1026	1030	mice	Species	10090
25530839	1050	1054	mice	Species	10090
25530839	1431	1438	miR-206	Gene	387202
25530839	1618	1625	miR-206	Gene	387202
25530839	1785	1792	miR-206	Gene	387202
25530839	1895	1902	miR-206	Gene	387202
25530839	1975	1979	Pax7	Gene	18509
25530839	1856	1859	mdx	Gene	13405
25530839	1860	1864	mice	Species	10090
25530839	2049	2056	miR-206	Gene	387202
25530839	2201	2206	miR-1	Gene	260145
25530839	2290	2297	miR-206	Gene	387202
25530839	2635	2640	miR-1	Gene	260145
25530839	2642	2649	miR-206	Gene	387202
25530839	2742	2747	miR-1	Gene	260145
25530839	2831	2836	miR-1	Gene	260145
25530839	2888	2895	miR-206	Gene	387202
25530839	2954	2962	miR-133b	Gene	723817
25530839	3036	3043	miR-206	Gene	387202
25530839	3065	3070	miR-1	Gene	260145
25530839	3085	3090	miR-1	Gene	260145
25530839	3095	3102	miR-206	Gene	387202
25530839	3218	3223	miR-1	Gene	260145
25530839	3496	3501	miR-1	Gene	260145
25530839	3687	3694	miR-206	Gene	387202
25530839	3401	3410	myocardin	Gene	214384
25530839	2716	2721	mouse	Species	10090
25530839	2923	2928	mouse	Species	10090
25530839	3732	3735	miR	Gene	735281
25530839	2999	3002	miR	Gene	735281
25530839	2841	2844	miR	Gene	735281
25530839	2654	2657	miR	Gene	735281
25530839	3849	3857	myopathy	Disease	MESH:D009135
25530839	3518	3533	cardiac defects	Disease	MESH:D006331
25530839	3311	3330	embryonic lethality	Disease	MESH:D020964
25530839	3968	3975	miR-206	Gene	387202
25530839	4170	4177	miR-206	Gene	387202
25530839	4256	4260	MyoD	Gene	17927
25530839	4281	4288	miR-206	Gene	387202
25530839	4324	4331	miR-206	Gene	387202
25530839	4371	4378	miR-206	Gene	387202
25530839	4383	4391	miR-133b	Gene	723817
25530839	4426	4434	linc-MD1	Gene	105661730
25530839	4492	4499	miR-206	Gene	387202
25530839	4504	4512	miR-133b	Gene	723817
25530839	4602	4609	miR-206	Gene	387202
25530839	4695	4702	miR-206	Gene	387202
25530839	4771	4775	Sod1	Gene	20655
25530839	4803	4808	miR-1	Gene	260145
25530839	4821	4826	Hdac4	Gene	208727
25530839	4997	5004	miR-206	Gene	387202
25530839	5078	5085	miR-206	Gene	387202
25530839	5321	5328	miR-206	Gene	387202
25530839	5449	5456	miR-206	Gene	387202
25530839	5562	5566	Pax7	Gene	18509
25530839	5611	5618	miR-206	Gene	387202
25530839	5623	5628	miR-1	Gene	260145
25530839	5687	5694	miR-206	Gene	387202
25530839	5711	5715	Pax7	Gene	18509
25530839	5783	5787	Pax7	Gene	18509
25530839	5791	5798	miR-206	Gene	387202
25530839	5847	5854	miR-206	Gene	387202
25530839	5866	5870	Pax7	Gene	18509
25530839	4099	4106	miR-206	Gene	387202
25530839	5457	5460	mdx	Gene	13405
25530839	5391	5394	mdx	Gene	13405
25530839	5093	5096	mdx	Gene	13405
25530839	4657	4661	mice	Species	10090
25530839	4754	4758	mice	Species	10090
25530839	5097	5102	mouse	Species	10090
25530839	5395	5399	mice	Species	10090
25530839	5112	5139	Duchenne muscular dystrophy	Disease	MESH:D020388
25530839	5270	5288	muscle innervation	Disease	MESH:D006732
25530839	5429	5445	muscle dystrophy	Disease	MESH:D009136
25530839	5041	5059	muscular dystrophy	Disease	MESH:D009136
25530839	5988	5995	miR-206	Gene	387202
25530839	6124	6129	miR-1	Gene	260145
25530839	6169	6176	miR-206	Gene	387202
25530839	6181	6189	miR-133b	Gene	723817
25530839	6396	6403	miR-206	Gene	387202
25530839	6463	6471	linc-MD1	Gene	105661730
25530839	6603	6610	miR-206	Gene	387202
25530839	6730	6737	miR-206	Gene	387202
25530839	6010	6017	miR-206	Gene	387202
25530839	6687	6694	miR-206	Gene	387202
25530839	5951	5955	mice	Species	10090
25530839	6339	6344	mouse	Species	10090
25530839	6417	6420	miR	Gene	735281
25530839	6354	6372	muscular dystrophy	Disease	MESH:D009136
25530839	7011	7018	miR-206	Gene	387202
25530839	7028	7035	miR-206	Gene	387202
25530839	7152	7159	miR-206	Gene	387202
25530839	7456	7464	miR-133b	Gene	723817
25530839	7901	7919	beta-galactosidase	Gene	12091
25530839	7974	7992	beta-galactosidase	Gene	12091
25530839	7076	7081	mouse	Species	10090
25530839	7614	7619	mouse	Species	10090
25530839	8052	8056	mice	Species	10090
25530839	8048	8051	mdx	Gene	13405
25530839	7271	7278	miR-206	Gene	387202
25530839	7636	7638	ES	CellLine	CVCL:M564
25530839	7180	7188	neomycin	Chemical	MESH:D009355
25530839	8590	8597	miR-206	Gene	387202
25530839	9712	9719	miR-206	Gene	387202
25530839	9746	9751	miR-1	Gene	260145
25530839	9312	9317	yeast	Species	4932
25530839	8623	8626	miR	Gene	735281
25530839	9543	9547	A/T1	DNAMutation	c.1A>T
25530839	9022	9029	PB20383	Chemical	MESH:D010634
25530839	9517	9525	TBE-Urea	Chemical	MESH:C531972
25530839	8973	8986	alpha-32P UTP	Chemical	MESH:D014544
25530839	8769	8774	polyT	Chemical	MESH:D011071
25530839	9111	9123	TBE-Urea Gel	Chemical	MESH:C531972
25530839	10426	10433	miR-206	Gene	387202
25530839	10438	10443	miR-1	Gene	260145
25530839	10491	10498	miR-206	Gene	387202
25530839	10713	10720	miR-206	Gene	387202
25530839	10724	10729	miR-1	Gene	260145
25530839	10759	10762	VIC	Gene	13615
25530839	10913	10917	male	Species	9606
25530839	10918	10924	C57Bl6	Species	10090
25530839	10925	10929	mice	Species	10090
25530839	10312	10321	MTAB-2439	Chemical	MESH:C073349
25530839	10374	10403	Biosystems StepOnePlus system	Disease	MESH:D019578
25530839	11159	11167	myogenin	Gene	17928
25530839	11308	11315	embryos	Species	6239
25530839	11373	11380	parents	Species	9606
25530839	12370	12381	acetic acid	Chemical	MESH:D019342
25530839	12410	12420	dehydrated	Disease	MESH:D003681
25530839	12313	12324	picric acid	Chemical	MESH:C005858
25530839	11715	11729	silver nitrate	Chemical	MESH:D012835
25530839	12139	12155	Iron-Hematoxylin	Chemical	MESH:D006416
25530839	11489	11492	PFA	Chemical	MESH:C101815
25530839	12018	12029	acetic acid	Chemical	MESH:D019342
25530839	11814	11817	H2O	Chemical	MESH:D014867
25530839	11921	11924	H2O	Chemical	MESH:D014867
25530839	11838	11856	sodium thiosulfate	Chemical	MESH:C017717
25530839	11972	11978	EosinG	Chemical	MESH:D004801
25530839	12194	12200	HT1079	CellLine	CVCL:5008
25530839	12817	12837	sodium desoxycholate	Chemical	MESH:D012964
25530839	12808	12811	PFA	Chemical	MESH:C101815
25530839	12608	12615	sucrose	Chemical	MESH:D013395
25530839	12565	12568	PFA	Chemical	MESH:C101815
25530839	13431	13438	miR-206	Gene	387202
25530839	13870	13873	Pen	Gene	27344
25530839	13897	13902	FGF-2	Gene	2247
25530839	14018	14021	Pen	Gene	27344
25530839	14326	14330	IgG1	Gene	105243590
25530839	13618	13623	mouse	Species	10090
25530839	13891	13896	human	Species	9606
25530839	14001	14006	horse	Species	9796
25530839	14077	14080	PFA	Chemical	MESH:C101815
25530839	14091	14111	sodium desoxycholate	Chemical	MESH:D012964
25530839	14493	14500	miR-206	Gene	387202
25530839	16518	16525	miR-206	Gene	387202
25530839	14513	14524	littermates	Species	10090
25530839	15919	15924	mouse	Species	10090
25530839	15925	15928	IPI	Chemical	MESH:C078466
25530839	14781	14784	SDS	Chemical	MESH:C032259
25530839	15719	15722	CID	Disease	
25530839	16180	16188	methione	Chemical	MESH:C529911
25530839	16112	16120	cysteine	Chemical	MESH:D003545
25530839	15964	15967	IPI	Chemical	MESH:C078466
25530839	14925	14937	acetonitrile	Chemical	MESH:C032159
25530839	15221	15232	acetic acid	Chemical	MESH:D019342
25530839	14854	14858	LysC	Chemical	MESH:C026591
25530839	14439	14446	13C6Lys	Chemical	MESH:C026591
25530839	16549	16556	13C6Lys	Chemical	MESH:C026591
25530839	15188	15199	acetic acid	Chemical	MESH:D019342
25530839	16951	16955	Pax7	Gene	18509
25530839	16751	16758	embryos	Species	6239
25530839	16858	16861	SDS	Chemical	MESH:C032259
25530839	17130	17141	eBioscience	Disease	
25530839	17174	17188	Cat#18-8816-31	Chemical	MESH:C465308
25530839	17771	17778	miR-206	Gene	387202
25530839	17849	17856	miR-206	Gene	387202
25530839	17889	17896	miR-206	Gene	387202
25530839	17898	17903	miR-1	Gene	260145
25530839	18013	18018	miR-1	Gene	260145
25530839	18069	18076	miR-206	Gene	387202
25530839	18104	18109	miR-1	Gene	260145
25530839	18115	18123	miR-133b	Gene	723817
25530839	18322	18329	miR-206	Gene	387202
25530839	18528	18535	miR-206	Gene	387202
25530839	18673	18680	miR-206	Gene	387202
25530839	18804	18811	miR-206	Gene	387202
25530839	18869	18874	miR-1	Gene	260145
25530839	18910	18917	miR-206	Gene	387202
25530839	17872	17876	mice	Species	10090
25530839	17948	17953	mouse	Species	10090
25530839	18933	18937	mice	Species	10090
25530839	18149	18152	miR	Gene	735281
25530839	19173	19180	miR-206	Gene	387202
25530839	19213	19220	miR-206	Gene	387202
25530839	19257	19264	miR-206	Gene	387202
25530839	19133	19140	miR-206	Gene	387202
25530839	19093	19100	miR-206	Gene	387202
25530839	19053	19060	miR-206	Gene	387202
25530839	19361	19368	miR-206	Gene	387202
25530839	19520	19530	dystrophin	Gene	13405
25530839	19653	19660	miR-206	Gene	406989
25530839	19679	19686	miR-206	Gene	406989
25530839	19712	19719	miR-206	Gene	406989
25530839	19728	19731	mdx	Gene	4096
25530839	19695	19698	mdx	Gene	4096
25530839	19500	19503	mdx	Gene	13405
25530839	19617	19621	male	Species	9606
25530839	19648	19652	male	Species	9606
25530839	19770	19777	miR-206	Gene	387202
25530839	19837	19844	miR-206	Gene	387202
25530839	19981	19989	myogenin	Gene	17928
25530839	20038	20045	embryos	Species	6239
25530839	20162	20169	miR-206	Gene	387202
25530839	20225	20237	miR-206/133b	Gene	387202;723817
25530839	20431	20439	linc-MD1	Gene	105661730
25530839	20471	20479	miR-133b	Gene	723817
25530839	20556	20564	linc-MD1	Gene	105661730
25530839	20642	20650	myogenin	Gene	17928
25530839	20654	20658	myoD	Gene	17927
25530839	20771	20778	miR-206	Gene	387202
25530839	20940	20947	miR-206	Gene	387202
25530839	21085	21092	miR-206	Gene	387202
25530839	21205	21213	myogenin	Gene	17928
25530839	21296	21304	myogenin	Gene	17928
25530839	21391	21398	miR-206	Gene	387202
25530839	21584	21591	miR-206	Gene	387202
25530839	21732	21740	miR-133b	Gene	723817
25530839	21799	21807	miR-133b	Gene	723817
25530839	20246	20251	mouse	Species	10090
25530839	20868	20872	mice	Species	10090
25530839	21053	21057	mice	Species	10090
25530839	21414	21418	mice	Species	10090
25530839	21660	21663	miR	Gene	735281
25530839	20512	20515	miR	Gene	735281
25530839	20404	20407	miR	Gene	735281
25530839	20372	20380	linc-MD1	Gene	105661730
25530839	20976	20985	embryonic	Disease	MESH:D018236
25530839	21858	21865	miR-206	Gene	387202
25530839	21912	21919	miR-206	Gene	387202
25530839	22040	22047	miR-206	Gene	387202
25530839	22106	22113	miR-206	Gene	387202
25530839	22161	22168	miR-206	Gene	387202
25530839	22249	22256	miR-206	Gene	387202
25530839	22318	22325	miR-206	Gene	387202
25530839	22404	22411	miR-206	Gene	387202
25530839	22544	22551	miR-206	Gene	387202
25530839	22652	22659	miR-206	Gene	387202
25530839	22706	22713	miR-206	Gene	387202
25530839	22797	22806	miR-1 (B)	Gene	100316783
25530839	22898	22905	miR-206	Gene	387202
25530839	22939	22942	Mdx	Gene	13405
25530839	23007	23012	miR-1	Gene	260145
25530839	22624	22627	mdx	Gene	13405
25530839	22086	22090	mice	Species	10090
25530839	22155	22159	mice	Species	10090
25530839	22220	22224	mice	Species	10090
25530839	22386	22390	mice	Species	10090
25530839	22398	22402	mice	Species	10090
25530839	22628	22632	mice	Species	10090
25530839	22921	22925	mice	Species	10090
25530839	23193	23200	miR-206	Gene	387202
25530839	23216	23220	mice	Species	10090
25530839	23301	23305	mice	Species	10090
25530839	23569	23573	mice	Species	10090
25530839	23639	23646	miR-206	Gene	387202
25530839	23916	23923	miR-206	Gene	387202
25530839	23982	23987	miR-1	Gene	260145
25530839	24028	24033	miR-1	Gene	260145
25530839	24255	24260	miR-1	Gene	260145
25530839	24309	24314	miR-1	Gene	260145
25530839	24359	24366	miR-206	Gene	387202
25530839	24233	24240	miR-206	Gene	387202
25530839	24006	24013	miR-206	Gene	387202
25530839	24088	24093	mouse	Species	10090
25530839	24176	24181	miR-1	Gene	260145
25530839	24168	24175	miR-206	Gene	387202
25530839	23989	23998	GSM539875	Chemical	MESH:C581775
25530839	24674	24681	miR-206	Gene	387202
25530839	24735	24758	molecular abnormalities	Disease	MESH:D030342
25530839	24811	24818	miR-206	Gene	387202
25530839	25094	25101	miR-206	Gene	387202
25530839	25106	25114	miR-133b	Gene	723817
25530839	24839	24843	mice	Species	10090
25530839	25743	25750	miR-206	Gene	387202
25530839	26107	26114	miR-206	Gene	387202
25530839	26199	26207	linc-MD1	Gene	105661730
25530839	26336	26343	miR-206	Gene	387202
25530839	26471	26477	IL-17a	Gene	16171
25530839	26514	26521	miR-206	Gene	387202
25530839	26750	26757	miR-206	Gene	387202
25530839	26761	26769	miR-133b	Gene	723817
25530839	25879	25884	mouse	Species	10090
25530839	26838	26842	PAX7	Gene	18509
25530839	26949	26956	miR-206	Gene	387202
25530839	27063	27070	miR-206	Gene	387202
25530839	27200	27207	miR-206	Gene	387202
25530839	27211	27219	miR-133b	Gene	723817
25530839	27359	27366	miR-206	Gene	387202
25530839	27405	27409	PAX7	Gene	18509
25530839	27504	27508	Pax7	Gene	18509
25530839	27561	27568	miR-206	Gene	387202
25530839	27573	27578	miR-1	Gene	260145
25530839	27619	27626	miR-206	Gene	387202
25530839	27631	27636	miR-1	Gene	260145
25530839	27695	27699	Pax7	Gene	18509
25530839	26852	26859	embryos	Species	6239
25530839	27440	27447	embryos	Species	6239
25530839	26794	26801	miR-206	Gene	387202
25530839	27515	27522	miRanda	Disease	MESH:C537402
25530839	27987	27994	miR-206	Gene	387202
25530839	28579	28586	miR-206	Gene	387202
25530839	28909	28917	miR-133b	Gene	723817
25530839	28007	28011	mice	Species	10090
25530839	28086	28090	mice	Species	10090
25530839	28071	28078	13C6Lys	Chemical	MESH:C026591
25530839	28291	28299	13C6-Lys	Chemical	MESH:C026591
25530839	28640	28647	miRanda	Disease	MESH:C537402
25530839	28262	28270	13C6-Lys	Chemical	MESH:C026591
25530839	29042	29049	miR-206	Gene	387202
25530839	29139	29146	miR-206	Gene	387202
25530839	29151	29155	Pax7	Gene	18509
25530839	29199	29203	Pax7	Gene	18509
25530839	29286	29293	miR-206	Gene	387202
25530839	29336	29340	Pax7	Gene	18509
25530839	29400	29405	miR-1	Gene	260145
25530839	29451	29458	miR-206	Gene	387202
25530839	29535	29542	miR-206	Gene	387202
25530839	29592	29597	miR-1	Gene	260145
25530839	29602	29609	miR-206	Gene	387202
25530839	29667	29671	Pax7	Gene	18509
25530839	29682	29689	miR-206	Gene	387202
25530839	29693	29698	miR-1	Gene	260145
25530839	29958	29965	miR-206	Gene	387202
25530839	29176	29183	embryos	Species	6239
25530839	29262	29269	embryos	Species	6239
25530839	29887	29891	mice	Species	10090
25530839	29981	29985	mice	Species	10090
25530839	29747	29754	miRanda	Disease	MESH:C537402
25530839	30001	30008	miR-206	Gene	387202
25530839	30069	30096	Duchenne muscular dystrophy	Disease	MESH:D020388
25530839	30154	30161	miR-206	Gene	387202
25530839	30434	30441	miR-206	Gene	406989
25530839	30467	30474	miR-206	Gene	406989
25530839	30527	30534	miR-206	Gene	387202
25530839	30610	30617	miR-206	Gene	387202
25530839	30569	30572	mdx	Gene	13405
25530839	30307	30310	mdx	Gene	4096
25530839	30171	30174	mdx	Gene	13405
25530839	30182	30186	mice	Species	10090
25530839	30211	30215	male	Species	9606
25530839	30633	30637	mice	Species	10090
25530839	30655	30662	miR-206	Gene	387202
25530839	30920	30935	miR-206/133b KO	Gene	387202
25530839	30757	30764	miR-206	Gene	387202
25530839	30909	30912	mdx	Gene	13405
25530839	30810	30813	mdx	Gene	13405
25530839	30770	30774	mice	Species	10090
25530839	30785	30789	mice	Species	10090
25530839	30942	30946	mice	Species	10090
25530839	30716	30724	Creatine	Chemical	MESH:D003401
25530839	30690	30698	creatine	Chemical	MESH:D003401
25530839	30851	30859	creatine	Chemical	MESH:D003401
25530839	30964	30971	miR-206	Gene	387202
25530839	31126	31133	miR-206	Gene	387202
25530839	31162	31172	dystrophin	Gene	13405
25530839	31331	31338	miR-206	Gene	387202
25530839	31376	31379	mdx	Gene	13405
25530839	31035	31038	Mdx	Gene	13405
25530839	31039	31043	mice	Species	10090
25530839	31156	31161	mouse	Species	10090
25530839	31517	31521	mice	Species	10090
25530839	31266	31274	fibrosis	Disease	MESH:D005355
25530839	31216	31230	calcifications	Disease	MESH:D002114
25530839	31004	31015	muscle loss	Disease	MESH:D009133
25530839	31636	31643	miR-206	Gene	387202
25530839	31741	31748	miR-206	Gene	387202
25530839	31882	31889	miR-206	Gene	387202
25530839	31982	31989	miR-206	Gene	387202
25530839	32067	32077	dystrophin	Gene	13405
25530839	32210	32217	miR-206	Gene	387202
25530839	32367	32374	miR-206	Gene	387202
25530839	32610	32617	miR-206	Gene	387202
25530839	32717	32724	miR-206	Gene	387202
25530839	32838	32843	miR-1	Gene	260145
25530839	33048	33055	miR-206	Gene	387202
25530839	33109	33119	dystrophin	Gene	13405
25530839	33157	33179	muscle creatine kinase	Gene	12715
25530839	33181	33184	MCK	Gene	12715
25530839	33393	33396	MCK	Gene	12715
25530839	33444	33447	MCK	Gene	12715
25530839	33480	33487	miR-206	Gene	387202
25530839	33642	33645	MCK	Gene	12715
25530839	34034	34041	miR-206	Gene	387202
25530839	34062	34069	miR-206	Gene	387202
25530839	34311	34318	miR-206	Gene	387202
25530839	34468	34478	dystrophin	Gene	13405
25530839	34742	34749	miR-206	Gene	387202
25530839	34930	34937	miR-206	Gene	387202
25530839	33736	33743	miR-206	Gene	387202
25530839	33347	33354	miR-206	Gene	387202
25530839	34986	34989	mdx	Gene	13405
25530839	34878	34881	mdx	Gene	13405
25530839	34758	34761	mdx	Gene	13405
25530839	34249	34252	mdx	Gene	13405
25530839	33891	33894	mdx	Gene	13405
25530839	33749	33752	mdx	Gene	13405
25530839	33660	33663	mdx	Gene	13405
25530839	33363	33366	mdx	Gene	13405
25530839	32852	32855	mdx	Gene	13405
25530839	32564	32567	mdx	Gene	13405
25530839	32518	32521	mdx	Gene	13405
25530839	32378	32381	mdx	Gene	13405
25530839	32226	32229	mdx	Gene	13405
25530839	32028	32031	Mdx	Gene	13405
25530839	32022	32026	mice	Species	10090
25530839	32032	32036	mice	Species	10090
25530839	32237	32241	mice	Species	10090
25530839	32389	32393	mice	Species	10090
25530839	32522	32526	mice	Species	10090
25530839	32568	32572	mice	Species	10090
25530839	33374	33378	mice	Species	10090
25530839	33424	33428	mice	Species	10090
25530839	33493	33497	mice	Species	10090
25530839	33664	33668	mice	Species	10090
25530839	33895	33899	mice	Species	10090
25530839	34086	34090	mice	Species	10090
25530839	34253	34257	mice	Species	10090
25530839	34762	34766	mice	Species	10090
25530839	34882	34886	mice	Species	10090
25530839	34990	34994	mice	Species	10090
25530839	34427	34435	fibrosis	Disease	MESH:D005355
25530839	32949	32967	dystrophic muscles	Disease	MESH:D009136
25530839	34507	34523	muscle dystrophy	Disease	MESH:D009136
25530839	34578	34586	fibrosis	Disease	MESH:D005355
25530839	34189	34197	fibrosis	Disease	MESH:D005355
25530839	34969	34982	muscle damage	Disease	MESH:D009135
25530839	34373	34382	von Kossa	Disease	MESH:D014842
25530839	32123	32155	damage and loss of muscle fibers	Disease	MESH:D009135
25530839	33253	33266	muscle injury	Disease	MESH:D009135
25530839	33330	33343	muscle damage	Disease	MESH:D009135
25530839	35298	35305	miR-206	Gene	387202
25530839	35751	35758	miR-206	Gene	387202
25530839	35777	35781	Pax7	Gene	18509
25530839	35886	35890	Pax7	Gene	18509
25530839	35930	35937	miR-206	Gene	387202
25530839	35321	35325	mice	Species	10090
25530839	35996	36003	miR-206	Gene	387202
25530839	36109	36116	miR-206	Gene	387202
25530839	36147	36154	miR-206	Gene	387202
25530839	36513	36520	miR-206	Gene	387202
25530839	36578	36585	miR-206	Gene	387202
25530839	36590	36595	miR-1	Gene	260145
25530839	36603	36607	Pax7	Gene	18509
25530839	36129	36133	mice	Species	10090
25530839	37144	37148	MyoD	Gene	17927
25530839	37197	37202	miR-1	Gene	260145
25530839	37358	37363	miR-1	Gene	260145
25530839	37398	37403	miR-1	Gene	260145
25530839	37487	37494	miR-206	Gene	387202
25530839	37614	37619	miR-1	Gene	260145
25530839	37774	37781	miR-206	Gene	387202
25530839	37920	37927	miR-206	Gene	387202
25530839	37949	37954	miR-1	Gene	260145
25530839	37998	38005	miR-206	Gene	387202
25530839	38019	38024	miR-1	Gene	260145
25530839	38031	38039	miR-133b	Gene	723817
25530839	38100	38107	miR-206	Gene	387202
25530839	38112	38117	miR-1	Gene	260145
25530839	38235	38242	miR-206	Gene	387202
25530839	38247	38252	miR-1	Gene	260145
25530839	38258	38265	miR-206	Gene	387202
25530839	38328	38336	linc-MD1	Gene	105661730
25530839	38458	38465	miR-206	Gene	387202
25530839	38059	38062	miR	Gene	735281
25530839	38498	38505	miR-206	Gene	387202
25530839	38576	38583	miR-206	Gene	387202
25530839	38587	38595	miR-133b	Gene	723817
25530839	38646	38654	linc-MD1	Gene	105661730
25530839	38732	38739	miR-206	Gene	387202
25530839	38937	38944	miR-206	Gene	387202
25530839	39007	39014	miR-206	Gene	387202
25530839	39270	39277	miR-206	Gene	387202
25530839	39279	39287	miR-133b	Gene	723817
25530839	39324	39332	linc-MD1	Gene	105661730
25530839	39439	39444	miR-1	Gene	260145
25530839	39508	39515	miR-206	Gene	387202
25530839	39557	39565	miR-133b	Gene	723817
25530839	39141	39148	miR-206	Gene	387202
25530839	38796	38800	mice	Species	10090
25530839	39159	39163	mice	Species	10090
25530839	39612	39615	miR	Gene	735281
25530839	39306	39309	miR	Gene	735281
25530839	38675	38678	miR	Gene	735281
25530839	39823	39830	miR-206	Gene	387202
25530839	39949	39956	miR-206	Gene	387202
25530839	40016	40023	miR-206	Gene	387202
25530839	40102	40109	miR-206	Gene	387202
25530839	40248	40255	miR-206	Gene	387202
25530839	40404	40411	miR-206	Gene	387202
25530839	40624	40631	miR-206	Gene	387202
25530839	40846	40853	miR-206	Gene	387202
25530839	40511	40518	miR-206	Gene	387202
25530839	40571	40575	mice	Species	10090
25530839	40795	40799	mice	Species	10090
25530839	40753	40761	creatine	Chemical	MESH:D003401
25530839	40903	40910	miR-206	Gene	387202
25530839	40940	40944	Pax7	Gene	18509
25530839	41046	41050	Pax7	Gene	18509
25530839	41063	41070	miR-206	Gene	387202
25530839	41215	41222	miR-206	Gene	387202
25530839	41226	41230	Pax7	Gene	18509
25530839	41334	41341	miR-206	Gene	387202
25530839	41379	41386	miR-206	Gene	387202
25530839	41558	41563	miR-1	Gene	260145
25530839	41589	41593	Pax7	Gene	18509
25530839	41649	41656	miR-206	Gene	387202
25530839	41792	41796	Pax7	Gene	18509
25530839	41832	41839	miR-206	Gene	387202
25530839	41932	41939	miR-206	Gene	387202
25530839	42072	42079	miR-206	Gene	387202
25530839	42152	42159	mir-206	Gene	387202
25530839	42164	42172	miR-133b	Gene	723817
25530839	42261	42268	miR-206	Gene	387202
25530839	42530	42535	miR-1	Gene	260145
25530839	42570	42577	miR-206	Gene	387202
25530839	42675	42682	miR-206	Gene	387202
25530839	42647	42654	miR-206	Gene	387202
25530839	41483	41486	miR	Gene	735281
25530839	41940	41943	mdx	Gene	13405
25530839	41951	41955	mice	Species	10090
25530839	41634	41639	miR-1	Gene	260145
25530839	41978	41997	muscle degeneration	Disease	MESH:D009135
25530839	42625	42643	muscular dystrophy	Disease	MESH:D009136
25530839	42035	42040	death	Disease	MESH:D003643
25530839	42788	42795	miR-206	Gene	387202
25530839	42922	42929	miR-206	Gene	387202
25530839	42939	42944	miR-1	Gene	260145
25530839	43153	43158	miR-1	Gene	260145
25530839	43182	43189	miR-206	Gene	387202
25530839	43302	43307	miR-1	Gene	260145
25530839	42873	42878	mouse	Species	10090
25530839	43455	43469	hybridoma bank	Disease	
25530839	43470	43473	DTA	Chemical	MESH:C522116
25530839	43493	43495	ES	CellLine	CVCL:M564
25530839	43521	43524	FCS	Disease	MESH:D056685
25530839	43646	43664	beta-galactosidase	Gene	12091
25530839	43676	43684	creatine	Chemical	MESH:D003401
25530839	43700	43703	MDX	Disease	MESH:C564108
25530839	43704	43709	mouse	Species	10090
25530839	43748	43756	X-linked	Disease	MESH:D040181
25530839	43719	43746	Duchenne Muscular Dystrophy	Disease	MESH:D020388
25530839	43771	43780	phosphate	Chemical	MESH:D010710
25530839	43797	43800	PFA	Chemical	MESH:C101815
25530839	43801	43817	paraformaldehyde	Chemical	MESH:C003043
25530839	43887	43890	SDS	Chemical	MESH:C032259
25530839	43896	43937	sodium dodecyl sulfate polyacrylamide gel	Chemical	MESH:D012967
25530839	44191	44193	SW	CellLine	CVCL:R777
25530839	44199	44201	HN	Chemical	MESH:C009802
25530839	44426	44431	miR-1	Gene	260145
25530839	44512	44521	myocardin	Gene	214384
25530839	44657	44666	mammalian	Species	9606
25530839	44818	44827	dynamin 2	Gene	13430
25530839	44783	44787	Mice	Species	10090
25530839	44852	44860	myopathy	Disease	MESH:D009135
25530839	45011	45016	miR-1	Gene	260145
25530839	45018	45025	miR-206	Gene	387202
25530839	45030	45033	miR	Gene	735281
25530839	45057	45062	mouse	Species	10090
25530839	45077	45082	Mouse	Species	10090
25530839	45189	45201	MicroRNA-206	Gene	387202
25530839	45378	45390	microRNA-206	Gene	387202
25530839	45455	45482	Duchenne muscular dystrophy	Disease	MESH:D020388
25530839	45504	45513	mammalian	Species	9606
25530839	45525	45552	duchenne muscular dystrophy	Disease	MESH:D020388
25530839	45639	45642	mdx	Gene	13405
25530839	45643	45648	mouse	Species	10090
25530839	45613	45631	muscular dystrophy	Disease	MESH:D009136
25530839	45667	45683	miR-206 and -486	Gene	387202;723876
25530839	45734	45737	Pax	Gene	19303
25530839	45857	45860	Pax	Gene	19303
25530839	45756	45768	microRNA-206	Gene	387202
25530839	45873	45876	mdx	Gene	13405
25530839	45897	45901	mice	Species	10090
25530839	46111	46121	Mir143/145	Gene	387161;387163
25530839	46060	46066	murine	Species	10090
25530839	46246	46255	kindlin-3	Gene	108101
25530839	46203	46208	mouse	Species	10090
25530839	46654	46663	Mammalian	Species	9606
25530839	46820	46830	Drosophila	Disease	
25530839	46921	46924	mdx	Gene	13405
25530839	46881	46919	X chromosome-linked muscular dystrophy	Disease	MESH:D009136
25530839	46962	46977	muscular damage	Disease	MESH:D009135
25530839	47058	47062	MyoD	Gene	17927
25530839	47072	47077	Fstl1	Gene	14314
25530839	47082	47086	Utrn	Gene	22288
25530839	47127	47130	miR	Gene	735281
25530839	47227	47239	MicroRNA-206	Gene	387202
25530839	47366	47384	muscular dystrophy	Disease	MESH:D009136
25530839	47472	47475	rat	Species	10116
25530839	47485	47498	muscle injury	Disease	MESH:D009135
25530839	47527	47533	canine	Species	9615
25530839	47618	47622	PAX7	Gene	18509
25530839	47675	47697	microrna dysregulation	Disease	MESH:D021081

25511509|t|Identification of skin-expressed genes possibly associated with wool growth regulation of Aohan fine wool sheep 
25511509|a|Background Sheep are valuable resources for the animal fibre industry. Therefore, identifying genes which regulate wool growth would offer strategies for improving the quality of fine wool. In this study, we employed Agilent sheep gene expression microarray and proteomic technology to compare the gene expression patterns of the body side (hair-rich) and groin (hairless) skins of Aohan fine wool sheep (a Chinese indigenous breed). Results Comparing the body side to the groin skins (S/G) of Aohan fine wool sheep, the microarray study revealed that 1494 probes were differentially expressed, including 602 more highly expressed and 892 less highly expressed probes. The microarray results were verified by means of quantitative PCR. Cluster analysis could distinguish the body side skin and the groin skin. Based on the Database for Annotation, Visualization and Integrated Discovery (DAVID), 38 of the differentially expressed genes were classified into four categories, namely regulation of receptor binding, multicellular organismal process, protein binding and macromolecular complex. Proteomic study revealed that 187 protein spots showed significant (p < 0.05) differences in their respective expression levels. Among them, 46 protein entries were further identified by MALDI-TOF/MS analyses. Conclusions Microarray analysis revealed thousands of differentially expressed genes, many of which were possibly associated with wool growth. Several potential gene families might participate in hair growth regulation. Proteomic analysis also indentified hundreds of differentially expressed proteins. Electronic supplementary material The online version of this article (doi:10.1186/s12863-014-0144-1) contains supplementary material, which is available to authorized users. 
25511509	123	128	Sheep	Species	9940
25511509	337	342	sheep	Species	9940
25511509	510	515	sheep	Species	9940
25511509	622	627	sheep	Species	9940
25511509	1906	1911	Sheep	Species	9940
25511509	2762	2767	sheep	Species	9940
25511509	2491	2505	tumor necrosis	Disease	MESH:D009336
25511509	2950	2954	mice	Species	10090
25511509	3025	3030	sheep	Species	9940
25511509	3035	3040	goats	Species	9925
25511509	3064	3073	parasites	Species	5811
25511509	3303	3307	goat	Species	9925
25511509	3312	3317	sheep	Species	9940
25511509	3649	3654	sheep	Species	9940
25511509	3681	3686	sheep	Species	9940
25511509	3915	3920	sheep	Species	9940
25511509	4059	4064	sheep	Species	9940
25511509	4244	4249	sheep	Species	9940
25511509	4456	4461	sheep	Species	9940
25511509	4728	4733	sheep	Species	9940
25511509	5018	5023	sheep	Species	9940
25511509	5518	5524	CYP1A1	Gene	100170113
25511509	5565	5576	Connexin 43	Gene	443455
25511509	5181	5186	sheep	Species	9940
25511509	5578	5581	SCD	Disease	MESH:C536778
25511509	5540	5549	LOC443300	Chemical	MESH:C492399
25511509	6051	6056	FGF10	Gene	443074
25511509	6085	6090	FGF18	Gene	780460
25511509	6100	6111	Connexin 43	Gene	443455
25511509	6137	6140	ZO1	Gene	443200
25511509	6066	6075	LOC443300	Chemical	MESH:C492399
25511509	6296	6301	FGF10	Gene	443074
25511509	6314	6319	FGF18	Gene	780460
25511509	6321	6331	Connexin43	Gene	443455
25511509	6338	6341	ZO1	Gene	443200
25511509	6343	6347	MMP2	Gene	443115
25511509	6349	6354	ITGB1	Gene	443141
25511509	6356	6361	PAG11	Gene	100034671
25511509	6366	6371	CRYAB	Gene	497274
25511509	6557	6562	FGF10	Gene	443074
25511509	6564	6567	ZO1	Gene	443200
25511509	6572	6577	CRYAB	Gene	497274
25511509	6303	6312	LOC443300	Chemical	MESH:C492399
25511509	6333	6336	SCD	Disease	MESH:C536778
25511509	6832	6837	sheep	Species	9940
25511509	6882	6887	sheep	Species	9940
25511509	9517	9521	FGF7	Gene	443095
25511509	9523	9529	IGFBP3	Gene	100286737
25511509	9534	9537	PRL	Gene	443317
25511509	9616	9620	IL1A	Gene	443404
25511509	9622	9625	IL6	Gene	443406
25511509	9630	9634	TAC1	Gene	100034669
25511509	9728	9734	CDKN1B	Gene	100127219
25511509	9739	9744	FGF18	Gene	780460
25511509	9902	9908	silver	Chemical	MESH:D012834
25511509	9917	9931	polyacrylamide	Chemical	MESH:C040388
25511509	12810	12815	sheep	Species	9940
25511509	12921	12925	mers	Species	1335626
25511509	13198	13203	sheep	Species	9940
25511509	13437	13442	sheep	Species	9940
25511509	13673	13678	IL-1A	Gene	443404
25511509	13683	13688	IL-1B	Gene	443539
25511509	13751	13756	IL-1A	Gene	443404
25511509	13841	13846	IL-1A	Gene	443404
25511509	13945	13949	SCD1	Gene	20249
25511509	13966	13970	mice	Species	10090
25511509	13990	14052	orthokeratotic hyperkeratosis and parakeratotic hyperkeratosis	Disease	MESH:D017488
25511509	14324	14327	SCD	Disease	MESH:C536778
25511509	14423	14426	SCD	Disease	MESH:C536778
25511509	14471	14475	MMP2	Gene	4313
25511509	14633	14637	MMP2	Gene	443115
25511509	14837	14841	MMP2	Gene	443115
25511509	14616	14621	human	Species	9606
25511509	14914	14919	sheep	Species	9940
25511509	14974	14979	human	Species	9606
25511509	14776	14784	thymosin	Chemical	MESH:D013947
25511509	15064	15069	ITGB1	Gene	443141
25511509	15141	15146	ITGB1	Gene	3688
25511509	15279	15284	ITGB1	Gene	443141
25511509	15341	15346	ITGB1	Gene	443141
25511509	15188	15193	human	Species	9606
25511509	15509	15515	CYP1A1	Gene	100170113
25511509	15604	15610	CYP1A1	Gene	100170113
25511509	15794	15799	GluD1	Gene	443239
25511509	15975	15980	GLUD1	Gene	443239
25511509	16064	16075	Connexin 43	Gene	443455
25511509	16077	16081	Cx43	Gene	443455
25511509	16225	16229	Cx43	Gene	14611
25511509	16297	16308	Connexin 43	Gene	443455
25511509	16172	16177	mouse	Species	10090
25511509	16551	16555	PGFS	Gene	443108
25511509	16460	16473	prostaglandin	Chemical	MESH:D011453
25511509	16527	16540	prostaglandin	Chemical	MESH:D011453
25511509	16849	16854	DGAT2	Gene	101110535
25511509	16856	16859	LPL	Gene	443408
25511509	16861	16864	ZO1	Gene	443200
25511509	16866	16870	GJB2	Gene	443345
25511509	16875	16880	ITGB1	Gene	443141
25511509	17070	17075	sheep	Species	9940
25511509	17506	17511	Cryab	Gene	497274
25511509	17589	17594	Cryab	Gene	497274
25511509	17897	17902	FGF18	Gene	780460
25511509	17988	17993	FGF18	Gene	780460
25511509	18095	18100	FGF18	Gene	780460
25511509	18210	18215	KRT14	Gene	100303604
25511509	18220	18227	KRT2.11	Gene	443415
25511509	18386	18391	PADI3	Gene	51702
25511509	18523	18528	PADI3	Gene	443369
25511509	18435	18441	S100A3	Gene	6274
25511509	18490	18495	human	Species	9606
25511509	18466	18470	Ca2+	Chemical	MESH:D002118
25511509	18684	18689	FGFR3	Gene	554324
25511509	18774	18779	FGFR3	Gene	554324
25511509	20123	20127	FGF7	Gene	443095
25511509	20142	20147	YWHAE	Gene	443300
25511509	20282	20286	FGF7	Gene	443095
25511509	20333	20337	MMP2	Gene	443115
25511509	20466	20470	FGF7	Gene	443095
25511509	20475	20484	LOC443300	Chemical	MESH:C492399
25511509	20918	20922	IL1A	Gene	443404
25511509	20923	20927	FGF7	Gene	443095
25511509	20928	20932	TAC1	Gene	100034669
25511509	20933	20939	IGFBP3	Gene	100286737
25511509	20940	20946	CDKN1B	Gene	100127219
25511509	20947	20950	IL6	Gene	443406
25511509	20951	20956	FGF18	Gene	780460
25511509	20961	20964	PRL	Gene	443317
25511509	21840	21845	sheep	Species	9940
25511509	22217	22222	sheep	Species	9940
25511509	22743	22748	Sheep	Species	9940
25511509	22647	22655	nitrogen	Chemical	MESH:D009584
25511509	23259	23264	Sheep	Species	9940
25511509	22845	22851	TRIzol	Chemical	MESH:C411644
25511509	24398	24403	GAPDH	Gene	443005
25511509	25827	25832	FGF10	Gene	443074
25511509	25981	25986	FGF18	Gene	780460
25511509	26055	26065	Connexin43	Gene	443455
25511509	26285	26289	MMP2	Gene	443115
25511509	26358	26363	ITGB1	Gene	443141
25511509	26433	26438	PAG11	Gene	100034671
25511509	26509	26514	CRYAB	Gene	497274
25511509	26212	26215	Zo1	Gene	443200
25511509	25712	25724	(5'-3')   Tm	Chemical	MESH:D013932
25511509	25727	25728	C	Chemical	MESH:D002244
25511509	25902	25911	LOC443300	Chemical	MESH:C492399
25511509	26692	26697	GAPDH	Gene	443005
25511509	27213	27218	GAPDH	Gene	443005
25511509	27291	27299	Thiourea	Chemical	MESH:D013890
25511509	28024	28026	S2	Chemical	MESH:D013455
25511509	28110	28112	S6	Chemical	MESH:C012008
25511509	28202	28205	SDS	Chemical	MESH:C032259
25511509	28432	28435	SDS	Chemical	MESH:C032259
25511509	28378	28381	SDS	Chemical	MESH:C032259
25511509	28419	28427	Tris-HCl	Chemical	MESH:C014843
25511509	28366	28373	Glycine	Chemical	MESH:D005998
25511509	28443	28452	Glycerine	Chemical	MESH:D005990
25511509	28223	28231	Tris-HCl	Chemical	MESH:C014843
25511509	28493	28496	SDS	Chemical	MESH:C032259
25511509	28667	28678	Acetic acid	Chemical	MESH:D019342
25511509	28651	28658	Ethanol	Chemical	MESH:D000431
25511509	28915	28928	visualization	Disease	MESH:D014786
25511509	28983	28990	Na2S2O3	Chemical	MESH:D012964
25511509	28996	29000	NaAc	Chemical	MESH:D012964
25511509	28967	28974	Ethanol	Chemical	MESH:D000431
25511509	29105	29110	ddH2O	Chemical	MESH:C062226
25511509	29213	29225	Formaldehyde	Chemical	MESH:D005557
25511509	29195	29200	AgNO3	Chemical	MESH:D012834
25511509	29151	29157	Silver	Chemical	MESH:D012834
25511509	29236	29241	ddH2O	Chemical	MESH:C062226
25511509	29343	29348	ddH2O	Chemical	MESH:C062226
25511509	29411	29423	Formaldehyde	Chemical	MESH:D005557
25511509	29392	29398	Na2CO3	Chemical	MESH:D012964
25511509	29434	29439	ddH2O	Chemical	MESH:C062226
25511509	29482	29489	Glycine	Chemical	MESH:D005998
25511509	29499	29504	ddH2O	Chemical	MESH:C062226
25511509	30082	30090	platinum	Chemical	MESH:D010984
25511509	29690	29698	platinum	Chemical	MESH:D010984
25511509	31434	31443	PASS00597	Chemical	
25511509	31221	31236	carbamidomethyl	Chemical	MESH:C018860
25511509	30334	30346	acetonitrile	Chemical	MESH:C032159
25511509	31308	31311	PMF	Disease	MESH:C565010
25511509	30648	30651	PMF	Disease	MESH:C565010
25511509	31241	31251	methionine	Chemical	MESH:D008715
25511509	31839	31848	PASS00597	Chemical	
25511509	32252	32254	WD	Disease	MESH:D006527
25511509	32079	32081	HL	CellLine	CVCL:2492
25511509	32700	32712	Merino sheep	Disease	MESH:D012757
25511509	32745	32751	Merino	Chemical	
25511509	32789	32801	Angora goats	Disease	MESH:D015511
25511509	33074	33078	Lhx2	Gene	101108898
25511509	33173	33178	human	Species	9606
25511509	33257	33262	human	Species	9606
25511509	33324	33329	sheep	Species	9940
25511509	33371	33397	gastrointestinal nematodes	Disease	MESH:D009349
25511509	33502	33522	Haemonchus contortus	Disease	
25511509	33482	33496	sheep infected	Disease	MESH:D012757
25511509	33534	33539	sheep	Species	9940
25511509	33626	33630	goat	Species	9925
25511509	33783	33788	goats	Species	9925
25511509	33853	33858	death	Disease	MESH:D003643
25511509	33952	33958	bovine	Species	9913
25511509	34031	34036	FBLN1	Gene	100037704
25511509	34041	34046	FABP4	Gene	100137067
25511509	34105	34111	Merino	Chemical	
25511509	34229	34245	Corriedale sheep	Disease	MESH:D012757
25511509	34306	34310	goat	Species	9925
25511509	34315	34320	sheep	Species	9940
25511509	34366	34375	mammalian	Species	9606
25511509	34520	34524	Li H	Chemical	MESH:D008094
25511509	34517	34518	N	Chemical	MESH:D009584
25511509	34739	34744	sheep	Species	9940
25511509	34789	34805	lipid metabolism	Disease	MESH:D052439
25511509	35211	35236	stearoyl-CoA desaturase-1	Gene	20249
25511509	35280	35284	mice	Species	10090
25511509	35312	35319	obesity	Disease	MESH:D009765
25511509	35472	35476	MMP2	Gene	4313
25511509	35388	35393	human	Species	9606
25511509	35487	35501	Thymosin beta4	Gene	101106384
25511509	35580	35585	human	Species	9606
25511509	35720	35735	beta 1 integrin	Gene	3688
25511509	35763	35768	human	Species	9606
25511509	35842	35857	beta 1 integrin	Gene	3688
25511509	35907	35913	CYP1A1	Gene	100170113
25511509	36057	36062	mouse	Species	10090
25511509	36155	36160	mouse	Species	10090
25511509	36135	36144	embryonic	Disease	MESH:D018236
25511509	36257	36267	connexin43	Gene	14609
25511509	36328	36333	mouse	Species	10090
25511509	36343	36348	human	Species	9606
25511509	36252	36256	G60S	ProteinMutation	p.G60S
25511509	36349	36376	oculodentodigital dysplasia	Disease	MESH:C563160
25511509	36405	36410	human	Species	9606
25511509	36377	36390	Prostaglandin	Chemical	MESH:D011453
25511509	36425	36438	Prostaglandin	Chemical	MESH:D011453
25511509	36525	36529	male	Species	9606
25511509	36535	36539	rats	Species	10116
25511509	36614	36643	keratin intermediate filament	Gene	100141298
25511509	36679	36708	keratin intermediate filament	Gene	100141298
25511509	36884	36889	KRT14	Gene	100303604
25511509	36836	36856	digital fibromatosis	Disease	MESH:D005350
25511509	36774	36810	dermatopathia pigmentosa reticularis	Disease	MESH:C535374
25511509	36994	37015	ectodermal dysplasias	Disease	MESH:D004476
25511509	36944	36980	dermatopathia pigmentosa reticularis	Disease	MESH:C535374
25511509	36899	36939	Naegeli-Franceschetti-Jadassohn syndrome	Disease	MESH:C538331
25511509	37201	37207	S100A3	Gene	6274
25511509	37256	37261	human	Species	9606
25511509	37233	37237	Ca2+	Chemical	MESH:D002118
25511509	37288	37303	alopecia areata	Disease	MESH:D000506
25511509	37494	37500	murine	Species	10090
25511509	37544	37570	non-small cell lung cancer	Disease	MESH:D002289

25497602|t|Proctitis following stereotactic body radiation therapy for prostate cancer 
25497602|a|Background Proctitis after radiation therapy for prostate cancer remains an ongoing clinical challenge and critical quality of life issue. SBRT could minimize rectal toxicity by reducing the volume of rectum receiving high radiation doses and offers the potential radiobiologic benefits of hypofractionation. This study sought to evaluate the incidence and severity of proctitis following SBRT for prostate cancer. Methods Between February 2008 and July 2011, 269 men with clinically localized prostate cancer were treated definitively with SBRT monotherapy at Georgetown University Hospital. All patients were treated to 35-36.25Gy in 5 fractions delivered with the CyberKnife Radiosurgical System (Accuray). Rectal bleeding was recorded and scored using the CTCAE v.4. Telangiectasias were graded using the Vienna Rectoscopy Score (VRS). Proctitis was assessed via the Bowel domain of the Expanded Prostate Index Composite (EPIC)-26 at baseline and at 1, 3, 6, 9, 12, 18 and 24 months post-SBRT. Results The median age was 69 years with a median prostate volume of 39 cc. The median follow-up was 3.9 years with a minimum follow-up of two years. The 2-year actuarial incidence of late rectal bleeding >= grade 2 was 1.5%. Endoscopy revealed VRS Grade 2 rectal telangiectasias in 11% of patients. All proctitis symptoms increased at one month post-SBRT but returned to near-baseline with longer follow-up. The most bothersome symptoms were bowel urgency and frequency. At one month post-SBRT, 11.2% and 8.5% of patients reported a moderate to big problem with bowel urgency and frequency, respectively. The EPIC bowel summary scores declined transiently at 1 month and experienced a second, more protracted decline between 6 months and 18 months before returning to near-baseline at two years post-SBRT. Prior to treatment, 4.1% of men felt their bowel function was a moderate to big problem which increased to 11.5% one month post-SBRT but returned to near-baseline at two years post-SBRT. Conclusions In this single institution cohort, the rate and severity of proctitis observed following SBRT is low. QOL decreased on follow-up; however, our results compare favorably to those reported for patients treated with alternative radiation modalities. Future prospective randomized studies are needed to confirm these observations. 
25497602	0	9	Proctitis	Disease	MESH:D011349
25497602	60	75	prostate cancer	Disease	MESH:D011471
25497602	445	454	proctitis	Disease	MESH:D011349
25497602	242	250	toxicity	Disease	MESH:D064420
25497602	474	489	prostate cancer	Disease	MESH:D011471
25497602	125	140	prostate cancer	Disease	MESH:D011471
25497602	87	96	Proctitis	Disease	MESH:D011349
25497602	540	543	men	Species	9606
25497602	673	681	patients	Species	9606
25497602	570	585	prostate cancer	Disease	MESH:D011471
25497602	916	925	Proctitis	Disease	MESH:D011349
25497602	847	862	Telangiectasias	Disease	MESH:D013684
25497602	1365	1373	patients	Species	9606
25497602	1589	1597	patients	Species	9606
25497602	1910	1913	men	Species	9606
25497602	1259	1279	late rectal bleeding	Disease	MESH:D012002
25497602	1339	1354	telangiectasias	Disease	MESH:D013684
25497602	2273	2281	patients	Species	9606
25497602	2730	2737	patient	Species	9606
25497602	2765	2773	Patients	Species	9606
25497602	2966	2974	patients	Species	9606
25497602	3044	3051	Patient	Species	9606
25497602	2876	2880	pain	Disease	MESH:D010146
25497602	2526	2541	prostate cancer	Disease	MESH:D011471
25497602	3282	3301	radiation proctitis	Disease	MESH:D011349
25497602	3119	3145	inflammatory bowel disease	Disease	MESH:D015212
25497602	2863	2871	bleeding	Disease	MESH:D006470
25497602	2660	2669	proctitis	Disease	MESH:D011349
25497602	3106	3117	hemorrhoids	Disease	MESH:D006484
25497602	2849	2861	incontinence	Disease	MESH:D014549
25497602	4031	4039	patients	Species	9606
25497602	4151	4159	patients	Species	9606
25497602	4109	4124	Telangiectasias	Disease	MESH:D013684
25497602	4063	4077	telangiectasia	Disease	MESH:D013684
25497602	3787	3794	atrophy	Disease	MESH:D001284
25497602	3446	3455	proctitis	Disease	MESH:D011349
25497602	3397	3405	toxicity	Disease	MESH:D064420
25497602	3650	3655	edema	Disease	MESH:D004487
25497602	3356	3365	Proctitis	Disease	MESH:D011349
25497602	4101	4107	ulcers	Disease	MESH:D014456
25497602	3745	3762	Chronic proctitis	Disease	MESH:D011349
25497602	3799	3824	obliterative endarteritis	Disease	MESH:D004692
25497602	4045	4054	proctitis	Disease	MESH:D011349
25497602	3732	3743	rectal pain	Disease	MESH:C563475
25497602	3863	3871	fibrosis	Disease	MESH:D005355
25497602	3846	3854	ischemia	Disease	MESH:D007511
25497602	3977	3992	rectal bleeding	Disease	MESH:D012002
25497602	4475	4478	PTV	Species	187978
25497602	4568	4585	rectal toxicities	Disease	MESH:D012002
25497602	4948	4957	proctitis	Disease	MESH:D011349
25497602	4599	4613	bowel toxicity	Disease	MESH:D015212
25497602	4234	4243	proctitis	Disease	MESH:D011349
25497602	5816	5824	patients	Species	9606
25497602	5092	5107	prostate cancer	Disease	MESH:D011471
25497602	5201	5216	prostate cancer	Disease	MESH:D011471
25497602	5133	5148	prostate cancer	Disease	MESH:D011471
25497602	6527	6530	PTV	Species	187978
25497602	5957	5982	localized prostate cancer	Disease	MESH:D011471
25497602	6693	6718	localized prostate cancer	Disease	MESH:D011471
25497602	6728	6735	Patient	Species	9606
25497602	6746	6754	Patients	Species	9606
25497602	6813	6828	prostate cancer	Disease	MESH:D011471
25497602	7689	7692	PTV	Species	187978
25497602	8027	8035	Patients	Species	9606
25497602	8135	8138	PTV	Species	187978
25497602	9076	9084	Patients	Species	9606
25497602	8205	8210	tumor	Disease	MESH:D009369
25497602	8396	8416	ischial tuberosities	Disease	MESH:D014402
25497602	9460	9468	Toxicity	Disease	MESH:D064420
25497602	9892	9906	Telangiectasia	Disease	MESH:D013684
25497602	9547	9555	toxicity	Disease	MESH:D064420
25497602	9503	9518	rectal bleeding	Disease	MESH:D012002
25497602	10075	10089	telangiectasia	Disease	MESH:D013684
25497602	9978	9992	telangiectasia	Disease	MESH:D013684
25497602	9346	9361	Rectal bleeding	Disease	MESH:D012002
25497602	9599	9614	rectal bleeding	Disease	MESH:D012002
25497602	9722	9730	bleeding	Disease	MESH:D006470
25497602	10027	10041	telangiectasia	Disease	MESH:D013684
25497602	10099	10108	Proctitis	Disease	MESH:D011349
25497602	11510	11517	patient	Species	9606
25497602	11297	11300	MID	Disease	MESH:D008661
25497602	11562	11569	patient	Species	9606
25497602	11607	11615	Patients	Species	9606
25497602	12296	12304	patients	Species	9606
25497602	12653	12661	patients	Species	9606
25497602	12823	12831	patients	Species	9606
25497602	12730	12738	androgen	Chemical	MESH:D000728
25497602	12280	12295	prostate cancer	Disease	MESH:D011471
25497602	12556	12563	aspirin	Chemical	MESH:D001241
25497602	12916	12924	patients	Species	9606
25497602	12978	12986	patients	Species	9606
25497602	13019	13027	patients	Species	9606
25497602	13149	13157	patients	Species	9606
25497602	13364	13372	patients	Species	9606
25497602	13051	13059	bleeding	Disease	MESH:D006470
25497602	13434	13454	late rectal bleeding	Disease	MESH:D012002
25497602	13003	13011	bleeding	Disease	MESH:D006470
25497602	13093	13108	rectal bleeding	Disease	MESH:D012002
25497602	13204	13217	rectal bleeds	Disease	MESH:D012002
25497602	13241	13256	rectal bleeding	Disease	MESH:D012002
25497602	12934	12949	rectal bleeding	Disease	MESH:D012002
25497602	13566	13574	patients	Species	9606
25497602	13717	13724	patient	Species	9606
25497602	13926	13934	patients	Species	9606
25497602	13942	13950	patients	Species	9606
25497602	14035	14042	patient	Species	9606
25497602	14139	14147	patients	Species	9606
25497602	13886	13901	telangiectasias	Disease	MESH:D013684
25497602	13996	14011	telangiectasias	Disease	MESH:D013684
25497602	14076	14090	telangiectasia	Disease	MESH:D013684
25497602	13683	13700	colorectal cancer	Disease	MESH:D015179
25497602	14187	14195	fistulas	Disease	MESH:D005402
25497602	13752	13767	rectal bleeding	Disease	MESH:D012002
25497602	14249	14264	prostate cancer	Disease	MESH:D011471
25497602	15415	15419	Pain	Disease	MESH:D010146
25497602	15761	15768	Patient	Species	9606
25497602	15848	15850	6B	Chemical	MESH:D001895
25497602	15883	15885	6C	Chemical	MESH:D002244
25497602	15967	15978	rectal pain	Disease	MESH:C563475
25497602	16063	16078	prostate cancer	Disease	MESH:D011471
25497602	16645	16660	prostate cancer	Disease	MESH:D011471
25497602	16924	16935	rectal pain	Disease	MESH:C563475
25497602	17302	17309	patient	Species	9606
25497602	17735	17743	patients	Species	9606
25497602	18194	18202	patients	Species	9606
25497602	18483	18490	patient	Species	9606
25497602	18160	18163	MID	Disease	MESH:D008661
25497602	18631	18639	patients	Species	9606
25497602	18813	18821	patients	Species	9606
25497602	18591	18609	proctitis symptoms	Disease	MESH:D051271
25497602	19062	19077	prostate cancer	Disease	MESH:D011471
25497602	19718	19721	MID	Disease	MESH:D008661
25497602	20005	20012	Patient	Species	9606
25497602	19988	20003	prostate cancer	Disease	MESH:D011471
25497602	20053	20060	EPIC-26	Chemical	MESH:C509968
25497602	20843	20851	patients	Species	9606
25497602	20920	20928	patients	Species	9606
25497602	21219	21227	patients	Species	9606
25497602	21521	21529	patients	Species	9606
25497602	21795	21803	patients	Species	9606
25497602	21498	21501	MID	Disease	MESH:D008661
25497602	22241	22249	patients	Species	9606
25497602	22073	22082	proctitis	Disease	MESH:D011349
25497602	22019	22027	toxicity	Disease	MESH:D064420
25497602	22145	22159	bowel symptoms	Disease	MESH:D020821
25497602	22389	22400	rectal pain	Disease	MESH:C563475
25497602	22102	22117	prostate cancer	Disease	MESH:D011471
25497602	22405	22420	rectal bleeding	Disease	MESH:D012002
25497602	22528	22542	bowel symptoms	Disease	MESH:D020821
25497602	21896	21931	Proctitis following prostate cancer	Disease	MESH:D011471
25497602	23413	23421	patients	Species	9606
25497602	23485	23500	rectal bleeding	Disease	MESH:D012002
25497602	22803	22818	rectal toxicity	Disease	MESH:D012002
25497602	23241	23247	bleeds	Disease	MESH:D006470
25497602	23395	23409	telangiectasia	Disease	MESH:D013684
25497602	23312	23322	hemorrhoid	Disease	MESH:D006484
25497602	23287	23308	acute anal irritation	Disease	MESH:D001005
25497602	23504	23510	cancer	Disease	MESH:D009369
25497602	22991	23006	rectal bleeding	Disease	MESH:D012002
25497602	23981	23989	patients	Species	9606
25497602	24340	24348	patients	Species	9606
25497602	24226	24246	SBRT rectal bleeding	Disease	MESH:D012002
25497602	24000	24015	rectal bleeding	Disease	MESH:D012002
25497602	23773	23788	rectal bleeding	Disease	MESH:D012002
25497602	23827	23837	toxicities	Disease	MESH:D064420
25497602	24561	24569	bleeding	Disease	MESH:D006470
25497602	24359	24374	rectal bleeding	Disease	MESH:D012002
25497602	24979	24994	prostate cancer	Disease	MESH:D011471
25497602	25606	25614	patients	Species	9606
25497602	26124	26132	patients	Species	9606
25497602	26598	26605	patient	Species	9606
25497602	26791	26798	patient	Species	9606
25497602	26934	26941	patient	Species	9606
25497602	27380	27388	toxicity	Disease	MESH:D064420
25497602	27465	27473	toxicity	Disease	MESH:D064420
25497602	27931	27939	patients	Species	9606
25497602	28238	28246	Androgen	Chemical	MESH:D000728
25497602	28301	28309	toxicity	Disease	MESH:D064420
25497602	28598	28601	MID	Disease	MESH:D008661
25497602	28668	28674	cancer	Disease	MESH:D009369
25497602	28748	28751	VRS	Disease	MESH:C564884
25497602	29451	29458	patient	Species	9606
25497602	29559	29567	patients	Species	9606
25497602	29846	29848	AD	Disease	MESH:D000544
25497602	29854	29856	JL	Chemical	MESH:C441720
25497602	30220	30248	localized prostate carcinoma	Disease	MESH:D011471
25497602	30337	30352	prostate cancer	Disease	MESH:D011471
25497602	30405	30420	prostate-cancer	Disease	MESH:D011471
25497602	30431	30438	Patient	Species	9606
25497602	30541	30566	localized prostate cancer	Disease	MESH:D011471
25497602	30602	30609	patient	Species	9606
25497602	30689	30704	prostate cancer	Disease	MESH:D011471
25497602	30747	30762	prostate cancer	Disease	MESH:D011471
25497602	30705	30726	Radiation proctopathy	Disease	MESH:D011832
25497602	30829	30844	prostate cancer	Disease	MESH:D011471
25497602	30922	30930	patients	Species	9606
25497602	30936	30951	prostate cancer	Disease	MESH:D011471
25497602	31021	31029	patients	Species	9606
25497602	31079	31088	carcinoma	Disease	MESH:D002277
25497602	31168	31176	toxicity	Disease	MESH:D064420
25497602	31224	31239	prostate cancer	Disease	MESH:D011471
25497602	31128	31135	illness	Disease	MESH:D002908
25497602	31267	31275	patients	Species	9606
25497602	31281	31307	inflammatory bowel disease	Disease	MESH:D015212
25497602	31349	31365	pelvic neoplasms	Disease	MESH:D010386
25497602	31255	31263	toxicity	Disease	MESH:D064420
25497602	31473	31490	bleeding toxicity	Disease	MESH:D064420
25497602	31397	31412	prostate cancer	Disease	MESH:D011471
25497602	31505	31524	radiation proctitis	Disease	MESH:D011349
25497602	31602	31617	prostate cancer	Disease	MESH:D011471
25497602	31680	31695	prostate cancer	Disease	MESH:D011471
25497602	31720	31728	MRC RT01	CellLine	CVCL:D923
25497602	31827	31852	localized prostate cancer	Disease	MESH:D011471
25497602	32000	32015	rectal toxicity	Disease	MESH:D012002
25497602	31900	31915	prostate cancer	Disease	MESH:D011471
25497602	31853	31862	Proctitis	Disease	MESH:D011349
25497602	32127	32140	rectal injury	Disease	MESH:D012002
25497602	32352	32360	toxicity	Disease	MESH:D064420
25497602	32561	32568	patient	Species	9606
25497602	32607	32614	patient	Species	9606
25497602	32793	32818	localized prostate cancer	Disease	MESH:D011471
25497602	32694	32704	toxicities	Disease	MESH:D064420
25497602	32831	32839	toxicity	Disease	MESH:D064420
25497602	33005	33020	prostate cancer	Disease	MESH:D011471
25497602	33047	33062	prostate cancer	Disease	MESH:D011471
25497602	33164	33182	prostate carcinoma	Disease	MESH:D011471
25497602	33183	33220	Hypofractionation for prostate cancer	Disease	MESH:D011471
25497602	33279	33304	localized prostate cancer	Disease	MESH:D011471
25497602	33378	33403	localized prostate cancer	Disease	MESH:D011471
25497602	33525	33550	Localized Prostate Cancer	Disease	MESH:D011471
25497602	33655	33680	Localized Prostate Cancer	Disease	MESH:D011471
25497602	33830	33845	prostate cancer	Disease	MESH:D011471
25497602	33906	33929	prostate adenocarcinoma	Disease	MESH:D011471
25497602	34092	34107	prostate cancer	Disease	MESH:D011471
25497602	34450	34475	localized prostate cancer	Disease	MESH:D011471
25497602	34563	34588	localized prostate cancer	Disease	MESH:D011471
25497602	34671	34690	prostatic carcinoma	Disease	MESH:D011471
25497602	34611	34637	late rectal mucosal damage	Disease	MESH:D012002
25497602	34839	34842	men	Species	9606
25497602	34848	34863	prostate cancer	Disease	MESH:D011471
25497602	34734	34749	prostate cancer	Disease	MESH:D011471
25497602	34931	34946	prostate cancer	Disease	MESH:D011471
25497602	35146	35171	localized prostate cancer	Disease	MESH:D011471
25497602	35263	35278	prostate cancer	Disease	MESH:D011471
25497602	35329	35344	prostate cancer	Disease	MESH:D011471
25497602	35402	35429	toxicity in prostate cancer	Disease	MESH:D011471
25497602	35553	35571	endorectal balloon	Disease	MESH:D054549
25497602	35641	35649	patients	Species	9606
25497602	35629	35637	toxicity	Disease	MESH:D064420
25497602	35715	35740	localized prostate cancer	Disease	MESH:D011471

25439054|t|A generalized matching law analysis of cocaine vs. food choice in rhesus monkeys: Effects of candidate 'agonist-based' medications on sensitivity to reinforcement  
25439054|a|Background We have previously demonstrated reductions in cocaine choice produced by either continuous 14-day phendimetrazine and D-amphetamine treatment or removing cocaine availability under a cocaine vs. food choice procedure in rhesus monkeys. The aim of the present investigation was to apply the concatenated generalized matching law (GML) to cocaine vs. food choice dose-effect functions incorporating sensitivity to both the relative magnitude and price of each reinforcer. Our goal was to determine potential behavioral mechanisms underlying pharmacological treatment efficacy to decrease cocaine choice. Methods A multi-model comparison approach was used to characterize dose- and time-course effects of both pharmacological and environmental manipulations on sensitivity to reinforcement. Results GML models provided an excellent fit of the cocaine choice dose-effect functions in individual monkeys. Reductions in cocaine choice by both pharmacological and environmental manipulations were principally produced by systematic decreases in sensitivity to reinforcer price and non-systematic changes in sensitivity to reinforcer magnitude. Conclusions The modeling approach used provides a theoretical link between the experimental analysis of choice and pharmacological treatments being evaluated as candidate 'agonist-based' medications for cocaine addiction. The analysis suggests that monoamine releaser treatment efficacy to decrease cocaine choice was mediated by selectively increasing the relative price of cocaine. Overall, the net behavioral effect of these pharmacological treatments was to increase substitutability of food pellets, a nondrug reinforcer, for cocaine. 
25439054	66	80	rhesus monkeys	Species	9544
25439054	39	46	cocaine	Chemical	MESH:D003042
25439054	401	415	rhesus monkeys	Species	9544
25439054	299	312	D-amphetamine	Chemical	MESH:D000661
25439054	767	774	cocaine	Chemical	MESH:D003042
25439054	518	525	cocaine	Chemical	MESH:D003042
25439054	335	342	cocaine	Chemical	MESH:D003042
25439054	279	294	phendimetrazine	Chemical	MESH:C100294
25439054	227	234	cocaine	Chemical	MESH:D003042
25439054	364	371	cocaine	Chemical	MESH:D003042
25439054	1095	1102	cocaine	Chemical	MESH:D003042
25439054	1021	1028	cocaine	Chemical	MESH:D003042
25439054	1849	1856	cocaine	Chemical	MESH:D003042
25439054	1693	1700	cocaine	Chemical	MESH:D003042
25439054	1521	1528	cocaine	Chemical	MESH:D003042
25439054	1617	1624	cocaine	Chemical	MESH:D003042
25439054	1567	1576	monoamine	Chemical	MESH:D015306
25439054	2760	2767	cocaine	Chemical	MESH:D003042
25439054	4214	4221	cocaine	Chemical	MESH:D003042
25439054	5326	5333	cocaine	Chemical	MESH:D003042
25439054	4326	4333	cocaine	Chemical	MESH:D003042
25439054	5076	5083	cocaine	Chemical	MESH:D003042
25439054	3716	3723	cocaine	Chemical	MESH:D003042
25439054	4000	4007	cocaine	Chemical	MESH:D003042
25439054	4820	4827	cocaine	Chemical	MESH:D003042
25439054	3884	3891	cocaine	Chemical	MESH:D003042
25439054	5569	5576	cocaine	Chemical	MESH:D003042
25439054	5762	5777	phendimetrazine	Chemical	MESH:C100294
25439054	5936	5943	cocaine	Chemical	MESH:D003042
25439054	5527	5536	monoamine	Chemical	MESH:D015306
25439054	5693	5700	cocaine	Chemical	MESH:D003042
25439054	5783	5796	phenmetrazine	Chemical	MESH:D010633
25439054	5747	5760	D-amphetamine	Chemical	MESH:D000661
25439054	5892	5899	cocaine	Chemical	MESH:D003042
25439054	6205	6212	cocaine	Chemical	MESH:D003042
25439054	6435	6439	male	Species	9606
25439054	6440	6454	rhesus monkeys	Species	9544
25439054	6456	6470	Macaca mulatta	Species	9544
25439054	7824	7830	banana	Species	4641
25439054	7521	7527	monkey	Disease	MESH:D008992
25439054	7688	7695	cocaine	Chemical	MESH:D003042
25439054	7985	7992	cocaine	Chemical	MESH:D003042
25439054	8470	8477	cocaine	Chemical	MESH:D003042
25439054	8771	8778	cocaine	Chemical	MESH:D003042
25439054	8545	8552	cocaine	Chemical	MESH:D003042
25439054	8367	8374	cocaine	Chemical	MESH:D003042
25439054	8916	8923	cocaine	Chemical	MESH:D003042
25439054	9533	9540	cocaine	Chemical	MESH:D003042
25439054	9401	9408	cocaine	Chemical	MESH:D003042
25439054	9238	9255	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	9161	9174	D-amphetamine	Chemical	MESH:D000661
25439054	9196	9215	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	9836	9843	cocaine	Chemical	MESH:D003042
25439054	9785	9792	cocaine	Chemical	MESH:D003042
25439054	10276	10293	food availability	Disease	MESH:D005517
25439054	10065	10072	cocaine	Chemical	MESH:D003042
25439054	10189	10196	cocaine	Chemical	MESH:D003042
25439054	10907	10914	cocaine	Chemical	MESH:D003042
25439054	10265	10272	cocaine	Chemical	MESH:D003042
25439054	11232	11239	cocaine	Chemical	MESH:D003042
25439054	12973	12975	H0	Chemical	MESH:C027727
25439054	13405	13412	Cocaine	Chemical	MESH:D003042
25439054	12962	12971	DeltaAICc	Chemical	MESH:D035923
25439054	14271	14278	cocaine	Chemical	MESH:D003042
25439054	14488	14501	D-amphetamine	Chemical	MESH:D000661
25439054	14439	14446	cocaine	Chemical	MESH:D003042
25439054	14224	14237	D-amphetamine	Chemical	MESH:D000661
25439054	14380	14393	D-amphetamine	Chemical	MESH:D000661
25439054	14754	14767	D-amphetamine	Chemical	MESH:D000661
25439054	14565	14578	D-amphetamine	Chemical	MESH:D000661
25439054	15555	15574	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	15277	15296	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	15043	15050	cocaine	Chemical	MESH:D003042
25439054	14990	15009	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	15419	15438	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	15228	15235	cocaine	Chemical	MESH:D003042
25439054	15152	15167	phendimetrazine	Chemical	MESH:C100294
25439054	16482	16499	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	16092	16105	phenmetrazine	Chemical	MESH:D010633
25439054	15983	15990	cocaine	Chemical	MESH:D003042
25439054	16214	16231	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	16165	16172	cocaine	Chemical	MESH:D003042
25439054	15932	15949	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	16643	16650	cocaine	Chemical	MESH:D003042
25439054	16578	16585	cocaine	Chemical	MESH:D003042
25439054	17060	17067	Cocaine	Chemical	MESH:D003042
25439054	16858	16865	cocaine	Chemical	MESH:D003042
25439054	16759	16766	cocaine	Chemical	MESH:D003042
25439054	17319	17328	monoamine	Chemical	MESH:D015306
25439054	17669	17676	cocaine	Chemical	MESH:D003042
25439054	17994	18001	cocaine	Chemical	MESH:D003042
25439054	18525	18539	rhesus monkeys	Species	9544
25439054	19116	19130	rhesus monkeys	Species	9544
25439054	19759	19766	cocaine	Chemical	MESH:D003042
25439054	21321	21328	cocaine	Chemical	MESH:D003042
25439054	21276	21283	cocaine	Chemical	MESH:D003042
25439054	21373	21380	cocaine	Chemical	MESH:D003042
25439054	21550	21557	cocaine	Chemical	MESH:D003042
25439054	22584	22591	cocaine	Chemical	MESH:D003042
25439054	21826	21833	cocaine	Chemical	MESH:D003042
25439054	22452	22459	cocaine	Chemical	MESH:D003042
25439054	22361	22368	cocaine	Chemical	MESH:D003042
25439054	22517	22524	cocaine	Chemical	MESH:D003042
25439054	23211	23227	food consumption	Disease	MESH:D014397
25439054	23075	23082	cocaine	Chemical	MESH:D003042
25439054	22931	22944	D-amphetamine	Chemical	MESH:D000661
25439054	23470	23483	D-amphetamine	Chemical	MESH:D000661
25439054	23358	23365	cocaine	Chemical	MESH:D003042
25439054	23169	23176	cocaine	Chemical	MESH:D003042
25439054	23413	23420	cocaine	Chemical	MESH:D003042
25439054	23199	23206	cocaine	Chemical	MESH:D003042
25439054	23904	23911	cocaine	Chemical	MESH:D003042
25439054	23729	23736	cocaine	Chemical	MESH:D003042
25439054	23322	23329	cocaine	Chemical	MESH:D003042
25439054	23564	23571	cocaine	Chemical	MESH:D003042
25439054	24372	24379	cocaine	Chemical	MESH:D003042
25439054	24013	24020	cocaine	Chemical	MESH:D003042
25439054	24593	24600	cocaine	Chemical	MESH:D003042
25439054	25269	25276	cocaine	Chemical	MESH:D003042
25439054	25697	25710	D-amphetamine	Chemical	MESH:D000661
25439054	25653	25660	cocaine	Chemical	MESH:D003042
25439054	25832	25839	cocaine	Chemical	MESH:D003042
25439054	25462	25469	Cocaine	Chemical	MESH:D003042
25439054	26637	26643	humans	Species	9606
25439054	27069	27084	phendimetrazine	Chemical	MESH:C100294
25439054	27051	27064	D-amphetamine	Chemical	MESH:D000661
25439054	25980	25987	Cocaine	Chemical	MESH:D003042
25439054	26809	26824	phendimetrazine	Chemical	MESH:C100294
25439054	26325	26332	cocaine	Chemical	MESH:D003042
25439054	26791	26804	D-amphetamine	Chemical	MESH:D000661
25439054	26898	26905	cocaine	Chemical	MESH:D003042
25439054	28035	28042	cocaine	Chemical	MESH:D003042
25439054	28337	28349	Parkinsonian	Disease	MESH:D010300
25439054	28376	28387	amphetamine	Chemical	MESH:D000661
25439054	28401	28408	cocaine	Chemical	MESH:D003042
25439054	28550	28564	norepinephrine	Chemical	MESH:D009638
25439054	28482	28491	monoamine	Chemical	MESH:D015306
25439054	28600	28607	cocaine	Chemical	MESH:D003042
25439054	28572	28581	serotonin	Chemical	MESH:D012701
25439054	28541	28549	dopamine	Chemical	MESH:D004298
25439054	28814	28821	cocaine	Chemical	MESH:D003042
25439054	28907	28922	phendimetrazine	Chemical	MESH:C100294
25439054	28941	28948	cocaine	Chemical	MESH:D003042
25439054	29150	29155	human	Species	9606
25439054	29515	29527	remifentanil	Chemical	MESH:C071741
25439054	29695	29702	cocaine	Chemical	MESH:D003042
25439054	29826	29830	rats	Species	10116
25439054	29815	29822	ethanol	Chemical	MESH:D000431
25439054	29847	29854	ethanol	Chemical	MESH:D000431
25439054	30185	30197	remifentanil	Chemical	MESH:C071741
25439054	30402	30409	cocaine	Chemical	MESH:D003042
25439054	30801	30808	cocaine	Chemical	MESH:D003042
25439054	31019	31026	cocaine	Chemical	MESH:D003042
25439054	31073	31086	D-amphetamine	Chemical	MESH:D000661
25439054	31100	31107	cocaine	Chemical	MESH:D003042
25439054	31291	31305	rhesus monkeys	Species	9544
25439054	31324	31353	analgesia and abuse liability	Disease	MESH:D000699
25439054	31389	31397	nicotine	Chemical	MESH:D009538
25439054	31572	31580	dopamine	Chemical	MESH:D004298
25439054	31590	31600	antagonism	Chemical	
25439054	31702	31709	cocaine	Chemical	MESH:D003042
25439054	31813	31820	cocaine	Chemical	MESH:D003042
25439054	32336	32343	cocaine	Chemical	MESH:D003042
25439054	32029	32036	cocaine	Chemical	MESH:D003042
25439054	32303	32310	cocaine	Chemical	MESH:D003042
25439054	32433	32440	cocaine	Chemical	MESH:D003042
25439054	32386	32399	D-amphetamine	Chemical	MESH:D000661
25439054	32634	32641	cocaine	Chemical	MESH:D003042
25439054	32542	32555	D-amphetamine	Chemical	MESH:D000661
25439054	32801	32814	D-amphetamine	Chemical	MESH:D000661
25439054	32671	32678	cocaine	Chemical	MESH:D003042
25439054	33492	33511	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	33325	33332	cocaine	Chemical	MESH:D003042
25439054	33065	33084	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	33362	33369	cocaine	Chemical	MESH:D003042
25439054	33227	33246	(+)-phendimetrazine	Chemical	MESH:C100294
25439054	33118	33125	cocaine	Chemical	MESH:D003042
25439054	34018	34025	cocaine	Chemical	MESH:D003042
25439054	33922	33939	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	34185	34202	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	33762	33779	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	34055	34062	cocaine	Chemical	MESH:D003042
25439054	33813	33820	cocaine	Chemical	MESH:D003042
25439054	34451	34458	cocaine	Chemical	MESH:D003042
25439054	34679	34686	cocaine	Chemical	MESH:D003042
25439054	34482	34489	cocaine	Chemical	MESH:D003042
25439054	34845	34862	(+)-phenmetrazine	Chemical	MESH:D010633
25439054	34715	34722	cocaine	Chemical	MESH:D003042
25439054	35388	35395	cocaine	Chemical	MESH:D003042
25439054	35448	35464	food consumption	Disease	MESH:D014397
25439054	35151	35158	cocaine	Chemical	MESH:D003042
25439054	35436	35443	cocaine	Chemical	MESH:D003042
25439054	35105	35118	D-amphetamine	Chemical	MESH:D000661
25439054	35756	35765	DeltaAICc	Chemical	MESH:D035923
25439054	36235	36244	DeltaAICc	Chemical	MESH:D035923

25101886|t|Potentiator Ivacaftor Abrogates Pharmacological Correction of DeltaF508 CFTR in Cystic Fibrosis 
25101886|a|Cystic Fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR). Newly developed "correctors" such as lumacaftor (VX-809) that improve CFTR maturation and trafficking and "potentiators" such as ivacaftor (VX-770) that enhance channel activity may provide important advances in CF therapy. Although VX-770 has demonstrated substantial clinical efficacy in the small subset of patients with a mutation (G551D) that affects only channel activity, a single compound is not sufficient to treat patients with the more common CFTR mutation, DeltaF508. Thus, patients with DeltaF508 will likely require treatment with both correctors and potentiators to achieve clinical benefit. However, whereas the effectiveness of acute treatment with this drug combination has been demonstrated in vitro, the impact of chronic therapy has not been established. In studies of human primary airway epithelial cells, we found that both acute and chronic treatment with VX-770 improved CFTR function in cells with the G551D mutation, consistent with clinical studies. In contrast, chronic VX-770 administration caused a dose-dependent reversal of VX-809-mediated CFTR correction in DeltaF508 homozygous cultures. This result reflected the destabilization of corrected DeltaF508 CFTR by VX-770, dramatically increasing its turnover rate. Chronic VX-770 treatment also reduced mature wild-type CFTR levels and function. These findings demonstrate that chronic treatment with CFTR potentiators and correctors may have unexpected effects that cannot be predicted from short-term studies. Combining of these drugs to maximize rescue of DeltaF508 CFTR may require changes in dosing and/or development of new potentiator compounds that do not interfere with CFTR stability. 
25101886	72	76	CFTR	Gene	1080
25101886	80	95	Cystic Fibrosis	Disease	MESH:D003550
25101886	187	191	CFTR	Gene	1080
25101886	264	268	CFTR	Gene	1080
25101886	648	652	CFTR	Gene	1080
25101886	1091	1095	CFTR	Gene	1080
25101886	1268	1272	CFTR	Gene	1080
25101886	1497	1501	CFTR	Gene	1080
25101886	1578	1582	CFTR	Gene	1080
25101886	1746	1750	CFTR	Gene	1080
25101886	1856	1860	CFTR	Gene	1080
25101886	1383	1387	CFTR	Gene	1080
25101886	504	512	patients	Species	9606
25101886	618	626	patients	Species	9606
25101886	680	688	patients	Species	9606
25101886	984	989	human	Species	9606
25101886	1123	1128	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	96	111	Cystic Fibrosis	Disease	MESH:D003550
25101886	113	115	CF	Disease	MESH:D003550
25101886	406	408	CF	Disease	MESH:D003550
25101886	147	149	CF	Disease	MESH:D003550
25101886	530	535	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	2132	2136	CFTR	Gene	1080
25101886	2156	2160	CFTR	Gene	1080
25101886	2092	2094	CF	Disease	MESH:D003550
25101886	2462	2471	infection	Disease	MESH:D007239
25101886	2015	2017	CF	Disease	MESH:D003550
25101886	1998	2013	cystic fibrosis	Disease	MESH:D003550
25101886	2431	2449	airway obstruction	Disease	MESH:D000402
25101886	2554	2582	hallmarks of CF lung disease	Disease	MESH:D003550
25101886	2473	2485	inflammation	Disease	MESH:D007249
25101886	2276	2284	pancreas	Disease	MESH:D010190
25101886	1901	1936	autosomal recessive genetic disease	Disease	MESH:D030342
25101886	2178	2182	HCO3	Chemical	MESH:C504136
25101886	2661	2665	CFTR	Gene	1080
25101886	2913	2917	CFTR	Gene	1080
25101886	2972	2976	CFTR	Gene	1080
25101886	3071	3075	CFTR	Gene	1080
25101886	3159	3163	CFTR	Gene	1080
25101886	2799	2801	CF	Disease	MESH:D003550
25101886	2717	2731	DeltaF508 CFTR	DNAMutation	c.508DELTA>CFTR
25101886	3243	3247	CFTR	Gene	1080
25101886	3350	3354	CFTR	Gene	1080
25101886	3413	3417	CFTR	Gene	1080
25101886	3794	3798	CFTR	Gene	1080
25101886	4499	4503	CFTR	Gene	1080
25101886	4709	4713	CFTR	Gene	1080
25101886	4922	4926	CFTR	Gene	1080
25101886	5175	5179	CFTR	Gene	1080
25101886	5297	5301	CFTR	Gene	1080
25101886	5671	5675	CFTR	Gene	1080
25101886	6060	6064	CFTR	Gene	1080
25101886	3370	3378	patients	Species	9606
25101886	3578	3586	patients	Species	9606
25101886	3685	3693	patients	Species	9606
25101886	3830	3838	patients	Species	9606
25101886	4020	4028	patients	Species	9606
25101886	4040	4048	patients	Species	9606
25101886	4428	4435	patient	Species	9606
25101886	4977	4982	human	Species	9606
25101886	5109	5117	patients	Species	9606
25101886	5756	5761	human	Species	9606
25101886	5794	5802	patients	Species	9606
25101886	5807	5812	human	Species	9606
25101886	6022	6030	patients	Species	9606
25101886	3391	3396	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	4425	4427	CF	Disease	MESH:D003550
25101886	3571	3573	CF	Disease	MESH:D003550
25101886	3733	3741	chloride	Chemical	MESH:D002712
25101886	4212	4214	CF	Disease	MESH:D003550
25101886	5528	5542	DeltaF508 CFTR	DNAMutation	c.508DELTA>CFTR
25101886	3928	3930	CF	Disease	MESH:D003550
25101886	5106	5108	CF	Disease	MESH:D003550
25101886	3367	3369	CF	Disease	MESH:D003550
25101886	5836	5838	CF	Disease	MESH:D003550
25101886	3299	3307	Kalydeco	Chemical	MESH:C545203
25101886	3881	3883	CF	Disease	MESH:D003550
25101886	3598	3603	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	6019	6021	CF	Disease	MESH:D003550
25101886	3827	3829	CF	Disease	MESH:D003550
25101886	4960	4962	CF	Disease	MESH:D003550
25101886	4037	4039	CF	Disease	MESH:D003550
25101886	3523	3526	ATP	Chemical	MESH:D000255
25101886	4777	4779	CF	Disease	MESH:D003550
25101886	3407	3412	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	5791	5793	CF	Disease	MESH:D003550
25101886	3951	3956	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	6189	6193	CFTR	Gene	1080
25101886	6495	6499	CFTR	Gene	1080
25101886	6922	6926	CFTR	Gene	1080
25101886	7097	7101	CFTR	Gene	1080
25101886	6281	6289	patients	Species	9606
25101886	6586	6591	Human	Species	9606
25101886	6785	6793	patients	Species	9606
25101886	6939	6947	patients	Species	9606
25101886	6992	6996	COPD	Disease	MESH:D029424
25101886	6803	6808	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	6953	6990	chronic obstructive pulmonary disease	Disease	MESH:D029424
25101886	6782	6784	CF	Disease	MESH:D003550
25101886	6379	6381	CF	Disease	MESH:D003550
25101886	6278	6280	CF	Disease	MESH:D003550
25101886	7220	7224	CFTR	Gene	1080
25101886	7214	7219	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	7311	7315	CFTR	Gene	1080
25101886	7356	7360	CFTR	Gene	1080
25101886	8081	8085	CFTR	Gene	1080
25101886	8434	8438	CFTR	Gene	1080
25101886	7400	7405	human	Species	9606
25101886	7455	7463	patients	Species	9606
25101886	8041	8050	forskolin	Chemical	MESH:D005576
25101886	8178	8187	forskolin	Chemical	MESH:D005576
25101886	7723	7728	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	8541	8550	forskolin	Chemical	MESH:D005576
25101886	7969	7978	amiloride	Chemical	MESH:D000584
25101886	8260	8269	forskolin	Chemical	MESH:D005576
25101886	7654	7659	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	7452	7454	CF	Disease	MESH:D003550
25101886	7627	7646	CF airway epithelia	Disease	MESH:D003550
25101886	7473	7478	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	7706	7712	CF HBE	CellLine	CVCL:3285
25101886	8788	8792	CFTR	Gene	1080
25101886	8965	8991	Ca2+ activated Cl- channel	Gene	55107
25101886	8993	8997	CaCC	Gene	55107
25101886	8933	8936	UTP	Chemical	MESH:D014544
25101886	8596	8603	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	8897	8899	CF	Disease	MESH:D003550
25101886	8654	8663	amiloride	Chemical	MESH:D000584
25101886	9192	9196	CFTR	Gene	1080
25101886	9228	9233	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	9333	9342	DeltaF508	Chemical	MESH:C025253
25101886	9384	9388	CFTR	Gene	1080
25101886	9473	9477	CFTR	Gene	1080
25101886	9631	9635	CFTR	Gene	1080
25101886	9351	9359	patients	Species	9606
25101886	9737	9745	patients	Species	9606
25101886	9348	9350	CF	Disease	MESH:D003550
25101886	9755	9761	CF HBE	CellLine	CVCL:3285
25101886	9772	9791	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	9912	9926	DeltaF508 CFTR	DNAMutation	c.508DELTA>CFTR
25101886	9734	9736	CF	Disease	MESH:D003550
25101886	10062	10066	CFTR	Gene	1080
25101886	10567	10571	CFTR	Gene	1080
25101886	10650	10654	CFTR	Gene	1080
25101886	10548	10552	CFTR	Gene	1080
25101886	10217	10221	CFTR	Gene	1080
25101886	10042	10046	cAMP	Chemical	MESH:D000242
25101886	10345	10354	forskolin	Chemical	MESH:D005576
25101886	10130	10136	CF HBE	CellLine	CVCL:3285
25101886	10827	10831	CFTR	Gene	1080
25101886	11139	11143	CFTR	Gene	1080
25101886	11346	11349	UTP	Chemical	MESH:D014544
25101886	11163	11174	CFTRinh-172	Chemical	MESH:C501920
25101886	11082	11091	forskolin	Chemical	MESH:D005576
25101886	11694	11698	CFTR	Gene	1080
25101886	11675	11684	forskolin	Chemical	MESH:D005576
25101886	11605	11607	CF	Disease	MESH:D003550
25101886	11511	11517	CF HBE	CellLine	CVCL:3285
25101886	11632	11638	CF HBE	CellLine	CVCL:3285
25101886	11965	11969	CFTR	Gene	1080
25101886	12668	12672	CFTR	Gene	1080
25101886	12715	12719	CFTR	Gene	1080
25101886	13003	13007	CFTR	Gene	1080
25101886	13019	13023	CFTR	Gene	1080
25101886	13265	13269	CFTR	Gene	1080
25101886	13440	13444	CFTR	Gene	1080
25101886	13521	13525	CFTR	Gene	1080
25101886	13864	13868	CFTR	Gene	1080
25101886	12857	12861	CFTR	Gene	1080
25101886	13069	13075	BHK-21	CellLine	CVCL:1914
25101886	12467	12473	CF HBE	CellLine	CVCL:3285
25101886	12536	12538	CF	Disease	MESH:D003550
25101886	12326	12332	CF HBE	CellLine	CVCL:3285
25101886	12574	12576	CF	Disease	MESH:D003550
25101886	13384	13397	cycloheximide	Chemical	MESH:D003513
25101886	12349	12351	CF	Disease	MESH:D003550
25101886	12555	12557	CF	Disease	MESH:D003550
25101886	13909	13913	CFTR	Gene	1080
25101886	14097	14101	CFTR	Gene	1080
25101886	14144	14148	CFTR	Gene	1080
25101886	14211	14215	CFTR	Gene	1080
25101886	14330	14334	CFTR	Gene	1080
25101886	15296	15300	CFTR	Gene	1080
25101886	14469	14475	CF HBE	CellLine	CVCL:3285
25101886	14186	14195	forskolin	Chemical	MESH:D005576
25101886	14446	14455	forskolin	Chemical	MESH:D005576
25101886	15119	15125	CF HBE	CellLine	CVCL:3285
25101886	14925	14934	forskolin	Chemical	MESH:D005576
25101886	14031	14037	CF HBE	CellLine	CVCL:3285
25101886	15476	15480	CFTR	Gene	1080
25101886	15632	15636	CFTR	Gene	1080
25101886	15759	15763	CFTR	Gene	1080
25101886	15869	15873	CFTR	Gene	1080
25101886	15977	15986	amiloride	Chemical	MESH:D000584
25101886	15687	15696	forskolin	Chemical	MESH:D005576
25101886	16129	16135	CF HBE	CellLine	CVCL:3285
25101886	16058	16061	UTP	Chemical	MESH:D014544
25101886	16802	16806	CFTR	Gene	1080
25101886	16812	16816	CaCC	Gene	55107
25101886	16542	16546	DMSO	Chemical	MESH:D004121
25101886	16745	16754	amiloride	Chemical	MESH:D000584
25101886	16964	16972	Nystatin	Chemical	MESH:D009761
25101886	16976	16983	polyene	Chemical	MESH:D011090
25101886	17626	17630	CFTR	Gene	1080
25101886	17583	17588	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	17679	17683	CFTR	Gene	1080
25101886	17824	17828	CFTR	Gene	1080
25101886	17870	17874	CFTR	Gene	1080
25101886	17922	17926	CFTR	Gene	1080
25101886	18135	18139	CFTR	Gene	1080
25101886	18274	18279	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	18168	18174	CF HBE	CellLine	CVCL:3285
25101886	18152	18159	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	17930	17936	CF HBE	CellLine	CVCL:3285
25101886	18342	18347	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	18416	18420	CFTR	Gene	1080
25101886	18496	18500	CFTR	Gene	1080
25101886	18573	18577	CFTR	Gene	1080
25101886	18666	18669	CL4	Gene	100862696
25101886	18777	18781	CFTR	Gene	1080
25101886	18923	18927	CFTR	Gene	1080
25101886	18970	18974	CFTR	Gene	1080
25101886	19271	19275	CFTR	Gene	1080
25101886	19388	19392	CFTR	Gene	1080
25101886	19446	19450	CFTR	Gene	1080
25101886	19118	19121	ATP	Chemical	MESH:D000255
25101886	19218	19223	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	19049	19054	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	19382	19387	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	19408	19413	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	19537	19541	CFTR	Gene	1080
25101886	19781	19785	CFTR	Gene	1080
25101886	19831	19835	CFTR	Gene	1080
25101886	20057	20061	CFTR	Gene	1080
25101886	20213	20217	CFTR	Gene	1080
25101886	19660	19668	patients	Species	9606
25101886	19761	19769	patients	Species	9606
25101886	19657	19659	CF	Disease	MESH:D003550
25101886	19850	19856	defect	Disease	MESH:D030342
25101886	19758	19760	CF	Disease	MESH:D003550
25101886	19699	19704	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	20567	20571	CFTR	Gene	1080
25101886	20664	20668	CFTR	Gene	1080
25101886	20890	20894	CFTR	Gene	1080
25101886	21209	21213	CFTR	Gene	1080
25101886	20309	20317	patients	Species	9606
25101886	20710	20718	patients	Species	9606
25101886	21152	21160	patients	Species	9606
25101886	20732	20737	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	20300	20305	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	21149	21151	CF	Disease	MESH:D003550
25101886	20955	20959	cAMP	Chemical	MESH:D000242
25101886	20551	20558	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	20392	20397	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	20917	20926	forskolin	Chemical	MESH:D005576
25101886	20306	20308	CF	Disease	MESH:D003550
25101886	21203	21208	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	21143	21148	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	21056	21060	cAMP	Chemical	MESH:D000242
25101886	20784	20791	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	20884	20889	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	21432	21436	CFTR	Gene	1080
25101886	22159	22163	CFTR	Gene	1080
25101886	22448	22452	CFTR	Gene	1080
25101886	21899	21905	CF HBE	CellLine	CVCL:3285
25101886	21486	21488	CF	Disease	MESH:D003550
25101886	22238	22244	CF HBE	CellLine	CVCL:3285
25101886	22625	22631	CF HBE	CellLine	CVCL:3285
25101886	21399	21405	CF HBE	CellLine	CVCL:3285
25101886	22717	22721	CFTR	Gene	1080
25101886	22951	22955	CFTR	Gene	1080
25101886	23018	23022	CFTR	Gene	1080
25101886	23411	23415	CFTR	Gene	1080
25101886	23535	23539	CFTR	Gene	1080
25101886	23597	23601	CFTR	Gene	1080
25101886	23660	23664	CFTR	Gene	1080
25101886	23328	23332	CFTR	Gene	1080
25101886	23064	23068	CFTR	Gene	1080
25101886	23529	23534	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	23670	23674	CFTR	Gene	1080
25101886	23771	23775	CFTR	Gene	1080
25101886	23813	23817	CFTR	Gene	1080
25101886	23913	23917	CFTR	Gene	1080
25101886	24470	24474	CFTR	Gene	1080
25101886	24514	24518	CFTR	Gene	1080
25101886	24553	24557	CFTR	Gene	1080
25101886	24588	24592	CFTR	Gene	1080
25101886	24673	24677	CFTR	Gene	1080
25101886	23758	23760	WT	Disease	MESH:C537389
25101886	24292	24297	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	24197	24201	cAMP	Chemical	MESH:D000242
25101886	24096	24101	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	24351	24355	cAMP	Chemical	MESH:D000242
25101886	24838	24842	CFTR	Gene	1080
25101886	24996	25000	CFTR	Gene	1080
25101886	25187	25191	CFTR	Gene	1080
25101886	25263	25267	CFTR	Gene	1080
25101886	25350	25354	CFTR	Gene	1080
25101886	25606	25610	CFTR	Gene	1080
25101886	25705	25709	CFTR	Gene	1080
25101886	24973	24981	patients	Species	9606
25101886	24968	24972	COPD	Disease	MESH:D029424
25101886	24797	24801	COPD	Disease	MESH:D029424
25101886	25722	25726	COPD	Disease	MESH:D029424
25101886	25378	25387	forskolin	Chemical	MESH:D005576
25101886	25406	25412	NL HBE	CellLine	CVCL:3285
25101886	24758	24795	chronic obstructive pulmonary disease	Disease	MESH:D029424
25101886	25763	25767	CFTR	Gene	1080
25101886	25800	25804	CFTR	Gene	1080
25101886	26139	26143	CFTR	Gene	1080
25101886	26807	26811	CFTR	Gene	1080
25101886	26924	26928	CFTR	Gene	1080
25101886	25876	25879	rat	Species	10116
25101886	26428	26435	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	27196	27200	CFTR	Gene	1080
25101886	27247	27251	CaCC	Gene	55107
25101886	27346	27350	CFTR	Gene	1080
25101886	27387	27391	CaCC	Gene	55107
25101886	27092	27095	UTP	Chemical	MESH:D014544
25101886	27294	27296	CF	Disease	MESH:D003550
25101886	27141	27160	CF airway epithelia	Disease	MESH:D003550
25101886	27232	27235	UTP	Chemical	MESH:D014544
25101886	27097	27100	UTP	Chemical	MESH:D014544
25101886	27619	27623	CFTR	Gene	1080
25101886	27963	27967	CFTR	Gene	1080
25101886	27915	27923	patients	Species	9606
25101886	27695	27701	NL HBE	CellLine	CVCL:3285
25101886	27912	27914	CF	Disease	MESH:D003550
25101886	28028	28030	CF	Disease	MESH:D003550
25101886	27571	27573	CF	Disease	MESH:D003550
25101886	27495	27504	amiloride	Chemical	MESH:D000584
25101886	28408	28412	CFTR	Gene	1080
25101886	28842	28850	patients	Species	9606
25101886	28471	28473	CF	Disease	MESH:D003550
25101886	30037	30041	CFTR	Gene	1080
25101886	30108	30112	CFTR	Gene	1080
25101886	30657	30661	CFTR	Gene	1080
25101886	30750	30754	CFTR	Gene	1080
25101886	30464	30472	patients	Species	9606
25101886	29977	29979	CF	Disease	MESH:D003550
25101886	30461	30463	CF	Disease	MESH:D003550
25101886	30125	30127	CF	Disease	MESH:D003550
25101886	29933	29935	CF	Disease	MESH:D003550
25101886	31372	31376	CFTR	Gene	1080
25101886	31649	31653	CFTR	Gene	1080
25101886	31681	31685	CFTR	Gene	1080
25101886	31867	31871	CFTR	Gene	1080
25101886	30961	30969	patients	Species	9606
25101886	31196	31201	human	Species	9606
25101886	31277	31285	patients	Species	9606
25101886	31316	31321	human	Species	9606
25101886	30958	30960	CF	Disease	MESH:D003550
25101886	31831	31837	BHK-21	CellLine	CVCL:1914
25101886	31274	31276	CF	Disease	MESH:D003550
25101886	31542	31548	CF HBE	CellLine	CVCL:3285
25101886	31886	31899	cycloheximide	Chemical	MESH:D003513
25101886	32306	32309	CO2	Gene	717
25101886	32016	32021	human	Species	9606
25101886	32154	32160	CF HBE	CellLine	CVCL:3285
25101886	32530	32534	CFTR	Gene	1080
25101886	32477	32480	CO2	Gene	717
25101886	32384	32390	BHK-21	CellLine	CVCL:1914
25101886	32482	32488	BHK-21	CellLine	CVCL:1914
25101886	32687	32691	CFTR	Gene	1080
25101886	32871	32874	Rad	Gene	6236
25101886	32961	32965	CFTR	Gene	1080
25101886	32852	32855	SDS	Chemical	MESH:C032259
25101886	33209	33222	Cycloheximide	Chemical	MESH:D003513
25101886	33314	33318	CFTR	Gene	1080
25101886	33273	33279	BHK-21	CellLine	CVCL:1914
25101886	33428	33441	cycloheximide	Chemical	MESH:D003513
25101886	33809	33811	CF	Disease	MESH:D003550
25101886	33723	33731	formalin	Chemical	MESH:D005557
25101886	33772	33789	hematoxylin-eosin	Chemical	MESH:D004801
25101886	34727	34731	CFTR	Gene	1080
25101886	34733	34737	CFTR	Gene	1080
25101886	34257	34260	CO2	Gene	717
25101886	34571	34580	Amiloride	Chemical	MESH:D000584
25101886	34186	34191	H2PO4	Chemical	MESH:C093415
25101886	34406	34412	CF HBE	CellLine	CVCL:3285
25101886	34334	34340	NL HBE	CellLine	CVCL:3285
25101886	34251	34253	O2	Chemical	MESH:D013481
25101886	34446	34455	potassium	Chemical	MESH:D011188
25101886	34154	34158	Ca2+	Chemical	MESH:D002118
25101886	34802	34805	UTP	Chemical	MESH:D014544
25101886	34210	34217	glucose	Chemical	MESH:D005947
25101886	34692	34701	genistein	Chemical	MESH:D019833
25101886	34164	34167	Mg2	Chemical	MESH:D008274
25101886	34631	34640	forskolin	Chemical	MESH:D005576
25101886	34085	34096	bicarbonate	Chemical	MESH:D001639
25101886	34197	34201	HCO3	Chemical	MESH:C504136
25101886	34854	34862	nystatin	Chemical	MESH:D009761
25101886	34461	34469	chloride	Chemical	MESH:D002712
25101886	34762	34773	CFTRinh-172	Chemical	MESH:C501920
25101886	35723	35727	MTBE	Chemical	MESH:C043243
25101886	35860	35868	methanol	Chemical	MESH:D000432
25101886	36354	36358	CFTR	Gene	1080
25101886	36405	36409	Eris	Gene	340061
25101886	36369	36373	Eris	Gene	340061
25101886	36341	36346	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	36654	36659	donor	Species	9606
25101886	37080	37083	UTP	Chemical	MESH:D014544
25101886	37066	37075	amiloride	Chemical	MESH:D000584
25101886	37087	37093	CF HBE	CellLine	CVCL:3285
25101886	37254	37257	UTP	Chemical	MESH:D014544
25101886	37240	37249	amiloride	Chemical	MESH:D000584
25101886	37261	37267	NL HBE	CellLine	CVCL:3285
25101886	37400	37404	CFTR	Gene	1080
25101886	37472	37477	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	37557	37560	UTP	Chemical	MESH:D014544
25101886	37543	37552	amiloride	Chemical	MESH:D000584
25101886	37831	37835	CFTR	Gene	1080
25101886	37984	37990	CF HBE	CellLine	CVCL:3285
25101886	37998	38017	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	38063	38069	CF HBE	CellLine	CVCL:3285
25101886	38080	38099	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	38173	38177	CFTR	Gene	1080
25101886	38221	38229	nystatin	Chemical	MESH:D009761
25101886	38424	38428	CFTR	Gene	1080
25101886	38751	38757	NL HBE	CellLine	CVCL:3285
25101886	38744	38746	CF	Disease	MESH:D003550
25101886	38640	38643	DMC	Chemical	MESH:C004944
25101886	38936	38941	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	38835	38838	DMC	Chemical	MESH:C004944
25101886	39278	39282	CFTR	Gene	1080
25101886	39487	39515	cystic fibrosis lung disease	Disease	MESH:D003550
25101886	39543	39558	cystic fibrosis	Disease	MESH:D003550
25101886	39522	39539	pulmonary disease	Disease	MESH:D008171
25101886	39559	39574	Cystic fibrosis	Disease	MESH:D003550
25101886	39608	39623	cystic fibrosis	Disease	MESH:D003550
25101886	39669	39684	cystic fibrosis	Disease	MESH:D003550
25101886	39763	39778	cystic fibrosis	Disease	MESH:D003550
25101886	39875	39879	CFTR	Gene	1080
25101886	39826	39828	CF	Disease	MESH:D003550
25101886	39926	39930	CFTR	Gene	1080
25101886	40021	40025	CFTR	Gene	1080
25101886	40052	40057	human	Species	9606
25101886	40058	40073	cystic fibrosis	Disease	MESH:D003550
25101886	40166	40170	CFTR	Gene	1080
25101886	40262	40313	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	40362	40371	glafenine	Chemical	MESH:D005897
25101886	40451	40455	CFTR	Gene	1080
25101886	40393	40403	sildenafil	Chemical	MESH:C101426
25101886	40503	40554	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	40556	40560	CFTR	Gene	1080
25101886	40562	40570	chloride	Chemical	MESH:D002712
25101886	40729	40780	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	40629	40656	amino-carbonitrile-pyrazole	Chemical	MESH:D011720
25101886	40801	40805	cAMP	Chemical	MESH:D000242
25101886	40904	40955	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	40892	40903	DeltaPhe508	Chemical	MESH:C025253
25101886	40956	40964	chloride	Chemical	MESH:D002712
25101886	40985	41000	cystic fibrosis	Disease	MESH:D003550
25101886	40814	40829	Cyanoquinolines	Chemical	MESH:D001190
25101886	41070	41074	CFTR	Gene	1080
25101886	41059	41069	Delta F508	DNAMutation	p.508delF
25101886	41172	41176	CFTR	Gene	1080
25101886	41129	41136	persons	Species	9606
25101886	41142	41157	cystic fibrosis	Disease	MESH:D003550
25101886	41166	41171	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	41188	41192	CFTR	Gene	1080
25101886	41208	41216	patients	Species	9606
25101886	41222	41237	cystic fibrosis	Disease	MESH:D003550
25101886	41246	41251	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	41335	41350	cystic fibrosis	Disease	MESH:D003550
25101886	41401	41452	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	41499	41503	CFTR	Gene	1080
25101886	41458	41473	Cystic fibrosis	Disease	MESH:D003550
25101886	41654	41658	CFTR	Gene	1080
25101886	41603	41618	cystic fibrosis	Disease	MESH:D003550
25101886	41717	41725	fibrosis	Disease	MESH:D005355
25101886	41766	41770	CFTR	Gene	1080
25101886	41813	41828	cystic fibrosis	Disease	MESH:D003550
25101886	41856	41907	Cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	41952	41967	cystic fibrosis	Disease	MESH:D003550
25101886	41985	41989	CFTR	Gene	1080
25101886	42125	42129	CFTR	Gene	1080
25101886	42218	42223	human	Species	9606
25101886	42224	42257	cystic fibrosis airway epithelium	Disease	MESH:D003550
25101886	42317	42321	CFTR	Gene	1080
25101886	42402	42406	CFTR	Gene	1080
25101886	42359	42374	cystic fibrosis	Disease	MESH:D003550
25101886	42416	42431	Cystic fibrosis	Disease	MESH:D003550
25101886	42494	42509	cystic fibrosis	Disease	MESH:D003550
25101886	42570	42574	CFTR	Gene	1080
25101886	42595	42631	cystic fibrosis intestinal organoids	Disease	MESH:D003550
25101886	42696	42700	CFTR	Gene	1080
25101886	42632	42647	Cystic Fibrosis	Disease	MESH:D003550
25101886	42792	42843	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	42875	42887	lung disease	Disease	MESH:D008171
25101886	42892	42943	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	43006	43010	CFTR	Gene	1080
25101886	43016	43020	cAMP	Chemical	MESH:D000242
25101886	43044	43050	sodium	Chemical	MESH:D012964
25101886	43138	43146	nystatin	Chemical	MESH:D009761
25101886	43229	43233	CFTR	Gene	1080
25101886	43157	43170	Phenylalanine	Chemical	MESH:C119108
25101886	43341	43392	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	43394	43398	CFTR	Gene	1080
25101886	43461	43465	CFTR	Gene	1080
25101886	43645	43649	CFTR	Gene	1080
25101886	43747	43751	CFTR	Gene	1080
25101886	43681	43687	G1349D	ProteinMutation	p.G1349D;RS#:193922525
25101886	43693	43695	CF	Disease	MESH:D003550
25101886	43777	43784	defects	Disease	MESH:D030342
25101886	43671	43676	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	43853	43857	Eris	Gene	340061
25101886	43954	44005	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	43907	43917	delta F508	DNAMutation	p.508delF
25101886	44142	44146	CFTR	Gene	1080
25101886	44249	44300	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	44238	44248	delta F508	DNAMutation	p.508delF
25101886	44400	44415	cystic fibrosis	Disease	MESH:D003550
25101886	44558	44562	CFTR	Gene	1080
25101886	44505	44556	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	44759	44763	CFTR	Gene	1080
25101886	44805	44820	cystic fibrosis	Disease	MESH:D003550
25101886	44866	44881	cystic fibrosis	Disease	MESH:D003550
25101886	45152	45156	CFTR	Gene	1080
25101886	45186	45190	IBMX	Chemical	MESH:D015056
25101886	45142	45151	deltaF508	DNAMutation	p.508delF
25101886	45199	45207	chloride	Chemical	MESH:D002712
25101886	45249	45259	delta F508	DNAMutation	p.508delF
25101886	45260	45275	cystic fibrosis	Disease	MESH:D003550
25101886	45300	45305	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	45322	45337	cystic fibrosis	Disease	MESH:D003550
25101886	45377	45385	patients	Species	9606
25101886	45361	45376	cystic fibrosis	Disease	MESH:D003550
25101886	45395	45400	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	45487	45491	CFTR	Gene	1080
25101886	45569	45573	CFTR	Gene	1080
25101886	45563	45568	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	45542	45544	CF	Disease	MESH:D003550
25101886	45669	45673	CFTR	Gene	1080
25101886	45616	45667	Cystic Fibrosis Transmembrane Conductance Regulator	Gene	1080
25101886	45869	45920	cystic fibrosis transmembrane conductance regulator	Gene	1080
25101886	45997	46001	CFTR	Gene	1080
25101886	46163	46168	human	Species	9606
25101886	46104	46108	Ca2+	Chemical	MESH:D002118
25101886	46180	46212	cystic fibrosis airway epithelia	Disease	MESH:D003550
25101886	46266	46270	CFTR	Gene	12638
25101886	46227	46233	murine	Species	10090
25101886	46275	46279	Ca2+	Chemical	MESH:D002118
25101886	46376	46381	mouse	Species	10090
25101886	46362	46364	CF	Disease	MESH:D003550
25101886	46447	46451	CFTR	Gene	1080
25101886	46538	46542	CFTR	Gene	1080
25101886	46585	46590	human	Species	9606
25101886	46623	46628	Human	Species	9606
25101886	46763	46767	CFTR	Gene	1080
25101886	46771	46786	cystic fibrosis	Disease	MESH:D003550
25101886	46793	46798	human	Species	9606
25101886	46835	46850	cystic fibrosis	Disease	MESH:D003550
25101886	46868	46869	N	Chemical	MESH:D009584
25101886	46932	46947	cystic fibrosis	Disease	MESH:D003550
25101886	47039	47043	CFTR	Gene	1080
25101886	47055	47060	human	Species	9606
25101886	47300	47305	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	47889	47897	patients	Species	9606
25101886	47933	47940	patient	Species	9606
25101886	47487	47491	DMSO	Chemical	MESH:D004121
25101886	47825	47831	CF HBE	CellLine	CVCL:3285
25101886	47842	47849	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	47608	47617	forskolin	Chemical	MESH:D005576
25101886	47780	47789	forskolin	Chemical	MESH:D005576
25101886	48979	48987	patients	Species	9606
25101886	49023	49030	patient	Species	9606
25101886	48314	48320	CF HBE	CellLine	CVCL:3285
25101886	48085	48091	CF HBE	CellLine	CVCL:3285
25101886	48277	48286	forskolin	Chemical	MESH:D005576
25101886	48149	48168	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	48498	48504	CF HBE	CellLine	CVCL:3285
25101886	48135	48141	CF HBE	CellLine	CVCL:3285
25101886	48197	48201	DMSO	Chemical	MESH:D004121
25101886	48928	48947	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	49173	49177	CFTR	Gene	1080
25101886	49343	49347	CFTR	Gene	1080
25101886	49427	49433	BHK-21	CellLine	CVCL:1914
25101886	49210	49212	CF	Disease	MESH:D003550
25101886	49533	49546	cycloheximide	Chemical	MESH:D003513
25101886	49968	49972	CFTR	Gene	1080
25101886	50160	50164	CFTR	Gene	1080
25101886	50194	50198	CFTR	Gene	1080
25101886	51192	51196	CFTR	Gene	1080
25101886	50625	50633	patients	Species	9606
25101886	50669	50676	patient	Species	9606
25101886	51006	51014	patients	Species	9606
25101886	51050	51057	patient	Species	9606
25101886	51695	51703	patients	Species	9606
25101886	49821	49840	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	51657	51676	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	51153	51159	CF HBE	CellLine	CVCL:3285
25101886	50567	50573	CF HBE	CellLine	CVCL:3285
25101886	50180	50189	forskolin	Chemical	MESH:D005576
25101886	51170	51189	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	50280	50282	CF	Disease	MESH:D003550
25101886	50622	50624	CF	Disease	MESH:D003550
25101886	51754	51760	CF HBE	CellLine	CVCL:3285
25101886	50883	50892	forskolin	Chemical	MESH:D005576
25101886	50773	50792	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	50756	50762	CF HBE	CellLine	CVCL:3285
25101886	51225	51231	CF HBE	CellLine	CVCL:3285
25101886	49807	49813	CF HBE	CellLine	CVCL:3285
25101886	51335	51337	CF	Disease	MESH:D003550
25101886	50960	50966	CF HBE	CellLine	CVCL:3285
25101886	51640	51646	CF HBE	CellLine	CVCL:3285
25101886	49871	49877	CF HBE	CellLine	CVCL:3285
25101886	51768	51787	DeltaF508/DeltaF508	ProteinMutation	DeltaF508/DeltaF508
25101886	52569	52573	CFTR	Gene	1080
25101886	52058	52062	DMSO	Chemical	MESH:D004121
25101886	52221	52230	forskolin	Chemical	MESH:D005576
25101886	52194	52203	forskolin	Chemical	MESH:D005576
25101886	51980	51986	NL HBE	CellLine	CVCL:3285
25101886	52256	52273	forskolin plateau	Chemical	MESH:D005576
25101886	52754	52765	hematoxylin	Chemical	MESH:D006416
25101886	52770	52775	eosin	Chemical	MESH:D004801
25101886	53155	53163	Nystatin	Chemical	MESH:D009761
25101886	53018	53026	Nystatin	Chemical	MESH:D009761
25101886	53385	53389	CFTR	Gene	1080
25101886	54183	54187	CFTR	Gene	1080
25101886	54288	54292	CFTR	Gene	1080
25101886	54313	54317	CFTR	Gene	1080
25101886	54388	54392	CFTR	Gene	1080
25101886	54473	54477	CFTR	Gene	1080
25101886	54573	54577	CFTR	Gene	1080
25101886	54679	54683	CFTR	Gene	1080
25101886	54737	54741	CFTR	Gene	1080
25101886	54773	54777	CFTR	Gene	1080
25101886	54895	54899	CFTR	Gene	1080
25101886	54090	54098	patients	Species	9606
25101886	53506	53510	CFTR	Gene	1080
25101886	53536	53541	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	54100	54107	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	54087	54089	CF	Disease	MESH:D003550
25101886	53407	53413	NL HBE	CellLine	CVCL:3285
25101886	53553	53555	CF	Disease	MESH:D003550
25101886	53477	53482	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	53945	53952	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	53566	53573	G551D/D	ProteinMutation	c.551G>D,D;RS#:75527207
25101886	54382	54387	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	54567	54572	G551D	ProteinMutation	p.G551D;RS#:75527207
25101886	54161	54166	G551D	ProteinMutation	p.G551D;RS#:75527207

23910958|t|GFI1B, EVI5, MYB:Additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas 
23910958|a|The BCL6 gene, which is expressed in certain B- and T-cell human lymphomas, is involved with chromosomal rearrangements and mutations in a number of these neoplasms. Lymphomagenesis is believed to evolve through a multi-step accumulation of genetic alterations in these tumors. We used retroviral insertional mutagenesis in transgenic mice expressing the human BCL6 transgene in order to identify genes that cooperate with BCL6 during lymphomatous transformation. We previously reported PIM1 as the most frequently recurring cooperating gene in this model. We now report three newly identified cooperating genes:GFI1B, EVI5, and MYB:that we identified in the lymphomas of retroviral-injected BCL6 transgenic mice (but not in retroviral-injected non-transgenic controls); mRNA and protein expression of GFI1B and EVI5 were decreased in the murine tumors, whereas MYB mRNA and protein expression were increased or decreased. These findings correlated with protein expression in human lymphomas, both B- and T-cell. Improved therapy of lymphomas may necessitate the development of combinations of drugs that target the alterations specific to each neoplasm. 
23910958	0	5	GFI1B	Gene	8328
23910958	7	11	EVI5	Gene	7813
23910958	13	16	MYB	Gene	4602
23910958	64	68	BCL6	Gene	604
23910958	58	63	human	Species	9606
23910958	104	113	lymphomas	Disease	MESH:D008223
23910958	120	124	BCL6	Gene	604
23910958	477	481	BCL6	Gene	604
23910958	539	543	BCL6	Gene	604
23910958	603	607	PIM1	Gene	18712
23910958	728	733	GFI1B	Gene	14582
23910958	735	739	EVI5	Gene	14020
23910958	745	748	MYB	Gene	17863
23910958	808	812	BCL6	Gene	12053
23910958	918	923	GFI1B	Gene	14582
23910958	928	932	EVI5	Gene	14020
23910958	978	981	MYB	Gene	17863
23910958	175	180	human	Species	9606
23910958	402	412	retroviral	Species	31931
23910958	440	455	transgenic mice	Species	10090
23910958	471	476	human	Species	9606
23910958	788	798	retroviral	Species	31931
23910958	813	828	transgenic mice	Species	10090
23910958	841	851	retroviral	Species	31931
23910958	955	961	murine	Species	10090
23910958	1092	1097	human	Species	9606
23910958	1261	1269	neoplasm	Disease	MESH:D009369
23910958	181	190	lymphomas	Disease	MESH:D008223
23910958	1149	1158	lymphomas	Disease	MESH:D008223
23910958	1098	1107	lymphomas	Disease	MESH:D008223
23910958	386	392	tumors	Disease	MESH:D009369
23910958	271	280	neoplasms	Disease	MESH:D009369
23910958	962	968	tumors	Disease	MESH:D009369
23910958	775	784	lymphomas	Disease	MESH:D008223
23910958	1367	1371	BCL6	Gene	604
23910958	1447	1451	BCL6	Gene	12053
23910958	1675	1679	BCL6	Gene	604
23910958	1749	1753	BCL6	Gene	604
23910958	1439	1445	humans	Species	9606
23910958	1611	1621	retroviral	Species	31931
23910958	1649	1653	mice	Species	10090
23910958	1669	1674	human	Species	9606
23910958	1411	1427	B-cell lymphomas	Disease	MESH:D016393
23910958	1761	1769	lymphoma	Disease	MESH:D008223
23910958	1497	1513	T-cell lymphomas	Disease	MESH:D016399
23910958	1875	1879	BCL6	Gene	604
23910958	2009	2013	PIM1	Gene	5292
23910958	2070	2074	BCL6	Gene	12053
23910958	2261	2265	BCL6	Gene	12053
23910958	2413	2441	growth factor independent 1B	Gene	14582
23910958	2443	2448	GFI1B	Gene	14582
23910958	2454	2488	ecotropic viral integration site 5	Gene	14020
23910958	2490	2494	EVI5	Gene	14020
23910958	2681	2685	BCL6	Gene	12053
23910958	2782	2786	BCL6	Gene	12053
23910958	2811	2815	BCL6	Gene	12053
23910958	2843	2847	BCL6	Gene	12053
23910958	2930	2953	myeloblastosis oncogene	Gene	17863
23910958	2955	2958	MYB	Gene	17863
23910958	3248	3252	BCL6	Gene	12053
23910958	1811	1821	retroviral	Species	31931
23910958	1849	1853	mice	Species	10090
23910958	1869	1874	human	Species	9606
23910958	1976	2005	Moloney murine leukemia virus	Species	11801
23910958	2157	2167	retroviral	Species	31931
23910958	2241	2251	retroviral	Species	31931
23910958	2266	2281	transgenic mice	Species	10090
23910958	2308	2318	retroviral	Species	31931
23910958	2696	2700	mice	Species	10090
23910958	2752	2762	retroviral	Species	31931
23910958	2858	2863	human	Species	9606
23910958	2086	2094	lymphoma	Disease	MESH:D008223
23910958	2212	2221	lymphomas	Disease	MESH:D008223
23910958	2864	2873	lymphomas	Disease	MESH:D008223
23910958	2532	2541	lymphomas	Disease	MESH:D008223
23910958	1898	1906	lymphoma	Disease	MESH:D008223
23910958	2293	2302	lymphomas	Disease	MESH:D008223
23910958	2993	3002	lymphomas	Disease	MESH:D008223
23910958	3169	3177	lymphoma	Disease	MESH:D008223
23910958	2654	2663	lymphomas	Disease	MESH:D008223
23910958	2722	2731	lymphomas	Disease	MESH:D008223
23910958	3295	3299	BCL6	Gene	12053
23910958	3300	3315	transgenic mice	Species	10090
23910958	3320	3330	retroviral	Species	31931
23910958	3413	3417	BCL6	Gene	12053
23910958	3488	3492	BCL6	Gene	12053
23910958	3500	3504	BCL6	Gene	604
23910958	3765	3769	BCL6	Gene	604
23910958	4000	4004	BCL6	Gene	12053
23910958	3359	3374	transgenic mice	Species	10090
23910958	3494	3499	human	Species	9606
23910958	3759	3764	human	Species	9606
23910958	3904	3919	transgenic mice	Species	10090
23910958	4078	4088	retrovirus	Species	31931
23910958	3593	3605	tetracycline	Chemical	MESH:D013754
23910958	4172	4177	death	Disease	MESH:D003643
23910958	3531	3543	tetracycline	Chemical	MESH:D013754
23910958	4292	4296	FACS	Gene	14081
23910958	4582	4622	glyceraldehyde-3-phosphate dehydrogenase	Gene	14433
23910958	4720	4725	GFI1B	Gene	14582
23910958	4727	4731	EVI5	Gene	14020
23910958	4736	4739	MYB	Gene	17863
23910958	4747	4752	GFI1B	Gene	14582
23910958	4828	4832	EVI5	Gene	14020
23910958	4909	4912	MYB	Gene	17863
23910958	4555	4565	beta-actin	Gene	11461
23910958	4471	4477	murine	Species	10090
23910958	4713	4719	murine	Species	10090
23910958	4478	4496	lymphoid neoplasms	Disease	MESH:D008223
23910958	4942	4965	5'-CTGGACAGAAGAGGAGGACA	Chemical	MESH:C068492
23910958	5229	5233	BCL6	Gene	12053
23910958	5418	5423	GFI1B	Gene	8328
23910958	5465	5469	EVI5	Gene	7813
23910958	5614	5619	GFI1B	Gene	14582
23910958	5646	5650	EVI5	Gene	14020
23910958	5723	5728	GFI1B	Gene	14582
23910958	5862	5865	MYB	Gene	17863
23910958	6064	6067	MYB	Gene	17863
23910958	5052	5057	Human	Species	9606
23910958	5181	5186	Human	Species	9606
23910958	5191	5197	murine	Species	10090
23910958	5441	5446	human	Species	9606
23910958	5487	5492	human	Species	9606
23910958	5497	5503	murine	Species	10090
23910958	5568	5574	rabbit	Species	9986
23910958	5690	5696	Murine	Species	10090
23910958	5768	5774	rabbit	Species	9986
23910958	6020	6026	Murine	Species	10090
23910958	5472	5481	HPA027339	Chemical	MESH:C047158
23910958	6236	6247	hematoxylin	Chemical	MESH:D006416
23910958	5058	5073	lymphoma blocks	Disease	MESH:D006327
23910958	7815	7820	GFI1B	Gene	14582
23910958	7860	7864	PIM1	Gene	18712
23910958	6778	6782	mice	Species	10090
23910958	6797	6807	retrovirus	Species	31931
23910958	6954	6958	mice	Species	10090
23910958	7084	7088	mice	Species	10090
23910958	7159	7169	retroviral	Species	31931
23910958	7288	7293	mouse	Species	10090
23910958	7308	7314	murine	Species	10090
23910958	7586	7601	transgenic mice	Species	10090
23910958	7567	7576	lymphomas	Disease	MESH:D008223
23910958	7493	7506	T-cell tumors	Disease	MESH:D005935
23910958	7071	7080	leukemias	Disease	MESH:D007938
23910958	7256	7265	lymphomas	Disease	MESH:D008223
23910958	7393	7402	lymphomas	Disease	MESH:D008223
23910958	7057	7066	lymphomas	Disease	MESH:D008223
23910958	7090	7108	lymphoid neoplasms	Disease	MESH:D008223
23910958	7662	7671	lymphomas	Disease	MESH:D008223
23910958	6825	6834	Lymphomas	Disease	MESH:D008223
23910958	7206	7215	lymphomas	Disease	MESH:D008223
23910958	7416	7433	aggressive tumors	Disease	MESH:D001523
23910958	7522	7561	T-cell lymphoblastic lymphoma/leukemias	Disease	MESH:D054218
23910958	7946	7951	GFI1B	Gene	14582
23910958	7953	7957	EVI5	Gene	14020
23910958	7963	7966	MYB	Gene	17863
23910958	7909	7919	retroviral	Species	31931
23910958	7888	7897	lymphomas	Disease	MESH:D008223
23910958	7998	8002	PIM1	Gene	18712
23910958	8187	8191	PIM1	Gene	18712
23910958	8354	8369	transgenic mice	Species	10090
23910958	8341	8350	lymphomas	Disease	MESH:D008223
23910958	8207	8216	lymphomas	Disease	MESH:D008223
23910958	8396	8405	lymphomas	Disease	MESH:D008223
23910958	8553	8558	GFI1B	Gene	14582
23910958	8596	8601	GFI1B	Gene	14582
23910958	8779	8783	BCL6	Gene	12053
23910958	8825	8830	GFI1B	Gene	14582
23910958	9051	9056	GFI1B	Gene	14582
23910958	8618	8624	murine	Species	10090
23910958	8874	8889	transgenic mice	Species	10090
23910958	8969	8979	retroviral	Species	31931
23910958	8859	8868	lymphomas	Disease	MESH:D008223
23910958	8625	8631	tumors	Disease	MESH:D009369
23910958	9265	9269	EVI5	Gene	14020
23910958	9371	9375	BCL6	Gene	12053
23910958	9495	9499	EVI5	Gene	14020
23910958	9629	9633	EVI5	Gene	14020
23910958	9821	9825	EVI5	Gene	14020
23910958	9510	9515	mouse	Species	10090
23910958	9537	9542	males	Species	9606
23910958	9704	9719	transgenic mice	Species	10090
23910958	9286	9299	T-cell tumors	Disease	MESH:D005935
23910958	9678	9694	T-cell lymphomas	Disease	MESH:D016399
23910958	9311	9350	T-cell lymphoblastic lymphoma/leukemias	Disease	MESH:D054218
23910958	9737	9750	T-cell tumors	Disease	MESH:D005935
23910958	10004	10007	MYB	Gene	17863
23910958	10615	10618	MYB	Gene	17863
23910958	9980	9990	retroviral	Species	31931
23910958	10515	10554	T-cell lymphoblastic lymphoma/leukemias	Disease	MESH:D054218
23910958	10216	10254	T-cell lymphoblastic lymphoma/leukemia	Disease	MESH:D054218
23910958	10354	10369	T-cell lymphoma	Disease	MESH:D016399
23910958	10461	10470	lymphomas	Disease	MESH:D008223
23910958	10336	10342	tumors	Disease	MESH:D009369
23910958	10735	10744	lymphomas	Disease	MESH:D008223
23910958	10834	10839	GFI1B	Gene	14582
23910958	10841	10845	EVI5	Gene	14020
23910958	10851	10854	MYB	Gene	17863
23910958	10908	10912	BCL6	Gene	12053
23910958	10956	10960	BCL6	Gene	604
23910958	10888	10898	retroviral	Species	31931
23910958	10913	10928	transgenic mice	Species	10090
23910958	10950	10955	human	Species	9606
23910958	10983	10992	lymphomas	Disease	MESH:D008223
23910958	11262	11267	GFI1B	Gene	14582
23910958	11310	11314	EVI5	Gene	14020
23910958	11319	11322	MYB	Gene	17863
23910958	11011	11017	murine	Species	10090
23910958	11094	11100	murine	Species	10090
23910958	11160	11165	human	Species	9606
23910958	11214	11220	murine	Species	10090
23910958	11166	11175	lymphomas	Disease	MESH:D008223
23910958	11101	11107	tumors	Disease	MESH:D009369
23910958	11450	11455	GFI1B	Gene	14582
23910958	11613	11618	GFI1B	Gene	14582
23910958	11643	11648	GFI1B	Gene	14582
23910958	11716	11721	GFI1B	Gene	14582
23910958	11799	11803	BCL6	Gene	12053
23910958	11914	11918	BCL6	Gene	12053
23910958	12000	12005	GFI1B	Gene	8328
23910958	12072	12076	BCL6	Gene	12053
23910958	12127	12131	BCL6	Gene	12053
23910958	12170	12175	GFI1B	Gene	14582
23910958	12208	12212	BCL6	Gene	12053
23910958	12253	12257	BCL6	Gene	12053
23910958	12321	12326	GFI1B	Gene	14582
23910958	12455	12460	GFI1B	Gene	14582
23910958	12480	12484	BCL6	Gene	12053
23910958	12552	12557	GFI1B	Gene	14582
23910958	12641	12645	BCL6	Gene	604
23910958	12727	12732	GFI1B	Gene	8328
23910958	11399	11414	transgenic mice	Species	10090
23910958	11426	11436	retroviral	Species	31931
23910958	11528	11538	retroviral	Species	31931
23910958	11851	11861	retroviral	Species	31931
23910958	11943	11948	human	Species	9606
23910958	12370	12375	human	Species	9606
23910958	12406	12410	mice	Species	10090
23910958	12437	12441	mice	Species	10090
23910958	12611	12617	murine	Species	10090
23910958	12633	12639	humans	Species	9606
23910958	12043	12059	T-cell neoplasms	Disease	MESH:D016399
23910958	12024	12030	tumors	Disease	MESH:D009369
23910958	12501	12507	tumors	Disease	MESH:D009369
23910958	12222	12231	lymphomas	Disease	MESH:D008223
23910958	12376	12385	lymphomas	Disease	MESH:D008223
23910958	12267	12273	tumors	Disease	MESH:D009369
23910958	11758	11764	tumors	Disease	MESH:D009369
23910958	12618	12627	lymphomas	Disease	MESH:D008223
23910958	11583	11589	tumors	Disease	MESH:D009369
23910958	12771	12780	lymphomas	Disease	MESH:D008223
23910958	11949	11958	lymphomas	Disease	MESH:D008223
23910958	11376	11385	lymphomas	Disease	MESH:D008223
23910958	11826	11832	tumors	Disease	MESH:D009369
23910958	12925	12929	EVI5	Gene	14020
23910958	13037	13041	EVI5	Gene	14020
23910958	13241	13245	EVI5	Gene	14020
23910958	13299	13303	BCL6	Gene	604
23910958	13329	13333	BCL6	Gene	12053
23910958	13433	13437	BCL6	Gene	12053
23910958	13497	13501	BCL6	Gene	12053
23910958	13534	13538	EVI5	Gene	14020
23910958	13589	13594	GFI1B	Gene	8328
23910958	13609	13613	EVI5	Gene	7813
23910958	13740	13744	EVI5	Gene	14020
23910958	13832	13836	EVI5	Gene	14020
23910958	13942	13946	EVI5	Gene	7813
23910958	14088	14092	BCL6	Gene	12053
23910958	14144	14148	EVI5	Gene	14020
23910958	12871	12877	murine	Species	10090
23910958	12899	12909	retroviral	Species	31931
23910958	13148	13158	retroviral	Species	31931
23910958	13260	13265	human	Species	9606
23910958	13617	13622	human	Species	9606
23910958	13660	13666	murine	Species	10090
23910958	13712	13717	mouse	Species	10090
23910958	13905	13910	human	Species	9606
23910958	13971	13975	BCL6	Gene	12053
23910958	13364	13368	BCL6	Gene	12053
23910958	12957	12979	lymphoblastic lymphoma	Disease	MESH:D054198
23910958	12878	12887	lymphomas	Disease	MESH:D008223
23910958	13560	13569	neoplasms	Disease	MESH:D009369
23910958	13511	13520	lymphomas	Disease	MESH:D008223
23910958	13667	13676	lymphomas	Disease	MESH:D008223
23910958	12980	12989	leukemias	Disease	MESH:D007938
23910958	14215	14217	4C	Chemical	MESH:C060809
23910958	13081	13111	BCL6-positive T-cell neoplasms	Disease	MESH:C563822
23910958	13870	13899	BCL-negative T-cell lymphomas	Disease	MESH:D016399
23910958	14183	14188	tumor	Disease	MESH:D009369
23910958	13999	14012	T-cell tumors	Disease	MESH:D005935
23910958	13266	13275	lymphomas	Disease	MESH:D008223
23910958	13623	13632	lymphomas	Disease	MESH:D008223
23910958	13718	13724	tumors	Disease	MESH:D009369
23910958	13379	13383	13 B	Chemical	MESH:C513342
23910958	13769	13796	BCL6-positive T-cell tumors	Disease	MESH:C563822
23910958	13911	13920	lymphomas	Disease	MESH:D008223
23910958	14259	14262	MYB	Gene	17863
23910958	14404	14408	BCL6	Gene	12053
23910958	14459	14462	MYB	Gene	17863
23910958	14599	14602	MYB	Gene	17863
23910958	14723	14726	MYB	Gene	17863
23910958	14771	14774	MYB	Gene	17863
23910958	15114	15118	BCL6	Gene	604
23910958	15234	15238	BCL6	Gene	604
23910958	15273	15277	BCL6	Gene	12053
23910958	15327	15330	MYB	Gene	17863
23910958	15356	15360	BCL6	Gene	12053
23910958	15439	15443	BCL6	Gene	12053
23910958	15477	15481	BCL6	Gene	12053
23910958	15558	15561	MYB	Gene	17863
23910958	15686	15689	MYB	Gene	17863
23910958	15732	15736	BCL6	Gene	12053
23910958	15800	15803	MYB	Gene	4602
23910958	15840	15844	BCL6	Gene	604
23910958	14292	14298	murine	Species	10090
23910958	14314	14329	transgenic mice	Species	10090
23910958	14476	14482	murine	Species	10090
23910958	14643	14648	mouse	Species	10090
23910958	14728	14734	Murine	Species	10090
23910958	14844	14849	Human	Species	9606
23910958	15058	15063	human	Species	9606
23910958	15616	15621	human	Species	9606
23910958	15652	15658	murine	Species	10090
23910958	15786	15791	human	Species	9606
23910958	15792	15798	tumors	Disease	MESH:D009369
23910958	15064	15073	lymphomas	Disease	MESH:D008223
23910958	15086	15095	13 T-cell	CellLine	CVCL:4V27
23910958	15417	15433	T-cell lymphomas	Disease	MESH:D016399
23910958	15287	15296	lymphomas	Disease	MESH:D008223
23910958	14418	14427	neoplasms	Disease	MESH:D009369
23910958	14340	14345	tumor	Disease	MESH:D009369
23910958	15659	15665	tumors	Disease	MESH:D009369
23910958	15746	15755	neoplasms	Disease	MESH:D009369
23910958	14361	14373	T-cell tumor	Disease	MESH:D005935
23910958	14483	14492	lymphomas	Disease	MESH:D008223
23910958	14662	14677	B-cell lymphoma	Disease	MESH:D016393
23910958	15029	15038	lymphomas	Disease	MESH:D008223
23910958	14735	14744	lymphomas	Disease	MESH:D008223
23910958	14850	14859	lymphomas	Disease	MESH:D008223
23910958	15622	15631	lymphomas	Disease	MESH:D008223
23910958	14299	14308	lymphomas	Disease	MESH:D008223
23910958	15935	15939	BCL6	Gene	12053
23910958	15949	15964	transgenic mice	Species	10090
23910958	16170	16174	BCL6	Gene	12053
23910958	16316	16319	MYC	Gene	17869
23910958	16196	16206	retroviral	Species	31931
23910958	16216	16231	transgenic mice	Species	10090
23910958	16257	16267	retroviral	Species	31931
23910958	16482	16486	BCL6	Gene	12053
23910958	16527	16531	PIM1	Gene	18712
23910958	16577	16581	PIM1	Gene	18712
23910958	16778	16783	GFI1B	Gene	14582
23910958	16785	16789	EVI5	Gene	14020
23910958	16795	16798	MYB	Gene	17863
23910958	16453	16463	retroviral	Species	31931
23910958	16487	16502	transgenic mice	Species	10090
23910958	16844	16859	transgenic mice	Species	10090
23910958	16823	16832	lymphomas	Disease	MESH:D008223
23910958	16627	16636	lymphomas	Disease	MESH:D008223
23910958	16899	16903	BCL6	Gene	604
23910958	17046	17050	BCL6	Gene	604
23910958	17111	17115	BCL6	Gene	604
23910958	17135	17139	BCL6	Gene	604
23910958	17264	17268	BCL6	Gene	12053
23910958	17376	17380	BCL6	Gene	12053
23910958	17468	17473	GFI1B	Gene	14582
23910958	17478	17481	MYB	Gene	17863
23910958	17524	17528	EVI5	Gene	14020
23910958	17694	17699	GFI1B	Gene	8328
23910958	17708	17712	EVI5	Gene	7813
23910958	17721	17724	MYB	Gene	4602
23910958	17732	17736	BCL6	Gene	604
23910958	17837	17842	GFI1B	Gene	14582
23910958	17847	17851	EVI5	Gene	14020
23910958	17873	17877	BCL6	Gene	12053
23910958	17939	17942	MYB	Gene	17863
23910958	17982	17986	BCL6	Gene	12053
23910958	16957	16963	humans	Species	9606
23910958	17226	17236	retroviral	Species	31931
23910958	17269	17284	transgenic mice	Species	10090
23910958	17659	17664	human	Species	9606
23910958	17790	17796	murine	Species	10090
23910958	17887	17896	lymphomas	Disease	MESH:D008223
23910958	16979	16988	neoplasms	Disease	MESH:D009369
23910958	17665	17674	lymphomas	Disease	MESH:D008223
23910958	17927	17933	tumors	Disease	MESH:D009369
23910958	17996	18005	lymphomas	Disease	MESH:D008223
23910958	17797	17806	lymphomas	Disease	MESH:D008223
23910958	18050	18055	GFI1B	Gene	8328
23910958	18073	18078	human	Species	9606
23910958	18125	18135	retroviral	Species	31931
23910958	18360	18366	humans	Species	9606
23910958	18231	18235	Gfi1	Gene	14581
23910958	18208	18209	N	Chemical	MESH:D009584
23910958	18252	18253	C	Chemical	MESH:D002244
23910958	18323	18336	hematopoiesis	Disease	MESH:C536227
23910958	18801	18805	EVI5	Gene	7813
23910958	19732	19736	EVI5	Gene	14020
23910958	19804	19808	GFI1	Gene	14581
23910958	19850	19854	EVI5	Gene	14020
23910958	20011	20015	EVI5	Gene	14020
23910958	20094	20097	EVI	Gene	68151
23910958	20176	20180	GFI1	Gene	14581
23910958	20325	20329	EVI5	Gene	14020
23910958	20114	20117	MYC	Gene	17869
23910958	18823	18828	human	Species	9606
23910958	18919	18923	mice	Species	10090
23910958	19101	19107	murine	Species	10090
23910958	19341	19356	transgenic mice	Species	10090
23910958	19663	19673	retroviral	Species	31931
23910958	20135	20139	mice	Species	10090
23910958	20156	20162	tumors	Disease	MESH:D009369
23910958	19322	19331	lymphomas	Disease	MESH:D008223
23910958	19066	19080	T-cell disease	Disease	MESH:D016399
23910958	18884	18900	T-cell lymphomas	Disease	MESH:D016399
23910958	20067	20076	lymphomas	Disease	MESH:D008223
23910958	19108	19117	lymphomas	Disease	MESH:D008223
23910958	20346	20349	MYB	Gene	17863
23910958	20660	20663	MYB	Gene	4602
23910958	20910	20913	MYB	Gene	17863
23910958	21255	21258	MYB	Gene	4602
23910958	21365	21369	BCL6	Gene	604
23910958	21384	21402	microRNA (miR)-155	Gene	406947
23910958	21429	21432	MYB	Gene	17863
23910958	21564	21567	MYB	Gene	17863
23910958	21662	21665	MYB	Gene	17863
23910958	20371	20381	retroviral	Species	31931
23910958	20421	20427	murine	Species	10090
23910958	20654	20659	Human	Species	9606
23910958	21233	21239	humans	Species	9606
23910958	21541	21544	MYB	Gene	17863
23910958	20461	20468	leucine	Chemical	MESH:C038361
23910958	21085	21090	colon	Disease	MESH:D015179
23910958	21136	21149	hematopoiesis	Disease	MESH:C536227
23910958	21817	21850	T-cell acute lymphocytic leukemia	Disease	MESH:D054218
23910958	20428	20454	hematopoietic malignancies	Disease	MESH:D019337
23910958	22202	22206	BCL6	Gene	12053
23910958	22240	22244	LMO2	Gene	4005
23910958	22379	22382	MN1	Gene	4330
23910958	22431	22435	AHI1	Gene	54806
23910958	22474	22481	BCR-ABL	Gene	25
23910958	22486	22500	Janus kinase 2	Gene	3717
23910958	22502	22506	JAK2	Gene	3717
23910958	22630	22634	BCOR	Gene	54880
23910958	22648	22652	BCL6	Gene	604
23910958	22730	22735	IKZF1	Gene	10320
23910958	22816	22821	IKZF1	Gene	10320
23910958	22908	22911	SYK	Gene	6850
23910958	23011	23048	interleukin 2-inducible T cell kinase	Gene	3702
23910958	23050	23053	ITK	Gene	3702
23910958	23191	23196	GATA1	Gene	2623
23910958	22335	22340	human	Species	9606
23910958	22401	22406	human	Species	9606
23910958	23112	23116	mice	Species	10090
23910958	23127	23132	human	Species	9606
23910958	22748	22754	IKAROS	Gene	22778
23910958	22566	22592	cutaneous T-cell lymphomas	Disease	MESH:D016410
23910958	22407	22429	acute myeloid leukemia	Disease	MESH:D015470
23910958	22354	22377	lymphoblastic leukemias	Disease	MESH:D054198
23910958	22519	22539	myelogenous leukemia	Disease	MESH:D007951
23910958	22719	22728	lymphomas	Disease	MESH:D008223
23910958	22268	22285	Hodgkin lymphomas	Disease	MESH:D006689
23910958	22111	22135	hematologic malignancies	Disease	MESH:D019337
23910958	22942	22964	acute myeloid leukemia	Disease	MESH:D015470
23910958	22884	22906	lymphoblastic leukemia	Disease	MESH:D054198
23910958	23074	23108	T-cell lymphoproliferative disease	Disease	MESH:D008232
23910958	22094	22107	hematopoiesis	Disease	MESH:C536227
23910958	23240	23244	BCL6	Gene	12053
23910958	24019	24022	MYB	Gene	17863
23910958	24185	24190	GFI1B	Gene	14582
23910958	24192	24196	EVI5	Gene	14020
23910958	24202	24205	MYB	Gene	17863
23910958	24244	24248	BCL6	Gene	12053
23910958	23914	23919	tumor	Disease	MESH:D009369
23910958	24099	24126	lymphomatous transformation	Disease	MESH:D013967
23910958	23776	23797	genetic abnormalities	Disease	MESH:D030342
23910958	23877	23885	neoplasm	Disease	MESH:D009369
23910958	24711	24720	neoplasms	Disease	MESH:D009369
23910958	23350	23383	aggressive hemato-logic neoplasms	Disease	MESH:C537032
23910958	24573	24582	lymphomas	Disease	MESH:D008223
23910958	23687	23723	T-cell acute lymphoblastic leukemias	Disease	MESH:D054218
23910958	23905	23910	tumor	Disease	MESH:D009369
23910958	23329	23345	T-cell lymphomas	Disease	MESH:D016399
23910958	25564	25568	BCL6	Gene	12053
23910958	25644	25652	lymphoma	Disease	MESH:D008223
23910958	25653	25657	BCL6	Gene	12053
23910958	25692	25721	T-cell lymphoblastic lymphoma	Disease	MESH:D054218
23910958	25760	25764	PIM1	Gene	5292
23910958	25792	25796	BCL6	Gene	604
23910958	25786	25791	human	Species	9606
23910958	25832	25841	lymphomas	Disease	MESH:D008223
23910958	25842	25870	Growth factor independent 1B	Gene	14582
23910958	25872	25877	Gfi1b	Gene	14582
23910958	25885	25888	E2A	Gene	21423
23910958	25916	25921	Gata3	Gene	14462
23910958	25925	25941	T-cell lymphomas	Disease	MESH:D016399
23910958	25971	25975	Evi5	Gene	14020
23910958	26116	26119	EBV	Species	10376
23910958	26178	26181	Myb	Gene	17863
23910958	26129	26145	Burkitt lymphoma	Disease	MESH:D002051
23910958	26201	26205	BCL6	Gene	604
23910958	26195	26200	human	Species	9606
23910958	26244	26253	lymphomas	Disease	MESH:D008223
23910958	26308	26326	lymphoid neoplasms	Disease	MESH:D008223
23910958	26395	26424	Moloney murine leukemia virus	Species	11801
23910958	26431	26441	retrovirus	Species	31931
23910958	26447	26452	4070A	Chemical	
23910958	26512	26519	myeloid	Disease	MESH:D007951
23910958	26531	26549	lymphoid neoplasms	Disease	MESH:D008223
23910958	26550	26554	BCL6	Gene	12053
23910958	26646	26650	Bcl6	Gene	12053
23910958	26833	26837	Evi5	Gene	14020
23910958	27022	27025	myb	Gene	17863
23910958	27137	27150	hematopoiesis	Disease	MESH:C536227
23910958	27155	27160	C-MYB	Gene	4602
23910958	27236	27241	human	Species	9606
23910958	27242	27271	T-cell acute leukemia (T-ALL)	Disease	MESH:D054218
23910958	27343	27347	Evi5	Gene	14020
23910958	27419	27424	Rab11	Gene	53869
23910958	27467	27471	Evi5	Gene	14020
23910958	27562	27567	Gfi1b	Gene	14582
23910958	27572	27576	Gfi1	Gene	14581
23910958	27580	27584	Gfi1	Gene	14581
23910958	27586	27590	Gfi1	Gene	14581
23910958	27595	27600	Gfi1b	Gene	14582
23910958	27620	27633	hematopoiesis	Disease	MESH:C536227
23910958	27634	27639	Gfi1b	Gene	14582
23910958	28146	28149	Myc	Gene	24577
23910958	28208	28211	rat	Species	10116
23910958	28212	28228	T-cell lymphomas	Disease	MESH:D016399
23910958	28372	28377	gfi-1	Gene	14581
23910958	28313	28316	myc	Gene	17869
23910958	28334	28338	mice	Species	10090
23910958	28291	28298	tumours	Disease	MESH:D009369
23910958	28431	28434	MYB	Gene	17863
23910958	28438	28446	leukemia	Disease	MESH:D007938
23910958	28470	28505	T cell acute lymphoblastic leukemia	Disease	MESH:D054218
23910958	28506	28509	MYB	Gene	17863
23910958	28533	28539	cancer	Disease	MESH:D009369
23910958	28598	28603	c-Myb	Gene	17863
23910958	28643	28648	PRMT4	Gene	59035
23910958	28675	28680	c-Myb	Gene	17863
23910958	28734	28739	c-Myb	Gene	17863
23910958	28813	28817	BCL6	Gene	12053
23910958	28839	28842	AID	Gene	11628
23910958	29065	29069	LMO2	Gene	16909
23910958	29124	29132	lymphoma	Disease	MESH:D008223
23910958	29227	29231	LYL1	Gene	4066
23910958	29236	29240	LMO2	Gene	4005
23910958	29201	29208	patient	Species	9606
23910958	29155	29200	pediatric T-cell acute lymphoblastic leukemia	Disease	MESH:D054218
23910958	29267	29270	MN1	Gene	433938
23910958	29295	29317	myeloid transformation	Disease	MESH:D002472
23910958	29402	29415	AHI-1-BCR-ABL	Gene	52906
23910958	29416	29420	JAK2	Gene	16452
23910958	29346	29362	myeloid leukemia	Disease	MESH:D007951
23910958	29441	29445	AHI1	Gene	52906
23910958	29450	29456	CDKN1C	Gene	12577
23910958	29460	29497	cutaneous T-cell lymphoma progression	Disease	MESH:D016410
23910958	29498	29502	BCL6	Gene	12053
23910958	29512	29520	lymphoma	Disease	MESH:D008223
23910958	29614	29619	IKZF1	Gene	22778
23910958	29698	29704	Ikaros	Gene	22778
23910958	29799	29821	lymphoblastic leukemia	Disease	MESH:D054198
23910958	29865	29868	Syk	Gene	20963
23910958	29875	29878	AML	Disease	MESH:D015470
23910958	29890	29893	ITK	Gene	16428
23910958	29894	29897	SYK	Gene	20963
23910958	29962	29966	mice	Species	10090
23910958	29977	29982	human	Species	9606
23910958	29924	29958	T-cell lymphoproliferative disease	Disease	MESH:D008232
23910958	29991	29996	RUNX1	Gene	12394
23910958	30039	30055	myeloid leukemia	Disease	MESH:D007951
23910958	30129	30133	Ldb1	Gene	16825
23910958	30288	30296	lymphoma	Disease	MESH:D008223
23910958	30343	30348	GFI1B	Gene	14582
23910958	30388	30392	BCL6	Gene	12053
23910958	30449	30453	BCL6	Gene	12053
23910958	30544	30549	GFI1B	Gene	14582
23910958	30632	30636	BCL6	Gene	12053
23910958	30708	30713	GFI1B	Gene	14582
23910958	30866	30871	GFI1B	Gene	14582
23910958	31224	31228	BCL6	Gene	12053
23910958	31293	31297	BCL6	Gene	12053
23910958	31346	31351	GFI1B	Gene	14582
23910958	31486	31490	BCL6	Gene	604
23910958	31514	31518	BCL6	Gene	604
23910958	31542	31546	BCL6	Gene	604
23910958	31570	31574	BCL6	Gene	604
23910958	31626	31631	GFI1B	Gene	14582
23910958	31684	31688	BCL6	Gene	12053
23910958	31756	31760	BCL6	Gene	12053
23910958	30416	30420	mice	Species	10090
23910958	30477	30483	murine	Species	10090
23910958	30488	30493	human	Species	9606
23910958	30612	30622	retroviral	Species	31931
23910958	30637	30652	transgenic mice	Species	10090
23910958	30782	30792	retroviral	Species	31931
23910958	31158	31164	murine	Species	10090
23910958	31197	31202	mouse	Species	10090
23910958	31395	31400	mouse	Species	10090
23910958	31465	31470	human	Species	9606
23910958	31604	31610	murine	Species	10090
23910958	31770	31779	neoplasms	Disease	MESH:D009369
23910958	31698	31707	lymphomas	Disease	MESH:D008223
23910958	31471	31480	lymphomas	Disease	MESH:D008223
23910958	30494	30503	lymphomas	Disease	MESH:D008223
23910958	31165	31174	lymphomas	Disease	MESH:D008223
23910958	30574	30583	lymphomas	Disease	MESH:D008223
23910958	31611	31620	lymphomas	Disease	MESH:D008223
23910958	30373	30382	lymphomas	Disease	MESH:D008223
23910958	31830	31834	EVI5	Gene	14020
23910958	31874	31878	BCL6	Gene	12053
23910958	31935	31939	BCL6	Gene	12053
23910958	32030	32034	EVI5	Gene	14020
23910958	32111	32115	BCL6	Gene	12053
23910958	32223	32227	EVI5	Gene	14020
23910958	32380	32384	EVI5	Gene	14020
23910958	32737	32741	BCL6	Gene	12053
23910958	32805	32809	BCL6	Gene	12053
23910958	32853	32857	BCL6	Gene	12053
23910958	32991	32995	BCL6	Gene	604
23910958	33017	33021	BCL6	Gene	604
23910958	33176	33179	CD3	Gene	12501
23910958	33254	33257	CD3	Gene	12501
23910958	33265	33269	BCL6	Gene	12053
23910958	33375	33379	EVI5	Gene	14020
23910958	33424	33428	BCL6	Gene	12053
23910958	31902	31906	mice	Species	10090
23910958	31963	31969	murine	Species	10090
23910958	31974	31979	human	Species	9606
23910958	32091	32101	retroviral	Species	31931
23910958	32116	32131	transgenic mice	Species	10090
23910958	32296	32306	retroviral	Species	31931
23910958	32671	32677	murine	Species	10090
23910958	32710	32715	mouse	Species	10090
23910958	32778	32783	mouse	Species	10090
23910958	32900	32905	mouse	Species	10090
23910958	32970	32975	human	Species	9606
23910958	33353	33359	murine	Species	10090
23910958	33360	33369	lymphomas	Disease	MESH:D008223
23910958	31980	31989	lymphomas	Disease	MESH:D008223
23910958	33557	33562	tumor	Disease	MESH:D009369
23910958	33445	33451	tumors	Disease	MESH:D009369
23910958	33116	33121	tumor	Disease	MESH:D009369
23910958	33570	33576	tumors	Disease	MESH:D009369
23910958	33487	33492	tumor	Disease	MESH:D009369
23910958	32678	32687	lymphomas	Disease	MESH:D008223
23910958	33303	33308	tumor	Disease	MESH:D009369
23910958	32976	32985	lymphomas	Disease	MESH:D008223
23910958	31859	31868	lymphomas	Disease	MESH:D008223
23910958	32274	32290	T-cell lymphomas	Disease	MESH:D016399
23910958	32059	32068	lymphomas	Disease	MESH:D008223
23910958	33683	33686	MYB	Gene	17863
23910958	33726	33730	BCL6	Gene	12053
23910958	33787	33791	BCL6	Gene	12053
23910958	33882	33885	MYB	Gene	17863
23910958	33947	33951	BCL6	Gene	12053
23910958	34047	34050	MYB	Gene	17863
23910958	34204	34207	MYB	Gene	17863
23910958	35111	35115	BCL6	Gene	12053
23910958	35319	35323	BCL6	Gene	12053
23910958	35355	35358	MYB	Gene	17863
23910958	35469	35473	BCL6	Gene	604
23910958	35574	35577	MYB	Gene	4602
23910958	35636	35641	BCL-6	Gene	12053
23910958	35750	35753	MYB	Gene	17863
23910958	35167	35170	MYB	Gene	17863
23910958	33754	33758	mice	Species	10090
23910958	33815	33821	murine	Species	10090
23910958	33826	33831	human	Species	9606
23910958	33927	33937	retroviral	Species	31931
23910958	33952	33967	transgenic mice	Species	10090
23910958	33987	33991	mice	Species	10090
23910958	34131	34141	retroviral	Species	31931
23910958	34159	34163	mice	Species	10090
23910958	34257	34262	mouse	Species	10090
23910958	34745	34750	mouse	Species	10090
23910958	35002	35008	murine	Species	10090
23910958	35094	35109	transgenic mice	Species	10090
23910958	35272	35287	transgenic mice	Species	10090
23910958	35428	35433	human	Species	9606
23910958	35667	35672	tumor	Disease	MESH:D009369
23910958	35682	35710	BCL-negative T-cell neoplasm	Disease	MESH:C563311
23910958	34362	34368	tumors	Disease	MESH:D009369
23910958	35434	35451	lymphomas: tumors	Disease	MESH:D008223
23910958	35501	35517	T-cell lymphomas	Disease	MESH:D016399
23910958	35200	35206	tumors	Disease	MESH:D009369
23910958	34718	34726	leukemia	Disease	MESH:D007938
23910958	35020	35026	tumors	Disease	MESH:D009369
23910958	35715	35721	tumors	Disease	MESH:D009369
23910958	33908	33917	lymphomas	Disease	MESH:D008223
23910958	34849	34902	T-cell lymphoblastic lymphoma/leukemia control tumors	Disease	MESH:D054218
23910958	34410	34416	tumors	Disease	MESH:D009369
23910958	34097	34113	T-cell lymphomas	Disease	MESH:D016399
23910958	34937	34950	T-cell tumors	Disease	MESH:D005935
23910958	33832	33841	lymphomas	Disease	MESH:D008223
23910958	35009	35018	lymphomas	Disease	MESH:D008223
23910958	34694	34716	lymphoblastic lymphoma	Disease	MESH:D054198
23910958	35605	35620	T-cell lymphoma	Disease	MESH:D016399
23910958	35231	35247	T-cell lymphomas	Disease	MESH:D016399
23910958	35057	35073	T-cell lymphomas	Disease	MESH:D016399
23910958	34639	34655	B-cell lymphomas	Disease	MESH:D016393
23910958	33969	33979	black bars	Disease	MESH:D001260
23910958	33711	33720	lymphomas	Disease	MESH:D008223
23910958	36172	36176	BCL6	Gene	12053
23910958	36081	36091	retroviral	Species	31931
23910958	36103	36118	transgenic mice	Species	10090
23910958	36177	36192	transgenic mice	Species	10090
23910958	36225	36235	retroviral	Species	31931
23910958	36270	36274	mice	Species	10090
23910958	36157	36166	lymphomas	Disease	MESH:D008223
23910958	36210	36219	lymphomas	Disease	MESH:D008223
23910958	36313	36319	murine	Species	10090
23910958	36424	36428	SYKb	Gene	20963
23910958	36444	36448	SYKb	Gene	20963
23910958	36557	36584	GTP-binding protein DI-RAS2	Gene	68203
23910958	36393	36401	lymphoma	Disease	MESH:D008223
23910958	36701	36706	IMPA2	Gene	114663
23910958	36749	36757	lymphoma	Disease	MESH:D008223
23910958	36665	36673	lymphoma	Disease	MESH:D008223
23910958	36624	36628	MPPE	Chemical	MESH:C508639
23910958	36891	36895	BCL6	Gene	12053
23910958	36859	36869	retroviral	Species	31931
23910958	36896	36911	transgenic mice	Species	10090

25568633|t|Work Stress and Risk Factors For Health Management Trainees in Canakkale, Turkey 
25568633|a|Aim: This study aims to investigate the general mental health situation, work-related stress and risk factors of health management trainees. Methods: This cross-sectional study was conducted on Health Management Musters students (N=96) in Canakkale Onsekiz Mart University Health Sciences Institute, May-June 2014. A total of 58 students who voluntarily participated in the study were reached (60.42%). Participants completed a 22-question sociodemographic survey form and a 12-item General Health Questionnaire in a face-to-face interview. Data were analyzed using the SPSS software version 20.0. Results: The average age of participants was 36.4+-6.2 (Min:24-Max:62) years. Thirty five of the participants were female (60.3%), 23 were male (39.7%). The number of people using cigarettes and alcohol were 23 (39.7%) and 9 (15.8%) respectively. In our study group according to GHQ scale 32 people (55.2%) were in the group at risk of depression. Eighty-six percent of participants reported experiencing work stress. The most frequently reported sources of stress were superiors (56.8%), work itself (41.3%), and work colleagues (25.8%). There was no significant difference between those at risk of depression and those not at risk in terms of gender, marital status, educational level, age, work-related factors (daily work, computer use, duration of sitting at desk), sleep duration, presence of chronic disease, substance use (cigarettes, alcohol), regular exercise, regular meals, fast-food consumption, sufficient family time and vacations (p>0.05). Conclusions: Our study results indicated that majority of participants reported experiencing work stress with more than half at high risk of developing depression. The most reported risk factors were superiors, the work itself and colleagues in the present study. Psychosocial risk factors at work environment should be investigated in terms of psychological, sociological and ergonomics in more detail to reduce the risk of health management trainees experiencing work stress and mental health problems. 
25568633	338	342	Mart	Gene	5414
25568633	484	496	Participants	Species	9606
25568633	707	719	participants	Species	9606
25568633	776	788	participants	Species	9606
25568633	818	822	male	Species	9606
25568633	846	852	people	Species	9606
25568633	971	977	people	Species	9606
25568633	1049	1061	participants	Species	9606
25568633	874	881	alcohol	Chemical	MESH:D000431
25568633	1279	1289	depression	Disease	MESH:D003866
25568633	1015	1025	depression	Disease	MESH:D003866
25568633	1522	1529	alcohol	Chemical	MESH:D000431
25568633	1478	1493	chronic disease	Disease	MESH:D002908
25568633	1693	1705	participants	Species	9606
25568633	1787	1797	depression	Disease	MESH:D003866
25568633	2166	2178	psychosocial	Disease	MESH:C535569
25568633	3725	3741	disability costs	Disease	MESH:D009069
25568633	3280	3303	migraine and depression	Disease	MESH:D003866
25568633	3207	3223	chronic diseases	Disease	MESH:D002908
25568633	3312	3322	Depression	Disease	MESH:D003866
25568633	3587	3607	depressive disorders	Disease	MESH:D003866
25568633	3464	3474	depression	Disease	MESH:D003866
25568633	3229	3252	cardiovascular diseases	Disease	MESH:D002318
25568633	3254	3278	musculoskeletal diseases	Disease	MESH:D009140
25568633	3031	3042	psychiatric	Disease	MESH:D001523
25568633	4616	4623	anxiety	Disease	MESH:D001008
25568633	4676	4697	Stress and depression	Disease	MESH:D003866
25568633	4601	4611	depression	Disease	MESH:D003866
25568633	5002	5012	depression	Disease	MESH:D003866
25568633	5178	5182	Mart	Gene	5414
25568633	5367	5371	Mart	Gene	5414
25568633	5628	5640	Participants	Species	9606
25568633	5911	5926	chronic disease	Disease	MESH:D002908
25568633	5886	5893	alcohol	Chemical	MESH:D000431
25568633	6385	6395	depression	Disease	MESH:D003866
25568633	6399	6406	anxiety	Disease	MESH:D001008
25568633	6690	6694	Mart	Gene	5414
25568633	7772	7779	alcohol	Chemical	MESH:D000431
25568633	7683	7698	chronic disease	Disease	MESH:D002908
25568633	7700	7727	healthy lifestyle behaviors	Disease	MESH:D002653
25568633	7910	7922	participants	Species	9606
25568633	7979	7991	participants	Species	9606
25568633	8021	8025	male	Species	9606
25568633	8143	8155	participants	Species	9606
25568633	8183	8189	people	Species	9606
25568633	8390	8396	people	Species	9606
25568633	8481	8487	people	Species	9606
25568633	8625	8637	participants	Species	9606
25568633	8951	8963	participants	Species	9606
25568633	8541	8567	thyroid function disorders	Disease	MESH:D013959
25568633	8585	8593	diabetes	Disease	MESH:D003920
25568633	8367	8374	alcohol	Chemical	MESH:D000431
25568633	8313	8320	alcohol	Chemical	MESH:D000431
25568633	8520	8526	asthma	Disease	MESH:D001249
25568633	8402	8418	chronic diseases	Disease	MESH:D002908
25568633	8493	8505	hypertension	Disease	MESH:D006973
25568633	8211	8218	alcohol	Chemical	MESH:D000431
25568633	9420	9426	people	Species	9606
25568633	9590	9596	people	Species	9606
25568633	9638	9644	people	Species	9606
25568633	9674	9680	people	Species	9606
25568633	9713	9719	person	Species	9606
25568633	9752	9758	people	Species	9606
25568633	9791	9797	people	Species	9606
25568633	9829	9835	people	Species	9606
25568633	9869	9875	person	Species	9606
25568633	9909	9915	people	Species	9606
25568633	9949	9955	people	Species	9606
25568633	9989	9995	people	Species	9606
25568633	10029	10035	people	Species	9606
25568633	10070	10076	people	Species	9606
25568633	10111	10117	people	Species	9606
25568633	10171	10177	people	Species	9606
25568633	10485	10488	GSA	Gene	2778
25568633	10303	10309	people	Species	9606
25568633	10892	10904	participants	Species	9606
25568633	10943	10955	participants	Species	9606
25568633	11143	11148	human	Species	9606
25568633	11258	11270	participants	Species	9606
25568633	10347	10357	depression	Disease	MESH:D003866
25568633	10705	10712	alcohol	Chemical	MESH:D000431
25568633	10435	10445	depression	Disease	MESH:D003866
25568633	10661	10676	chronic disease	Disease	MESH:D002908
25568633	11684	11688	Mart	Gene	5414
25568633	11907	11919	participants	Species	9606
25568633	12186	12191	women	Species	9606
25568633	12197	12200	men	Species	9606
25568633	12255	12267	participants	Species	9606
25568633	12383	12395	participants	Species	9606
25568633	12911	12915	male	Species	9606
25568633	13711	13717	people	Species	9606
25568633	14035	14047	participants	Species	9606
25568633	14150	14162	participants	Species	9606
25568633	13939	13962	cardiovascular diseases	Disease	MESH:D002318
25568633	12646	12656	depression	Disease	MESH:D003866
25568633	13914	13930	chronic diseases	Disease	MESH:D002908
25568633	13030	13041	weight gain	Disease	MESH:D015430
25568633	13811	13837	thyroid function disorders	Disease	MESH:D013959
25568633	13967	13991	musculoskeletal diseases	Disease	MESH:D009140
25568633	13842	13850	diabetes	Disease	MESH:D003920
25568633	13229	13239	depression	Disease	MESH:D003866
25568633	12430	12437	alcohol	Chemical	MESH:D000431
25568633	13789	13801	hypertension	Disease	MESH:D006973
25568633	13803	13809	asthma	Disease	MESH:D001249
25568633	12722	12729	obesity	Disease	MESH:D009765
25568633	14980	14983	GSA	Gene	2778
25568633	14772	14778	people	Species	9606
25568633	15451	15463	participants	Species	9606
25568633	16042	16054	participants	Species	9606
25568633	16479	16491	participants	Species	9606
25568633	16866	16873	anxiety	Disease	MESH:D001008
25568633	16218	16225	anxiety	Disease	MESH:D001008
25568633	16097	16104	anxiety	Disease	MESH:D001008
25568633	16082	16092	depression	Disease	MESH:D003866
25568633	15495	15502	anxiety	Disease	MESH:D001008
25568633	16203	16213	depression	Disease	MESH:D003866
25568633	15480	15490	depression	Disease	MESH:D003866
25568633	16855	16865	depression	Disease	MESH:D003866
25568633	15200	15207	alcohol	Chemical	MESH:D000431
25568633	14845	14852	anxiety	Disease	MESH:D001008
25568633	15858	15868	depression	Disease	MESH:D003866
25568633	15156	15171	chronic disease	Disease	MESH:D002908
25568633	16524	16534	depression	Disease	MESH:D003866
25568633	16539	16546	anxiety	Disease	MESH:D001008
25568633	14930	14940	depression	Disease	MESH:D003866
25568633	14830	14840	depression	Disease	MESH:D003866
25568633	17154	17166	participants	Species	9606
25568633	18222	18227	human	Species	9606
25568633	17319	17331	psychosocial	Disease	MESH:C535569
25568633	17675	17685	depression	Disease	MESH:D003866
25568633	17687	17729	anxiety and post-traumatic stress disorder	Disease	MESH:D001008
25568633	19275	19287	participants	Species	9606
25568633	20076	20083	patient	Species	9606
25568633	20163	20175	participants	Species	9606
25568633	20444	20454	depression	Disease	MESH:D003866
25568633	20030	20039	tiredness	Disease	MESH:D005221
25568633	19818	19823	sleep	Disease	MESH:D012893
25568633	19055	19075	psychosocial factors	Disease	MESH:C535569
25568633	19600	19615	sleep disorders	Disease	MESH:D012893
25568633	19090	19100	depression	Disease	MESH:D003866
25568633	19553	19563	depression	Disease	MESH:D003866
25568633	19102	19109	anxiety	Disease	MESH:D001008
25568633	19120	19144	musculoskeletal diseases	Disease	MESH:D009140
25568633	20506	20509	Lao	Gene	259307
25568633	21267	21275	patients	Species	9606
25568633	21809	21819	depression	Disease	MESH:D003866
25568633	22449	22461	participants	Species	9606
25568633	22976	23011	mental health problems psychosocial	Disease	MESH:D008607
25568633	22777	22787	depression	Disease	MESH:D003866
25568633	22543	22553	depression	Disease	MESH:D003866
25568633	23307	23323	guvenilirliginin	Chemical	
25568633	23780	23820	cikma ve stress belirtileri ile iliskisi	Disease	MESH:C535750
25568633	23879	23901	low back and neck pain	Disease	MESH:D017116
25568633	24260	24270	depression	Disease	MESH:D003866
25568633	24336	24346	Depression	Disease	MESH:D003866
25568633	24417	24427	depression	Disease	MESH:D003866
25568633	24964	24971	anxiety	Disease	MESH:D001008
25568633	24942	24962	decreased depression	Disease	MESH:D003866
25568633	24983	24989	Trauma	Disease	MESH:D014947
25568633	25277	25281	male	Species	9606
25568633	25251	25258	obesity	Disease	MESH:D009765
25568633	25444	25448	male	Species	9606
25568633	25546	25554	cortisol	Chemical	MESH:D006854
25568633	25758	25768	depressive	Disease	MESH:D003866
25568633	25773	25790	anxiety disorders	Disease	MESH:D001008
25568633	26011	26023	psychosocial	Disease	MESH:C535569
25568633	26537	26548	psychiatric	Disease	MESH:D001523
25568633	26597	26607	Depression	Disease	MESH:D003866
25568633	26645	26654	neck pain	Disease	MESH:D019547
25568633	26612	26619	anxiety	Disease	MESH:D001008
25568633	27184	27203	depressive symptoms	Disease	MESH:D003866
25568633	27437	27440	Lao	Gene	259307

25568626|t|The Pulmonary Thromboembolism as a Risk of Surgical Treatments and the Role of Anticoagulant Prophylaxiss 
25568626|a|Objective: Our objective is to show the number of patients with postoperative pulmonary thromboembolism (PPTE) treated in Intensive care unit of Clinic for pulmonary diseases an TB "Podhrastovi" in three-year period : from June 1, 2011 - June 1, 2014 and to indicate the importance of various surgical operations in the development of pulmonary thromboembolism (PTE). Material and methods: This is the retrospective study which shows the number of patients with PPTE treated in Intensive care unit of Clinic for pulmonary diseases an TB "Podhrastovi" in three-year period : from 01.06.2011.-01.06.2014. It represents the number of these patients, per cent of patients with PPTE of total patients with PTE, age and sex of patients, type of surgery, period expressed in days from surgery to diagnosis of PTE, presence of deep venous thrombosis (DVT) of lower extremities, massiveness of PPTE e.g. level of pulmonary artery with embolus. Results: In three-year period 232 patients with PTE were treated in Intensive care unit of Clinic "Podhrastovi". 60 of them or 25.86% were patients with 24 males or 40% middle-aged 58.5 years, and 36 females or 60% middle-aged 56.3 years. PPTE developed in 15 patients with abdominal, 11 with urologic, 8 with gynecologic, 15 with orthopedic, 4 with cardiologic, 2 with vascular, 3 with neurosurgical, 1 with glandular and 1 with orl operations. The average period from operation to diagnosis of PPTE was 10.5 days for women, and 13.8 days for men. Only two patients had acute DVT after operation (one man and one woman), and five had amnesias of previous DVT or PTE. The level or the site of pulmonary embolus was different from segmental to main branches of pulmonary artery. Conclusion: Different surgical operations are the big risk factor for the development of PTE. There is great significance of anticoagulant prophylaxis before surgery even in patients with no anamnesis of previous DVT or PTE. 
25568626	4	29	Pulmonary Thromboembolism	Disease	MESH:D011655
25568626	156	164	patients	Species	9606
25568626	468	471	PTE	Disease	MESH:D011655
25568626	262	280	pulmonary diseases	Disease	MESH:D008171
25568626	441	466	pulmonary thromboembolism	Disease	MESH:D011655
25568626	170	209	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	211	215	PPTE	Disease	MESH:D011655
25568626	558	566	patients	Species	9606
25568626	747	755	patients	Species	9606
25568626	769	777	patients	Species	9606
25568626	797	805	patients	Species	9606
25568626	831	839	patients	Species	9606
25568626	1036	1043	embolus	Disease	MESH:D004617
25568626	572	576	PPTE	Disease	MESH:D011655
25568626	995	999	PPTE	Disease	MESH:D011655
25568626	929	951	deep venous thrombosis	Disease	MESH:D020246
25568626	811	814	PTE	Disease	MESH:D011655
25568626	783	787	PPTE	Disease	MESH:D011655
25568626	622	640	pulmonary diseases	Disease	MESH:D008171
25568626	953	956	DVT	Disease	MESH:D020246
25568626	912	915	PTE	Disease	MESH:D011655
25568626	1083	1091	patients	Species	9606
25568626	1188	1196	patients	Species	9606
25568626	1205	1210	males	Species	9606
25568626	1309	1317	patients	Species	9606
25568626	1568	1573	women	Species	9606
25568626	1593	1596	men	Species	9606
25568626	1607	1615	patients	Species	9606
25568626	1651	1654	man	Species	9606
25568626	1663	1668	woman	Species	9606
25568626	1684	1692	amnesias	Disease	MESH:D000647
25568626	1742	1759	pulmonary embolus	Disease	MESH:D004617
25568626	1097	1100	PTE	Disease	MESH:D011655
25568626	1626	1629	DVT	Disease	MESH:D020246
25568626	1288	1292	PPTE	Disease	MESH:D011655
25568626	1712	1715	PTE	Disease	MESH:D011655
25568626	1705	1708	DVT	Disease	MESH:D020246
25568626	1545	1549	PPTE	Disease	MESH:D011655
25568626	2005	2013	patients	Species	9606
25568626	1920	1923	PTE	Disease	MESH:D011655
25568626	2051	2054	PTE	Disease	MESH:D011655
25568626	2044	2047	DVT	Disease	MESH:D020246
25568626	2309	2325	phlebothrombosis	Disease	MESH:D020246
25568626	2072	2104	Embolism of the pulmonary artery	Disease	MESH:D011655
25568626	2298	2305	embolus	Disease	MESH:D004617
25568626	2329	2345	thrombophlebitis	Disease	MESH:D013924
25568626	2182	2204	thromboembolic disease	Disease	MESH:D013923
25568626	2458	2476	Pulmonary embolism	Disease	MESH:D011655
25568626	2640	2656	phlebothrombosis	Disease	MESH:D020246
25568626	2440	2456	pulmonary emboli	Disease	MESH:D011655
25568626	2736	2761	pulmonary thromboembolism	Disease	MESH:D011655
25568626	2765	2829	Phlebothrombosis and thrombophlebitis of lower extremities veins	Disease	MESH:D020246
25568626	2834	2860	Phlebothrombosis of pelvic	Disease	MESH:D020246
25568626	2981	2987	trauma	Disease	MESH:D014947
25568626	2907	2944	Thrombophlebitis and phlebothrombosis	Disease	MESH:D020246
25568626	3037	3047	thrombosis	Disease	MESH:D013927
25568626	3083	3117	Thrombosis of the pulmonary artery	Disease	MESH:D013927
25568626	3219	3222	fat	Gene	2195
25568626	3229	3241	gas embolism	Disease	MESH:D004618
25568626	3286	3306	deep vein thrombosis	Disease	MESH:D020246
25568626	3311	3336	pulmonary thromboembolism	Disease	MESH:D011655
25568626	3362	3369	patient	Species	9606
25568626	3395	3402	Obesity	Disease	MESH:D009765
25568626	3499	3517	pulmonary embolism	Disease	MESH:D011655
25568626	3480	3495	vein thrombosis	Disease	MESH:D020246
25568626	3533	3578	Thrombophilia, deficiency of antithrombin(AT)	Disease	MESH:D020152
25568626	3669	3683	hemocistinemia	Disease	
25568626	3753	3759	Trauma	Disease	MESH:D014947
25568626	3891	3904	Heart failure	Disease	MESH:D006333
25568626	3916	3937	myocardial infarction	Disease	MESH:D009203
25568626	3960	3968	estrogen	Chemical	MESH:D004967
25568626	3970	3982	progesterone	Chemical	MESH:D011374
25568626	3998	4011	contraceptive	Chemical	MESH:D003270
25568626	4022	4032	Paraplegia	Disease	MESH:D010264
25568626	4044	4053	infection	Disease	MESH:D007239
25568626	4069	4082	inflammations	Disease	MESH:D007249
25568626	4087	4099	Polycythemia	Disease	MESH:D011086
25568626	4104	4119	Paraproteinemia	Disease	MESH:D010265
25568626	4131	4140	s disease	Disease	MESH:D010300
25568626	4145	4180	Paroxysmal nocturnal hemoglobinuria	Disease	MESH:D006457
25568626	4242	4267	pulmonary thromboembolism	Disease	MESH:D011655
25568626	4323	4362	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	4452	4460	patients	Species	9606
25568626	4737	4762	pulmonary thromboembolism	Disease	MESH:D011655
25568626	4466	4505	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	4507	4511	PPTE	Disease	MESH:D011655
25568626	4764	4767	PTE	Disease	MESH:D011655
25568626	4558	4576	pulmonary diseases	Disease	MESH:D008171
25568626	4856	4864	patients	Species	9606
25568626	5074	5082	patients	Species	9606
25568626	5096	5104	patients	Species	9606
25568626	5159	5167	patients	Species	9606
25568626	5215	5223	patients	Species	9606
25568626	5304	5329	pulmonary thromboembolism	Disease	MESH:D011655
25568626	4955	4973	pulmonary diseases	Disease	MESH:D008171
25568626	5343	5365	deep venous thrombosis	Disease	MESH:D020246
25568626	5173	5198	pulmonary thromboembolism	Disease	MESH:D011655
25568626	5110	5149	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	4870	4909	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	5367	5370	DVT	Disease	MESH:D020246
25568626	5409	5413	PPTE	Disease	MESH:D011655
25568626	5575	5583	patients	Species	9606
25568626	5680	5688	patients	Species	9606
25568626	5738	5743	males	Species	9606
25568626	5694	5711	postoperative PTE	Disease	MESH:D011655
25568626	5589	5592	PTE	Disease	MESH:D011655
25568626	5834	5837	man	Species	9606
25568626	6058	6063	woman	Species	9606
25568626	6068	6071	DVT	Disease	MESH:D020246
25568626	6147	6150	PTE	Disease	MESH:D011655
25568626	5951	5954	DVT	Disease	MESH:D020246
25568626	6140	6143	DVT	Disease	MESH:D020246
25568626	5842	5845	DVT	Disease	MESH:D020246
25568626	5847	5875	deep venous phlebothrombosis	Disease	MESH:D020246
25568626	6152	6160	Patients	Species	9606
25568626	6251	6254	PTE	Disease	MESH:D011655
25568626	6425	6433	patients	Species	9606
25568626	6405	6408	PTE	Disease	MESH:D011655
25568626	6400	6403	PTE	Disease	MESH:D011655
25568626	7011	7016	women	Species	9606
25568626	7049	7052	men	Species	9606
25568626	6974	6978	PPTE	Disease	MESH:D011655
25568626	6685	6688	PTE	Disease	MESH:D011655
25568626	6680	6683	PTE	Disease	MESH:D011655
25568626	7069	7073	PPTE	Disease	MESH:D011655
25568626	7291	7296	women	Species	9606
25568626	7421	7429	patients	Species	9606
25568626	7237	7254	pulmonary embolus	Disease	MESH:D004617
25568626	7311	7329	pulmonary embolism	Disease	MESH:D011655
25568626	7529	7532	men	Species	9606
25568626	7657	7665	patients	Species	9606
25568626	7547	7565	pulmonary embolism	Disease	MESH:D011655
25568626	7475	7492	pulmonary embolus	Disease	MESH:D004617
25568626	7741	7749	patients	Species	9606
25568626	7973	7981	patients	Species	9606
25568626	8069	8077	patients	Species	9606
25568626	7819	7837	pulmonary diseases	Disease	MESH:D008171
25568626	7755	7780	pulmonary thromboembolism	Disease	MESH:D011655
25568626	8384	8387	PTE	Disease	MESH:D011655
25568626	8084	8087	PTE	Disease	MESH:D011655
25568626	7987	7990	PTE	Disease	MESH:D011655
25568626	8219	8258	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	8743	8751	patients	Species	9606
25568626	8757	8774	postoperative PTE	Disease	MESH:D011655
25568626	8705	8708	PTE	Disease	MESH:D011655
25568626	9159	9162	DVT	Disease	MESH:D020246
25568626	9166	9169	PTE	Disease	MESH:D011655
25568626	9037	9040	PTE	Disease	MESH:D011655
25568626	9362	9370	patients	Species	9606
25568626	9516	9524	patients	Species	9606
25568626	9530	9535	males	Species	9606
25568626	9691	9699	patients	Species	9606
25568626	9847	9855	patients	Species	9606
25568626	9881	9886	women	Species	9606
25568626	9920	9923	men	Species	9606
25568626	9949	9954	women	Species	9606
25568626	9960	9968	patients	Species	9606
25568626	10080	10088	patients	Species	9606
25568626	10139	10147	patients	Species	9606
25568626	10189	10193	PPTE	Disease	MESH:D011655
25568626	9628	9652	congestive heart failure	Disease	MESH:D006333
25568626	10368	10383	tract infection	Disease	MESH:D014552
25568626	10254	10257	PTE	Disease	MESH:D011655
25568626	10385	10406	myocardial infarction	Disease	MESH:D009203
25568626	10318	10327	pneumonia	Disease	MESH:D011014
25568626	9585	9622	chronic obstructive pulmonary disease	Disease	MESH:D029424
25568626	10482	10486	PPTE	Disease	MESH:D011655
25568626	9666	9669	PTE	Disease	MESH:D011655
25568626	9566	9583	diabetes mellitus	Disease	MESH:D003920
25568626	10497	10505	patients	Species	9606
25568626	10548	10551	man	Species	9606
25568626	10560	10565	woman	Species	9606
25568626	10807	10815	patients	Species	9606
25568626	10523	10526	DVT	Disease	MESH:D020246
25568626	10838	10841	DVT	Disease	MESH:D020246
25568626	11234	11273	postoperative pulmonary thromboembolism	Disease	MESH:D011655
25568626	10845	10848	PTE	Disease	MESH:D011655
25568626	11451	11459	patients	Species	9606
25568626	11497	11500	PTE	Disease	MESH:D011655
25568626	11490	11493	DVT	Disease	MESH:D020246
25568626	11366	11369	PTE	Disease	MESH:D011655
25568626	11571	11591	plucna tromboemblija	Disease	
25568626	11596	11602	Plucne	Chemical	
25568626	11620	11645	pulmonary thromboembolism	Disease	MESH:D011655
25568626	11768	11790	deep venous thrombosis	Disease	MESH:D020246
25568626	11856	11864	patients	Species	9606
25568626	11870	11894	acute pulmonary embolism	Disease	MESH:D011655
25568626	11926	11943	pulmonary disease	Disease	MESH:D008171
25568626	11960	11970	chest pain	Disease	MESH:D002637
25568626	12018	12036	pulmonary embolism	Disease	MESH:D011655
25568626	12037	12077	Postoperative pulmonary thromoboembolism	Disease	MESH:D001261
25568626	12140	12162	venous thromboembolism	Disease	MESH:D054556
25568626	12177	12199	venous thromboembolism	Disease	MESH:D054556
25568626	12333	12355	venous thromboembolism	Disease	MESH:D054556
25568626	12477	12485	patients	Species	9606
25568626	12510	12518	patients	Species	9606
25568626	12431	12453	venous thromboembolism	Disease	MESH:D054556
25568626	12385	12395	enoxaparin	Chemical	MESH:D017984
25568626	12524	12534	enoxaparin	Chemical	MESH:D017984

25568627|t|Relationship of Weight and Body Mass Index with Bone Mineral Density in Adult Men from Kosovo 
25568627|a|Background and objective: Body weight and body mass index (BMI) are considered strong predictors of osteoporotic fractures, though optimal BMI levels remain unsettled. There are several studies conducted on women about the relationship between BMI and bone mineral density (BMD), and just a few so far on men. Therefore, the objective of current study was to analyze the relationship between weight and BMI and BMD measured in lumbar spine (L1-L4), femur neck and total hip in 64 men from Kosovo. Methods: This cross-sectional study included a population of 64 men divided into three BMI groups. Dual-energy X-ray absorptiometry (DEXA) measurements were done in all the study participants.  Results: Pearson's correlation analysis showed a significant positive correlation between weight and BMI and BMD in femur neck and in total hip, and a significant negative correlation between age and femur neck BMD. Age-adjusted linear regression analysis showed that weight and BMI had a significant positive association with BMD levels. Conclusion: Although the results show significant relationship between BMI and BMD, the negative relationship between age and femur neck BMD may serve as guidance to initiate early assessment of the BMD in this region as well as preventive measures of osteoporosis and fractures among ageing men population 
25568627	78	81	Men	Species	9606
25568627	301	306	women	Species	9606
25568627	399	402	men	Species	9606
25568627	574	577	men	Species	9606
25568627	194	216	osteoporotic fractures	Disease	MESH:D058866
25568627	655	658	men	Species	9606
25568627	770	782	participants	Species	9606
25568627	1416	1419	men	Species	9606
25568627	1393	1402	fractures	Disease	MESH:D050723
25568627	1376	1388	osteoporosis	Disease	MESH:D010024
25568627	1203	1206	BMD	Disease	MESH:D010024
25568627	2524	2532	patients	Species	9606
25568627	1888	1895	obesity	Disease	MESH:D009765
25568627	1750	1772	osteoporotic fractures	Disease	MESH:D058866
25568627	1447	1482	Fractures accompanying osteoporosis	Disease	MESH:D010024
25568627	2518	2523	obese	Disease	MESH:D009765
25568627	2383	2386	BMD	Disease	MESH:D010024
25568627	2478	2487	fractures	Disease	MESH:D050723
25568627	2755	2758	men	Species	9606
25568627	2824	2829	women	Species	9606
25568627	2904	2907	men	Species	9606
25568627	2982	2985	men	Species	9606
25568627	3261	3264	men	Species	9606
25568627	3701	3713	participants	Species	9606
25568627	3636	3651	bisphosphonates	Chemical	MESH:D004164
25568627	4144	4156	participants	Species	9606
25568627	4473	4485	participants	Species	9606
25568627	4684	4694	osteopenia	Disease	MESH:D001851
25568627	4272	4277	obese	Disease	MESH:D009765
25568627	4648	4660	osteoporosis	Disease	MESH:D010024
25568627	4576	4588	osteoporosis	Disease	MESH:D010024
25568627	4593	4603	osteopenia	Disease	MESH:D001851
25568627	5333	5339	Person	Species	9606
25568627	5770	5775	males	Species	9606
25568627	5990	5993	men	Species	9606
25568627	6027	6032	obese	Disease	MESH:D009765
25568627	5972	5977	obese	Disease	MESH:D009765
25568627	6168	6171	BMD	Disease	MESH:D010024
25568627	6942	6948	FN BMD	Disease	MESH:D010024
25568627	7070	7076	FN BMD	Disease	MESH:D010024
25568627	8095	8102	insulin	Gene	3630
25568627	8064	8069	women	Species	9606
25568627	8041	8049	estrogen	Chemical	MESH:D004967
25568627	7822	7831	fractures	Disease	MESH:D050723
25568627	8273	8280	obesity	Disease	MESH:D009765
25568627	7805	7817	osteoporosis	Disease	MESH:D010024
25568627	8442	8454	parathormone	Chemical	MESH:D010281
25568627	8724	8728	male	Species	9606
25568627	9106	9114	patients	Species	9606
25568627	9100	9105	obese	Disease	MESH:D009765
25568627	8709	8716	hip BMD	Disease	MESH:D010024
25568627	8843	8848	obese	Disease	MESH:D009765
25568627	8695	8698	BMD	Disease	MESH:D010024
25568627	9660	9663	men	Species	9606
25568627	9891	9895	male	Species	9606
25568627	9869	9878	fractures	Disease	MESH:D050723
25568627	9852	9864	osteoporosis	Disease	MESH:D010024
25568627	9956	9960	Male	Species	9606
25568627	9961	9973	osteoporosis	Disease	MESH:D010024
25568627	10053	10056	men	Species	9606
25568627	10158	10161	men	Species	9606
25568627	10389	10392	men	Species	9606
25568627	10367	10379	triglyceride	Chemical	MESH:D014280
25568627	10654	10672	osteoporotic women	Disease	MESH:D058866
25568627	10639	10649	osteopenic	Disease	MESH:C567172
25568627	10790	10795	women	Species	9606
25568627	10800	10803	men	Species	9606
25568627	10818	10842	Multicentre Osteoporosis	Disease	MESH:D010024
25568627	10850	10855	CaMos	Chemical	MESH:C075752
25568627	10931	10934	Men	Species	9606
25568627	11216	11238	obese adolescent girls	Disease	MESH:D063766
25568627	11339	11344	women	Species	9606
25568627	11349	11352	men	Species	9606
25568627	11366	11374	fracture	Disease	MESH:D050723
25568627	11354	11361	Obesity	Disease	MESH:D009765
25568627	11406	11418	osteoporosis	Disease	MESH:D010024
25568627	11383	11390	obesity	Disease	MESH:D009765
25568627	11533	11540	obesity	Disease	MESH:D009765
25568627	11651	11656	women	Species	9606
25568627	11624	11632	fracture	Disease	MESH:D050723
25568627	11699	11703	male	Species	9606
25568627	11805	11809	MrOS	Gene	8011
25568627	11759	11762	men	Species	9606
25568627	11794	11797	men	Species	9606
25568627	11768	11790	osteoporotic fractures	Disease	MESH:D058866
25568627	11848	11855	obesity	Disease	MESH:D009765
25568627	11835	11843	fracture	Disease	MESH:D050723
25568627	11977	11980	men	Species	9606
25568627	11966	11973	obesity	Disease	MESH:D009765

25568634|t|Characteristics of Rotavirus Diarrhea in Hospitalized Children in Kosovo 
25568634|a|Background: Diarrhea is a leading cause of child mortality worldwide. Rotavirus is one of the most common causes of severe diarrhea and dehydration in children. Authors reviewed epidemiological and clinical data of the rotavirus diarrhea in Kosovo. Methods: This is a prospective study carried between January 1st and December 31st 2011. All data, comprising demographics, nutrition, clinical presentation, laboratory findings, management and outcome of the rotavirus diarrhea are collected on the specially designed form. Results: 116 children with rotavirus diarrhea are included in the study. The majority boys (74.4%) and children aged 0 - 12 months (82.75%). Mean age of children in the study was 16.38 months. Almost every third child in the study was hypotrophic (29.2%). More than half of the infants (55.2%) were on mixed food, somewhat more than every third was breast feeding (36.45%), and every twelfth (8.33%) was on artificial milk (animal or formula). Apart from diarrhea, present in all patients, vomiting (97.41%) and fever (43.96%) were characteristics of the clinical presentation of the diarrhea. Two thirds of the children had mild grade dehydration (70.7%). All patients recovered with no sequels. Conclusion: Rotavirus continues to be responsible for a significant portion of acute diarrhea in Kosovo. Clinical features, epidemiological data and the agglutination test are safe enough to establish the diagnosis. Treated correctly rotavirus diarrhea has a favorable outcome. 
25568634	54	62	Children	Species	9606
25568634	19	37	Rotavirus Diarrhea	Disease	MESH:D012400
25568634	116	121	child	Species	9606
25568634	224	232	children	Species	9606
25568634	85	93	Diarrhea	Disease	MESH:D003967
25568634	209	220	dehydration	Disease	MESH:D003681
25568634	196	204	diarrhea	Disease	MESH:D003967
25568634	292	310	rotavirus diarrhea	Disease	MESH:D012400
25568634	531	549	rotavirus diarrhea	Disease	MESH:D012400
25568634	609	617	children	Species	9606
25568634	682	686	boys	Species	9606
25568634	699	707	children	Species	9606
25568634	749	757	children	Species	9606
25568634	808	813	child	Species	9606
25568634	874	881	infants	Species	9606
25568634	1076	1084	patients	Species	9606
25568634	1208	1216	children	Species	9606
25568634	1257	1265	patients	Species	9606
25568634	1232	1243	dehydration	Disease	MESH:D003681
25568634	1086	1094	vomiting	Disease	MESH:D014839
25568634	1180	1188	diarrhea	Disease	MESH:D003967
25568634	623	641	rotavirus diarrhea	Disease	MESH:D012400
25568634	1108	1113	fever	Disease	MESH:D005334
25568634	1051	1059	diarrhea	Disease	MESH:D003967
25568634	831	842	hypotrophic	Disease	
25568634	1529	1547	rotavirus diarrhea	Disease	MESH:D012400
25568634	1380	1388	diarrhea	Disease	MESH:D003967
25568634	1682	1690	children	Species	9606
25568634	1909	1917	children	Species	9606
25568634	2038	2046	patients	Species	9606
25568634	2091	2099	children	Species	9606
25568634	1743	1761	Rotavirus diarrhea	Disease	MESH:D012400
25568634	1711	1725	acute diarrhea	Disease	MESH:D003967
25568634	1894	1902	diarrhea	Disease	MESH:D003967
25568634	1629	1638	rotavirus	Disease	MESH:D012400
25568634	1985	1993	diarrhea	Disease	MESH:D003967
25568634	2813	2831	rotavirus diarrhea	Disease	MESH:D012400
25568634	2878	2888	Retrovirus	Species	31931
25568634	2918	2926	patients	Species	9606
25568634	3039	3047	children	Species	9606
25568634	3083	3091	diarrhea	Disease	MESH:D003967
25568634	3230	3238	children	Species	9606
25568634	3257	3261	boys	Species	9606
25568634	3273	3280	infants	Species	9606
25568634	3306	3314	children	Species	9606
25568634	3365	3370	child	Species	9606
25568634	3441	3446	girls	Species	9606
25568634	3455	3459	boys	Species	9606
25568634	3384	3395	hypotrophic	Disease	
25568634	3409	3419	hypotrophy	Disease	
25568634	3485	3493	children	Species	9606
25568634	3503	3510	infants	Species	9606
25568634	3542	3549	infants	Species	9606
25568634	3854	3861	patient	Species	9606
25568634	3867	3885	rotavirus diarrhea	Disease	MESH:D012400
25568634	3935	3943	patients	Species	9606
25568634	4078	4082	boys	Species	9606
25568634	4091	4096	girls	Species	9606
25568634	4161	4169	patients	Species	9606
25568634	4195	4198	boy	Species	9606
25568634	4207	4211	girl	Species	9606
25568634	4272	4283	convulsions	Disease	MESH:D012640
25568634	4038	4046	diarrhea	Disease	MESH:D003967
25568634	4223	4233	convulsion	Disease	MESH:D012640
25568634	3910	3918	diarrhea	Disease	MESH:D003967
25568634	3945	3953	vomiting	Disease	MESH:D014839
25568634	3966	3971	fever	Disease	MESH:D005334
25568634	4310	4318	patients	Species	9606
25568634	4412	4419	patient	Species	9606
25568634	4520	4525	girls	Species	9606
25568634	4530	4534	boys	Species	9606
25568634	4500	4511	dehydration	Disease	MESH:D003681
25568634	4355	4366	dehydration	Disease	MESH:D003681
25568634	4565	4583	rotavirus diarrhea	Disease	MESH:D012400
25568634	4602	4613	dehydration	Disease	MESH:D003681
25568634	4699	4706	patient	Species	9606
25568634	4680	4691	dehydration	Disease	MESH:D003681
25568634	4712	4730	rotavirus diarrhea	Disease	MESH:D012400
25568634	4776	4784	patients	Species	9606
25568634	4931	4939	patients	Species	9606
25568634	5127	5132	girls	Species	9606
25568634	5146	5151	girls	Species	9606
25568634	4997	5031	upper respiratory tract infections	Disease	MESH:D012141
25568634	4790	4808	rotavirus diarrhea	Disease	MESH:D012400
25568634	4881	4897	bronchopneumonia	Disease	MESH:D001996
25568634	5200	5208	patients	Species	9606
25568634	5214	5232	rotavirus diarrhea	Disease	MESH:D012400
25568634	5297	5304	patient	Species	9606
25568634	5310	5328	rotavirus diarrhea	Disease	MESH:D012400
25568634	5454	5462	patients	Species	9606
25568634	5488	5495	patient	Species	9606
25568634	5566	5571	girls	Species	9606
25568634	5580	5584	boys	Species	9606
25568634	5652	5660	patients	Species	9606
25568634	5674	5681	patient	Species	9606
25568634	5697	5718	neurological symptoms	Disease	MESH:D009422
25568634	5720	5728	seizures	Disease	MESH:D012640
25568634	5634	5641	ascites	Disease	MESH:D001201
25568634	5398	5416	rotavirus diarrhea	Disease	MESH:D012400
25568634	5342	5357	Paralytic ileus	Disease	MESH:D007418
25568634	5761	5769	patients	Species	9606
25568634	5839	5847	patients	Species	9606
25568634	6016	6024	patients	Species	9606
25568634	6072	6080	patients	Species	9606
25568634	6184	6192	patients	Species	9606
25568634	6252	6260	patients	Species	9606
25568634	6227	6239	trimethoprim	Chemical	MESH:D014295
25568634	6206	6222	sulfamethoxazole	Chemical	MESH:D013420
25568634	6137	6145	Amikacin	Chemical	MESH:D000583
25568634	6113	6121	amikacin	Chemical	MESH:D000583
25568634	6095	6110	aminoglycosides	Chemical	MESH:D000617
25568634	5916	5927	Ceftriaxone	Chemical	MESH:D002443
25568634	6125	6135	gentamicin	Chemical	MESH:D005839
25568634	6412	6420	patients	Species	9606
25568634	6488	6496	amikacin	Chemical	MESH:D000583
25568634	6426	6444	rotavirus diarrhea	Disease	MESH:D012400
25568634	6500	6510	gentamicin	Chemical	MESH:D005839
25568634	6723	6731	patients	Species	9606
25568634	6558	6576	rotavirus diarrhea	Disease	MESH:D012400
25568634	6788	6806	rotavirus diarrhea	Disease	MESH:D012400
25568634	6870	6876	infant	Species	9606
25568634	7004	7012	children	Species	9606
25568634	7160	7168	children	Species	9606
25568634	7276	7284	children	Species	9606
25568634	6854	6862	diarrhea	Disease	MESH:D003967
25568634	7145	7153	diarrhea	Disease	MESH:D003967
25568634	7240	7257	rotavirus disease	Disease	MESH:D012400
25568634	7313	7330	rotavirus disease	Disease	MESH:D012400
25568634	6980	6997	Rotavirus disease	Disease	MESH:D012400
25568634	7430	7438	children	Species	9606
25568634	7668	7673	child	Species	9606
25568634	7737	7754	rotavirus disease	Disease	MESH:D012400
25568634	7581	7598	rotavirus disease	Disease	MESH:D012400
25568634	7895	7912	rotavirus disease	Disease	MESH:D012400
25568634	8271	8279	children	Species	9606
25568634	8440	8449	toxicosis	Disease	MESH:C565846
25568634	8395	8403	diarrhea	Disease	MESH:D003967
25568634	8577	8591	acute diarrhea	Disease	MESH:D003967
25568634	8008	8016	diarrhea	Disease	MESH:D003967
25568634	8427	8438	dehydration	Disease	MESH:D003681
25568634	8814	8819	virus	Species	12081
25568634	8944	8952	diarrhea	Disease	MESH:D003967
25568634	9446	9471	rotavirus gastroenteritis	Disease	MESH:D012400
25568634	8992	9000	diarrhea	Disease	MESH:D003967
25568634	9340	9347	Romania	Disease	
25568634	9782	9790	children	Species	9606
25568634	9829	9836	infants	Species	9606
25568634	9847	9851	boys	Species	9606
25568634	9888	9892	boys	Species	9606
25568634	9802	9810	diarrhea	Disease	MESH:D003967
25568634	9898	9916	rotavirus diarrhea	Disease	MESH:D012400
25568634	10318	10326	children	Species	9606
25568634	10350	10355	child	Species	9606
25568634	10127	10135	diarrhea	Disease	MESH:D003967
25568634	10362	10373	dehydration	Disease	MESH:D003681
25568634	10287	10298	dehydration	Disease	MESH:D003681
25568634	10435	10443	children	Species	9606
25568634	10697	10705	children	Species	9606
25568634	11045	11053	patients	Species	9606
25568634	11127	11135	children	Species	9606
25568634	10772	10810	rotavirus versus non-rotavirus disease	Disease	MESH:D012400
25568634	10449	10460	dehydration	Disease	MESH:D003681
25568634	11189	11200	dehydration	Disease	MESH:D003681
25568634	10664	10675	dehydration	Disease	MESH:D003681
25568634	11009	11020	dehydration	Disease	MESH:D003681
25568634	11342	11357	gastroenteritis	Disease	MESH:D005759
25568634	10740	10751	dehydration	Disease	MESH:D003681
25568634	11290	11301	dehydration	Disease	MESH:D003681
25568634	11659	11667	patients	Species	9606
25568634	11744	11759	paralytic ileus	Disease	MESH:D007418
25568634	11685	11701	bronchopneumonia	Disease	MESH:D001996
25568634	11827	11835	children	Species	9606
25568634	11884	11892	patients	Species	9606
25568634	12077	12085	children	Species	9606
25568634	12185	12193	patients	Species	9606
25568634	11943	11961	rotavirus diarrhea	Disease	MESH:D012400
25568634	11841	11859	rotavirus diarrhea	Disease	MESH:D012400
25568634	12437	12441	girl	Species	9606
25568634	12408	12422	encephalopathy	Disease	MESH:D001927
25568634	12737	12745	patients	Species	9606
25568634	12641	12659	rotavirus diarrhea	Disease	MESH:D012400
25568634	12860	12876	bronchopneumonia	Disease	MESH:D001996
25568634	12894	12912	Rotavirus diarrhea	Disease	MESH:D012400
25568634	13032	13050	Rotavirus diarrhea	Disease	MESH:D012400
25568634	13293	13298	Virus	Species	12081
25568634	13353	13361	children	Species	9606
25568634	13377	13386	bacterial	Species	2
25568634	13387	13402	gastroenteritis	Disease	MESH:D005759
25568634	13478	13486	children	Species	9606
25568634	13502	13522	cholera immunisation	Disease	MESH:D002771
25568634	13446	13465	diarrhoeal diseases	Disease	MESH:D030342
25568634	13608	13616	Children	Species	9606
25568634	13584	13601	Rotavirus Disease	Disease	MESH:D012400
25568634	13690	13698	children	Species	9606
25568634	13704	13713	toxicosis	Disease	MESH:C565846
25568634	13775	13784	rotavirus	Disease	MESH:D012400
25568634	13761	13769	diarrhea	Disease	MESH:D003967
25568634	13795	13820	rotavirus gastroenteritis	Disease	MESH:D012400
25568634	13916	13923	illness	Disease	MESH:D002908
25568634	13971	14002	Rotavirus Acute Gastroenteritis	Disease	MESH:D012400
25568634	14106	14115	rotavirus	Disease	MESH:D012400
25568634	14092	14100	diarrhea	Disease	MESH:D003967
25568634	14126	14190	diseases afecting gastrointestinal system in pediatric toxicosis	Disease	MESH:D005767
25568634	14232	14251	pediatric toxicosis	Disease	MESH:C565846
25568634	14297	14305	children	Species	9606
25568634	14311	14381	diarrhea toxicosis.12th Congress of the pediatritian of the Yugoslavia	Disease	MESH:D003967
25568634	14435	14454	rotavirus diarrhoea	Disease	MESH:D012400
25568634	14485	14495	adenovirus	Species	10535
25568634	14512	14520	patients	Species	9606
25568634	14526	14547	acute gastroenteritis	Disease	MESH:D005759
25568634	14662	14669	infants	Species	9606
25568634	14675	14683	diarrhea	Disease	MESH:D003967
25568634	14635	14655	adenovirus infection	Disease	MESH:D000257
25568634	14735	14741	Turkey	Species	9103
25568634	14714	14723	diarrhoea	Disease	MESH:D003967
25568634	14889	14897	children	Species	9606
25568634	14867	14885	rotavirus diarrhea	Disease	MESH:D012400
25568634	14988	14996	children	Species	9606
25568634	14965	14984	rotaviral diarrhoea	Disease	MESH:D003967
25568634	15062	15070	children	Species	9606
25568634	15046	15055	diarrhoea	Disease	MESH:D003967
25568634	15134	15159	Rotavirus gastroenteritis	Disease	MESH:D012400
25568634	15204	15229	rotavirus gastroenteritis	Disease	MESH:D012400
25568634	15336	15355	rotavirus infection	Disease	MESH:D012400
25568634	15465	15473	Children	Species	9606
25568634	15485	15500	Gastroenteritis	Disease	MESH:D005759

25568625|t|Characteristics of Calculi in the Urinary Tract 
25568625|a|Introduction: Elimination of stone is determined by size and its localization. Stone from the ureter in 80% of cases can be eliminated spontaneously. If the stone by its characteristics is not spontaneously eliminated, taken are further steps and therapeutic protocols to solve this problem. Material and methods: The study was prospective, open and comparative. It was conducted at the Urology Clinic Clinical Center of Sarajevo University in the period from 2007 to 2013. The study included 404 patients with urinary tract lithiasis treated by ESWL. ESWL treatment is performed on the machine Siemens Model Lithostar Multiline, which has a combined ultrasonographic and fluoroscopic display, large energy density in order to obtain optimum focus (without damaging surrounding tissue) and minimal pain that on rare occasions requires for mild sedation-sedation. Results: From a total of 404 patients included in the study there were 234 (57.92%) male and 170 (42.08%) female patients. The most common type of stone both in female and male patients was calcium type. From a total of 262 calcium stones, 105 of them (40.07%) was present in female patients and 157 (59.92%) in male. Share of infectious type of stone in female patients was 63 (49.60%) and 64 among males (50.39%). Other stones were less abundant in both the gender groups and their total number was only 17. In women their frequency was 2 (13.33%) and 13 among males (86.67%). There was a significant difference in the frequency of different types of stones by gender (chi2 = 11.47, p = 0.009). Conclusion: There was no statistically significant correlation between the number of treatments and localization of stones in the ureter, as well as a statistically significant correlation between the size of the stone and the localization of calculus in the ureter. 
25568625	545	553	patients	Species	9606
25568625	846	850	pain	Disease	MESH:D010146
25568625	720	732	fluoroscopic	Chemical	
25568625	559	582	urinary tract lithiasis	Disease	MESH:D052878
25568625	435	442	Urology	Disease	MESH:D014570
25568625	940	948	patients	Species	9606
25568625	995	999	male	Species	9606
25568625	1024	1032	patients	Species	9606
25568625	1083	1087	male	Species	9606
25568625	1088	1096	patients	Species	9606
25568625	1194	1202	patients	Species	9606
25568625	1223	1227	male	Species	9606
25568625	1273	1281	patients	Species	9606
25568625	1311	1316	males	Species	9606
25568625	1424	1429	women	Species	9606
25568625	1474	1479	males	Species	9606
25568625	1135	1142	calcium	Chemical	MESH:D002118
25568625	1101	1108	calcium	Chemical	MESH:D002118
25568625	1851	1873	calculus in the ureter	Disease	MESH:D002137
25568625	1927	1934	persons	Species	9606
25568625	1981	1985	male	Species	9606
25568625	1963	1973	calculosis	Disease	MESH:D020347
25568625	2517	2525	patients	Species	9606
25568625	2548	2556	patients	Species	9606
25568625	3030	3034	dogs	Species	9615
25568625	3036	3040	cats	Species	9685
25568625	3042	3049	rabbits	Species	9986
25568625	3051	3056	minks	Species	452646
25568625	3102	3108	humans	Species	9606
25568625	3161	3166	human	Species	9606
25568625	3261	3269	newborns	Species	9606
25568625	3274	3281	fetuses	Species	10090
25568625	3308	3316	children	Species	9606
25568625	3404	3407	men	Species	9606
25568625	3418	3423	women	Species	9606
25568625	3588	3591	men	Species	9606
25568625	3727	3732	women	Species	9606
25568625	3842	3847	women	Species	9606
25568625	3923	3926	men	Species	9606
25568625	2715	2727	word nephros	Disease	MESH:D004410
25568625	3963	3970	calcium	Chemical	MESH:D002118
25568625	3647	3654	oxalate	Chemical	MESH:D010070
25568625	2622	2658	nephrolithiasis-meaning kidney stone	Disease	MESH:D007669
25568625	3691	3703	testosterone	Chemical	MESH:D013739
25568625	3870	3888	urinary infections	Disease	MESH:D001745
25568625	3292	3304	urolithiasis	Disease	MESH:D052878
25568625	3971	3980	lithiasis	Disease	MESH:D020347
25568625	3939	3959	idiopathic lithiasis	Disease	MESH:D020347
25568625	4024	4034	calculosis	Disease	MESH:D020347
25568625	2918	2931	word calculus	Disease	MESH:D002137
25568625	3771	3778	citrate	Chemical	MESH:C102006
25568625	3114	3126	Urolithiasis	Disease	MESH:D052878
25568625	3985	3994	uric acid	Chemical	MESH:D014527
25568625	2888	2902	renal calculus	Disease	MESH:D007669
25568625	3893	3912	metabolic disorders	Disease	MESH:D008659
25568625	2765	2785	urolithiasis-urinary	Disease	MESH:D052878
25568625	3818	3825	calcium	Chemical	MESH:D002118
25568625	2970	2982	Urolithiasis	Disease	MESH:D052878
25568625	2660	2675	nephrolithiasis	Disease	MESH:D053040
25568625	2222	2234	urolithiasis	Disease	MESH:D052878
25568625	4374	4379	human	Species	9606
25568625	4565	4573	patients	Species	9606
25568625	4627	4633	people	Species	9606
25568625	5988	5996	patients	Species	9606
25568625	5944	5960	calculous anuria	Disease	MESH:D001002
25568625	5936	5942	sepsis	Disease	MESH:D018805
25568625	5909	5926	urinary infection	Disease	MESH:D001745
25568625	4466	4478	urolithiasis	Disease	MESH:D052878
25568625	6011	6023	urolithiasis	Disease	MESH:D052878
25568625	5690	5703	ureter stones	Disease	MESH:D014516
25568625	5604	5634	kidney urostasis and infection	Disease	MESH:D007674
25568625	6831	6839	patients	Species	9606
25568625	7251	7259	patients	Species	9606
25568625	7294	7302	patients	Species	9606
25568625	7440	7448	patients	Species	9606
25568625	7689	7700	obstruction	Disease	MESH:D007415
25568625	7804	7821	renal obstruction	Disease	MESH:D007674
25568625	7706	7747	dilatation of the renal colorectal system	Disease	MESH:D015179
25568625	7749	7782	reduction of the renal parenchyma	Disease	MESH:D051437
25568625	8224	8228	pain	Disease	MESH:D010146
25568625	7265	7288	urinary tract lithiasis	Disease	MESH:D052878
25568625	7141	7148	Urology	Disease	MESH:D014570
25568625	8098	8110	fluoroscopic	Chemical	
25568625	8748	8756	patients	Species	9606
25568625	8803	8807	male	Species	9606
25568625	8832	8840	patients	Species	9606
25568625	9089	9093	male	Species	9606
25568625	9094	9102	patients	Species	9606
25568625	9200	9208	patients	Species	9606
25568625	9229	9233	male	Species	9606
25568625	9279	9287	patients	Species	9606
25568625	9317	9322	males	Species	9606
25568625	9430	9435	women	Species	9606
25568625	9480	9485	males	Species	9606
25568625	9107	9114	calcium	Chemical	MESH:D002118
25568625	9141	9148	calcium	Chemical	MESH:D002118
25568625	10039	10043	male	Species	9606
25568625	10044	10052	patients	Species	9606
25568625	10208	10212	male	Species	9606
25568625	10213	10221	patients	Species	9606
25568625	9812	9821	uric acid	Chemical	MESH:D014527
25568625	9890	9898	xanthine	Chemical	MESH:D019820
25568625	9919	9928	uric acid	Chemical	MESH:D014527
25568625	9792	9800	xanthine	Chemical	MESH:D019820
25568625	9783	9790	cystine	Chemical	MESH:D003553
25568625	9847	9862	cystine calculi	Disease	MESH:D002137
25568625	9990	9998	calculus	Disease	MESH:D002137
25568625	10472	10477	women	Species	9606
25568625	10505	10508	men	Species	9606
25568625	10609	10614	women	Species	9606
25568625	10642	10645	men	Species	9606
25568625	10736	10741	women	Species	9606
25568625	10769	10772	men	Species	9606
25568625	10899	10902	men	Species	9606
25568625	11182	11187	males	Species	9606
25568625	11337	11340	men	Species	9606
25568625	11214	11226	urolithiasis	Disease	MESH:D052878
25568625	11072	11084	urolithiasis	Disease	MESH:D052878
25568625	11918	11923	women	Species	9606
25568625	11951	11954	men	Species	9606
25568625	12057	12062	males	Species	9606
25568625	12292	12300	patients	Species	9606
25568625	12507	12515	patients	Species	9606
25568625	12894	12902	patients	Species	9606
25568625	13006	13014	patients	Species	9606
25568625	13095	13103	patients	Species	9606
25568625	13254	13262	patients	Species	9606
25568625	12678	12686	calculus	Disease	MESH:D002137
25568625	12553	12561	calculus	Disease	MESH:D002137
25568625	12338	12346	calculus	Disease	MESH:D002137
25568625	13296	13304	patients	Species	9606
25568625	13388	13396	patients	Species	9606
25568625	13542	13550	patients	Species	9606
25568625	13376	13384	calculus	Disease	MESH:D002137
25568625	13284	13292	calculus	Disease	MESH:D002137
25568625	13323	13335	urolithiasis	Disease	MESH:D052878
25568625	13420	13432	urolithiasis	Disease	MESH:D052878
25568625	13808	13816	calculus	Disease	MESH:D002137
25568625	15793	15801	calculus	Disease	MESH:D002137
25568625	16061	16086	enlargement of the ureter	Disease	MESH:D014516
25568625	16103	16111	patients	Species	9606
25568625	16376	16384	patients	Species	9606
25568625	16650	16658	patients	Species	9606
25568625	16144	16151	calcium	Chemical	MESH:D002118
25568625	16231	16238	calcium	Chemical	MESH:D002118
25568625	17046	17054	calculus	Disease	MESH:D002137
25568625	17261	17269	patients	Species	9606
25568625	17096	17111	Renal lithiasis	Disease	MESH:D020347
25568625	17687	17708	calciuria, cystinuria	Disease	MESH:D003555
25568625	17721	17786	primary hyperparathyroidism, hyperthereodosis and hypovitaminosis	Disease	MESH:D049950
25568625	17624	17633	infection	Disease	MESH:D007239
25568625	17576	17589	sponge kidney	Disease	MESH:D007691
25568625	18356	18364	bacteria	Species	562
25568625	17953	17966	kidney stones	Disease	MESH:D007669
25568625	18875	18895	type of urolithiasis	Disease	MESH:D052878
25568625	19002	19014	urolithiasis	Disease	MESH:D052878
25568625	19604	19627	urinary bladder calculi	Disease	MESH:D001744
25568625	19691	19694	men	Species	9606
25568625	19843	19846	men	Species	9606
25568625	19863	19868	women	Species	9606
25568625	19869	19877	patients	Species	9606
25568625	19906	19909	men	Species	9606
25568625	19931	19939	patients	Species	9606
25568625	19978	19981	men	Species	9606
25568625	20105	20117	kidney stone	Disease	MESH:D007669
25568625	19801	19814	kidney stones	Disease	MESH:D007669
25568625	20241	20244	men	Species	9606
25568625	20249	20254	women	Species	9606
25568625	20350	20353	men	Species	9606
25568625	20367	20372	women	Species	9606
25568625	20420	20423	men	Species	9606
25568625	20428	20433	women	Species	9606
25568625	20327	20339	urolithiasis	Disease	MESH:D052878
25568625	20611	20615	male	Species	9606
25568625	20804	20808	male	Species	9606
25568625	20809	20817	patients	Species	9606
25568625	20870	20873	men	Species	9606
25568625	20983	20986	men	Species	9606
25568625	21034	21037	men	Species	9606
25568625	21447	21450	men	Species	9606
25568625	21545	21548	men	Species	9606
25568625	21507	21519	urolithiasis	Disease	MESH:D052878
25568625	21688	21691	men	Species	9606
25568625	21745	21753	patients	Species	9606
25568625	21983	21988	Women	Species	9606
25568625	21784	21805	Prostatic hyperplasia	Disease	MESH:D011470
25568625	22224	22252	efficiency reduction bladder	Disease	MESH:D001745
25568625	21759	21782	urinary bladder calculi	Disease	MESH:D001744
25568625	23343	23352	uric acid	Chemical	MESH:D014527
25568625	23116	23125	uric acid	Chemical	MESH:D014527
25568625	23027	23042	calcium oxalate	Chemical	MESH:D002129
25568625	23000	23007	calcium	Chemical	MESH:D002118
25568625	23456	23465	uric acid	Chemical	MESH:D014527
25568625	23538	23546	patients	Species	9606
25568625	24246	24254	patients	Species	9606
25568625	23754	23761	calcium	Chemical	MESH:D002118
25568625	24284	24291	calcium	Chemical	MESH:D002118
25568625	23579	23586	calcium	Chemical	MESH:D002118
25568625	23936	23943	calcium	Chemical	MESH:D002118
25568625	24414	24421	calcium	Chemical	MESH:D002118
25568625	24877	24883	people	Species	9606
25568625	24703	24718	calcium oxalate	Chemical	MESH:D002129
25568625	24951	24966	calcium oxalate	Chemical	MESH:D002129
25568625	24846	24861	calcium oxalate	Chemical	MESH:D002129
25568625	24690	24702	urolithiasis	Disease	MESH:D052878
25568625	25272	25282	Cystinuria	Disease	MESH:D003555
25568625	25288	25307	hereditary disorder	Disease	MESH:D030342
25568625	25472	25505	hereditary disorder of metabolism	Disease	MESH:D030342
25568625	25140	25158	hereditary disease	Disease	MESH:D030342
25568625	25640	25654	Hypercalciuria	Disease	MESH:D053565
25568625	25683	25690	calcium	Chemical	MESH:D002118
25568625	25257	25270	kidney stones	Disease	MESH:D007669
25568625	25507	25520	hyperoxaluria	Disease	MESH:D006959
25568625	25602	25609	calcium	Chemical	MESH:D002118
25568625	25787	25796	uric acid	Chemical	MESH:D014527
25568625	25843	25852	uric acid	Chemical	MESH:D014527
25568625	25160	25182	renal tubular acidosis	Disease	MESH:D000141
25568625	25439	25460	cystine kidney stones	Disease	MESH:D007669
25568625	25042	25062	hereditary disorders	Disease	MESH:D030342
25568625	25374	25381	cystine	Chemical	MESH:D003553
25568625	25118	25131	kidney stones	Disease	MESH:D007669
25568625	25752	25767	Hiperuricosuria	Disease	
25568625	25625	25638	kidney stones	Disease	MESH:D007669
25568625	25553	25560	oxalate	Chemical	MESH:D010070
25568625	25737	25750	kidney stones	Disease	MESH:D007669
25568625	26138	26145	oxalate	Chemical	MESH:D010070
25568625	25914	25920	sodium	Chemical	MESH:D012964
25568625	26111	26118	calcium	Chemical	MESH:D002118
25568625	25943	25950	oxalate	Chemical	MESH:D010070
25568625	25990	25997	calcium	Chemical	MESH:D002118
25568625	26290	26298	patients	Species	9606
25568625	26751	26759	patients	Species	9606
25568625	26477	26489	urolithiasis	Disease	MESH:D052878
25568625	26798	26810	urolithiasis	Disease	MESH:D052878
25568625	26336	26348	urolithiasis	Disease	MESH:D052878
25568625	26261	26273	urolithiasis	Disease	MESH:D052878
25568625	27080	27088	patients	Species	9606
25568625	27157	27165	patients	Species	9606
25568625	27256	27261	males	Species	9606
25568625	27126	27138	urolithiasis	Disease	MESH:D052878
25568625	27753	27765	renal damage	Disease	MESH:D007674
25568625	28225	28242	urinary infection	Disease	MESH:D001745
25568625	27996	28016	urolythiasis depends	Disease	MESH:D000437
25568625	28320	28328	patients	Species	9606
25568625	28368	28372	male	Species	9606
25568625	28406	28410	male	Species	9606
25568625	28486	28494	patients	Species	9606
25568625	28578	28581	men	Species	9606
25568625	28589	28594	women	Species	9606
25568625	28500	28512	urolithiasis	Disease	MESH:D052878
25568625	28655	28659	male	Species	9606
25568625	28701	28709	patients	Species	9606
25568625	28730	28737	calcium	Chemical	MESH:D002118
25568625	28779	28786	calcium	Chemical	MESH:D002118
25568625	28676	28683	calcium	Chemical	MESH:D002118
25568625	29315	29327	urolithiasis	Disease	MESH:D052878
25568625	29871	29884	Stone Disease	Disease	MESH:D007669
25568625	29942	29968	Hirurgija mokracnih organa	Disease	
25568625	30025	30033	children	Species	9606
25568625	30044	30052	calculus	Disease	MESH:D002137
25568625	30057	30076	acute renal failure	Disease	MESH:D058186
25568625	30101	30117	Ureteal Calculus	Disease	MESH:D002137
25568625	30177	30189	urolithiasis	Disease	MESH:D052878
25568625	30344	30357	kidney stones	Disease	MESH:D007669
25568625	30386	30411	Diabetes and calculations	Disease	MESH:D003920
25568625	30517	30530	kidney stones	Disease	MESH:D007669
25568625	30509	30516	Calcium	Chemical	MESH:D002118
25568625	30549	30562	stone disease	Disease	MESH:D007669

25568583|t|Outcome of Endovenous Laser Ablation of Varicose Veins 
25568583|a|ABSTRACT Introduction: In Bosnia and Herzegovina according to available data, treatment of incompetent superficial lower extremity varicose veins by endovenous laser ablation (EVLA) has been introduced two years ago and so far no paper has been published regarding results of EVLA treatment of patients from our country. We wanted to present our results with EVLA treatment. Aim of study: to evaluate and compare primary posttreatment outcomes of endovenous laser ablation (EVLA) with classical surgical method of varicose vein treatment. Patients and methods: The study was clinical and prospective. It was carried out at Clinic for vascular surgery in Sarajevo where fifty-eight (58) patients received surgical treatment for varicose veins and in Aesthetic Surgery Center "Nasa mala klinika" in Sarajevo were sixty-one (61) patients with varicose veins were treated by endovenous laser ablation. Total 119 patients (limbs) with pathologic reflux only in great saphenous vein were evaluated between 1st of January 2013 and 31st of April 2014. Following primary outcome endpoints were evaluated smean day of return to normal everyday activities, patient subjective quantification of pain during first seven days after intervention, incidence of deep venous thrombosis (DVT), incidence of wound bleeding requiring surgical intervention, incidence of peri-saphenous vein hematoma and infection rate. Results: Mean of return to normal activities (expressed in days after intervention); EVLA vs. stripping (surgery) =1.21vs12.24, T test 13,619; p=0, 000, p<0,05. T test was used for comparing Mean value of visual pain analog scale for the first 7 days between groups, for all seven days pain was significantly higher in surgical group of patients as compared to EVLA group; p<0,05. Incidence of hematoma greater than 1% of total body surface area was significantly higher in patients receiving surgical treatment; Pearson Chi Square=23,830, p<0,05; odds ratio:10,453. Incidences of infection, deep venous thrombosis and posttreatment bleeding were not statistically different between analyzed groups; EVLA vs Surgery (Pearson Chi Square =3,237; p>0,05; Pearson Chi Square=2,139, p>0,05, Pearson Chi Square=2,139, p>0,05, respectively.) Conclusion: EVLA offers better patient recovery in terms of significantly lower post treatment pain, faster return to everyday activities and lower incidence of bruising (hematomas). 
25568583	40	48	Varicose	Chemical	MESH:C077381
25568583	349	357	patients	Species	9606
25568583	594	602	Patients	Species	9606
25568583	741	749	patients	Species	9606
25568583	881	889	patients	Species	9606
25568583	963	971	patients	Species	9606
25568583	1201	1208	patient	Species	9606
25568583	1349	1357	bleeding	Disease	MESH:D006470
25568583	1324	1327	DVT	Disease	MESH:D020246
25568583	1300	1322	deep venous thrombosis	Disease	MESH:D020246
25568583	1419	1446	vein hematoma and infection	Disease	MESH:D006406
25568583	1238	1242	pain	Disease	MESH:D010146
25568583	1794	1802	patients	Species	9606
25568583	1931	1939	patients	Species	9606
25568583	2049	2071	deep venous thrombosis	Disease	MESH:D020246
25568583	1662	1673	visual pain	Disease	MESH:D014786
25568583	2038	2047	infection	Disease	MESH:D007239
25568583	1743	1747	pain	Disease	MESH:D010146
25568583	1851	1859	hematoma	Disease	MESH:D006406
25568583	2090	2098	bleeding	Disease	MESH:D006470
25568583	2323	2330	patient	Species	9606
25568583	2453	2461	bruising	Disease	MESH:D003288
25568583	2463	2472	hematomas	Disease	MESH:D006406
25568583	2387	2391	pain	Disease	MESH:D010146
25568583	2648	2651	SSV	Species	10836
25568583	3352	3365	vein hematoma	Disease	MESH:D006406
25568583	3324	3332	bleeding	Disease	MESH:D006470
25568583	3286	3304	postoperative pain	Disease	MESH:D010149
25568583	3217	3261	aggressiveness of avulsion of saphenous vein	Disease	MESH:D001523
25568583	3401	3410	infection	Disease	MESH:D007239
25568583	3650	3657	patient	Species	9606
25568583	3664	3668	EVLA	Chemical	
25568583	3912	3920	patients	Species	9606
25568583	4261	4269	PATIENTS	Species	9606
25568583	4390	4398	patients	Species	9606
25568583	4572	4580	patients	Species	9606
25568583	4715	4723	patients	Species	9606
25568583	4880	4888	patients	Species	9606
25568583	5102	5109	patient	Species	9606
25568583	5602	5610	patients	Species	9606
25568583	5720	5727	patient	Species	9606
25568583	5925	5932	patient	Species	9606
25568583	6135	6142	patient	Species	9606
25568583	6255	6263	Patients	Species	9606
25568583	6378	6382	Pain	Disease	MESH:D010146
25568583	5225	5228	DVT	Disease	MESH:D020246
25568583	6335	6343	hematoma	Disease	MESH:D006406
25568583	5201	5223	deep venous thrombosis	Disease	MESH:D020246
25568583	6451	6455	pain	Disease	MESH:D010146
25568583	6303	6311	hematoma	Disease	MESH:D006406
25568583	5250	5258	bleeding	Disease	MESH:D006470
25568583	5139	5143	pain	Disease	MESH:D010146
25568583	5320	5347	vein hematoma and infection	Disease	MESH:D006406
25568583	6475	6479	pain	Disease	MESH:D010146
25568583	5767	5771	pain	Disease	MESH:D010146
25568583	5948	5956	Hematoma	Disease	MESH:D006406
25568583	6516	6520	pain	Disease	MESH:D010146
25568583	7018	7025	patient	Species	9606
25568583	7088	7095	patient	Species	9606
25568583	7377	7385	patients	Species	9606
25568583	7426	7434	patients	Species	9606
25568583	7543	7551	patients	Species	9606
25568583	7650	7654	calf	Species	9913
25568583	8435	8443	patients	Species	9606
25568583	9035	9043	patients	Species	9606
25568583	9116	9124	patients	Species	9606
25568583	9336	9344	patients	Species	9606
25568583	9378	9386	patients	Species	9606
25568583	7901	7911	skin ulcer	Disease	MESH:D012883
25568583	7988	8004	arterial disease	Disease	MESH:D003324
25568583	6589	6611	deep venous thrombosis	Disease	MESH:D020246
25568583	7807	7816	phlebitis	Disease	MESH:D010689
25568583	7078	7081	DVT	Disease	MESH:D020246
25568583	6770	6778	bleeding	Disease	MESH:D006470
25568583	6861	6869	bleeding	Disease	MESH:D006470
25568583	7942	7964	deep venous thrombosis	Disease	MESH:D020246
25568583	7966	7983	diabetes mellitus	Disease	MESH:D003920
25568583	7880	7897	hyperpigmentation	Disease	MESH:D017495
25568583	7766	7773	allergy	Disease	MESH:D004342
25568583	8683	8692	Lidocaine	Chemical	MESH:D008012
25568583	9244	9259	povidone-iodine	Chemical	MESH:D011206
25568583	7777	7786	lidocaine	Chemical	MESH:D008012
25568583	6663	6671	bleeding	Disease	MESH:D006470
25568583	6613	6616	DVT	Disease	MESH:D020246
25568583	10491	10499	patients	Species	9606
25568583	10440	10444	pain	Disease	MESH:D010146
25568583	10352	10363	visual pain	Disease	MESH:D014786
25568583	10014	10022	hematoma	Disease	MESH:D006406
25568583	10841	10852	visual pain	Disease	MESH:D014786
25568583	10992	11000	patients	Species	9606
25568583	10912	10920	hematoma	Disease	MESH:D006406
25568583	11407	11415	hematoma	Disease	MESH:D006406
25568583	11472	11481	infection	Disease	MESH:D007239
25568583	11501	11509	bleeding	Disease	MESH:D006470
25568583	11542	11564	deep venous thrombosis	Disease	MESH:D020246
25568583	11828	11836	patients	Species	9606
25568583	12005	12008	DVT	Disease	MESH:D020246
25568583	12112	12119	patient	Species	9606
25568583	12580	12587	patient	Species	9606
25568583	12650	12658	patients	Species	9606
25568583	12408	12414	trauma	Disease	MESH:D014947
25568583	12334	12338	pain	Disease	MESH:D010146
25568583	13254	13262	hematoma	Disease	MESH:D006406
25568583	12903	12911	bruising	Disease	MESH:D003288
25568583	12894	12898	pain	Disease	MESH:D010146
25568583	12371	12377	trauma	Disease	MESH:D014947
25568583	12172	12183	visual pain	Disease	MESH:D014786
25568583	13607	13615	hematoma	Disease	MESH:D006406
25568583	12257	12261	pain	Disease	MESH:D010146
25568583	12694	12698	pain	Disease	MESH:D010146
25568583	12024	12028	Pain	Disease	MESH:D010146
25568583	13299	13307	hematoma	Disease	MESH:D006406
25568583	12597	12601	pain	Disease	MESH:D010146
25568583	13632	13655	Postoperative hematomas	Disease	MESH:D010149
25568583	13830	13838	patients	Species	9606
25568583	13873	13881	patients	Species	9606
25568583	13885	13893	patients	Species	9606
25568583	14591	14599	patients	Species	9606
25568583	14660	14668	patients	Species	9606
25568583	14857	14865	patients	Species	9606
25568583	15379	15387	patients	Species	9606
25568583	15676	15683	patient	Species	9606
25568583	16176	16184	patients	Species	9606
25568583	14560	14568	bleeding	Disease	MESH:D006470
25568583	13777	13786	infection	Disease	MESH:D007239
25568583	14455	14463	bleeding	Disease	MESH:D006470
25568583	15106	15109	DVT	Disease	MESH:D020246
25568583	14170	14178	bleeding	Disease	MESH:D006470
25568583	15832	15842	thrombosis	Disease	MESH:D013927
25568583	14947	14954	heparin	Chemical	MESH:D006493
25568583	15034	15037	DVT	Disease	MESH:D020246
25568583	15214	15217	DVT	Disease	MESH:D020246
25568583	15501	15505	LMWH	Chemical	MESH:D006495
25568583	15192	15212	deep vein thrombosis	Disease	MESH:D020246
25568583	14776	14779	DVT	Disease	MESH:D020246
25568583	15844	15848	EHIT	Disease	MESH:D013927
25568583	14648	14656	bleeding	Disease	MESH:D006470
25568583	14183	14191	hematoma	Disease	MESH:D006406
25568583	16069	16077	thrombus	Disease	MESH:D013927
25568583	15887	15890	DVT	Disease	MESH:D020246
25568583	14811	14821	crural DVT	Disease	MESH:D020246
25568583	16276	16284	patients	Species	9606
25568583	16463	16472	hematomas	Disease	MESH:D006406
25568583	16453	16461	bruising	Disease	MESH:D003288
25568583	16387	16391	pain	Disease	MESH:D010146
25568583	16592	16600	bleeding	Disease	MESH:D006470
25568583	16602	16611	infection	Disease	MESH:D007239
25568583	16620	16623	DVT	Disease	MESH:D020246
25568583	16861	16865	CEAP	Gene	282991
25568583	16663	16671	patients	Species	9606
25568583	16804	16812	patients	Species	9606
25568583	16894	16901	patient	Species	9606
25568583	16954	16958	pain	Disease	MESH:D010146
25568583	18247	18255	patients	Species	9606
25568583	18261	18269	varicose	Chemical	MESH:C077381
25568583	18636	18646	Thrombosis	Disease	MESH:D013927
25568583	18668	18671	DVT	Disease	MESH:D020246
25568583	18558	18561	DVT	Disease	MESH:D020246
25568583	18536	18556	Deep Vein Thrombosis	Disease	MESH:D020246
25568583	18856	18864	patients	Species	9606
25568583	18789	18811	venous thromboembolism	Disease	MESH:D054556
25568583	18910	18930	deep vein thrombosis	Disease	MESH:D020246

25568577|t|Preoperative Kidney Tumor Embolization as Procedure for Therapy of Advanced Kidney Cancer 
25568577|a|ABSTRACT Introduction: Preoperative kidney tumor embolization is standard procedure for therapy in advanced kidney cancer. Preoperative embolization has a goal to reduce intraoperative bleeding and also to shorten the time of surgery. Materials and methods: We retrospectively observed 50 patients between 2000-2011, in which the preoperative embolization was performed. Mean age of patients was 64 years. All patients with preoperative embolization were compared with the group of 51 patients from Urology Sarajevo, who underwent nephrectomy without preoperative embolization. Results: Symptoms that are dominating among patients were haematuria and pain. Analysis of mean size of tumors based on CT evaluation showed statistically significance in between the biggest size of tumors in group from Hamburg (9.11+-3cm) and the smallest size of tumors in Sarajevo group (4.94+-1.6cm) p=0.0001. Reason for this is difference in selection of patients for treatment in Hamburg from Sarajevo. Conclusion Kidney as functional finishing organ is extremely suitable for transcatheter therapeutic procedures. The gold standard in the treatment of advanced and metastatic tumor is the nephrectomy. As preparation for nephrectomy in metastatic cancer total capillary embolization is performed. After embolization, surgery is shorter, procedure can be done 24-48 hours after embolization or delayed nephrectomy done 2-3 weeks after the intervention. 
25568577	76	89	Kidney Cancer	Disease	MESH:D007680
25568577	13	25	Kidney Tumor	Disease	MESH:D007680
25568577	260	283	intraoperative bleeding	Disease	MESH:D016063
25568577	198	211	kidney cancer	Disease	MESH:D007680
25568577	126	151	kidney tumor embolization	Disease	MESH:D009360
25568577	379	387	patients	Species	9606
25568577	473	481	patients	Species	9606
25568577	500	508	patients	Species	9606
25568577	575	583	patients	Species	9606
25568577	712	720	patients	Species	9606
25568577	1028	1036	patients	Species	9606
25568577	867	873	tumors	Disease	MESH:D009369
25568577	772	778	tumors	Disease	MESH:D009369
25568577	933	939	tumors	Disease	MESH:D009369
25568577	726	745	haematuria and pain	Disease	MESH:D010146
25568577	1251	1256	tumor	Disease	MESH:D009369
25568577	1452	1464	embolization	Disease	MESH:D004617
25568577	1322	1328	cancer	Disease	MESH:D009369
25568577	1713	1736	end stage kidney cancer	Disease	MESH:D007676
25568577	1691	1704	kidney cancer	Disease	MESH:D007680
25568577	1677	1683	tumors	Disease	MESH:D009369
25568577	1655	1665	malignancy	Disease	MESH:D009369
25568577	1576	1588	kidney tumor	Disease	MESH:D007680
25568577	1543	1556	Kidney cancer	Disease	MESH:D007680
25568577	2156	2162	humans	Species	9606
25568577	2137	2151	tumor necrosis	Disease	MESH:D009336
25568577	1932	1945	kidney cancer	Disease	MESH:D007680
25568577	1866	1891	Kidney tumor embolization	Disease	MESH:D009360
25568577	2321	2327	tumors	Disease	MESH:D009369
25568577	2564	2572	patients	Species	9606
25568577	2529	2547	tumor embolization	Disease	MESH:D009360
25568577	2597	2602	tumor	Disease	MESH:D009369
25568577	2663	2676	venous system	Disease	MESH:D020246
25568577	2701	2714	kidney hillus	Disease	MESH:D007674
25568577	2715	2732	Metastatic tumors	Disease	MESH:D018223
25568577	2737	2745	Patients	Species	9606
25568577	3008	3034	infiltration of renal vein	Disease	MESH:D059228
25568577	2841	2864	intraoperative bleeding	Disease	MESH:D016063
25568577	2995	3001	tumors	Disease	MESH:D009369
25568577	2936	2941	tumor	Disease	MESH:D009369
25568577	3115	3123	patients	Species	9606
25568577	3213	3221	patients	Species	9606
25568577	3312	3320	patients	Species	9606
25568577	3368	3376	patients	Species	9606
25568577	3396	3404	patients	Species	9606
25568577	3410	3414	male	Species	9606
25568577	3416	3424	Patients	Species	9606
25568577	3462	3470	patients	Species	9606
25568577	3540	3548	patients	Species	9606
25568577	3480	3485	tumor	Disease	MESH:D009369
25568577	3560	3582	bilateral kidney tumor	Disease	MESH:D007680
25568577	3584	3592	Patients	Species	9606
25568577	3632	3640	patients	Species	9606
25568577	3726	3733	patient	Species	9606
25568577	3769	3777	patients	Species	9606
25568577	3923	3927	male	Species	9606
25568577	4003	4011	patients	Species	9606
25568577	4021	4029	Patients	Species	9606
25568577	4096	4104	patients	Species	9606
25568577	3677	3682	tumor	Disease	MESH:D009369
25568577	3646	3651	tumor	Disease	MESH:D009369
25568577	5009	5017	patients	Species	9606
25568577	4713	4720	alcohol	Chemical	MESH:D000431
25568577	5110	5117	alcohol	Chemical	MESH:D000431
25568577	4753	4760	Alcohol	Chemical	MESH:D000431
25568577	4992	4999	alcohol	Chemical	MESH:D000431
25568577	4407	4413	tumors	Disease	MESH:D009369
25568577	4844	4851	alcohol	Chemical	MESH:D000431
25568577	5334	5339	tumor	Disease	MESH:D009369
25568577	6159	6166	patient	Species	9606
25568577	6225	6233	patients	Species	9606
25568577	6271	6279	patients	Species	9606
25568577	6313	6321	patients	Species	9606
25568577	6421	6429	patients	Species	9606
25568577	6443	6451	patients	Species	9606
25568577	6518	6526	patients	Species	9606
25568577	6598	6606	patients	Species	9606
25568577	6657	6664	patient	Species	9606
25568577	6842	6850	patients	Species	9606
25568577	6899	6907	patients	Species	9606
25568577	6993	7001	patients	Species	9606
25568577	7266	7274	patients	Species	9606
25568577	7299	7307	patients	Species	9606
25568577	7380	7388	patients	Species	9606
25568577	6719	6724	tumor	Disease	MESH:D009369
25568577	7336	7346	metastases	Disease	MESH:D009362
25568577	6832	6838	tumors	Disease	MESH:D009369
25568577	7086	7096	metastases	Disease	MESH:D009362
25568577	6476	6490	tumor thrombus	Disease	MESH:D013927
25568577	7406	7416	Haematuria	Disease	MESH:D006417
25568577	7443	7447	pain	Disease	MESH:D010146
25568577	7497	7505	patients	Species	9606
25568577	7871	7879	patients	Species	9606
25568577	7922	7930	patients	Species	9606
25568577	8100	8108	patients	Species	9606
25568577	7832	7837	tumor	Disease	MESH:D009369
25568577	8086	8091	tumor	Disease	MESH:D009369
25568577	7787	7792	tumor	Disease	MESH:D009369
25568577	8204	8212	patients	Species	9606
25568577	8254	8262	patients	Species	9606
25568577	8876	8883	alcohol	Chemical	MESH:D000431
25568577	8895	8903	lipiodol	Chemical	MESH:D004998
25568577	9072	9084	kidney tumor	Disease	MESH:D007680
25568577	9184	9197	kidney cancer	Disease	MESH:D007680
25568577	9422	9430	patients	Species	9606
25568577	9665	9673	children	Species	9606
25568577	9523	9534	Wilms tumor	Disease	MESH:D009396
25568577	9536	9547	Wilms tumor	Disease	MESH:D009396
25568577	9700	9712	renal cancer	Disease	MESH:D007680
25568577	9650	9661	Wilms tumor	Disease	MESH:D009396
25568577	9750	9760	blood loss	Disease	MESH:D006473
25568577	9809	9814	tumor	Disease	MESH:D009369
25568577	10444	10454	blood loss	Disease	MESH:D006473
25568577	10067	10090	Intraoperative bleeding	Disease	MESH:D016063
25568577	9915	9960	decisive loss of blood atypical blood vessels	Disease	MESH:D009383
25568577	10260	10266	tumors	Disease	MESH:D009369
25568577	11204	11212	patients	Species	9606
25568577	11257	11265	patients	Species	9606
25568577	10704	10721	venous thrombosis	Disease	MESH:D020246
25568577	10584	10590	cancer	Disease	MESH:D009369
25568577	10676	10681	tumor	Disease	MESH:D009369
25568577	10596	10617	vascularized thrombus	Disease	MESH:D013927
25568577	10502	10512	blood loss	Disease	MESH:D006473
25568577	12088	12095	patient	Species	9606
25568577	12741	12749	patients	Species	9606
25568577	12765	12782	balloon occlusion	Disease	MESH:D054549
25568577	12714	12721	alcohol	Chemical	MESH:D000431
25568577	11883	11890	alcohol	Chemical	MESH:D000431
25568577	12116	12133	balloon occlusion	Disease	MESH:D054549
25568577	12325	12332	alcohol	Chemical	MESH:D000431
25568577	11388	11395	Alcohol	Chemical	MESH:D000431
25568577	12262	12269	alcohol	Chemical	MESH:D000431
25568577	11371	11378	alcohol	Chemical	MESH:D000431
25568577	11565	11572	Alcohol	Chemical	MESH:D000431
25568577	12042	12049	alcohol	Chemical	MESH:D000431
25568577	12503	12510	alcohol	Chemical	MESH:D000431
25568577	12899	12906	alcohol	Chemical	MESH:D000431
25568577	12798	12805	alcohol	Chemical	MESH:D000431
25568577	12653	12675	branch of renal artery	Disease	MESH:D007674
25568577	11489	11506	balloon occlusion	Disease	MESH:D054549
25568577	11752	11766	tumor necrosis	Disease	MESH:D009336
25568577	13332	13350	occlusion balloons	Disease	MESH:D054549
25568577	12980	12987	alcohol	Chemical	MESH:D000431
25568577	13139	13148	vasospasm	Disease	MESH:D020301
25568577	13627	13634	alcohol	Chemical	MESH:D000431
25568577	13016	13023	alcohol	Chemical	MESH:D000431
25568577	13501	13520	Ivalon embolization	Disease	MESH:D004617
25568577	13883	13891	patients	Species	9606
25568577	13961	13969	patients	Species	9606
25568577	14018	14026	patients	Species	9606
25568577	14153	14161	patients	Species	9606
25568577	14199	14207	patients	Species	9606
25568577	14487	14495	patients	Species	9606
25568577	14611	14619	patients	Species	9606
25568577	14850	14858	patients	Species	9606
25568577	14961	14969	patients	Species	9606
25568577	15140	15148	patients	Species	9606
25568577	15168	15176	patients	Species	9606
25568577	14721	14729	Lipiodol	Chemical	MESH:D004998
25568577	14432	14455	reduction of blood loss	Disease	MESH:D007022
25568577	15304	15312	patients	Species	9606
25568577	15392	15400	patients	Species	9606
25568577	15448	15455	patient	Species	9606
25568577	15601	15609	patients	Species	9606
25568577	15661	15669	patients	Species	9606
25568577	16634	16642	patients	Species	9606
25568577	16775	16783	patients	Species	9606
25568577	16805	16813	patients	Species	9606
25568577	15920	15933	kidney cancer	Disease	MESH:D007680
25568577	16220	16227	alcohol	Chemical	MESH:D000431
25568577	16159	16166	alcohol	Chemical	MESH:D000431
25568577	16311	16319	Lipiodol	Chemical	MESH:D004998
25568577	16403	16421	thru less bleeding	Disease	MESH:D006470
25568577	15719	15732	Kidney cancer	Disease	MESH:D007680
25568577	16000	16011	small tumor	Disease	MESH:D058405
25568577	15745	15750	tumor	Disease	MESH:D009369
25568577	16030	16035	tumor	Disease	MESH:D009369
25568577	17013	17019	tumors	Disease	MESH:D009369
25568577	16992	16999	infarct	Disease	MESH:D007238
25568577	17033	17053	renal adenocarcinoma	Disease	MESH:D002292
25568577	17057	17099	embolic occlusion of the renal circulation	Disease	MESH:D007674
25568577	17100	17122	Nierentumoremboisation	Disease	
25568577	17147	17155	children	Species	9606
25568577	17123	17143	Renal cell carcinoma	Disease	MESH:D002292
25568577	17225	17233	children	Species	9606
25568577	17201	17221	Renal cell carcinoma	Disease	MESH:D002292
25568577	17258	17271	Nephroblastom	Disease	
25568577	17365	17378	kidney tumors	Disease	MESH:D007680
25568577	17379	17409	Preopertive renal embolization	Disease	MESH:D007674
25568577	17478	17485	ethanol	Chemical	MESH:D000431
25568577	17502	17517	renal carcinoma	Disease	MESH:D002292
25568577	17555	17575	renal cell carcinoma	Disease	MESH:D002292
25568577	17614	17634	renal cell carcinoma	Disease	MESH:D002292
25568577	17719	17761	Embolization von Nierentumoren mit Athanol	Disease	MESH:D004617
25568577	18050	18081	Nephrektomie wegen Hypernephrom	Disease	MESH:D014890
25568577	18139	18159	renal cell carcinoma	Disease	MESH:D002292
25568577	18314	18334	renal cell carcinoma	Disease	MESH:D002292
25568577	18222	18247	renal artery embolization	Disease	MESH:D007674
25568577	18535	18555	renal cell carcinoma	Disease	MESH:D002292
25568577	18556	18605	Palliative capillary embolization renal carcinoma	Disease	MESH:D002292
25568577	18706	18717	renal tumor	Disease	MESH:D007680
25568577	18734	18753	capillary occlusion	Disease	OMIM:163000
25568577	18814	18829	renal carcinoma	Disease	MESH:D002292
25568577	18908	18920	Embolization	Disease	MESH:D004617
25568577	18921	18953	Einfluss der Nierenocclusion auf	Disease	MESH:C535733
25568577	19072	19084	renal tumors	Disease	MESH:D007680
25568577	19085	19110	Renal artery embolization	Disease	MESH:D007674

25568624|t|Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes 
25568624|a|Background: Accurate prediction of a patient's prognosis is useful to define the risk posed by the disease. Age, gender, peripheral blood cytopenia, proportion of bone marrow (BM) blasts, performance status, comorbidities, transfusion dependence, specific karyotype abnormalities and molecular biomarkers can refine the prediction of prognosis in MDS. Aim: to assess the influence of the some prognostic factors like age, gender, cytopenia, BM blast percentage, transfusion dependence, ferritin, hemoglobin (Hb), lactate dehydrogenase (LDH), albumin and specific karyotype abnormalities in myelodysplastic syndromes on overall survival (OS). Patients and methods: we retrospectively analyzed the cohort of 108 patients diagnosed between 1.1.2011 and 31.12.2013 at the University Clinic of Hematology, Ss Cyril and Methodius University, Skopje, Macedonia. They were evaluated for clinical and hematologic features at diagnosis and at leukemic transformation. Results: in the study group 62 were man and 46 women. Male to female ratio was 1.35 to 1. The differences in OS between men and women were significant (p = .03015). The mean age at diagnosis was 66,6 years. According to the age OS was 16,4 months. FAB subtypes influenced OS significantly (p = .03015). OS inversely correlated with BM blast percentage (p= .02327). Cytopenia had no impact on OS (p=.33755). Hb as a whole and groups with different levels of Hb had no influence on OS (p = .12142) and (p= .07535), respectively. The group with ferritin <500 microg/L had better OS (p=.04720). Transfusion dependence, LDH and albumin had no impact on OS. Leukemic transformation was noticed in 10 (9,3%) patients. Mortality was 36,1%. Conclusion: gender, FAB subtypes, BM blast percentage and the serum levels of ferritin had an influence on OS, while age, hemoglobin level, transfusion dependence, LDH and albumin had no impact on OS. 
25568624	54	79	Myelodysplastic Syndromes	Disease	MESH:D009190
25568624	117	124	patient	Species	9606
25568624	243	254	bone marrow	Disease	MESH:D001855
25568624	346	359	abnormalities	Disease	MESH:D002869
25568624	427	430	MDS	Disease	MESH:D009190
25568624	256	258	BM	Disease	MESH:D001855
25568624	212	227	blood cytopenia	Disease	MESH:D006402
25568624	510	519	cytopenia	Disease	MESH:D006402
25568624	593	600	lactate	Chemical	MESH:D019344
25568624	670	695	myelodysplastic syndromes	Disease	MESH:D009190
25568624	521	523	BM	Disease	MESH:D001855
25568624	722	730	Patients	Species	9606
25568624	790	798	patients	Species	9606
25568624	1013	1021	leukemic	Disease	MESH:D007938
25568624	1074	1077	man	Species	9606
25568624	1085	1090	women	Species	9606
25568624	1092	1096	Male	Species	9606
25568624	1158	1161	men	Species	9606
25568624	1166	1171	women	Species	9606
25568624	1739	1747	patients	Species	9606
25568624	1370	1372	BM	Disease	MESH:D001855
25568624	1403	1412	Cytopenia	Disease	MESH:D006402
25568624	1804	1806	BM	Disease	MESH:D001855
25568624	2261	2283	acute myeloid leukemia	Disease	MESH:D015470
25568624	2076	2085	dysplasia	Disease	MESH:D015792
25568624	1987	2012	Myelodysplastic syndromes	Disease	MESH:D009190
25568624	2014	2018	MDSs	Disease	MESH:D009190
25568624	2199	2219	peripheral cytopenia	Disease	MESH:D010523
25568624	2285	2288	AML	Disease	MESH:D015470
25568624	2503	2511	patients	Species	9606
25568624	2551	2558	patient	Species	9606
25568624	2864	2872	patients	Species	9606
25568624	3040	3047	patient	Species	9606
25568624	3469	3477	patients	Species	9606
25568624	3570	3572	BM	Disease	MESH:D001855
25568624	3761	3764	MDS	Disease	MESH:D009190
25568624	3601	3640	cytopenia and cytogenetic abnormalities	Disease	MESH:D002869
25568624	3394	3397	MDS	Disease	MESH:D009190
25568624	3292	3295	MDS	Disease	MESH:D009190
25568624	3852	3858	anemia	Disease	MESH:D000740
25568624	4332	4335	B12	Gene	4709
25568624	4402	4419	arsenic poisoning	Disease	MESH:D020261
25568624	4024	4026	BM	Disease	MESH:D001855
25568624	4343	4360	copper deficiency	Disease	MESH:C535468
25568624	4362	4378	viral infections	Disease	MESH:D014777
25568624	4200	4209	dysplasia	Disease	MESH:D015792
25568624	4288	4307	erythroid dysplasia	Disease	MESH:C538442
25568624	4336	4342	folate	Chemical	MESH:D005492
25568624	4780	4784	RARS	Gene	5917
25568624	4506	4514	children	Species	9606
25568624	4785	4793	patients	Species	9606
25568624	4773	4775	RA	Disease	MESH:D001172
25568624	4576	4579	MDS	Disease	MESH:D009190
25568624	4491	4494	MDS	Disease	MESH:D009190
25568624	4443	4456	MDS increases	Disease	MESH:D009190
25568624	4980	4985	males	Species	9606
25568624	5016	5020	Male	Species	9606
25568624	5021	5029	patients	Species	9606
25568624	5172	5180	patients	Species	9606
25568624	5127	5136	cytopenia	Disease	MESH:D006402
25568624	4954	4957	MDS	Disease	MESH:D009190
25568624	5313	5321	patients	Species	9606
25568624	5369	5372	MDS	Disease	MESH:D009190
25568624	5309	5312	MDS	Disease	MESH:D009190
25568624	5433	5439	anemia	Disease	MESH:D000740
25568624	5249	5258	cytopenia	Disease	MESH:D006402
25568624	5553	5561	patients	Species	9606
25568624	5549	5552	MDS	Disease	MESH:D009190
25568624	5640	5670	OS and leukemic transformation	Disease	MESH:D011475
25568624	5591	5593	BM	Disease	MESH:D001855
25568624	5789	5797	patients	Species	9606
25568624	5983	5991	patients	Species	9606
25568624	5849	5852	MDS	Disease	MESH:D009190
25568624	5764	5770	anemia	Disease	MESH:D000740
25568624	5803	5806	MDS	Disease	MESH:D009190
25568624	6263	6271	patients	Species	9606
25568624	6284	6292	patients	Species	9606
25568624	6327	6340	heart failure	Disease	MESH:D006333
25568624	6364	6394	disorders of the thyroid gland	Disease	MESH:D013959
25568624	6342	6350	diabetes	Disease	MESH:D003920
25568624	6707	6715	patients	Species	9606
25568624	6721	6724	MDS	Disease	MESH:D009190
25568624	6549	6552	MDS	Disease	MESH:D009190
25568624	6454	6461	Lactate	Chemical	MESH:D019344
25568624	6726	6741	Hypoalbuminemia	Disease	MESH:D034141
25568624	6477	6480	LDH	Disease	MESH:C580233
25568624	6772	6775	MDS	Disease	MESH:D009190
25568624	6891	6894	MDS	Disease	MESH:D009190
25568624	6866	6869	MDS	Disease	MESH:D009190
25568624	6792	6817	chromosomal abnormalities	Disease	MESH:D002869
25568624	7587	7595	patients	Species	9606
25568624	7628	7636	patients	Species	9606
25568624	7601	7604	MDS	Disease	MESH:D009190
25568624	7883	7891	patients	Species	9606
25568624	8154	8157	MDS	Disease	MESH:D009190
25568624	8330	8333	MDS	Disease	MESH:D009190
25568624	7950	7962	hypertension	Disease	MESH:D006973
25568624	8264	8272	diabetes	Disease	MESH:D003920
25568624	8193	8225	chronic obstructive lung disease	Disease	MESH:D029424
25568624	8164	8188	Congestive heart disease	Disease	MESH:D006333
25568624	7879	7882	MDS	Disease	MESH:D009190
25568624	7797	7810	MDS increases	Disease	MESH:D009190
25568624	7964	7977	lung diseases	Disease	MESH:D008171
25568624	7979	7987	diabetes	Disease	MESH:D003920
25568624	8277	8302	cerebro-vascular diseases	Disease	MESH:D014652
25568624	8023	8029	tumors	Disease	MESH:D009369
25568624	7924	7948	Congestive heart disease	Disease	MESH:D006333
25568624	7989	8002	liver failure	Disease	MESH:D017093
25568624	8004	8012	bleeding	Disease	MESH:D006470
25568624	8402	8410	patients	Species	9606
25568624	8357	8360	MDS	Disease	MESH:D009190
25568624	8416	8419	MDS	Disease	MESH:D009190
25568624	8724	8733	cytopenia	Disease	MESH:D006402
25568624	8684	8709	myelodysplastic syndromes	Disease	MESH:D009190
25568624	8735	8737	BM	Disease	MESH:D001855
25568624	8818	8825	lactate	Chemical	MESH:D019344
25568624	8901	8909	PATIENTS	Species	9606
25568624	8968	8976	patients	Species	9606
25568624	8981	8985	male	Species	9606
25568624	9797	9805	patients	Species	9606
25568624	9909	9917	patients	Species	9606
25568624	9976	9984	patients	Species	9606
25568624	9991	9999	patients	Species	9606
25568624	10219	10227	patients	Species	9606
25568624	10431	10439	patients	Species	9606
25568624	10551	10554	MDS	Disease	MESH:D009190
25568624	10514	10516	BM	Disease	MESH:D001855
25568624	10116	10124	vitamins	Chemical	MESH:C059630
25568624	9605	9614	cytopenia	Disease	MESH:D006402
25568624	10126	10141	corticosteroids	Chemical	MESH:D000305
25568624	10477	10502	hemorrhagic complications	Disease	MESH:D006470
25568624	9691	9694	LDH	Disease	MESH:C580233
25568624	10354	10359	death	Disease	MESH:D003643
25568624	10143	10147	iron	Chemical	MESH:D007501
25568624	9616	9618	BM	Disease	MESH:D001855
25568624	9495	9499	iron	Chemical	MESH:D007501
25568624	9212	9235	leukemic transformation	Disease	MESH:D007938
25568624	9812	9814	BM	Disease	MESH:D001855
25568624	11050	11054	RARS	Gene	5917
25568624	10765	10773	patients	Species	9606
25568624	10779	10782	men	Species	9606
25568624	10795	10800	women	Species	9606
25568624	10802	10806	Male	Species	9606
25568624	10838	10843	Women	Species	9606
25568624	10863	10866	men	Species	9606
25568624	10929	10937	patients	Species	9606
25568624	10969	10977	patients	Species	9606
25568624	11021	11023	RA	Disease	MESH:D000753
25568624	11162	11193	chronic myelomonocytic leukemia	Disease	MESH:D015477
25568624	11106	11112	3-RAEB	Chemical	MESH:C065459
25568624	11007	11009	RA	Disease	MESH:D000753
25568624	11066	11068	RA	Disease	MESH:D000753
25568624	10988	11005	refractory anemia	Disease	MESH:D000753
25568624	11262	11270	patients	Species	9606
25568624	11368	11376	patients	Species	9606
25568624	11382	11384	RA	Disease	MESH:D000753
25568624	11523	11531	patients	Species	9606
25568624	11573	11581	patients	Species	9606
25568624	11613	11621	patients	Species	9606
25568624	11711	11719	patients	Species	9606
25568624	11594	11605	bicytopenia	Disease	
25568624	11559	11568	cytopenia	Disease	MESH:D006402
25568624	11735	11744	cytopenia	Disease	MESH:D006402
25568624	11462	11471	Cytopenia	Disease	MESH:D006402
25568624	11635	11647	pancytopenia	Disease	MESH:D010198
25568624	11773	11775	BM	Disease	MESH:D001855
25568624	12272	12282	Hb <70 g/L	Gene	3956
25568624	12178	12186	patients	Species	9606
25568624	12321	12329	patients	Species	9606
25568624	12366	12374	patients	Species	9606
25568624	12450	12459	anemia-15	Disease	MESH:D000740
25568624	12417	12426	anemia-14	Disease	MESH:D000740
25568624	12264	12270	anemia	Disease	MESH:D000740
25568624	12249	12255	anemia	Disease	MESH:D000740
25568624	12294	12300	anemia	Disease	MESH:D000740
25568624	12824	12832	ferritin	Chemical	MESH:C072979
25568624	13369	13377	patients	Species	9606
25568624	13423	13431	patients	Species	9606
25568624	12881	12884	MDS	Disease	MESH:D009190
25568624	14203	14211	patients	Species	9606
25568624	14226	14234	patients	Species	9606
25568624	14296	14303	patient	Species	9606
25568624	14387	14395	patients	Species	9606
25568624	15054	15062	Patients	Species	9606
25568624	15042	15047	death	Disease	MESH:D003643
25568624	15856	15860	RARS	Gene	5917
25568624	15548	15551	men	Species	9606
25568624	15570	15575	women	Species	9606
25568624	15843	15850	patient	Species	9606
25568624	16678	16686	patients	Species	9606
25568624	16614	16629	Hypoalbuminemia	Disease	MESH:D034141
25568624	15900	15909	Cytopenia	Disease	MESH:D006402
25568624	16674	16677	MDS	Disease	MESH:D009190
25568624	15769	15771	RA	Disease	MESH:D000753
25568624	16066	16068	BM	Disease	MESH:D001855
25568624	16823	16831	patients	Species	9606
25568624	16916	16924	patients	Species	9606
25568624	17191	17199	patients	Species	9606
25568624	17287	17290	LDH	Disease	MESH:C580233
25568624	17524	17552	myeloproliferative neoplasms	Disease	MESH:D009196
25568624	17477	17522	myelodysplastic syndromes and myelodysplastic	Disease	MESH:D009190
25568624	17603	17616	hematopoiesis	Disease	MESH:C536227
25568624	17553	17568	Myelodysplastic	Disease	MESH:D009190
25568624	17665	17690	Myelodysplastic Syndromes	Disease	MESH:D009190
25568624	17731	17756	myelodysplastic syndromes	Disease	MESH:D009190
25568624	17814	17839	myelodysplastic syndromes	Disease	MESH:D009190
25568624	17932	17940	patients	Species	9606
25568624	17893	17897	iron	Chemical	MESH:D007501
25568624	17946	17949	MDS	Disease	MESH:D009190
25568624	18049	18062	myelofibrosis	Disease	MESH:D055728
25568624	17974	17980	anemia	Disease	MESH:D000740
25568624	18011	18036	myelodysplastic syndromes	Disease	MESH:D009190
25568624	18099	18107	patients	Species	9606
25568624	18063	18087	Myelodysplastic syndrome	Disease	MESH:D009190
25568624	18163	18188	Myelodysplastic syndromes	Disease	MESH:D009190
25568624	18231	18256	myelodysplastic syndromes	Disease	MESH:D009190
25568624	18306	18314	patients	Species	9606
25568624	18320	18345	myelodysplastic syndromes	Disease	MESH:D009190
25568624	18281	18287	anemia	Disease	MESH:D000740
25568624	18433	18458	Myelodysplastic syndromes	Disease	MESH:D009190
25568624	18584	18599	Myelodysplastic	Disease	MESH:D009190
25568624	18676	18701	myelodysplastic syndromes	Disease	MESH:D009190
25568624	18658	18662	iron	Chemical	MESH:D007501
25568624	18751	18783	Complications of Myelodysplastic	Disease	MESH:D009190
25568624	18884	18892	patients	Species	9606
25568624	18920	18923	MDS	Disease	MESH:D009190
25568624	18928	18943	aplastic anemia	Disease	MESH:D000741
25568624	18978	18982	iron	Chemical	MESH:D007501
25568624	19032	19040	patients	Species	9606
25568624	19068	19092	myelodysplastic syndrome	Disease	MESH:D009190
25568624	19015	19019	Iron	Chemical	MESH:D007501
25568624	19193	19201	patients	Species	9606
25568624	19207	19232	myelodysplastic syndromes	Disease	MESH:D009190
25568624	19145	19152	lactate	Chemical	MESH:D019344
25568624	19233	19250	Hypoalbuminenemia	Disease	
25568624	19311	19336	myelodysplastic syndromes	Disease	MESH:D009190
25568624	19385	19410	myelodysplastic syndromes	Disease	MESH:D009190
25568624	19433	19438	ASXL1	Gene	171023
25568624	19440	19443	CBL	Gene	867
25568624	19445	19449	FLT3	Gene	2322
25568624	19451	19455	IDH1	Gene	3417
25568624	19456	19460	IDH2	Gene	3418
25568624	19462	19466	JAK2	Gene	3717
25568624	19468	19472	KRAS	Gene	3845
25568624	19474	19478	NPM1	Gene	4869
25568624	19480	19484	NRAS	Gene	4893
25568624	19486	19491	RUNX1	Gene	861
25568624	19493	19497	TET2	Gene	54790
25568624	19502	19505	WT1	Gene	7490
25568624	19515	19540	myelodysplastic syndromes	Disease	MESH:D009190
25568624	19551	19568	myeloid leukemias	Disease	MESH:D007951
25568624	19596	19621	Myelodysplastic Syndromes	Disease	MESH:D009190
25568624	19732	19756	myelodysplastic syndrome	Disease	MESH:D009190
25568624	19867	19903	myeloid neoplasms and acute leukemia	Disease	MESH:D015470
25568624	19937	19952	Myelodysplastic	Disease	MESH:D009190
25568624	20055	20063	patients	Species	9606
25568624	20093	20117	myelodysplastic syndrome	Disease	MESH:D009190
25568624	20180	20200	myelogenous leukemia	Disease	MESH:D007951
25568624	20225	20250	myelodysplastic syndromes	Disease	MESH:D009190
25568624	20295	20320	myelodysplastic syndromes	Disease	MESH:D009190
25568624	20375	20403	myeloproliferative disorders	Disease	MESH:D009196
25568624	20337	20362	myelodysplastic syndromes	Disease	MESH:D009190
25568624	20630	20638	patients	Species	9606
25568624	20644	20677	primary myelodysplastic syndromes	Disease	MESH:D009190
25568624	20679	20682	MDS	Disease	MESH:D009190
25568624	20737	20745	patients	Species	9606
25568624	20759	20784	myelodysplastic syndromes	Disease	MESH:D009190
25568624	20856	20872	thrombocytopenia	Disease	MESH:D013921
25568624	20885	20909	myelodysplastic syndrome	Disease	MESH:D009190
25568624	20793	20808	Myelodysplastic	Disease	MESH:D009190
25568624	20914	20939	Myelodysplastic Syndromes	Disease	MESH:D009190
25568624	21000	21008	patients	Species	9606
25568624	21026	21041	myelodysplastic	Disease	MESH:D009190
25568624	21065	21076	azacitidine	Chemical	MESH:D001374
25568624	21119	21134	Myelodysplastic	Disease	MESH:D009190
25568624	21242	21267	Myelodysplastic syndromes	Disease	MESH:D009190

25568575|t|The Perceptions of Professionalism by 1st and 5th Grade Medical Students 
25568575|a|ABSTRACT Introduction: Professionalism is essential for the development of mature physicians but not much education is devoted to that theme. Aim: We aimed to determine the views of undergraduate medical students on medical professionalism. Methods: This was a qualitative study, based on focus groups of the first and fifth-year undergraduate medical students. Transcripts of the focus groups were independently evaluated by two researches. Segments of transcripts, identified as important, were marked as verbatims. A grounded theory method with open coding was applied. A list of codes was developed and reviewed by both researchers until the consensus was reached. Then, the codes were reviewed and put into the categories and dimensions. Results: Students recognized 10 main medical professionalism dimensions (empathy, respect, responsibility, autonomy, trust, communication, difference between professional and private life, team work, partnership) and two dimensions associated with it (physician's characteristics, external factors). Slight change of the attitudes towards a more self-centred future physicians' figure was observed in the fifth-year medical students. Conclusion: The students have an appropriate picture of the physicians' figure even at the beginning of their medical studies but still needs an education in professionalism. It seems that the fifth-year students perceive physicians as more self-centred when compared to their first-year colleagues. 
25568575	889	896	empathy	Disease	
25568575	2345	2353	altruism	Disease	
25568575	3060	3067	patient	Species	9606
25568575	3077	3084	patient	Species	9606
25568575	3250	3258	altruism	Disease	
25568575	4566	4573	patient	Species	9606
25568575	5350	5358	Slovenia	Disease	
25568575	5465	5477	Participants	Species	9606
25568575	5869	5874	women	Species	9606
25568575	5883	5886	men	Species	9606
25568575	5975	5978	men	Species	9606
25568575	5988	5993	women	Species	9606
25568575	6141	6153	participants	Species	9606
25568575	6316	6328	participants	Species	9606
25568575	7125	7133	patients	Species	9606
25568575	7159	7166	patient	Species	9606
25568575	7294	7301	patient	Species	9606
25568575	7392	7399	Empathy	Disease	
25568575	7513	7519	person	Species	9606
25568575	7574	7580	person	Species	9606
25568575	7653	7660	patient	Species	9606
25568575	7698	7706	patients	Species	9606
25568575	7776	7784	patients	Species	9606
25568575	8018	8022	male	Species	9606
25568575	7912	7919	empathy	Disease	
25568575	8311	8317	person	Species	9606
25568575	8383	8390	patient	Species	9606
25568575	8582	8586	male	Species	9606
25568575	8719	8727	patients	Species	9606
25568575	8795	8803	patients	Species	9606
25568575	8971	8979	patients	Species	9606
25568575	9361	9369	patients	Species	9606
25568575	9652	9660	patients	Species	9606
25568575	9846	9854	patients	Species	9606
25568575	9996	10003	patient	Species	9606
25568575	10265	10272	patient	Species	9606
25568575	10545	10552	patient	Species	9606
25568575	10656	10660	male	Species	9606
25568575	10951	10958	patient	Species	9606
25568575	11024	11031	patient	Species	9606
25568575	11071	11079	patients	Species	9606
25568575	11360	11366	people	Species	9606
25568575	11512	11516	male	Species	9606
25568575	11599	11606	patient	Species	9606
25568575	11792	11796	male	Species	9606
25568575	12219	12227	patients	Species	9606
25568575	12590	12598	patients	Species	9606
25568575	12621	12625	male	Species	9606
25568575	12657	12665	patients	Species	9606
25568575	12870	12878	patients	Species	9606
25568575	12949	12956	patient	Species	9606
25568575	13086	13093	patient	Species	9606
25568575	13389	13400	personality	Disease	MESH:D010554
25568575	13598	13604	people	Species	9606
25568575	13696	13702	people	Species	9606
25568575	14095	14103	patients	Species	9606
25568575	14197	14201	male	Species	9606
25568575	14470	14474	male	Species	9606
25568575	14686	14694	patients	Species	9606
25568575	14839	14846	patient	Species	9606
25568575	14902	14910	patients	Species	9606
25568575	15200	15204	male	Species	9606
25568575	15394	15402	patients	Species	9606
25568575	15422	15428	humans	Species	9606
25568575	15443	15447	male	Species	9606
25568575	15529	15535	people	Species	9606
25568575	15871	15877	people	Species	9606
25568575	17935	17943	altruism	Disease	
25568575	17119	17126	empathy	Disease	
25568575	17302	17310	altruism	Disease	
25568575	21094	21101	patient	Species	9606
25568575	23696	23704	patients	Species	9606
25568575	24984	25002	decline in empathy	Disease	MESH:D029424

25568628|t|Assessments of the Socioeconomic Status and Diet on the Prevalence of Dental Caries at School Children in Central Bosnian Canton 
25568628|a|Aim: The main aim of this research was to determine the influence of socioeconomic status and residence/living conditions on the status of oral health (e.g. health of mouth and teeth) in primary school students residing in Canton Central Bosnia. Methods: The study was designed as a cross-sectional study. Our research included two-phased stratified random sample of 804 participants. The quantitative research method and newly designed survey instrument were utilized in order to provide data on the oral health of the examined children. The alternate hypothesis foresaw that "there were significant statistical differences between the levels of incidence of dental caries in comparison to the incidence in children of different socioeconomic status. Results: The Chi square () of 22.814, degree of freedom (Df) = 8, coefficient of contingency of 0.163 and T-test (Stat) of-0.18334 showed that there were no significant statistical differences at p < 0.05 level between the primary school children from urban and rural areas. The obtained results showed that the caries indexes in elementary schools in Central Bosnia Canton were fairly uniform. Research showed that there were a difference in the attitudes towards a regular dental visits, which correlated with social-educational structure of the children's' families. Conclusion: According to the results, we can see that the socioeconomic status of patients had an effect on the occurrence of dental caries and oral hygiene in patients in relation to the rural and urban areas, because we can see that by the number of respondents, the greater unemployment of parents in both, rural and urban areas, caused a host of other factors, which were, either, directly or indirectly connected with the development of caries. 
25568628	94	102	Children	Species	9606
25568628	500	512	participants	Species	9606
25568628	658	666	children	Species	9606
25568628	837	845	children	Species	9606
25568628	789	802	dental caries	Disease	MESH:D003731
25568628	1121	1129	children	Species	9606
25568628	1431	1439	children	Species	9606
25568628	1539	1547	patients	Species	9606
25568628	1617	1625	patients	Species	9606
25568628	1750	1757	parents	Species	9606
25568628	1583	1596	dental caries	Disease	MESH:D003731
25568628	1978	1986	children	Species	9606
25568628	2144	2152	children	Species	9606
25568628	2475	2483	children	Species	9606
25568628	2518	2526	children	Species	9606
25568628	2599	2606	parents	Species	9606
25568628	2702	2710	children	Species	9606
25568628	2742	2749	parents	Species	9606
25568628	2754	2762	children	Species	9606
25568628	2788	2793	mouth	Disease	MESH:D014987
25568628	3731	3736	F.B&H	Gene	2767
25568628	3162	3167	F.B&H	Gene	2767
25568628	3621	3626	F.B&H	Gene	2767
25568628	3091	3099	children	Species	9606
25568628	3327	3335	children	Species	9606
25568628	3871	3879	children	Species	9606
25568628	3568	3570	Re	Chemical	MESH:D012211
25568628	4333	4341	bacteria	Species	562
25568628	4192	4205	periodontitis	Disease	MESH:D010518
25568628	4081	4090	infection	Disease	MESH:D007239
25568628	4388	4401	caries damage	Disease	MESH:D003731
25568628	4912	4925	Carbohydrates	Chemical	MESH:D002241
25568628	5127	5132	mucin	Gene	100508689
25568628	5034	5048	parondotopathy	Disease	
25568628	5464	5484	Streptococcus mutans	Species	1309
25568628	5554	5567	carbohydrates	Chemical	MESH:D002241
25568628	5896	5904	children	Species	9606
25568628	5833	5838	mouth	Disease	MESH:D014987
25568628	6555	6558	OHI	Chemical	MESH:C489255
25568628	7233	7241	children	Species	9606
25568628	7942	7950	children	Species	9606
25568628	8037	8045	children	Species	9606
25568628	8352	8360	children	Species	9606
25568628	8976	8984	children	Species	9606
25568628	9183	9196	dental caries	Disease	MESH:D003731
25568628	10537	10544	parents	Species	9606
25568628	12000	12008	patients	Species	9606
25568628	12798	12806	children	Species	9606
25568628	12382	12395	dental caries	Disease	MESH:D003731
25568628	13362	13370	children	Species	9606
25568628	14083	14098	tooth nutrition	Disease	MESH:D044342
25568628	14304	14312	patients	Species	9606
25568628	14382	14390	patients	Species	9606
25568628	14538	14545	parents	Species	9606
25568628	14347	14360	dental caries	Disease	MESH:D003731
25568628	14903	14914	tooth decay	Disease	MESH:D003731
25568628	15235	15248	Dental caries	Disease	MESH:D003731
25568628	15405	15413	patients	Species	9606
25568628	15536	15549	dental caries	Disease	MESH:D003731
25568628	15973	15986	dental caries	Disease	MESH:D003731
25568628	16023	16032	fluorides	Chemical	MESH:D005459
25568628	16312	16325	dental caries	Disease	MESH:D003731
25568628	16362	16377	Dental diseases	Disease	MESH:D009057
25568628	16427	16432	child	Species	9606
25568628	16827	16840	dental caries	Disease	MESH:D003731

25568585|t|A Design Protocol to Develop Radiology Dashboards 
25568585|a|ABSTRACT Aim: The main objective of this descriptive and development research was to introduce a design protocol to develop radiology dashboards. Material and methods: The first step was to determine key performance indicators for radiology department. The second step was to determine required infrastructure for implementation of radiology dashboards. Infrastructure was extracted from both data and technology perspectives. The third step was to determine main features of the radiology dashboards. The fourth step was to determine the key criteria for evaluating the dashboards. In all these steps, non-probability sampling methods including convenience and purposive were employed and sample size determined based on a persuasion model. Results: Results showed that there are 92 KPIs, 10 main features for designing dashboards and 53 key criteria for dashboards evaluation. As well as, a Prototype of radiology management dashboards in four aspects including services, clients, personnel and cost-income were implemented and evaluated. Applying such dashboards could help managers to enhance performance, productivity and quality of services in radiology department. 
25568585	1339	1346	patient	Species	9606
25568585	1697	1704	patient	Species	9606
25568585	1806	1811	labor	Disease	MESH:D048949
25568585	1922	1926	PACS	Chemical	MESH:C508168
25568585	3077	3095	hospital infection	Disease	MESH:D003428
25568585	3059	3067	diabetes	Disease	MESH:D003920
25568585	5823	5827	KPIs	Disease	
25568585	8897	8904	patient	Species	9606
25568585	9688	9695	patient	Species	9606
25568585	10814	10824	dashboards	Disease	
25568585	12985	12990	drill	Species	9568
25568585	16312	16337	dashboards implementation	Disease	
25568585	17400	17403	HL7	CellLine	CVCL:2492
25568585	19106	19110	PACS	Chemical	MESH:C508168
25568585	19592	19600	diabetes	Disease	MESH:D003920
25568585	19492	19511	diabetes dashboards	Disease	MESH:D003920
25568585	19683	19693	infections	Disease	MESH:D007239
25568585	19944	19951	quality	Disease	
25568585	20473	20477	PACS	Chemical	MESH:C508168
25568585	21555	21562	patient	Species	9606
25568585	21847	21864	visual dashboards	Disease	MESH:D014786

25568636|t|Communication Patterns in Preschool Education Institutions - Practical Examples 
25568636|a|Introduction: Proper communication in pre-school institutions for education is undeniable importance to the development of the child, as evidenced by numerous studies. After the child's birth follows the most complex phase in its early phases - preschool education. Only high-quality, synergistic relationship triad: parent-child-educator and the modern postulates of preschool child education, warrants successful preschool child education. Methods and materials: Description, with examples from daily practice in a large institution for preschool education, marked were the critical points on the complex way in child education, many pitfalls encountered by both parents and educators. Considered are the errors in communication with the proposed solution to avoid the same in practice. Conclusion: Proper, daily communication in the preschool institution for education, within a relationship between parent-child-educator, mutual consultation, respect, acceptance, facilitation, resulting in successful common goal - the proper education and socialization of children in institutions for preschool education. 
25568636	209	214	child	Species	9606
25568636	260	265	child	Species	9606
25568636	406	411	child	Species	9606
25568636	460	465	child	Species	9606
25568636	507	512	child	Species	9606
25568636	696	701	child	Species	9606
25568636	747	754	parents	Species	9606
25568636	718	726	pitfalls	Disease	
25568636	992	997	child	Species	9606
25568636	1144	1152	children	Species	9606
25568636	1210	1218	Children	Species	9606
25568636	1439	1444	Child	Species	9606
25568636	1647	1659	participants	Species	9606
25568636	1746	1751	human	Species	9606
25568636	1802	1808	people	Species	9606
25568636	1819	1824	child	Species	9606
25568636	2826	2832	person	Species	9606
25568636	2871	2877	person	Species	9606
25568636	2908	2915	PARENTS	Species	9606
25568636	2916	2921	CHILD	Species	9606
25568636	2988	2993	child	Species	9606
25568636	3076	3081	child	Species	9606
25568636	3133	3138	child	Species	9606
25568636	3153	3158	child	Species	9606
25568636	3519	3526	parents	Species	9606
25568636	3627	3632	child	Species	9606
25568636	3634	3642	children	Species	9606
25568636	3749	3754	child	Species	9606
25568636	3756	3764	children	Species	9606
25568636	3783	3790	parents	Species	9606
25568636	3976	3984	children	Species	9606
25568636	4339	4344	child	Species	9606
25568636	4412	4419	parents	Species	9606
25568636	4532	4539	parents	Species	9606
25568636	4660	4667	parents	Species	9606
25568636	4694	4699	child	Species	9606
25568636	4736	4743	parents	Species	9606
25568636	4944	4952	children	Species	9606
25568636	4983	4990	parents	Species	9606
25568636	4994	5002	children	Species	9606
25568636	5355	5363	children	Species	9606
25568636	5440	5445	child	Species	9606
25568636	5554	5561	parents	Species	9606
25568636	5620	5625	child	Species	9606
25568636	5663	5670	parents	Species	9606
25568636	5752	5757	child	Species	9606
25568636	5901	5909	children	Species	9606
25568636	5922	5930	children	Species	9606
25568636	5992	5999	parents	Species	9606
25568636	6058	6066	children	Species	9606
25568636	6082	6087	child	Species	9606
25568636	6267	6272	child	Species	9606
25568636	6412	6417	child	Species	9606
25568636	6427	6430	man	Species	9606
25568636	6482	6490	children	Species	9606
25568636	6619	6624	child	Species	9606
25568636	6647	6654	parents	Species	9606
25568636	6670	6675	child	Species	9606
25568636	6690	6698	children	Species	9606
25568636	6760	6765	child	Species	9606
25568636	6769	6774	child	Species	9606
25568636	6939	6944	child	Species	9606
25568636	7073	7081	children	Species	9606
25568636	7150	7158	children	Species	9606
25568636	7264	7272	children	Species	9606
25568636	7320	7325	child	Species	9606
25568636	7418	7426	children	Species	9606
25568636	7432	7437	child	Species	9606
25568636	7682	7687	child	Species	9606
25568636	7768	7775	parents	Species	9606
25568636	7914	7919	child	Species	9606
25568636	8330	8340	aggression	Disease	MESH:D001523
25568636	8396	8401	child	Species	9606
25568636	8447	8455	children	Species	9606
25568636	8460	8467	parents	Species	9606
25568636	8565	8570	child	Species	9606
25568636	8810	8815	child	Species	9606
25568636	8954	8959	child	Species	9606
25568636	9057	9062	child	Species	9606
25568636	9086	9094	children	Species	9606
25568636	9139	9144	child	Species	9606
25568636	9308	9316	children	Species	9606
25568636	9589	9596	parents	Species	9606
25568636	9627	9634	parents	Species	9606
25568636	9679	9684	child	Species	9606
25568636	9729	9736	parents	Species	9606
25568636	9794	9799	child	Species	9606
25568636	9850	9855	child	Species	9606
25568636	9992	9999	parents	Species	9606
25568636	9978	9988	aggression	Disease	MESH:D001523
25568636	10239	10244	child	Species	9606
25568636	10254	10259	child	Species	9606
25568636	10331	10338	parents	Species	9606
25568636	10379	10384	child	Species	9606
25568636	10594	10599	child	Species	9606
25568636	10671	10676	child	Species	9606
25568636	10720	10725	child	Species	9606
25568636	10749	10756	parents	Species	9606
25568636	10800	10805	child	Species	9606
25568636	10954	10959	child	Species	9606
25568636	11179	11184	child	Species	9606
25568636	11256	11261	child	Species	9606
25568636	11299	11304	child	Species	9606
25568636	11379	11387	children	Species	9606
25568636	11432	11437	child	Species	9606
25568636	11463	11470	parents	Species	9606
25568636	11740	11745	child	Species	9606
25568636	11788	11793	child	Species	9606
25568636	11886	11894	children	Species	9606
25568636	12022	12027	child	Species	9606
25568636	12053	12059	people	Species	9606
25568636	12120	12125	child	Species	9606
25568636	12165	12172	parents	Species	9606
25568636	12341	12348	parents	Species	9606
25568636	12423	12428	child	Species	9606
25568636	11516	11526	aggression	Disease	MESH:D001523
25568636	12517	12522	child	Species	9606
25568636	12608	12615	parents	Species	9606
25568636	12695	12700	child	Species	9606
25568636	12878	12890	participants	Species	9606
25568636	13016	13021	child	Species	9606
25568636	13114	13119	child	Species	9606
25568636	13291	13299	children	Species	9606
25568636	13395	13400	child	Species	9606
25568636	13440	13448	children	Species	9606
25568636	13483	13488	child	Species	9606
25568636	13582	13590	children	Species	9606
25568636	13844	13852	children	Species	9606
25568636	14024	14029	child	Species	9606
25568636	14031	14036	Child	Species	9606
25568636	14327	14332	child	Species	9606
25568636	14481	14486	child	Species	9606
25568636	14651	14656	child	Species	9606
25568636	14780	14785	child	Species	9606
25568636	14841	14846	child	Species	9606
25568636	14921	14926	child	Species	9606
25568636	15027	15032	child	Species	9606
25568636	15093	15099	person	Species	9606
25568636	15190	15198	children	Species	9606
25568636	15296	15301	child	Species	9606
25568636	15366	15371	child	Species	9606
25568636	15408	15415	parents	Species	9606
25568636	15420	15428	children	Species	9606
25568636	15469	15474	child	Species	9606
25568636	15562	15567	child	Species	9606
25568636	15620	15625	child	Species	9606
25568636	15630	15637	parents	Species	9606
25568636	15670	15675	child	Species	9606
25568636	15747	15752	child	Species	9606
25568636	15839	15844	child	Species	9606
25568636	15873	15878	child	Species	9606
25568636	15925	15932	parents	Species	9606
25568636	15983	15990	parents	Species	9606
25568636	16088	16093	child	Species	9606
25568636	16101	16109	children	Species	9606
25568636	16222	16227	child	Species	9606
25568636	16331	16336	child	Species	9606
25568636	16475	16480	child	Species	9606
25568636	16507	16514	parents	Species	9606
25568636	16566	16573	parents	Species	9606
25568636	16579	16584	child	Species	9606
25568636	16597	16604	parents	Species	9606
25568636	16784	16789	child	Species	9606
25568636	16795	16802	parents	Species	9606
25568636	16922	16927	child	Species	9606
25568636	17168	17173	child	Species	9606
25568636	17201	17208	parents	Species	9606
25568636	17248	17253	child	Species	9606
25568636	17309	17314	child	Species	9606
25568636	17331	17336	child	Species	9606
25568636	17433	17438	child	Species	9606
25568636	17481	17486	child	Species	9606
25568636	17617	17622	child	Species	9606
25568636	17829	17834	child	Species	9606
25568636	18421	18426	child	Species	9606
25568636	18563	18568	child	Species	9606
25568636	18723	18731	children	Species	9606
25568636	18868	18875	parents	Species	9606
25568636	18978	18983	child	Species	9606
25568636	19032	19040	children	Species	9606
25568636	19044	19051	parents	Species	9606
25568636	18902	18929	syndrome sexual allegations	Disease	MESH:D012735
25568636	19210	19213	lap	Gene	7939
25568636	19181	19186	child	Species	9606
25568636	19442	19447	child	Species	9606
25568636	19849	19854	child	Species	9606
25568636	19973	19978	child	Species	9606
25568636	20094	20101	parents	Species	9606
25568636	20118	20121	boy	Species	9606
25568636	20338	20343	child	Species	9606
25568636	20141	20144	MCD	Disease	MESH:D012514
25568636	20827	20834	parents	Species	9606
25568636	20857	20862	child	Species	9606
25568636	20992	20997	woman	Species	9606
25568636	21076	21084	children	Species	9606
25568636	21190	21197	parents	Species	9606
25568636	20892	20899	anxiety	Disease	MESH:D001008
25568636	21323	21331	children	Species	9606
25568636	21351	21358	parents	Species	9606
25568636	21498	21503	child	Species	9606
25568636	21802	21807	child	Species	9606
25568636	21843	21850	parents	Species	9606
25568636	22108	22113	child	Species	9606
25568636	22260	22268	children	Species	9606
25568636	22316	22321	child	Species	9606
25568636	22429	22437	children	Species	9606
25568636	22490	22495	child	Species	9606
25568636	22531	22538	parents	Species	9606
25568636	22610	22617	parents	Species	9606
25568636	22726	22734	children	Species	9606
25568636	22969	22972	boy	Species	9606
25568636	22982	22985	boy	Species	9606
25568636	23183	23190	parents	Species	9606
25568636	23213	23218	child	Species	9606
25568636	23282	23290	children	Species	9606
25568636	23579	23584	child	Species	9606
25568636	23683	23688	child	Species	9606
25568636	23782	23787	Child	Species	9606
25568636	23872	23878	people	Species	9606
25568636	23949	23954	child	Species	9606
25568636	23753	23760	anxiety	Disease	MESH:D001008
25568636	24176	24179	Ida	Gene	3425
25568636	24426	24429	Ida	Gene	3425
25568636	24129	24136	parents	Species	9606
25568636	24521	24528	parents	Species	9606
25568636	24707	24712	woman	Species	9606
25568636	24780	24785	woman	Species	9606
25568636	25019	25024	child	Species	9606
25568636	25122	25130	children	Species	9606
25568636	26741	26745	rain	Gene	54922
25568636	25245	25250	child	Species	9606
25568636	25255	25262	parents	Species	9606
25568636	25334	25342	children	Species	9606
25568636	25357	25362	child	Species	9606
25568636	25423	25430	Parents	Species	9606
25568636	25444	25449	child	Species	9606
25568636	25565	25572	parents	Species	9606
25568636	25574	25581	Parents	Species	9606
25568636	25605	25610	child	Species	9606
25568636	25724	25729	child	Species	9606
25568636	25731	25738	Parents	Species	9606
25568636	25830	25835	child	Species	9606
25568636	25895	25902	parents	Species	9606
25568636	25933	25938	child	Species	9606
25568636	26034	26039	child	Species	9606
25568636	26165	26172	parents	Species	9606
25568636	26255	26260	child	Species	9606
25568636	26329	26336	parents	Species	9606
25568636	26351	26358	parents	Species	9606
25568636	26402	26407	child	Species	9606
25568636	26491	26496	child	Species	9606
25568636	26535	26543	children	Species	9606
25568636	26586	26591	child	Species	9606
25568636	26631	26636	Child	Species	9606
25568636	26845	26853	children	Species	9606
25568636	27013	27019	people	Species	9606
25568636	27073	27078	child	Species	9606
25568636	27115	27122	parents	Species	9606
25568636	27162	27170	children	Species	9606
25568636	27215	27220	child	Species	9606
25568636	27287	27295	children	Species	9606
25568636	27341	27349	children	Species	9606
25568636	27391	27399	Children	Species	9606
25568636	27413	27421	children	Species	9606
25568636	27458	27465	parents	Species	9606
25568636	27514	27519	child	Species	9606
25568636	27702	27710	children	Species	9606
25568636	27722	27729	parents	Species	9606
25568636	27984	27989	child	Species	9606
25568636	26916	26925	infection	Disease	MESH:D007239
25568636	28545	28550	human	Species	9606
25568636	28620	28625	human	Species	9606
25568636	28688	28695	Parents	Species	9606
25568636	28715	28720	Child	Species	9606
25568636	28982	28987	child	Species	9606
25568636	28998	29018	sexual abuse telling	Disease	MESH:D012735
25568636	29060	29065	Child	Species	9606
25568636	29191	29196	Child	Species	9606
25568636	29312	29319	Parents	Species	9606

25568584|t|Occupational Overuse Syndrome (Technological Diseases): Carpal Tunnel Syndrome, a Mouse Shoulder, Cervical Pain Syndrome 
25568584|a|ABSTRACT Technological diseases are diseases of the modern era. Some are caused by occupational exposures, and are marked with direct professional relation, or the action of harmful effects in the workplace. Due to the increasing incidence of these diseases on specific workplaces which may be caused by one or more causal factors present in the workplace today, these diseases are considered as professional diseases. Severity of technological disease usually responds to the level and duration of exposure, and usually occurs after many years of exposure to harmful factor. Technological diseases occur due to excessive work at the computer, or excessive use of keyboards and computer mice, especially the non-ergonomic ones. This paper deals with the diseases of the neck, shoulder, elbow and wrist (cervical radiculopathy, mouse shoulder and carpal tunnel syndrome), as is currently the most common diseases of technology in our country and abroad. These three diseases can be caused by long-term load and physical effort, and are tied to specific occupations, such as occupations associated with prolonged sitting, working at the computer and work related to the fixed telephone communication, as well as certain types of sports (tennis, golf and others). 
25568584	82	87	Mouse	Species	10090
25568584	0	29	Occupational Overuse Syndrome	Disease	MESH:D012090
25568584	107	120	Pain Syndrome	Disease	MESH:D010146
25568584	808	812	mice	Species	10090
25568584	948	953	mouse	Species	10090
25568584	967	989	carpal tunnel syndrome	Disease	MESH:D002349
25568584	924	946	cervical radiculopathy	Disease	MESH:D011843
25568584	1787	1790	CTS	Gene	7276
25568584	1795	1800	Mouse	Species	10090
25568584	2447	2451	mice	Species	10090
25568584	2590	2594	mice	Species	10090
25568584	2870	2875	mouse	Species	10090
25568584	3019	3061	Bosnia and Herzegovina to overuse injuries	Disease	MESH:D012090
25568584	2762	2779	Cervical syndrome	Disease	MESH:D002575
25568584	1819	1832	Cervical Pain	Disease	MESH:D019547
25568584	3429	3446	cervical syndrome	Disease	MESH:D002575
25568584	1843	1846	CPS	Disease	MESH:D019547
25568584	2738	2760	Carpal Tunnel Syndrome	Disease	MESH:D002349
25568584	3390	3412	carpal tunnel syndrome	Disease	MESH:D002349
25568584	3779	3782	lat	Gene	27040
25568584	3652	3655	CTS	Gene	7276
25568584	3859	3867	numbness	Disease	MESH:D006987
25568584	3676	3696	canaliculus syndrome	Disease	MESH:D061325
25568584	3840	3844	pain	Disease	MESH:D010146
25568584	3628	3650	Carpal tunnel syndrome	Disease	MESH:D002349
25568584	3884	3899	muscle weakness	Disease	MESH:D018908
25568584	4092	4095	lat	Gene	27040
25568584	4025	4028	lat	Gene	27040
25568584	4291	4306	palmaris longus	Disease	MESH:D007645
25568584	4606	4609	CTS	Gene	7276
25568584	4830	4836	people	Species	9606
25568584	4725	4735	neuropathy	Disease	MESH:D009422
25568584	4582	4604	Carpal tunnel syndrome	Disease	MESH:D002349
25568584	5127	5135	numbness	Disease	MESH:D006987
25568584	5045	5049	pain	Disease	MESH:D010146
25568584	5678	5700	carpal tunnel syndrome	Disease	MESH:D002349
25568584	5483	5489	trauma	Disease	MESH:D014947
25568584	5428	5450	carpal tunnel syndrome	Disease	MESH:D002349
25568584	5508	5549	tenosynovitis of the rheumatoid arthritis	Disease	MESH:D001172
25568584	5847	5854	patient	Species	9606
25568584	6036	6043	patient	Species	9606
25568584	5874	5886	nerve damage	Disease	MESH:D003389
25568584	5762	5769	illness	Disease	MESH:D002908
25568584	6307	6310	CTS	Gene	7276
25568584	6279	6287	patients	Species	9606
25568584	6396	6404	patients	Species	9606
25568584	6560	6568	patients	Species	9606
25568584	6670	6678	patients	Species	9606
25568584	6936	6943	patient	Species	9606
25568584	7062	7069	patient	Species	9606
25568584	7173	7181	patients	Species	9606
25568584	7329	7334	Euros	Species	9319
25568584	7471	7478	patient	Species	9606
25568584	7602	7609	patient	Species	9606
25568584	7761	7764	CTS	Gene	7276
25568584	8023	8027	pain	Disease	MESH:D010146
25568584	8290	8312	carpal tunnel syndrome	Disease	MESH:D002349
25568584	7891	7897	Phalen	Chemical	
25568584	8203	8207	pain	Disease	MESH:D010146
25568584	8585	8589	pain	Disease	MESH:D010146
25568584	8793	8797	pain	Disease	MESH:D010146
25568584	8965	8987	carpal tunnel syndrome	Disease	MESH:D002349
25568584	9136	9140	EMNG	Chemical	
25568584	9522	9528	trauma	Disease	MESH:D014947
25568584	9327	9369	Carpal tunnel syndrome the primary disease	Disease	MESH:D002349
25568584	9471	9486	corticosteroids	Chemical	MESH:D000305
25568584	9650	9656	Turkey	Species	9103
25568584	9804	9812	patients	Species	9606
25568584	9909	9919	vitamin B6	Chemical	MESH:D025101
25568584	9881	9903	carpal tunnel syndrome	Disease	MESH:D002349
25568584	9818	9840	carpal tunnel syndrome	Disease	MESH:D002349
25568584	9713	9723	vitamin B6	Chemical	MESH:D025101
25568584	9942	9948	Turkey	Species	9103
25568584	10053	10061	patients	Species	9606
25568584	10081	10103	carpal tunnel syndrome	Disease	MESH:D002349
25568584	10325	10333	patients	Species	9606
25568584	10339	10361	carpal tunnel syndrome	Disease	MESH:D002349
25568584	10459	10467	patients	Species	9606
25568584	10693	10701	patients	Species	9606
25568584	10473	10495	carpal tunnel syndrome	Disease	MESH:D002349
25568584	10909	10913	PAIN	Disease	MESH:D009477
25568584	11093	11102	Neck pain	Disease	MESH:D019547
25568584	11060	11064	pain	Disease	MESH:D010146
25568584	10923	10945	Cervical pain syndrome	Disease	MESH:D019547
25568584	10947	10950	CPS	Disease	MESH:D019547
25568584	11624	11629	C6-C2	Chemical	MESH:C023714
25568584	11682	11704	Cervical radiculopathy	Disease	MESH:D011843
25568584	12038	12046	weakness	Disease	MESH:D018908
25568584	12018	12022	pain	Disease	MESH:D010146
25568584	12195	12203	Patients	Species	9606
25568584	12351	12364	radiculopathy	Disease	MESH:D011843
25568584	12374	12389	spine disorders	Disease	MESH:D016135
25568584	12427	12440	radiculopathy	Disease	MESH:D011843
25568584	12301	12314	radiculopathy	Disease	MESH:D011843
25568584	12114	12127	radiculopathy	Disease	MESH:D011843
25568584	12469	12486	cervical syndrome	Disease	MESH:D002575
25568584	12693	12706	radiculopathy	Disease	MESH:D011843
25568584	12595	12608	radiculopathy	Disease	MESH:D011843
25568584	12769	12780	osteophytes	Disease	MESH:D054850
25568584	12645	12657	acute injury	Disease	MESH:D058186
25568584	12910	12918	patients	Species	9606
25568584	12931	12935	pain	Disease	MESH:D010146
25568584	13345	13354	auricular	Disease	MESH:D004428
25568584	13201	13209	headache	Disease	MESH:D006261
25568584	13246	13254	Headache	Disease	MESH:D006261
25568584	13129	13139	irritation	Disease	MESH:D001523
25568584	13398	13408	irritation	Disease	MESH:D001523
25568584	13687	13705	vascular disorders	Disease	MESH:D014652
25568584	13810	13862	spondylosis (osteophytes), uncarthrosis, spondylosis	Disease	MESH:D055009
25568584	13864	13879	Atherosclerosis	Disease	MESH:D050197
25568584	13943	13951	patients	Species	9606
25568584	14245	14253	headache	Disease	MESH:D006261
25568584	13957	13974	cervical syndrome	Disease	MESH:D002575
25568584	14083	14087	pain	Disease	MESH:D010146
25568584	14011	14015	pain	Disease	MESH:D010146
25568584	14480	14484	pain	Disease	MESH:D010146
25568584	14561	14570	dizziness	Disease	MESH:D004244
25568584	14668	14678	tenderness	Disease	
25568584	14607	14615	headache	Disease	MESH:D006261
25568584	14588	14602	blurred vision	Disease	MESH:D014786
25568584	14575	14583	tinnitus	Disease	MESH:D014012
25568584	14527	14531	pain	Disease	MESH:D010146
25568584	14302	14306	pain	Disease	MESH:D010146
25568584	14620	14628	diplopia	Disease	MESH:D004172
25568584	15253	15257	pain	Disease	MESH:D010146
25568584	15152	15165	radiculopathy	Disease	MESH:D011843
25568584	15269	15277	weakness	Disease	MESH:D018908
25568584	15738	15744	people	Species	9606
25568584	15828	15836	patients	Species	9606
25568584	15999	16002	hot	Gene	137872
25568584	16545	16553	patients	Species	9606
25568584	16485	16499	sleep problems	Disease	MESH:D012893
25568584	16559	16568	neck pain	Disease	MESH:D019547
25568584	16658	16666	patients	Species	9606
25568584	16650	16654	pain	Disease	MESH:D010146
25568584	16607	16614	steroid	Chemical	MESH:D013256
25568584	16672	16689	cervical syndrome	Disease	MESH:D002575
25568584	16939	16947	steroids	Chemical	MESH:D013256
25568584	16911	16925	radicular pain	Disease	MESH:D011842
25568584	16814	16822	steroids	Chemical	MESH:D013256
25568584	16875	16887	inflammation	Disease	MESH:D007249
25568584	17232	17236	pain	Disease	MESH:D010146
25568584	17115	17122	steroid	Chemical	MESH:D013256
25568584	17383	17391	patients	Species	9606
25568584	17296	17313	cervical syndrome	Disease	MESH:D002575
25568584	17609	17631	cervical radiculopathy	Disease	MESH:D011843
25568584	17641	17646	MOUSE	Species	10090
25568584	17836	17842	people	Species	9606
25568584	17984	17988	mice	Species	10090
25568584	18138	18142	mice	Species	10090
25568584	18300	18304	mice	Species	10090
25568584	18611	18631	musculoskeletal pain	Disease	MESH:D059352
25568584	18638	18642	pain	Disease	MESH:D010146
25568584	19036	19044	children	Species	9606
25568584	18715	18738	inflammation of tendons	Disease	MESH:D007249
25568584	18851	18863	inflammation	Disease	MESH:D007249
25568584	19179	19183	pain	Disease	MESH:D010146
25568584	19233	19248	muscle weakness	Disease	MESH:D018908
25568584	19560	19575	sleep disorders	Disease	MESH:D012893
25568584	19350	19354	pain	Disease	MESH:D010146
25568584	19976	19980	pain	Disease	MESH:D010146
25568584	20202	20207	mouse	Species	10090
25568584	20305	20312	patient	Species	9606
25568584	20378	20385	patient	Species	9606
25568584	20417	20423	injury	Disease	MESH:D014947
25568584	20443	20455	inflammation	Disease	MESH:D007249
25568584	20646	20650	pain	Disease	MESH:D010146
25568584	20736	20740	pain	Disease	MESH:D010146
25568584	20502	20506	pain	Disease	MESH:D010146
25568584	20895	20899	rays	Species	255564
25568584	20959	20985	inflammation of the joints	Disease	MESH:D007249
25568584	21101	21106	mouse	Species	10090
25568584	21199	21204	mouse	Species	10090
25568584	21213	21220	patient	Species	9606
25568584	21330	21335	mouse	Species	10090
25568584	21411	21416	mouse	Species	10090
25568584	21820	21824	pain	Disease	MESH:D010146
25568584	21489	21493	pain	Disease	MESH:D010146
25568584	21896	21904	patients	Species	9606
25568584	21926	21933	painful	Disease	MESH:D010146
25568584	22061	22065	pain	Disease	MESH:D010146
25568584	22307	22312	mouse	Species	10090
25568584	22587	22592	mouse	Species	10090
25568584	22641	22645	pain	Disease	MESH:D010146
25568584	22338	22355	upper extremities	Disease	MESH:D009207
25568584	22443	22447	pain	Disease	MESH:D010146
25568584	22713	22726	TECHNOLOGICAL	Chemical	
25568584	22823	22830	patient	Species	9606
25568584	23348	23354	people	Species	9606
25568584	23360	23372	disabilities	Disease	MESH:D009069
25568584	23514	23520	people	Species	9606
25568584	23526	23538	disabilities	Disease	MESH:D009069
25568584	23872	23879	persons	Species	9606
25568584	23943	23951	patients	Species	9606
25568584	23885	23897	disabilities	Disease	MESH:D009069
25568584	24294	24300	people	Species	9606
25568584	24306	24318	disabilities	Disease	MESH:D009069
25568584	24434	24441	patient	Species	9606
25568584	24500	24510	disability	Disease	MESH:D009069
25568584	24862	24870	patients	Species	9606
25568584	24943	24951	patients	Species	9606
25568584	25033	25041	patients	Species	9606
25568584	25150	25158	Children	Species	9606
25568584	25169	25175	people	Species	9606
25568584	25190	25198	children	Species	9606
25568584	25073	25084	Lumbar pain	Disease	MESH:D010146
25568584	25098	25116	Rheumatic diseases	Disease	MESH:D012216
25568584	25142	25148	stroke	Disease	MESH:D020521
25568584	25046	25059	Cervical pain	Disease	MESH:D019547
25568584	25527	25533	people	Species	9606
25568584	25660	25688	implementation of the vision	Disease	MESH:D014786
25568584	25836	25843	persons	Species	9606
25568584	26732	26740	patients	Species	9606
25568584	27274	27282	patients	Species	9606
25568584	27417	27424	patient	Species	9606
25568584	27540	27547	patient	Species	9606
25568584	27954	27962	patients	Species	9606
25568584	28214	28221	patient	Species	9606
25568584	28408	28416	patients	Species	9606
25568584	28645	28651	people	Species	9606
25568584	28657	28669	disabilities	Disease	MESH:D009069
25568584	28971	28976	labor	Disease	MESH:D048949
25568584	29109	29124	musculoskeletal	Disease	MESH:D009140
25568584	29192	29203	THERAPEUTIC	Chemical	MESH:D045506
25568584	29382	29385	CTS	Gene	7276
25568584	29609	29612	CTS	Gene	7276
25568584	29884	29889	mouse	Species	10090
25568584	30084	30092	patients	Species	9606
25568584	31417	31424	patient	Species	9606
25568584	30336	30346	disability	Disease	MESH:D009069
25568584	30774	30782	steroids	Chemical	MESH:D013256
25568584	30952	30956	pain	Disease	MESH:D010146
25568584	30448	30467	radicular neck pain	Disease	MESH:D019547
25568584	30098	30120	cervical radiculopathy	Disease	MESH:D011843
25568584	30261	30286	musculoskeletal disorders	Disease	MESH:D009140
25568584	30801	30806	ozone	Chemical	MESH:D010126
25568584	30164	30173	neck pain	Disease	MESH:D019547
25568584	30241	30254	low back pain	Disease	MESH:D017116
25568584	31609	31624	musculoskeletal	Disease	MESH:D009140
25568584	31725	31734	neck pain	Disease	MESH:D019547
25568584	32001	32005	pain	Disease	MESH:D010146
25568584	32412	32425	low back pain	Disease	MESH:D017116
25568584	32333	32346	low back pain	Disease	MESH:D017116
25568584	32532	32546	osteoarthritis	Disease	MESH:D010003
25568584	32560	32569	neck pain	Disease	MESH:D019547
25568584	32750	32769	calcific tendonitis	Disease	MESH:D052256
25568584	33052	33069	repetitive injury	Disease	MESH:D012090
25568584	33272	33281	neck pain	Disease	MESH:D019547
25568584	32992	33010	injury or accident	Disease	MESH:D020521
25568584	33028	33037	neck pain	Disease	MESH:D019547
25568584	33071	33080	Neck pain	Disease	MESH:D019547
25568584	32957	32966	neck pain	Disease	MESH:D019547
25568584	33559	33563	pain	Disease	MESH:D010146
25568584	33487	33491	pain	Disease	MESH:D010146
25568584	34035	34039	mice	Species	10090
25568584	34349	34370	occupational diseases	Disease	MESH:D009784
25568584	34004	34021	overuse keyboards	Disease	MESH:D012090
25568584	35153	35157	mice	Species	10090
25568584	35231	35238	fatigue	Disease	MESH:D005221
25568584	35243	35262	exhaustion syndrome	Disease	MESH:D006359
25568584	35583	35605	carpal tunnel syndrome	Disease	MESH:D002349
25568584	35654	35676	carpal tunnel syndrome	Disease	MESH:D002349
25568584	35686	35699	carpal tunnel	Disease	MESH:D002349
25568584	35816	35824	patients	Species	9606
25568584	35751	35761	vitamin B6	Chemical	MESH:D025101
25568584	35930	35938	patients	Species	9606
25568584	35944	35966	carpal tunnel syndrome	Disease	MESH:D002349
25568584	36113	36117	Pain	Disease	MESH:D010146
25568584	36187	36200	radiculopathy	Disease	MESH:D011843
25568584	36216	36223	steroid	Chemical	MESH:D013256
25568584	36255	36277	cervical radiculopathy	Disease	MESH:D011843
25568584	36321	36346	spondylotic radiculopathy	Disease	MESH:D011843
25568584	36468	36488	Musculoskeletal pain	Disease	MESH:D059352
25568584	36785	36793	children	Species	9606
25568584	36888	36896	Patients	Species	9606
25568584	36902	36924	Cervical Radiculopathy	Disease	MESH:D011843
25568584	36932	36947	Disc Herniation	Disease	MESH:D007405
25568584	36975	36996	Carpal Tunel Syndrome	Gene	7276
25568584	36998	37001	CTS	Gene	7276
25568584	37045	37053	Patients	Species	9606
25568584	37059	37072	Low Back Pain	Disease	MESH:D017116

25568637|t|Tretatment Approach of Nontransplant Patients with Multiple Myeloma 
25568637|a|Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment. In recent years there is a huge improvement in treatment of patients with multiple myeloma. The milestones of these improvement are: autologous transplantation and high-dose melphalan, imunomodulating drugs (thalidomide, lenalidomide), proteosom inhibitors (bortesomib, carfilzomib). The most significant improvement in overall survival has been achieved in the patients younger than 65 years. So, the major challenge for hematologist is to translate this improvement in the elderly patients with multiple myeloma. Today, physicians are able to offer wider variety of treatment options for elderly patients with multiple myeloma. Therapeutic options should be tailored and personalized according to patient's characteristics by balancing efficacy and toxicity of each drug which is especially important for elderly patients. In the mode of sequencing treatment for elderly patients with multiple myeloma, our goal is to achieve and maintain maximal response while limiting treatment -related toxicities as much as possible. Second-generation novel agent, such as carfilzomib, pomalidomide, elotuzumab, bendamustine are currently being evaluated as an option to improve treatment outcome in elderly patients. 
25568637	37	45	Patients	Species	9606
25568637	51	67	Multiple Myeloma	Disease	MESH:D009101
25568637	248	256	patients	Species	9606
25568637	370	378	patients	Species	9606
25568637	672	680	patients	Species	9606
25568637	793	801	patients	Species	9606
25568637	908	916	patients	Species	9606
25568637	1009	1016	patient	Species	9606
25568637	1125	1133	patients	Species	9606
25568637	1183	1191	patients	Species	9606
25568637	1508	1516	patients	Species	9606
25568637	1412	1424	bendamustine	Chemical	MESH:C001758
25568637	384	400	multiple myeloma	Disease	MESH:D009101
25568637	1386	1398	pomalidomide	Chemical	MESH:C467566
25568637	484	493	melphalan	Chemical	MESH:D008558
25568637	518	529	thalidomide	Chemical	MESH:D013792
25568637	1061	1069	toxicity	Disease	MESH:D064420
25568637	68	84	Multiple myeloma	Disease	MESH:D009101
25568637	1302	1312	toxicities	Disease	MESH:D064420
25568637	1197	1213	multiple myeloma	Disease	MESH:D009101
25568637	922	938	multiple myeloma	Disease	MESH:D009101
25568637	807	823	multiple myeloma	Disease	MESH:D009101
25568637	531	543	lenalidomide	Chemical	MESH:C467567
25568637	212	219	myeloma	Disease	MESH:D009101
25568637	580	591	carfilzomib	Chemical	MESH:C524865
25568637	1373	1384	carfilzomib	Chemical	MESH:C524865
25568637	1518	1535	Myeloma multiplex	Disease	MESH:D009101
25568637	1991	2008	myeloma multiplex	Disease	MESH:D009101
25568637	1886	1893	myeloma	Disease	MESH:D009101
25568637	1541	1559	malignant disorder	Disease	MESH:D009369
25568637	2572	2580	patients	Species	9606
25568637	2341	2348	cancers	Disease	MESH:D009369
25568637	2059	2076	Myeloma multiplex	Disease	MESH:D009101
25568637	2291	2308	Myeloma multiplex	Disease	MESH:D009101
25568637	2379	2399	hematologic neoplasm	Disease	MESH:D019337
25568637	2082	2100	malignant disorder	Disease	MESH:D009369
25568637	2452	2469	Myeloma multiplex	Disease	MESH:D009101
25568637	3384	3390	beta 2	Gene	10242
25568637	3530	3535	beta2	Gene	10242
25568637	2667	2674	Patient	Species	9606
25568637	2757	2765	Patients	Species	9606
25568637	3231	3239	Patients	Species	9606
25568637	2680	2687	myeloma	Disease	MESH:D009101
25568637	3578	3603	chromosomal abnormalities	Disease	MESH:D002869
25568637	3760	3772	Hiperdiplpdy	Disease	
25568637	3951	3959	patients	Species	9606
25568637	4128	4135	patient	Species	9606
25568637	4433	4445	prolongation	Disease	MESH:D008133
25568637	3903	3927	multiple myeloma depends	Disease	MESH:D009101
25568637	4353	4361	toxicity	Disease	MESH:D064420
25568637	4277	4283	cancer	Disease	MESH:D009369
25568637	4254	4259	tumor	Disease	MESH:D009369
25568637	4723	4731	patients	Species	9606
25568637	4780	4788	patients	Species	9606
25568637	5233	5240	patient	Species	9606
25568637	5332	5339	patient	Species	9606
25568637	5435	5443	patients	Species	9606
25568637	4852	4868	multiple myeloma	Disease	MESH:D009101
25568637	5392	5402	toxicities	Disease	MESH:D064420
25568637	5500	5508	toxicity	Disease	MESH:D064420
25568637	4715	4722	myeloma	Disease	MESH:D009101
25568637	4893	4908	chronic disease	Disease	MESH:D002908
25568637	5698	5706	patients	Species	9606
25568637	5840	5848	patients	Species	9606
25568637	6506	6514	patients	Species	9606
25568637	6608	6616	Patients	Species	9606
25568637	6773	6781	Patients	Species	9606
25568637	7084	7092	patients	Species	9606
25568637	7315	7323	patients	Species	9606
25568637	7235	7245	prednisone	Chemical	MESH:D011241
25568637	5544	5560	multiple myeloma	Disease	MESH:D009101
25568637	5934	5943	melphalan	Chemical	MESH:D008558
25568637	7220	7230	melpahalan	Chemical	
25568637	6022	6034	prednisolone	Chemical	MESH:D011239
25568637	6007	6016	melphalan	Chemical	MESH:D008558
25568637	7979	7987	patients	Species	9606
25568637	8329	8337	patients	Species	9606
25568637	7732	7764	melphalan-prednisone-thalidomide	Chemical	MESH:D013792
25568637	8038	8049	thalidomide	Chemical	MESH:D013792
25568637	8252	8255	MPT	Chemical	MESH:C042416
25568637	8364	8372	patients	Species	9606
25568637	8405	8413	patients	Species	9606
25568637	8759	8767	patients	Species	9606
25568637	8627	8640	dexamethasone	Chemical	MESH:D003907
25568637	8606	8622	cyclophosphamide	Chemical	MESH:D003520
25568637	8559	8566	steroid	Chemical	MESH:D013256
25568637	8496	8507	thalidomide	Chemical	MESH:D013792
25568637	9027	9035	patients	Species	9606
25568637	9084	9092	patients	Species	9606
25568637	8799	8811	Lenalidomide	Chemical	MESH:C467567
25568637	9067	9083	multiple myeloma	Disease	MESH:D009101
25568637	8942	8954	Lenalidomide	Chemical	MESH:C467567
25568637	9019	9026	myeloma	Disease	MESH:D009101
25568637	8914	8932	neurotoxic adverse	Disease	MESH:D020258
25568637	8878	8889	thalidomide	Chemical	MESH:D013792
25568637	9254	9262	patients	Species	9606
25568637	9365	9373	patients	Species	9606
25568637	9456	9464	patients	Species	9606
25568637	9577	9585	patients	Species	9606
25568637	9616	9624	patients	Species	9606
25568637	9171	9183	lenalidomide	Chemical	MESH:C467567
25568637	9630	9643	renal failure	Disease	MESH:D051437
25568637	9198	9210	dexamethason	Chemical	
25568637	9761	9763	Rd	Chemical	MESH:C049863
25568637	9569	9576	myeloma	Disease	MESH:D009101
25568637	9118	9130	lenalidomide	Chemical	MESH:C467567
25568637	9237	9253	multiple myeloma	Disease	MESH:D009101
25568637	9660	9664	pain	Disease	MESH:D010146
25568637	9645	9658	hypercalcemia	Disease	MESH:D006934
25568637	9782	9794	lenalidomide	Chemical	MESH:C467567
25568637	10390	10402	malignancies	Disease	MESH:D009369
25568637	9850	9883	melphalan-prednisone-lenalidomide	Chemical	MESH:C467567
25568637	9896	9908	lenalidomide	Chemical	MESH:C467567
25568637	10183	10195	Lenalidomide	Chemical	MESH:C467567
25568637	10294	10300	cancer	Disease	MESH:D009369
25568637	10444	10447	VMP	Gene	140767
25568637	10589	10592	VMP	Gene	140767
25568637	10413	10418	VISTA	Gene	64115
25568637	10476	10486	bortezomib	Chemical	MESH:C400082
25568637	10802	10805	VMP	Gene	140767
25568637	11002	11005	VMP	Gene	140767
25568637	10648	10656	patients	Species	9606
25568637	10983	10991	patients	Species	9606
25568637	11114	11122	patients	Species	9606
25568637	10876	10887	thalidomide	Chemical	MESH:D013792
25568637	11135	11145	bortezomib	Chemical	MESH:C400082
25568637	11097	11113	multiple myeloma	Disease	MESH:D009101
25568637	10847	10856	melphalan	Chemical	MESH:D008558
25568637	11245	11255	neuropathy	Disease	MESH:D009422
25568637	10618	10625	PETHEMA	Chemical	MESH:C037167
25568637	10759	10797	bortezomib-thalidomeide-prednisone VTP	Chemical	MESH:C400082
25568637	11272	11282	bortezomib	Chemical	MESH:C400082
25568637	11402	11410	patients	Species	9606
25568637	11357	11360	VRD	Disease	
25568637	11416	11432	multiple myeloma	Disease	MESH:D009101
25568637	11318	11355	bortezomib-lenalidomide-dexamethasone	Chemical	MESH:C400082
25568637	11497	11500	VMP	Gene	140767
25568637	11638	11641	VMP	Gene	140767
25568637	11722	11730	patients	Species	9606
25568637	11643	11646	VMP	Gene	140767
25568637	11608	11611	VMP	Gene	140767
25568637	11450	11461	thalidomide	Chemical	MESH:D013792
25568637	11840	11872	particular peripheral neuropathy	Disease	MESH:D010523
25568637	11830	11838	toxicity	Disease	MESH:D064420
25568637	11513	11535	bortezomib-thalidomide	Chemical	MESH:C400082
25568637	11612	11614	VT	Disease	MESH:D017180
25568637	11647	11649	VT	Disease	MESH:D017180
25568637	11667	11677	bortezomib	Chemical	MESH:C400082
25568637	12197	12204	patient	Species	9606
25568637	12604	12612	patients	Species	9606
25568637	12651	12659	patients	Species	9606
25568637	12587	12603	multiple myeloma	Disease	MESH:D009101
25568637	12147	12155	toxicity	Disease	MESH:D064420
25568637	12742	12752	Bortezomib	Chemical	MESH:C400082
25568637	12789	12797	toxicity	Disease	MESH:D064420
25568637	12507	12519	lenalidomide	Chemical	MESH:C467567
25568637	12726	12728	VT	Disease	MESH:D017180
25568637	12436	12448	lenalidomide	Chemical	MESH:C467567
25568637	12943	12950	patient	Species	9606
25568637	12982	12990	patients	Species	9606
25568637	13255	13263	patients	Species	9606
25568637	13404	13412	patients	Species	9606
25568637	13699	13707	patients	Species	9606
25568637	13835	13842	patient	Species	9606
25568637	13713	13729	multiple myeloma	Disease	MESH:D009101
25568637	13108	13120	lenalidomide	Chemical	MESH:C467567
25568637	13805	13821	multiple myeloma	Disease	MESH:D009101
25568637	13370	13391	neurological toxicity	Disease	MESH:D009422
25568637	13172	13184	lenalidomide	Chemical	MESH:C467567
25568637	13027	13038	thalidomide	Chemical	MESH:D013792
25568637	13886	13901	Myeloma Network	Disease	MESH:D009101
25568637	12996	13023	renal impairment bortezomib	Disease	MESH:D007674
25568637	13269	13303	peripheral neuropathy lenalidomide	Disease	MESH:D010523
25568637	14102	14110	patients	Species	9606
25568637	14427	14435	patients	Species	9606
25568637	14528	14535	patient	Species	9606
25568637	14644	14652	patients	Species	9606
25568637	14702	14710	patients	Species	9606
25568637	14066	14073	myeloma	Disease	MESH:D009101
25568637	14892	14903	carfilzomib	Chemical	MESH:C524865
25568637	14228	14253	tumor reduction and tumor	Disease	MESH:D009369
25568637	14441	14457	multiple myeloma	Disease	MESH:D009101
25568637	14716	14732	multiple myeloma	Disease	MESH:D009101
25568637	13922	13938	Multiple myeloma	Disease	MESH:D009101
25568637	14905	14917	pomalidomide	Chemical	MESH:C467566
25568637	14580	14588	toxicity	Disease	MESH:D064420
25568637	14821	14831	toxicities	Disease	MESH:D064420
25568637	14173	14180	myeloma	Disease	MESH:D009101
25568637	14931	14943	bendamustine	Chemical	MESH:C001758
25568637	15089	15105	Multiple myeloma	Disease	MESH:D009101
25568637	15138	15154	multiple myeloma	Disease	MESH:D009101
25568637	15155	15171	Multiple myeloma	Disease	MESH:D009101
25568637	15205	15221	multiple myeloma	Disease	MESH:D009101
25568637	15311	15318	myeloma	Disease	MESH:D009101
25568637	15352	15368	Multiple myeloma	Disease	MESH:D009101
25568637	15383	15398	Myeloma Working	Disease	MESH:D009101
25568637	15433	15449	multiple myeloma	Disease	MESH:D009101
25568637	15588	15603	Myeloma Working	Disease	MESH:D009101
25568637	15562	15569	myeloma	Disease	MESH:D009101
25568637	15740	15748	Patients	Species	9606
25568637	15646	15661	Myeloma Working	Disease	MESH:D009101
25568637	15754	15761	myeloma	Disease	MESH:D009101
25568637	15917	15925	patients	Species	9606
25568637	15834	15841	myeloma	Disease	MESH:D009101
25568637	15931	15947	multiple myeloma	Disease	MESH:D009101
25568637	16001	16009	patients	Species	9606
25568637	15985	16000	multple myeloma	Disease	MESH:D009101
25568637	16032	16040	patients	Species	9606
25568637	16046	16062	multiple myeloma	Disease	MESH:D009101
25568637	16126	16142	multiple myeloma	Disease	MESH:D009101
25568637	16202	16218	multiple myeloma	Disease	MESH:D009101
25568637	16249	16256	myeloma	Disease	MESH:D009101
25568637	16403	16418	Myeloma Network	Disease	MESH:D009101
25568637	16315	16331	multiple myeloma	Disease	MESH:D009101
25568637	16420	16423	EMN	Chemical	
25568637	16469	16476	myeloma	Disease	MESH:D009101
25568637	16497	16505	patients	Species	9606
25568637	16511	16527	multiple myeloma	Disease	MESH:D009101
25568637	16583	16591	patients	Species	9606
25568637	16597	16613	multiple myeloma	Disease	MESH:D009101
25568637	16663	16679	multiple myeloma	Disease	MESH:D009101
25568637	16715	16723	patients	Species	9606
25568637	16729	16745	Multiple myeloma	Disease	MESH:D009101
25568637	16898	16906	patients	Species	9606
25568637	16746	16753	Myeloma	Disease	MESH:D009101
25568637	16859	16875	myltiple myeloma	Disease	MESH:D009101
25568637	16816	16825	melphalan	Chemical	MESH:D008558
25568637	16831	16841	prednisone	Chemical	MESH:D011241
25568637	17082	17090	patients	Species	9606
25568637	16996	17006	prednisone	Chemical	MESH:D011241
25568637	16963	16974	thalidomide	Chemical	MESH:D013792
25568637	16947	16957	prednisone	Chemical	MESH:D011241
25568637	17096	17112	multiple myeloma	Disease	MESH:D009101
25568637	17114	17123	IFM 99-06	Chemical	MESH:C000595265
25568637	16982	16991	melphalan	Chemical	MESH:D008558
25568637	16933	16942	Melphalan	Chemical	MESH:D008558
25568637	17202	17210	patients	Species	9606
25568637	17171	17181	prednisone	Chemical	MESH:D011241
25568637	17187	17198	thalidomide	Chemical	MESH:D013792
25568637	17252	17268	multiple myeloma	Disease	MESH:D009101
25568637	17157	17166	melphalan	Chemical	MESH:D008558
25568637	17341	17349	patients	Species	9606
25568637	17317	17326	melphalan	Chemical	MESH:D008558
25568637	17452	17459	Myeloma	Disease	MESH:D009101
25568637	17297	17308	thalidomide	Chemical	MESH:D013792
25568637	17355	17371	multiple myeloma	Disease	MESH:D009101
25568637	17327	17337	prednisone	Chemical	MESH:D011241
25568637	17536	17544	patients	Species	9606
25568637	17550	17566	multiple myeloma	Disease	MESH:D009101
25568637	17486	17496	prednisone	Chemical	MESH:D011241
25568637	17472	17481	Melphalan	Chemical	MESH:D008558
25568637	17502	17513	thalidomide	Chemical	MESH:D013792
25568637	17657	17665	patients	Species	9606
25568637	17635	17645	prednisone	Chemical	MESH:D011241
25568637	17599	17610	thalidomide	Chemical	MESH:D013792
25568637	17687	17703	multiple myeloma	Disease	MESH:D009101
25568637	17620	17629	melphalan	Chemical	MESH:D008558
25568637	17779	17787	patients	Species	9606
25568637	17756	17767	thalidomide	Chemical	MESH:D013792
25568637	17793	17809	multiple myeloma	Disease	MESH:D009101
25568637	17740	17750	prednisone	Chemical	MESH:D011241
25568637	17729	17738	melphalan	Chemical	MESH:D008558
25568637	17916	17924	patients	Species	9606
25568637	17966	17974	patients	Species	9606
25568637	17908	17915	myeloma	Disease	MESH:D009101
25568637	17869	17880	thalidomide	Chemical	MESH:D013792
25568637	18077	18085	patients	Species	9606
25568637	18018	18029	thalidomide	Chemical	MESH:D013792
25568637	18034	18047	dexamathasone	Chemical	
25568637	18000	18016	Cyclophosphamide	Chemical	MESH:D003520
25568637	18091	18107	multiple myeloma	Disease	MESH:D009101
25568637	18150	18162	lenalidomide	Chemical	MESH:C467567
25568637	18226	18239	dexamethasone	Chemical	MESH:D003907
25568637	18199	18211	lenalidomide	Chemical	MESH:C467567
25568637	18178	18191	dexamathasone	Chemical	
25568637	18279	18295	multiple myeloma	Disease	MESH:D009101
25568637	18355	18367	lenalidomide	Chemical	MESH:C467567
25568637	18398	18414	multiple myeloma	Disease	MESH:D009101
25568637	18469	18485	Multiple Myeloma	Disease	MESH:D009101
25568637	18502	18511	melphalan	Chemical	MESH:D008558
25568637	18486	18496	Bortezomib	Chemical	MESH:C400082
25568637	18552	18568	multiple myeloma	Disease	MESH:D009101
25568637	18516	18526	prednisone	Chemical	MESH:D011241
25568637	18755	18760	VISTA	Gene	64115
25568637	18585	18594	melphalan	Chemical	MESH:D008558
25568637	18569	18579	Bortezomib	Chemical	MESH:C400082
25568637	18683	18690	myeloma	Disease	MESH:D009101
25568637	18638	18648	prednisone	Chemical	MESH:D011241
25568637	18599	18609	prednisone	Chemical	MESH:D011241
25568637	18624	18633	melphalan	Chemical	MESH:D008558
25568637	18984	18992	patients	Species	9606
25568637	18767	18777	Bortezomib	Chemical	MESH:C400082
25568637	18913	18923	bortezomib	Chemical	MESH:C400082
25568637	18825	18836	thalidomide	Chemical	MESH:D013792
25568637	18962	18972	prednisone	Chemical	MESH:D011241
25568637	18779	18788	melphalan	Chemical	MESH:D008558
25568637	18813	18823	bortezomib	Chemical	MESH:C400082
25568637	18947	18957	bortezomib	Chemical	MESH:C400082
25568637	18794	18804	prednisone	Chemical	MESH:D011241
25568637	18842	18852	prednisone	Chemical	MESH:D011241
25568637	19008	19024	multiple myeloma	Disease	MESH:D009101
25568637	18928	18939	thalidomide	Chemical	MESH:D013792
25568637	19118	19140	bortezomib-thalidomide	Chemical	MESH:C400082
25568637	19155	19186	bortezomib-melphalan-prednisone	Chemical	MESH:C400082
25568637	19212	19228	multiple myeloma	Disease	MESH:D009101
25568637	19310	19326	multiple myeloma	Disease	MESH:D009101
25568637	19296	19306	bortezomib	Chemical	MESH:C400082
25568637	19397	19405	patients	Species	9606
25568637	19442	19449	patient	Species	9606
25568637	19389	19396	myeloma	Disease	MESH:D009101

25568587|t|The Most Influential Scientists in the Development of the Medical Informatics (2): Morris F. Collen 
25568587|a|
25568587	823	826	Drs	Gene	8406
25568587	1126	1140	infrastructure	Disease	
25568587	1411	1420	pneumonia	Disease	MESH:D011014
25568587	3269	3273	Trib	Gene	26150

25568631|t|Effect of Sperm Count on Success of Intrauterine Insemination in Couples Diagnosed with Male Factor Infertility 
25568631|a|Objective: To exam semen parameters in predicting intrauterine insemination (IUI) outcomes in couples with male factor. Study design: This retrospective study was performed at department of infertility and sexual medicine from September 2007 to February 2014. 307 couples with male factor infertility were included and 672 IUI cycles were analyzed. Results: From 672 inseminations performed on 307 couples, there are 27.36% couples get pregnancy (84 out of 307) and the overall pregnancy rate was 12.95% (87 out of 672) of IUI. With the increase of post total progressive sperm count, the clinical pregnancy rate increased. When the initial progressive sperm count was lower than 5*106, there was no pregnant in the IUI cycle. At the end of the third cycle, 85 clinical pregnancies had been achieved (97.70%). Conclusions: The initial total progressive sperm count lower than 5*106 means the poor outcome of IUI in the infertile couples with male factor. If the infertile couples with male factor don't get pregnancy after three IUI cycles, the couples should receive re-assessment or other artificial reproductive technology. 
25568631	88	111	Male Factor Infertility	Disease	MESH:D007248
25568631	219	223	male	Species	9606
25568631	189	192	IUI	Disease	MESH:D005317
25568631	389	393	male	Species	9606
25568631	401	412	infertility	Disease	MESH:D007246
25568631	435	438	IUI	Disease	MESH:D005317
25568631	302	313	infertility	Disease	MESH:D007246
25568631	828	831	IUI	Disease	MESH:D005317
25568631	635	638	IUI	Disease	MESH:D005317
25568631	1054	1058	male	Species	9606
25568631	1097	1101	male	Species	9606
25568631	1074	1083	infertile	Disease	MESH:D007246
25568631	1020	1023	IUI	Disease	MESH:D005317
25568631	1031	1040	infertile	Disease	MESH:D007246
25568631	1141	1144	IUI	Disease	MESH:D005317
25568631	1479	1484	woman	Species	9606
25568631	1587	1591	male	Species	9606
25568631	1656	1667	infertility	Disease	MESH:D007246
25568631	1599	1610	infertility	Disease	MESH:D007246
25568631	1284	1287	IUI	Disease	MESH:D005317
25568631	1565	1585	cervical infertility	Disease	MESH:D007246
25568631	1343	1354	infertility	Disease	MESH:D007246
25568631	1625	1638	endometriosis	Disease	MESH:D004715
25568631	1422	1425	IUI	Disease	MESH:D005317
25568631	1958	1965	patient	Species	9606
25568631	1918	1921	IUI	Disease	MESH:D005317
25568631	1860	1871	infertility	Disease	MESH:D007246
25568631	1742	1745	IUI	Disease	MESH:D005317
25568631	2010	2029	infertility factors	Disease	MESH:D007246
25568631	1825	1846	endometrial thickness	Disease	MESH:D016889
25568631	2467	2471	male	Species	9606
25568631	2668	2672	male	Species	9606
25568631	2429	2432	IUI	Disease	MESH:D005317
25568631	2680	2691	infertility	Disease	MESH:D007246
25568631	2202	2218	male infertility	Disease	MESH:D007248
25568631	2629	2632	IUI	Disease	MESH:D005317
25568631	3159	3163	Male	Species	9606
25568631	3204	3208	male	Species	9606
25568631	3367	3371	male	Species	9606
25568631	3487	3490	IUI	Disease	MESH:D005317
25568631	3379	3390	infertility	Disease	MESH:D007246
25568631	3027	3036	infertile	Disease	MESH:D007246
25568631	2819	2830	infertility	Disease	MESH:D007246
25568631	3171	3182	infertility	Disease	MESH:D007246
25568631	2969	2992	male factor infertility	Disease	MESH:D007248
25568631	3297	3300	IUI	Disease	MESH:D005317
25568631	4109	4112	hCG	Gene	93659
25568631	4149	4152	HCG	Gene	93659
25568631	3984	3987	hCG	Gene	93659
25568631	3522	3530	Patients	Species	9606
25568631	3954	3959	human	Species	9606
25568631	4162	4170	patients	Species	9606
25568631	3604	3622	Clomiphene citrate	Chemical	MESH:D002996
25568631	3648	3657	letrozole	Chemical	MESH:C067431
25568631	4241	4253	progesterone	Chemical	MESH:D011374
25568631	4227	4236	estradiol	Chemical	MESH:D004958
25568631	4732	4736	CASA	Gene	1446
25568631	5511	5518	patient	Species	9606
25568631	5557	5564	patient	Species	9606
25568631	5673	5678	human	Species	9606
25568631	5708	5711	hCG	Gene	93659
25568631	5754	5757	IUI	Disease	MESH:D005317
25568631	6597	6605	patients	Species	9606
25568631	6621	6632	infertility	Disease	MESH:D007246
25568631	6868	6879	infertility	Disease	MESH:D007246
25568631	6332	6335	IUI	Disease	MESH:D005317
25568631	7861	7864	IUI	Disease	MESH:D005317
25568631	7972	7976	male	Species	9606
25568631	8285	8288	IUI	Disease	MESH:D005317
25568631	8063	8085	infertility conditions	Disease	MESH:D007246
25568631	8373	8376	IUI	Disease	MESH:D005317
25568631	9532	9535	IUI	Disease	MESH:D005317
25568631	8790	8793	TMS	Disease	
25568631	10347	10351	male	Species	9606
25568631	10626	10631	donor	Species	9606
25568631	10914	10917	IUI	Disease	MESH:D005317
25568631	10359	10370	infertility	Disease	MESH:D007246
25568631	10632	10635	IUI	Disease	MESH:D005317
25568631	12045	12056	infertility	Disease	MESH:D007246
25568631	11400	11403	IUI	Disease	MESH:D005317
25568631	12111	12124	endometriosis	Disease	MESH:D004715
25568631	11612	11623	infertility	Disease	MESH:D007246
25568631	11826	11829	IUI	Disease	MESH:D005317
25568631	11754	11757	IUI	Disease	MESH:D005317
25568631	12133	12156	male factor infertility	Disease	MESH:D007248
25568631	12237	12241	male	Species	9606
25568631	12370	12374	male	Species	9606
25568631	12403	12407	male	Species	9606
25568631	12347	12356	infertile	Disease	MESH:D007246
25568631	12215	12224	infertile	Disease	MESH:D007246
25568631	12177	12180	IUI	Disease	MESH:D005317
25568631	12415	12426	infertility	Disease	MESH:D007246
25568631	12336	12339	IUI	Disease	MESH:D005317
25568631	12459	12462	IUI	Disease	MESH:D005317
25568631	12678	12695	tubal infertility	Disease	MESH:D007246
25568631	12777	12780	IUI	Disease	MESH:D005317
25568631	12749	12752	IUI	Disease	MESH:D005317
25568631	12843	12868	intrauterine insemination	Disease	MESH:D005317
25568631	13013	13016	IUI	Disease	MESH:D005317
25568631	13134	13142	patients	Species	9606
25568631	13441	13464	male factor infertility	Disease	MESH:D007248
25568631	14000	14004	CASA	Gene	1446
25568631	14027	14032	donor	Species	9606
25568631	14488	14499	infertility	Disease	MESH:D007246
25568631	14404	14428	ovarian hyperstimulation	Disease	MESH:D016471
25568631	14579	14591	Intrauterine	Chemical	

25568582|t|Organizational Factors that Affect the Implementation of Information Technology: Perspectives of Middle Managers in Iran 
25568582|a|ABSTRACT Objective: to examine the organizational factors affecting the application of information technology in hospitals. Since the organizational factors are one of the most important determinants of successful projects, by understanding their impact and identifying them it can help planning a systematic IT implementation. Methods: In this cross-sectional descriptive study 110 middle managers were chosen from teaching hospitals. Structured questionnaire was used for the data collection. Results: There was a significant relationship between organization resource, organizational knowledge, process, management structure and values and goals with implementation of information technology. Conclusion: Findings showed that organizational factors had a considerable impact on implementation of information technology. Top managers must consider the important aspects of effective organizational factors. 
25568582	2723	2731	patients	Species	9606
25568582	2746	2753	patient	Species	9606
25568582	4665	4671	people	Species	9606
25568582	6444	6450	people	Species	9606
25568582	6662	6667	woman	Species	9606
25568582	6682	6685	men	Species	9606
25568582	6710	6716	people	Species	9606
25568582	6781	6793	participants	Species	9606
25568582	7014	7026	participants	Species	9606
25568582	7140	7152	participants	Species	9606
25568582	7262	7265	men	Species	9606
25568582	7278	7283	women	Species	9606
25568582	7390	7402	participants	Species	9606
25568582	9553	9557	male	Species	9606
25568582	9732	9744	participants	Species	9606
25568582	9860	9862	Al	Chemical	MESH:D000535
25568582	9618	9628	Al-Gahtani	Chemical	MESH:D000535
25568582	10200	10205	human	Species	9606
25568582	11735	11741	people	Species	9606
25568582	12734	12740	people	Species	9606
25568582	14446	14452	people	Species	9606
25568582	15058	15063	human	Species	9606
25568582	16034	16038	FITT	Chemical	MESH:C043685
25568582	16898	16905	patient	Species	9606

25568586|t|Identification of an Alternate Maxillary Apical Base Landmark from Pre-existing Substitutions 
25568586|a|ABSTRACT Background: Cephalometrically the position of maxilla is usually assessed by point A, which is one of the most common cephalometric landmarks used for spatial analysis of maxilla, however in certain scenarios we require a alternative landmark. Aims: In this study a nearest alternative maxillary apical base landmark was identified for Point A substitutions given by different authors. Methods and Material: A cross sectional study was conducted on thirty (30) good quality lateral cephalograms. Only those lateral cephalograms were selected where Point A was easily identified. Landmarks: Sella (S), Nasion (N), Point A and three substitution points Y, L, X were traced. Angles formed by SN with Point A (Angle SNA) and three substitution points (Angle SNY, SNX, SNL) were measured. Correlation of angle SNA with angles SNY, SNX and SNL were derived. Statistical analysis used Results: Mean and standard deviation for Angles SNA, SNY, SNL and SNX were calculated individually for males and females. 'T' Test was applied to determine statistical significance for all the parameters i.e Age, Angles SNA, SNY, SNL and SNX respectively. Karl Pearson correlation coefficient was carried out to determine the statistical significant correlation for Angle SNA with SNY, SNL and SNX. Results: A mean value of 82.8  +-1.9 , 83.1  +-1.8 , 78.3  +-2.9  and 78.7  +-2.7  for Angle's SNA, SNY, SNL and SNX respectively was observed. A statistically significant correlation was observed between angles SNA & SNY, SNL, SNX & strong positive correlation was observed with angle SNY. Conclusions: We conclude that Point Y is the most nearing maxillary apical base landmark to Point A. Hence maxillary apical base landmark can be substituted by Point Y where identification of point A is not obvious. 
25568586	867	870	SNL	Gene	6624
25568586	937	940	SNL	Gene	6624
25568586	815	818	SNA	Gene	6615
25568586	908	911	SNA	Gene	6615
25568586	1039	1042	SNL	Gene	6624
25568586	1211	1214	SNL	Gene	6624
25568586	1367	1370	SNL	Gene	6624
25568586	1485	1488	SNL	Gene	6624
25568586	1603	1606	SNL	Gene	6624
25568586	1592	1595	SNA	Gene	6615
25568586	1475	1478	SNA	Gene	6615
25568586	1353	1356	SNA	Gene	6615
25568586	1201	1204	SNA	Gene	6615
25568586	1029	1032	SNA	Gene	6615
25568586	1084	1089	males	Species	9606
25568586	1943	1951	patients	Species	9606
25568586	3746	3751	males	Species	9606
25568586	3817	3825	patients	Species	9606
25568586	4055	4063	Patients	Species	9606
25568586	4122	4130	Patients	Species	9606
25568586	4316	4324	Patients	Species	9606
25568586	4277	4301	craniofacial deformities	Disease	MESH:D019465
25568586	4175	4198	developmental anomalies	Disease	MESH:D000014
25568586	4136	4150	tooth agenesis	Disease	MESH:D000848
25568586	4200	4237	traumatic injuries or fractured upper	Disease	MESH:D050723
25568586	5032	5035	SNL	Gene	6624
25568586	5022	5025	SNA	Gene	6615
25568586	4825	4832	acetate	Chemical	MESH:D000085
25568586	5220	5223	SNL	Gene	6624
25568586	5192	5195	SNA	Gene	6615
25568586	5374	5377	SNL	Gene	6624
25568586	5546	5549	SNL	Gene	6624
25568586	5702	5705	SNL	Gene	6624
25568586	5688	5691	SNA	Gene	6615
25568586	5536	5539	SNA	Gene	6615
25568586	5364	5367	SNA	Gene	6615
25568586	5419	5424	males	Species	9606
25568586	5961	5964	SNL	Gene	6624
25568586	5832	5835	SNA	Gene	6615
25568586	5730	5735	Males	Species	9606
25568586	6063	6066	SNL	Gene	6624
25568586	6053	6056	SNA	Gene	6615
25568586	6482	6485	SNL	Gene	6624
25568586	6472	6475	SNA	Gene	6615
25568586	6502	6505	SNA	Gene	6615
25568586	6203	6206	SNA	Gene	6615
25568586	6319	6322	SNL	Gene	6624
25568586	6647	6650	SNL	Gene	6624
25568586	6637	6640	SNA	Gene	6615
25568586	6686	6689	SNA	Gene	6615
25568586	6696	6699	SNL	Gene	6624
25568586	6882	6885	SNL	Gene	6624
25568586	6809	6812	SNA	Gene	6615
25568586	6972	6975	SNL	Gene	6624
25568586	6962	6965	SNA	Gene	6615
25568586	7018	7021	SNA	Gene	6615
25568586	7028	7031	SNL	Gene	6624
25568586	7146	7149	SNA	Gene	6615
25568586	6992	6997	males	Species	9606
25568586	7298	7301	SNL	Gene	6624
25568586	7288	7291	SNA	Gene	6615
25568586	7359	7362	SNA	Gene	6615
25568586	7369	7372	SNL	Gene	6624
25568586	7552	7555	SNL	Gene	6624
25568586	7482	7485	SNA	Gene	6615
25568586	7641	7644	SNL	Gene	6624
25568586	7631	7634	SNA	Gene	6615
25568586	9050	9053	SNL	Gene	6624
25568586	9098	9101	SNL	Gene	6624
25568586	9189	9192	SNA	Gene	6615
25568586	9194	9197	SNL	Gene	6624
25568586	9226	9229	SNL	Gene	6624
25568586	9508	9511	SNL	Gene	6624
25568586	10060	10063	SNL	Gene	6624
25568586	10029	10032	SNA	Gene	6615
25568586	9991	9994	SNA	Gene	6615
25568586	9700	9703	SNA	Gene	6615
25568586	9612	9615	SNA	Gene	6615
25568586	9528	9531	SNA	Gene	6615
25568586	9498	9501	SNA	Gene	6615
25568586	9264	9267	SNA	Gene	6615
25568586	9093	9096	SNA	Gene	6615
25568586	9029	9032	SNA	Gene	6615
25568586	9721	9724	SNL	Gene	6624
25568586	9949	9954	males	Species	9606
25568586	10139	10144	males	Species	9606
25568586	10864	10867	SNA	Gene	6615
25568586	10328	10331	SNA	Gene	6615
25568586	11643	11648	males	Species	9606
25568586	12418	12430	Malocclusion	Disease	MESH:D008310

25568630|t|Effect of Diet Education on Blood Pressure Changes and Interdialytic Weight in Hemodialysis Patients Admitted in Hajar Hospital in Shahrekord 
25568630|a|Background and aim: Nutrition is a key factor in the treatment of patients with chronic kidney disease because kidney burden decrease causes uremic reduction and its side effects. The aim of this research is to examine the effect of diet education on blood pressure changes and interdialytic weight in Hemodialysis patients admitted to Hemodialysis ward of Hajar hospital in Shahrekord. Methods: This quasi-experimental and interventional study of 100 dialysis patients referred to Hemodialysis ward of Hajar hospital was performed in a pre-test and post-test in 2011. Diet education, including face to face training with instruction booklets, were conducted in the two sessions. Having carried out the educational program, blood pressure and interdialytic weight gain were measured and recorded one month before and during three stages and after the educational program by researcher-designed checklists. The data were analyzed through Spss16 software by Paired t-test and ANOVA. Results: The results showed that mean of primary weight of the patients increase from 66.15+-15.10 to 64.43+-14.67. Mean of Systolic and diastolic blood pressure in patients in three stages were reduced to 6.65+-1.51 mmg 2.24+-1.82 mmg respectively. There was a significant difference between the creatinine amount in patients before and after of training (p<=0.01) but no meaningful difference was observed between the BUN amount before and after of training (p<=0.031). Conclusion: Training to patients underwent hemodialysis in order to observe diet and its effects on improvement in treatment are of significant importance. 
25568630	92	100	Patients	Species	9606
25568630	69	91	Weight in Hemodialysis	Disease	MESH:D015431
25568630	208	216	patients	Species	9606
25568630	457	465	patients	Species	9606
25568630	222	299	chronic kidney disease because kidney burden decrease causes uremic reduction	Disease	MESH:D007676
25568630	603	611	patients	Species	9606
25568630	885	910	interdialytic weight gain	Disease	MESH:D015430
25568630	1186	1194	patients	Species	9606
25568630	1288	1296	patients	Species	9606
25568630	1441	1449	patients	Species	9606
25568630	1420	1430	creatinine	Chemical	MESH:D003404
25568630	1621	1629	patients	Species	9606
25568630	2012	2020	patients	Species	9606
25568630	2280	2286	people	Species	9606
25568630	2445	2453	patients	Species	9606
25568630	2641	2649	patients	Species	9606
25568630	2665	2673	patients	Species	9606
25568630	2876	2884	patients	Species	9606
25568630	2992	3000	patients	Species	9606
25568630	3111	3119	patients	Species	9606
25568630	3345	3353	patients	Species	9606
25568630	3581	3589	patients	Species	9606
25568630	3694	3702	patients	Species	9606
25568630	3833	3841	patients	Species	9606
25568630	3933	3941	patients	Species	9606
25568630	4009	4016	patient	Species	9606
25568630	4201	4208	patient	Species	9606
25568630	4373	4381	patients	Species	9606
25568630	4571	4579	patients	Species	9606
25568630	4097	4126	delaying renal osteodystrophy	Disease	MESH:D012080
25568630	3412	3427	pulmonary edema	Disease	MESH:D011654
25568630	2626	2640	renal dialysis	Disease	MESH:D007674
25568630	3919	3932	renal failure	Disease	MESH:D051437
25568630	1997	2003	uremia	Disease	MESH:D014511
25568630	2813	2819	uremia	Disease	MESH:D014511
25568630	2744	2763	renal complications	Disease	MESH:D007674
25568630	3605	3617	malnutrition	Disease	MESH:D044342
25568630	2419	2432	renal disease	Disease	MESH:D007674
25568630	4082	4087	edema	Disease	MESH:D004487
25568630	4037	4049	malnutrition	Disease	MESH:D044342
25568630	1778	1799	chronic renal failure	Disease	MESH:D007676
25568630	3240	3261	chronic renal failure	Disease	MESH:D007676
25568630	2312	2325	renal failure	Disease	MESH:D051437
25568630	2702	2728	reduction of kidney burden	Disease	MESH:D051437
25568630	3429	3453	congestive heart failure	Disease	MESH:D006333
25568630	2190	2203	Renal failure	Disease	MESH:D051437
25568630	4157	4164	calcium	Chemical	MESH:D002118
25568630	3394	3404	depression	Disease	MESH:D003866
25568630	3459	3474	premature death	Disease	MESH:D003643
25568630	4142	4152	phosphorus	Chemical	MESH:D010758
25568630	3365	3392	impaired physical abilities	Disease	MESH:D059445
25568630	3622	3658	inflammation increase cardiovascular	Disease	MESH:D002318
25568630	2035	2056	chronic renal failure	Disease	MESH:D007676
25568630	4707	4715	patients	Species	9606
25568630	4837	4845	Patients	Species	9606
25568630	4895	4903	patients	Species	9606
25568630	5465	5473	patients	Species	9606
25568630	5729	5737	patients	Species	9606
25568630	6112	6120	patients	Species	9606
25568630	6343	6351	patients	Species	9606
25568630	5154	5176	chronic kidney failure	Disease	MESH:D007676
25568630	5633	5635	Cr	Chemical	MESH:D002857
25568630	5396	5418	diastolic hypertension	Disease	MESH:C563897
25568630	6654	6662	patients	Species	9606
25568630	6743	6747	male	Species	9606
25568630	7179	7186	patient	Species	9606
25568630	7332	7340	patients	Species	9606
25568630	7374	7381	patient	Species	9606
25568630	7265	7288	cardiovascular problems	Disease	MESH:D002318
25568630	7558	7566	patients	Species	9606
25568630	7771	7779	patients	Species	9606
25568630	7843	7851	patients	Species	9606
25568630	7551	7553	Cr	Chemical	MESH:D002857
25568630	7761	7763	Cr	Chemical	MESH:D002857
25568630	8377	8381	urea	Chemical	MESH:D014508
25568630	8365	8375	creatinine	Chemical	MESH:D003404
25568630	8560	8568	patients	Species	9606
25568630	8963	8968	males	Species	9606
25568630	9108	9113	males	Species	9606
25568630	9161	9166	males	Species	9606
25568630	8652	8663	weight gain	Disease	MESH:D015430
25568630	9230	9255	interdialytic weight gain	Disease	MESH:D015430
25568630	8732	8736	Urea	Chemical	MESH:D014508
25568630	8738	8748	creatinine	Chemical	MESH:D003404
25568630	8951	8953	Cr	Chemical	MESH:D002857
25568630	9436	9444	patients	Species	9606
25568630	9590	9598	patients	Species	9606
25568630	9751	9759	Patients	Species	9606
25568630	9828	9836	patients	Species	9606
25568630	9523	9548	Interdialytic weight loss	Disease	MESH:D015431
25568630	9894	9902	patients	Species	9606
25568630	10147	10155	patients	Species	9606
25568630	10405	10413	patients	Species	9606
25568630	10477	10485	patients	Species	9606
25568630	10598	10605	patient	Species	9606
25568630	10920	10927	patient	Species	9606
25568630	11203	11211	patients	Species	9606
25568630	11425	11433	patients	Species	9606
25568630	11667	11675	patients	Species	9606
25568630	11891	11899	patients	Species	9606
25568630	11930	11938	patients	Species	9606
25568630	12104	12112	patients	Species	9606
25568630	12213	12221	patients	Species	9606
25568630	12367	12375	patients	Species	9606
25568630	12469	12477	patients	Species	9606
25568630	13076	13084	patients	Species	9606
25568630	13137	13145	patients	Species	9606
25568630	13175	13183	patients	Species	9606
25568630	12578	12589	weight loss	Disease	MESH:D015431
25568630	9943	9954	memory loss	Disease	MESH:D008569
25568630	10565	10571	sodium	Chemical	MESH:D012964
25568630	12091	12103	hemodialysis	Disease	
25568630	11410	11424	renal dialysis	Disease	MESH:D007674
25568630	11862	11890	malnutrition in hemodialysis	Disease	MESH:D044342
25568630	9956	9966	drowsiness	Disease	MESH:D006970
25568630	12191	12203	hypertension	Disease	MESH:D006973
25568630	9906	9912	Uremia	Disease	MESH:D014511
25568630	10004	10045	Interdialytic weight gain increases blood	Disease	MESH:D015430
25568630	13396	13404	patients	Species	9606
25568630	13453	13461	patients	Species	9606
25568630	13618	13626	patients	Species	9606
25568630	13410	13423	renal failure	Disease	MESH:D051437
25568630	13722	13729	Brunner	Disease	MESH:C563156
25568630	13734	13742	Suddarth	Chemical	
25568630	13757	13765	Suddarth	Chemical	
25568630	13745	13752	Brunner	Disease	MESH:C563156
25568630	13768	13789	Chronic renal failure	Disease	MESH:D007676
25568630	13863	13883	chronic hemodialysis	Disease	MESH:D002908
25568630	13942	13949	patient	Species	9606
25568630	13993	14001	patients	Species	9606
25568630	14007	14029	chronic kidney disease	Disease	MESH:D051436
25568630	14044	14051	persons	Species	9606
25568630	14057	14070	renal failure	Disease	MESH:D051437
25568630	14130	14151	chronic renal failure	Disease	MESH:D007676
25568630	14180	14188	patients	Species	9606
25568630	14296	14304	patients	Species	9606
25568630	14382	14390	patients	Species	9606
25568630	14346	14358	hypertension	Disease	MESH:D006973
25568630	14415	14419	HEMO	Chemical	
25568630	14454	14462	patients	Species	9606
25568630	14574	14582	patients	Species	9606
25568630	14587	14599	hypertension	Disease	MESH:D006973
25568630	14696	14704	patients	Species	9606
25568630	14689	14695	kidney	Disease	MESH:D007674
25568630	14801	14809	patients	Species	9606
25568630	14914	14922	patients	Species	9606
25568630	14901	14913	hemodialysis	Disease	
25568630	15051	15059	patients	Species	9606

25568576|t|Back Pain in Children and Diagnostic Value of 99mTc MDP Bone Scintigraphy 
25568576|a|ABSTRACT Aim: The aim of our study is to assess the diagnostic value of Technituim-99m-Methyle diphosphonate (99mTc-MDP) Bone scintigraphy in the assessment of children with back pain. Methods: Included in this retrospective study were 68 child referred to us complaining of back pain (mean age of 13+ 2). There were 45 boys and 23 girls. All children have been investigated with conventional x-ray which revealed normal or inconclusive result. All underwent bone scintigraphy after the injection of 99mTc-MDP with calculated doses according to there body weights. Results: Bone scintigraphy revealed 17 (25%) abnormal scans in 11 boys and 6 girls. Scans findings were suggestive of spondylolysis (n=4); malignancy including primary tumors and metastases (n=3); infection including osteomyelitis and discitis (n=3); sacroiliitis (n=2); benign tumors (n=2); pseudo fractures in ribs (n=1); necrosis in femoral head epiphysis(n=1) and nonskeletal-renal retention due to hydronephrosis (n=1). Sensitivity, specificity and accuracy of bone scan in detecting gross skeletal abnormality as a cause for back pain were 94% and 100% and 99% respectively. Conclusion: Bone isotope scan is a sensitive imaging modality in the assessment of pediatric patients with back pain. It is a reliable modality to detect and role out most benign and aggressive serious etiologies. 
25568576	13	21	Children	Species	9606
25568576	52	55	MDP	Gene	1800
25568576	5	9	Pain	Disease	MESH:D010146
25568576	190	193	MDP	Gene	1800
25568576	234	242	children	Species	9606
25568576	146	182	Technituim-99m-Methyle diphosphonate	Chemical	MESH:C029045
25568576	248	257	back pain	Disease	MESH:D001416
25568576	580	583	MDP	Gene	1800
25568576	313	318	child	Species	9606
25568576	394	398	boys	Species	9606
25568576	406	411	girls	Species	9606
25568576	417	425	children	Species	9606
25568576	349	358	back pain	Disease	MESH:D001416
25568576	705	709	boys	Species	9606
25568576	716	721	girls	Species	9606
25568576	836	845	infection	Disease	MESH:D007239
25568576	975	1034	femoral head epiphysis(n=1) and nonskeletal-renal retention	Disease	MESH:D060048
25568576	818	828	metastases	Disease	MESH:D009362
25568576	1170	1179	back pain	Disease	MESH:D001416
25568576	856	882	osteomyelitis and discitis	Disease	MESH:D015299
25568576	778	788	malignancy	Disease	MESH:D009369
25568576	890	902	sacroiliitis	Disease	MESH:D058566
25568576	910	923	benign tumors	Disease	MESH:D009369
25568576	807	813	tumors	Disease	MESH:D009369
25568576	1042	1056	hydronephrosis	Disease	MESH:D006869
25568576	938	947	fractures	Disease	MESH:D050723
25568576	963	971	necrosis	Disease	MESH:D009336
25568576	1313	1321	patients	Species	9606
25568576	1327	1336	back pain	Disease	MESH:D001416
25568576	1489	1497	children	Species	9606
25568576	1547	1555	children	Species	9606
25568576	1534	1543	back pain	Disease	MESH:D001416
25568576	1455	1459	pain	Disease	MESH:D010146
25568576	1948	1957	back pain	Disease	MESH:D001416
25568576	2062	2071	back pain	Disease	MESH:D001416
25568576	2244	2253	back pain	Disease	MESH:D001416
25568576	2752	2756	rays	Species	255564
25568576	2605	2614	bone pain	Disease	MESH:D010146
25568576	2948	2956	children	Species	9606
25568576	2972	2981	back pain	Disease	MESH:D001416
25568576	3225	3233	PATIENTS	Species	9606
25568576	3291	3299	children	Species	9606
25568576	3373	3377	boys	Species	9606
25568576	3385	3390	girls	Species	9606
25568576	3396	3404	children	Species	9606
25568576	3492	3500	children	Species	9606
25568576	3670	3678	patients	Species	9606
25568576	3695	3698	MDP	Gene	1800
25568576	3532	3541	back pain	Disease	MESH:D001416
25568576	3420	3429	back pain	Disease	MESH:D001416
25568576	4185	4193	children	Species	9606
25568576	4615	4624	back pain	Disease	MESH:D001416
25568576	4727	4735	Patients	Species	9606
25568576	4899	4903	boys	Species	9606
25568576	4910	4915	girls	Species	9606
25568576	5370	5392	femoral head epiphysis	Disease	MESH:D060048
25568576	5176	5186	malignancy	Disease	MESH:D009369
25568576	5308	5321	benign tumors	Disease	MESH:D009369
25568576	5358	5366	necrosis	Disease	MESH:D009336
25568576	5254	5263	infection	Disease	MESH:D007239
25568576	5205	5211	tumors	Disease	MESH:D009369
25568576	5216	5226	metastases	Disease	MESH:D009362
25568576	5234	5246	sacroiliitis	Disease	MESH:D058566
25568576	5274	5300	osteomyelitis and discitis	Disease	MESH:D015299
25568576	5597	5621	bone scans abnormalities	Disease	MESH:D004401
25568576	5868	5871	PPV	Species	12211
25568576	5791	5800	back pain	Disease	MESH:D001416
25568576	5992	6000	children	Species	9606
25568576	6312	6320	patients	Species	9606
25568576	6326	6342	simple back pain	Disease	MESH:D001416
25568576	6124	6133	back pain	Disease	MESH:D001416
25568576	5972	5976	pain	Disease	MESH:D010146
25568576	6247	6256	infection	Disease	MESH:D007239
25568576	6237	6243	cancer	Disease	MESH:D009369
25568576	6216	6233	systemic diseases	Disease	MESH:D034721
25568576	6607	6615	children	Species	9606
25568576	6791	6800	back pain	Disease	MESH:D001416
25568576	7121	7124	MDP	Gene	1800
25568576	7061	7069	children	Species	9606
25568576	7553	7561	patients	Species	9606
25568576	7532	7538	trauma	Disease	MESH:D014947
25568576	7714	7726	pars defects	Disease	MESH:D015868
25568576	7618	7622	pain	Disease	MESH:D010146
25568576	7485	7500	stress fracture	Disease	MESH:D015775
25568576	7378	7391	Spondylolysis	Disease	MESH:D013169
25568576	7358	7371	low back pain	Disease	MESH:D017116
25568576	7567	7580	spondylolysis	Disease	MESH:D013169
25568576	7686	7699	low back pain	Disease	MESH:D017116
25568576	8114	8117	LBP	Gene	3929
25568576	8100	8104	male	Species	9606
25568576	8105	8108	boy	Species	9606
25568576	8493	8498	child	Species	9606
25568576	8584	8606	metabolic bone disease	Disease	MESH:D001851
25568576	8303	8317	bone fractures	Disease	MESH:D050723
25568576	8388	8397	fractures	Disease	MESH:D050723
25568576	8632	8636	male	Species	9606
25568576	8637	8642	child	Species	9606
25568576	8746	8754	children	Species	9606
25568576	9481	9489	patients	Species	9606
25568576	8788	8821	Lumbosacral transitional vertebra	Disease	MESH:C536344
25568576	9036	9065	hyperextension overuse injury	Disease	MESH:D012090
25568576	8839	8859	Schuermann's Disease	Disease	MESH:D010300
25568576	8729	8742	low back pain	Disease	MESH:D017116
25568576	9523	9536	low back pain	Disease	MESH:D017116
25568576	9115	9122	anomaly	Disease	MESH:D000014
25568576	9353	9368	pseudoarthrosis	Disease	MESH:D011542
25568576	9510	9518	vertebra	Disease	MESH:C562952
25568576	8760	8786	Spinal process apophysitis	Disease	MESH:D016301
25568576	9270	9289	Bertolotti syndrome	Disease	MESH:D061325
25568576	9595	9599	pain	Disease	MESH:D010146
25568576	10028	10036	kyphosis	Disease	MESH:D007738
25568576	10615	10633	avascular necrosis	Disease	MESH:D010020
25568576	10437	10452	Perth's disease	Disease	MESH:D007873
25568576	10579	10596	Femoral Epiphysis	Disease	MESH:D060048
25568576	10500	10542	photopenic defect within femoral epiphysis	Disease	MESH:D060048
25568576	10789	10792	MDP	Gene	1800
25568576	11024	11037	Osteomyelitis	Disease	MESH:D010019
25568576	10891	10904	osteomyelitis	Disease	MESH:D010019
25568576	10807	10820	osteomyelitis	Disease	MESH:D010019
25568576	11200	11208	children	Species	9606
25568576	11287	11295	children	Species	9606
25568576	11380	11388	children	Species	9606
25568576	11188	11196	discitis	Disease	MESH:D015299
25568576	11525	11533	discitis	Disease	MESH:D015299
25568576	11649	11653	girl	Species	9606
25568576	11817	11825	discitis	Disease	MESH:D015299
25568576	11659	11668	back pain	Disease	MESH:D001416
25568576	11833	11836	MDP	Gene	1800
25568576	11996	12013	sacroiliac joints	Disease	MESH:C563037
25568576	11860	11897	inflammations of rheumatoid arthritis	Disease	MESH:D001172
25568576	11902	11924	ankylosing spondylitis	Disease	MESH:D013167
25568576	11926	11938	Sacroiliitis	Disease	MESH:D058566
25568576	12035	12057	bilateral sacroiliitis	Disease	MESH:D058566
25568576	12244	12247	boy	Species	9606
25568576	12411	12423	sacroiliitis	Disease	MESH:D058566
25568576	12253	12266	low back pain	Disease	MESH:D017116
25568576	12830	12838	patients	Species	9606
25568576	12431	12434	MDP	Gene	1800
25568576	12853	12863	metastases	Disease	MESH:D009362
25568576	12780	12790	metastases	Disease	MESH:D009362
25568576	12505	12515	metastases	Disease	MESH:D009362
25568576	13258	13266	children	Species	9606
25568576	13320	13328	patients	Species	9606
25568576	13361	13366	tumor	Disease	MESH:D009369
25568576	13555	13568	osteomyelitis	Disease	MESH:D010019
25568576	13294	13310	Ewing's sarcomas	Disease	MESH:D012512
25568576	13245	13254	back pain	Disease	MESH:D001416
25568576	13203	13222	Primary bone tumors	Disease	MESH:D001859
25568576	13608	13613	child	Species	9606
25568576	13619	13632	low back pain	Disease	MESH:D017116
25568576	13791	13804	Ewing sarcoma	Disease	MESH:D012512
25568576	14165	14180	Osteoid osteoma	Disease	MESH:D010017
25568576	14405	14422	painful scoliosis	Disease	MESH:D012600
25568576	13975	14010	osteoblastomas and ostioid osteomas	Disease	MESH:D018215
25568576	14130	14139	sclerotic	Disease	MESH:C538213
25568576	13845	13860	osteoid osteoma	Disease	MESH:D010017
25568576	14067	14081	Osteoblastomas	Disease	MESH:D018215
25568576	13806	13840	Benign lesions like osteoblastomas	Disease	MESH:D018215
25568576	14509	14512	MDP	Gene	1800
25568576	14644	14658	Hydronephrosis	Disease	MESH:D006869
25568576	14503	14508	99mTc	Chemical	MESH:C107828
25568576	14731	14751	obstructive uropathy	Disease	MESH:C536483
25568576	14799	14803	girl	Species	9606
25568576	14809	14818	back pain	Disease	MESH:D001416
25568576	14902	14929	hydronephrosis-PUJ stenosis	Disease	MESH:D006869
25568576	15009	15017	patients	Species	9606
25568576	15100	15108	patients	Species	9606
25568576	15390	15395	child	Species	9606
25568576	15819	15824	child	Species	9606
25568576	15968	15973	child	Species	9606
25568576	15717	15726	back pain	Disease	MESH:D001416
25568576	15401	15410	back pain	Disease	MESH:D001416
25568576	15487	15499	bone isotope	Disease	MESH:D001847
25568576	15023	15032	back pain	Disease	MESH:D001416
25568576	16226	16234	patients	Species	9606
25568576	16240	16249	back pain	Disease	MESH:D001416
25568576	16511	16519	children	Species	9606
25568576	16503	16507	pain	Disease	MESH:D010146
25568576	16570	16578	children	Species	9606
25568576	16546	16559	Low back pain	Disease	MESH:D017116
25568576	16610	16614	pain	Disease	MESH:D010146
25568576	16660	16668	patients	Species	9606
25568576	16680	16693	low-back pain	Disease	MESH:D017116
25568576	16710	16712	MR	Disease	MESH:C564570
25568576	16798	16811	Low Back Pain	Disease	MESH:D017116
25568576	16860	16868	children	Species	9606
25568576	16891	16895	pain	Disease	MESH:D010146
25568576	16896	16909	Low-back pain	Disease	MESH:D017116
25568576	16947	16960	stress injury	Disease	MESH:D040701
25568576	17038	17060	ankylosing spondylitis	Disease	MESH:D013167
25568576	17107	17110	MDP	Gene	1800
25568576	17074	17082	discitis	Disease	MESH:D015299
25568576	17223	17231	patients	Species	9606
25568576	17237	17250	low-back pain	Disease	MESH:D017116
25568576	17257	17291	lumbrosacral transitional vertebra	Disease	MESH:C562952
25568576	17323	17336	Low back pain	Disease	MESH:D017116
25568576	17433	17437	pain	Disease	MESH:D010146
25568576	17518	17534	stress fractures	Disease	MESH:D015775
25568576	17578	17583	child	Species	9606
25568576	17584	17589	abuse	Disease	MESH:C535569
25568576	17621	17629	patients	Species	9606
25568576	17635	17648	low-back pain	Disease	MESH:D017116
25568576	17655	17689	lumbrosacral transitional vertebra	Disease	MESH:C562952
25568576	17756	17770	facet syndrome	Disease	MESH:D061325
25568576	17836	17843	gallium	Chemical	MESH:D005708
25568576	17845	17851	indium	Chemical	MESH:D007204
25568576	17793	17818	musculoskeletal infection	Disease	MESH:D009140
25568576	17998	18001	MDP	Gene	1800
25568576	17940	17955	bone infections	Disease	MESH:D001847
25568576	17981	17986	Ga-67	Chemical	MESH:C048993
25568576	18074	18096	ankylosing spondylitis	Disease	MESH:D013167
25568576	18278	18291	Ewing sarcoma	Disease	MESH:D012512
25568576	18302	18308	tumors	Disease	MESH:D009369
25568576	18365	18391	osteoblastoma of the spine	Disease	MESH:D018215
25568576	18344	18360	Osteoid osteomas	Disease	MESH:D010017
25568576	18438	18453	osteoid osteoma	Disease	MESH:D010017
25568576	18467	18487	obstructive uropathy	Disease	MESH:C536483

25568580|t|Telemetric Detection of Chronic Obstructive Pulmonary Disease and Investigation of Quality of Life for People Working in Shipbuilding Industry 
25568580|a|ABSTRACT Introduction: Chronic Obstructive Pulmonary Disease (COPD) has a significant impact on quality of life-related health. Aim: It was the detection of Chronic Obstructive Pulmonary Disease by using telemetric methods and the investigation of the quality of life for people working in Shipbuilding Industry compared with a control group. Methods: A group of one hundred men working in the shipbuilding industry aged 51.8 +- 8.2 years old and a control group of one hundred men of the general population aged 51.1 +- 6.4 years were studied. All participants completed the General Health Questionnaire - 28, the Fagerstrom test and a form with demographic characteristics. Pulmonary function test results were electronically sent to a specialist for evaluation. Results: People working in the shipbuilding zone had significantly lower values (p<0.001) in FVC, FEV1 and FEV1/FVC compared with the general population participants. Worse social functionality was exhibited by workers in the shipbuilding zone, people with elementary education, unemployed and by those suffering from comorbidities (p <0.001). Conclusions: Health level and its individual dimensions are both associated with health self-assessment and occupational and economic status. The coexistence of chronic diseases and smoking dependence affects emotion and social functioning of individuals. 
25568580	103	109	People	Species	9606
25568580	205	209	COPD	Disease	MESH:D029424
25568580	415	421	people	Species	9606
25568580	518	521	men	Species	9606
25568580	621	624	men	Species	9606
25568580	692	704	participants	Species	9606
25568580	919	925	People	Species	9606
25568580	1063	1075	participants	Species	9606
25568580	1155	1161	people	Species	9606
25568580	1415	1431	chronic diseases	Disease	MESH:D002908
25568580	1732	1738	people	Species	9606
25568580	2082	2085	men	Species	9606
25568580	2097	2102	women	Species	9606
25568580	1903	1907	COPD	Disease	MESH:D029424
25568580	1565	1569	COPD	Disease	MESH:D029424
25568580	1761	1765	COPD	Disease	MESH:D029424
25568580	1896	1901	death	Disease	MESH:D003643
25568580	3189	3197	patients	Species	9606
25568580	3366	3372	people	Species	9606
25568580	2782	2786	COPD	Disease	MESH:D029424
25568580	2549	2553	COPD	Disease	MESH:D029424
25568580	3236	3244	diabetes	Disease	MESH:D003920
25568580	3228	3234	asthma	Disease	MESH:D001249
25568580	2418	2423	death	Disease	MESH:D003643
25568580	2925	2929	COPD	Disease	MESH:D029424
25568580	2295	2299	COPD	Disease	MESH:D029424
25568580	2353	2375	multi systemic disease	Disease	MESH:C564969
25568580	3203	3219	chronic diseases	Disease	MESH:D002908
25568580	3249	3253	COPD	Disease	MESH:D029424
25568580	3899	3905	people	Species	9606
25568580	4136	4142	people	Species	9606
25568580	3911	3915	COPD	Disease	MESH:D029424
25568580	4254	4260	people	Species	9606
25568580	4357	4363	people	Species	9606
25568580	4412	4415	men	Species	9606
25568580	5437	5455	airway obstruction	Disease	MESH:D000402
25568580	5405	5421	mental disorders	Disease	MESH:D001523
25568580	5249	5257	wheezing	Disease	MESH:D012135
25568580	4963	4980	pulmonary disease	Disease	MESH:D008171
25568580	5259	5266	dyspnea	Disease	MESH:D004417
25568580	5341	5348	dyspnea	Disease	MESH:D004417
25568580	5234	5239	cough	Disease	MESH:D003371
25568580	5554	5562	nicotine	Chemical	MESH:D009538
25568580	5752	5760	nicotine	Chemical	MESH:D009538
25568580	6386	6398	Participants	Species	9606
25568580	6533	6551	airway obstruction	Disease	MESH:D000402
25568580	6250	6254	COPD	Disease	MESH:D029424
25568580	6326	6344	airway obstruction	Disease	MESH:D000402
25568580	7682	7688	people	Species	9606
25568580	7831	7843	participants	Species	9606
25568580	8036	8043	COPD 10	Gene	544442
25568580	8213	8220	COPD 13	Gene	544417
25568580	8196	8208	hypertension	Disease	MESH:D006973
25568580	8223	8237	heart diseases	Disease	MESH:D006331
25568580	8266	8283	diabetes mellitus	Disease	MESH:D003920
25568580	8018	8030	hypertension	Disease	MESH:D006973
25568580	8089	8106	diabetes mellitus	Disease	MESH:D003920
25568580	8046	8060	heart diseases	Disease	MESH:D006331
25568580	8304	8315	participant	Species	9606
25568580	8376	8383	persons	Species	9606
25568580	8424	8430	people	Species	9606
25568580	8623	8635	participants	Species	9606
25568580	8716	8728	participants	Species	9606
25568580	8812	8816	COPD	Disease	MESH:D029424
25568580	8702	8706	COPD	Disease	MESH:D029424
25568580	9328	9334	people	Species	9606
25568580	9497	9509	participants	Species	9606
25568580	9613	9625	Participants	Species	9606
25568580	9699	9711	participants	Species	9606
25568580	9754	9766	Participants	Species	9606
25568580	9903	9915	participants	Species	9606
25568580	9953	9965	participants	Species	9606
25568580	9410	9414	COPD	Disease	MESH:D029424
25568580	10454	10466	participants	Species	9606
25568580	10613	10625	participants	Species	9606
25568580	10827	10839	participants	Species	9606
25568580	10424	10428	COPD	Disease	MESH:D029424
25568580	10377	10392	chronic disease	Disease	MESH:D002908
25568580	11512	11519	patient	Species	9606
25568580	11229	11233	COPD	Disease	MESH:D029424
25568580	11924	11927	men	Species	9606
25568580	12047	12050	men	Species	9606
25568580	12009	12013	COPD	Disease	MESH:D029424
25568580	11810	11814	COPD	Disease	MESH:D029424
25568580	12659	12662	men	Species	9606
25568580	12780	12786	people	Species	9606
25568580	13222	13228	people	Species	9606
25568580	12634	12638	COPD	Disease	MESH:D029424
25568580	12225	12249	obstructive lung disease	Disease	MESH:D008173
25568580	13039	13061	respiratory infections	Disease	MESH:D012141
25568580	12966	12970	COPD	Disease	MESH:D029424
25568580	13201	13205	COPD	Disease	MESH:D029424
25568580	12458	12492	Burden of Obstructive Lung Disease	Disease	MESH:D008173
25568580	12717	12721	COPD	Disease	MESH:D029424
25568580	12545	12549	COPD	Disease	MESH:D029424
25568580	13460	13464	COPD	Disease	MESH:D029424
25568580	12304	12308	COPD	Disease	MESH:D029424
25568580	12452	12456	BOLD	Disease	MESH:D008173
25568580	13588	13600	participants	Species	9606
25568580	13894	13900	people	Species	9606
25568580	14337	14344	tobacco	Species	4097
25568580	14540	14552	participants	Species	9606
25568580	14673	14681	patients	Species	9606
25568580	14687	14691	COPD	Disease	MESH:D029424
25568580	15275	15282	patient	Species	9606
25568580	15429	15435	person	Species	9606
25568580	15400	15424	chronic diseases burdens	Disease	MESH:D002908
25568580	15199	15219	psychosocial impacts	Disease	MESH:C535569
25568580	15764	15776	Participants	Species	9606
25568580	15930	15936	people	Species	9606
25568580	16033	16045	participants	Species	9606
25568580	16067	16073	people	Species	9606
25568580	16446	16454	patients	Species	9606
25568580	16621	16633	participants	Species	9606
25568580	17575	17593	social dysfunction	Disease	OMIM:300082
25568580	17647	17651	COPD	Disease	MESH:D029424
25568580	17904	17908	COPD	Disease	MESH:D029424
25568580	17972	18004	Chronic Obstructive Lung Disease	Disease	MESH:D029424
25568580	18070	18074	COPD	Disease	MESH:D029424
25568580	18106	18114	patients	Species	9606
25568580	18120	18157	chronic obstructive pulmonary disease	Disease	MESH:D029424
25568580	18178	18182	COPD	Disease	MESH:D029424
25568580	18378	18382	COPD	Disease	MESH:D029424
25568580	18547	18555	Nicotine	Chemical	MESH:D009538
25568580	18744	18748	COPD	Disease	MESH:D029424
25568580	18819	18843	obstructive lung disease	Disease	MESH:D008173
25568580	18905	18937	Pulmonary Diseases and Disorders	Disease	MESH:D008171
25568580	18938	18942	BOLD	Disease	MESH:D008173
25568580	19280	19292	COPD disease	Disease	MESH:D029424
25568580	19352	19360	patients	Species	9606
25568580	19366	19403	chronic obstructive pulmonary disease	Disease	MESH:D029424
25568580	19478	19482	COPD	Disease	MESH:D029424
25568580	19563	19567	COPD	Disease	MESH:D029424
25568580	19679	19687	patients	Species	9606
25568580	19693	19718	diabetes mellitus type II	Disease	MESH:D003924
25568580	19631	19645	Mood disorders	Disease	MESH:D019964
25568580	19776	19813	chronic obstructive pulmonary disease	Disease	MESH:D029424
25568580	19888	19896	patients	Species	9606

